1 | (+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 271 271 💬 |
2 | (-)-3-(4-Aminophenyl)-2-methoxypropionic acid | - | - | - | - | 1件: 97 97 💬 |
3 | (-)-trans-delta-9-Tetrahydrocannabinol | 1件: Dronabinol Dronabinol | 1件: Dronabinol
Dronabinol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
4 | (1-13C) Sodium Acetate | 2件: Acetate Acetate, Sodium acetate | 1件: Sodium acetate
Sodium acetate
💬 | - | - | 1件: 251 251 💬 |
5 | (1-3)-beta-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 💬 |
6 | (1-3)-ß-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 💬 |
7 | (11C)PE2I | - | - | - | - | 1件: 6 6 💬 |
8 | (18)F-FDG | - | - | - | - | 1件: 85 85 💬 |
9 | (18F)FPGLU | - | - | - | - | 1件: 86 86 💬 |
10 | (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide | - | - | - | - | 1件: 11 11 💬 |
11 | (2)-epigallocatechin-3-gallate (EGCG) | 2件: Epigallocatechin Epigallocatechin, Epigallocatechin gallate | - | - | - | 1件: 8 8 💬 |
12 | (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) | - | - | - | - | 1件: 6 6 💬 |
13 | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide | - | - | - | - | 1件: 309 309 💬 |
14 | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide | - | - | - | - | 1件: 309 309 💬 |
15 | (3beta, 5beta, 25R)-spirostan-3-ol | - | - | - | - | 1件: 6 6 💬 |
16 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
17 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 💬 |
18 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
19 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 💬 |
20 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
21 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
22 | (3ß, 5ß, 25R)-spirostan-3-ol | - | - | - | - | 1件: 6 6 💬 |
23 | (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile | - | - | - | - | 1件: 231 231 💬 |
24 | (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’- | - | - | - | - | 1件: 79 79 💬 |
25 | (6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate | - | - | - | - | 1件: 2 2 💬 |
26 | (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol | - | - | - | - | 1件: 6 6 💬 |
27 | (7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine | - | - | - | - | 1件: 301 301 💬 |
28 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime | - | - | - | - | 1件: 161 161 💬 |
29 | (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate | - | - | - | - | 1件: 6 6 💬 |
30 | (Pyr1)apelin-13 | - | - | - | - | 1件: 86 86 💬 |
31 | (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide | - | - | - | - | 1件: 13 13 💬 |
32 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4- | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
33 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
34 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
35 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4YL)SULFONYL)4,4A,5,6,7,8HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN4AYL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
36 | (R)-3-(1-oxo-propoxy)-4-(N,N,N-trimethyl amonium chloride)-butanoic acid | 2件: Butyric Acid Butyric Acid, Chloride ion | - | - | - | 1件: 97 97 💬 |
37 | (R)-[N-metil-11C1-PK11195(PK) | - | - | - | - | 1件: 127 127 💬 |
38 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 💬 |
39 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 💬 |
40 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1HPYRAZOLE-4-CARBOXAMIDE | - | - | - | - | 1件: 58 58 💬 |
41 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 272 272 💬 |
42 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 272 272 💬 |
43 | (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol | - | - | - | - | 1件: 6 6 💬 |
44 | (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate | - | - | - | - | 1件: 6 6 💬 |
45 | (S)-(-)-3-(4-Aminophenyl)-2-methoxypropionic Acid | - | - | - | - | 1件: 97 97 💬 |
46 | (S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid | - | - | - | - | 1件: 86 86 💬 |
47 | (S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one | - | - | - | - | 1件: 240 240 💬 |
48 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 💬 |
49 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 💬 |
50 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazo | - | - | - | - | 1件: 284 284 💬 |
51 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: Magnesium hydroxide
Magnesium hydroxide
💬 | - | - | 1件: 284 284 💬 |
52 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m | - | - | - | - | 1件: 284 284 💬 |
53 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: Magnesium hydroxide
Magnesium hydroxide
💬 | - | - | 1件: 284 284 💬 |
54 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5- yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 💬 |
55 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxyben | - | - | - | - | 1件: 97 97 💬 |
56 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 💬 |
57 | * D.3.4 Solution for infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
58 | * D.3.4 Solution for injection in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
59 | * D.3.4 Solution for injection/infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
60 | * D.3.6.2.1 - valore : Every 4 weeks dosing of 200 mg | - | - | - | - | 1件: 41 41 💬 |
61 | * D.3.6.2.1 - valore :Every 4 weeks dosing of 400 mg | - | - | - | - | 1件: 41 41 💬 |
62 | 0.005% Lacripep | - | - | - | - | 1件: 53 53 💬 |
63 | 0.01% Lacripep | - | - | - | - | 1件: 53 53 💬 |
64 | 0.02% Fm, SH | - | - | - | - | 1件: 53 53 💬 |
65 | 0.02% Fm, SH, 0.05% CsA | - | - | - | - | 1件: 53 53 💬 |
66 | 0.02% Fm, SH, AS | - | - | - | - | 1件: 53 53 💬 |
67 | 0.04 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
68 | 0.05%cyclosporin eye drop | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 38 38 💬 |
69 | 0.08 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
70 | 0.12% saline | - | - | - | - | 1件: 299 299 💬 |
71 | 0.15mg KPG-818 dose | - | - | - | - | 1件: 49 49 💬 |
72 | 0.3 mg tropicamide | 1件: Tropicamide Tropicamide | 1件: Tropicamide
Tropicamide
💬 | 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
73 | 0.6 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
74 | 0.6mg KPG-818 dose | - | - | - | - | 1件: 49 49 💬 |
75 | 0.7mL prefilled syringes | - | - | - | - | 1件: 107 107 💬 |
76 | 0.9% Isotonic Saline (IS) | - | - | - | - | 1件: 299 299 💬 |
77 | 0.9% Isotonic Saline (IS), 4mL | - | - | - | - | 1件: 299 299 💬 |
78 | 0.9% normal saline (control) | - | - | - | - | 1件: 299 299 💬 |
79 | 0.9% physiological saline | - | - | - | - | 1件: 266 266 💬 |
80 | 0.9% saline | - | - | - | - | 2件: 6 6, 70 💬 |
81 | 0.9% sodium chloride | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 4件: 6 6, 14, 51, 53 💬 |
82 | 0.9% sodium chloride (normal saline) | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 6 6 💬 |
83 | 0.9% Sodium Chloride Injection | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 168 168 💬 |
84 | 0.9% w/v isotonic sodium chloride solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 50 50 💬 |
85 | 0.9% w/v sodium chloride solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
86 | 009-0 | - | - | - | - | 1件: 6 6 💬 |
87 | 009-1 | - | - | - | - | 1件: 6 6 💬 |
88 | 009-3 | - | - | - | - | 1件: 6 6 💬 |
89 | 0109-0012A 100 mg/ml | - | - | - | - | 1件: 46 46 💬 |
90 | 0109-0012A 25 mg/ml | - | - | - | - | 1件: 46 46 💬 |
91 | 0109-0012A 50 mg/ml | - | - | - | - | 1件: 46 46 💬 |
92 | 0114-0006B | - | - | - | - | 2件: 46 46, 96 💬 |
93 | 1 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
94 | 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
95 | 1 mg/kg CNTO 136 | - | - | - | - | 1件: 49 49 💬 |
96 | 1 ml 0.9 % NaCl | - | - | - | - | 1件: 46 46 💬 |
97 | 1,2-Dihexadecanoyl-sn-Glycero-3-Phospho-(1-raac-glycerol) | 1件: Glycerin Glycerin | 1件: Glycerin
Glycerin
💬 | - | - | 1件: 79 79 💬 |
98 | 1,5 (Butylimino)-1,5-dideoxy-D-glucitol | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 299 299 💬 |
99 | 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c | - | - | - | - | 1件: 46 46 💬 |
100 | 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 58 58 💬 |
101 | 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | 1件: 17 17 💬 |
102 | 1-(6-BENZOTHIAZOLYLSULFONYL)-5-CHLORO-1H-INDOLE-2-BUTANOIC ACID | 2件: Butyric Acid Butyric Acid, Indole | - | - | - | 1件: 51 51 💬 |
103 | 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid | - | - | - | - | 1件: 299 299 💬 |
104 | 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone | - | - | - | - | 1件: 13 13 💬 |
105 | 1.0 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
106 | 1.0 mg rasagiline mesylate | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
107 | 1.0 mg RPC103 | - | - | - | - | 1件: 97 97 💬 |
108 | 1.0 mg RPC1063 | - | - | - | - | 1件: 97 97 💬 |
109 | 1.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
110 | 1.0mg RPC1063 | - | - | - | - | 1件: 13 13 💬 |
111 | 10 mg/kg CNTO 136 | - | - | - | - | 1件: 49 49 💬 |
112 | 10-nitro-9(E)-octadec-9-enoic acid | - | - | - | - | 1件: 86 86 💬 |
113 | 100 mg ELX (VX-445) / 50 mg TEZ / 75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
114 | 100 mg ELX /50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
115 | 100 mg ELX/50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
116 | 100 mg ELX/50 mg TEZ/75 mg IVA fixed dose combination | - | - | - | - | 1件: 299 299 💬 |
117 | 100 mg TEZ/150 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
118 | 100 mg VX-445 /50 mg TEZ/75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
119 | 100 mg VX-445/50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
120 | 100-mg ELX (VX-445) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
121 | 100-mg ELX (VX-455) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
122 | 100-mg ELX / 50-mg TEZ / 75 -mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
123 | 100-mg VX-445 / 50-mg TEZ / 75- mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
124 | 100-mg VX-445 / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
125 | 100-mg VX-445 /50-mg TEZ/75-mg | - | - | - | - | 1件: 299 299 💬 |
126 | 100-mg VX-445/50-mg TEZ/75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
127 | 100g ELX / 50mg TEZ / 75mg IVA | - | - | - | - | 1件: 299 299 💬 |
128 | 100mcg rhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
129 | 100mg ELX/50mg TEZ /75mg IVA | - | - | - | - | 1件: 299 299 💬 |
130 | 100mg VX-445/50mg TEZ /75mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
131 | 11-beta-hydroxysteroid dehydrogenase type 1 | - | - | - | - | 1件: 75 75 💬 |
132 | 11-ß-hydroxysteroid dehydrogenase type 1 | - | - | - | - | 1件: 75 75 💬 |
133 | 118-42-3 | - | - | - | - | 1件: 46 46 💬 |
134 | 11C-BMS-986196 | - | - | - | - | 1件: 13 13 💬 |
135 | 11C]-PK-11195 | - | - | - | - | 1件: 13 13 💬 |
136 | 124I-labeled monoclonal antibody Mu 11-1F4 | - | - | - | - | 1件: 28 28 💬 |
137 | 124I-p5+14 Injection | - | - | - | - | 1件: 28 28 💬 |
138 | 13-15mg/kg/d Ursodeoxycholic | - | - | - | - | 1件: 93 93 💬 |
139 | 13-valent pneumococcal conjugate vaccine (13-PCV) | - | - | - | - | 1件: 13 13 💬 |
140 | 1393641-34-3 | - | - | - | - | 1件: 13 13 💬 |
141 | 14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration | - | - | - | - | 3件: 13 13, 96, 97 💬 |
142 | 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
143 | 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
144 | 15-0 H20 | - | - | - | - | 2件: 6 6, 19 💬 |
145 | 150mg CXA-10 | 1件: CXA-10 CXA-10 | - | - | - | 1件: 86 86 💬 |
146 | 15N ammonium chloride (15NH4Cl) | 2件: Ammonium chloride Ammonium chloride, Chloride ion | 1件: Ammonium chloride
Ammonium chloride
💬 | - | - | 1件: 251 251 💬 |
147 | 1639325-43-1 | - | - | - | - | 1件: 254 254 💬 |
148 | 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione | - | - | - | - | 1件: 41 41 💬 |
149 | 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 💬 |
150 | 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 💬 |
151 | 18-F]DPA-714 | - | - | - | - | 1件: 127 127 💬 |
152 | 18F-AV-133 | 1件: Florbenazine F-18 Florbenazine F-18 | - | - | - | 1件: 6 6 💬 |
153 | 18F-AV-1451 | - | - | - | - | 3件: 5 5, 7, 127 💬 |
154 | 18F-DPA-714 and 18F-FDG | 1件: Fludeoxyglucose (18F) Fludeoxyglucose (18F) | - | - | - | 1件: 13 13 💬 |
155 | 18F-DTBZ AV-133 | - | - | - | - | 1件: 6 6 💬 |
156 | 18F-FTC-146 | - | - | - | - | 1件: 206 206 💬 |
157 | 18F] LBT-999 | - | - | - | - | 1件: 6 6 💬 |
158 | 18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane | - | - | - | - | 1件: 6 6 💬 |
159 | 18F]DPA-714 | - | - | - | - | 2件: 13 13, 127 💬 |
160 | 1[(6- Allyl- 8beta- erg | - | - | - | - | 1件: 6 6 💬 |
161 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 💬 |
162 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 💬 |
163 | 1[(6- Allyl- 8ß- erg | - | - | - | - | 1件: 6 6 💬 |
164 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 💬 |
165 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 💬 |
166 | 2 x 10 mg Natura-alpha capsules | - | - | - | - | 1件: 97 97 💬 |
167 | 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid | 1件: Diflunisal Diflunisal | 1件: Diflunisal
Diflunisal
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 28 28 💬 |
168 | 2,3-dihydroxybutanedioic acid | - | - | - | - | 1件: 299 299 💬 |
169 | 2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide | - | - | - | - | 1件: 6 6 💬 |
170 | 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid | 1件: Benzoic acid Benzoic acid | 1件: Benzoic acid
Benzoic acid
💬 | - | - | 1件: 51 51 💬 |
171 | 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester | 1件: Famciclovir Famciclovir | 1件: Famciclovir
Famciclovir
💬 | - | - | 1件: 13 13 💬 |
172 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylat | - | - | - | - | 1件: 28 28 💬 |
173 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate | - | - | - | - | 1件: 28 28 💬 |
174 | 2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide | - | - | - | - | 1件: 86 86 💬 |
175 | 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE | - | - | - | - | 2件: 6 6, 162 💬 |
176 | 2-amino-4-(methyl[11C]sulfanyl)butanoic acid | 1件: Butyric Acid Butyric Acid | - | - | - | 1件: 34 34 💬 |
177 | 2-deoxy-2 [F-18] fluoro-2-d-glucose | 2件: D-glucose D-glucose, Dextrose, unspecified form | 1件: Glucose
Glucose
💬 | - | - | 1件: 49 49 💬 |
178 | 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide | 1件: Acetamide Acetamide | - | - | - | 1件: 86 86 💬 |
179 | 2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt | 1件: Hydroxide ion Hydroxide ion | - | - | - | 1件: 46 46 💬 |
180 | 2.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
181 | 20 mg BID of PF-02545920 | - | - | - | - | 1件: 8 8 💬 |
182 | 200 mg BIA 6-512 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
183 | 2019171-69-6 | - | - | - | - | 1件: 61 61 💬 |
184 | 207-3120 | - | - | - | - | 1件: 6 6 💬 |
185 | 20mg/0.5ml GA | - | - | - | - | 1件: 13 13 💬 |
186 | 20mg/0.5ml glatiramer acetate | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
187 | 225mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 💬 |
188 | 25 mg BIA9 1067 | - | - | - | - | 1件: 6 6 💬 |
189 | 25mcg rhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
190 | 29180.00.00, 34681.00.00, 34681.01.00, 34681.02.00 | - | - | - | - | 1件: 113 113 💬 |
191 | 3 mg [14C]-A4250 capsule | - | - | - | - | 3件: 93 93, 297, 338 💬 |
192 | 3 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
193 | 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
194 | 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate | - | - | - | - | 1件: 6 6 💬 |
195 | 3-(3,4-Dihydroxyphenyl)-L-alanine | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 6 6 💬 |
196 | 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID | 1件: Pyrazole Pyrazole | - | - | - | 1件: 28 28 💬 |
197 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- | - | - | - | - | 1件: 93 93 💬 |
198 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic acid | - | - | - | - | 1件: 93 93 💬 |
199 | 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt | - | - | - | - | 2件: 51 51, 85 💬 |
200 | 3-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1), Ferric (3-hydroxy-2-methyl-4-pyrone), Tris-maltol-iron (III), Tri=maltol-iron (III) | 1件: Tromethamine Tromethamine | 1件: Tromethamine
Tromethamine
💬 | - | - | 2件: 96 96, 97 💬 |
201 | 3-methyl-1-phenyl-4, 5-dihydro-1H-pyrazol-5-one. | 1件: Pyrazole Pyrazole | - | - | - | 1件: 2 2 💬 |
202 | 30 or 60 mg | - | - | - | - | 1件: 67 67 💬 |
203 | 30 or 90 mg | - | - | - | - | 1件: 67 67 💬 |
204 | 331731-18-1 | - | - | - | - | 4件: 46 46, 96, 97, 271 💬 |
205 | 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-oic acid | - | - | - | - | 1件: 93 93 💬 |
206 | 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-oic acid | - | - | - | - | 1件: 93 93 💬 |
207 | 4 cholesten-3-one, oxime | - | - | - | - | 1件: 2 2 💬 |
208 | 4 mg/kg CNTO 136 | - | - | - | - | 1件: 49 49 💬 |
209 | 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base | 1件: Methane Methane | - | - | - | 1件: 2 2 💬 |
210 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzenesulfonamide | 1件: Pyrazole Pyrazole | - | - | - | 1件: 46 46 💬 |
211 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide | 1件: Pyrazole Pyrazole | - | - | - | 1件: 46 46 💬 |
212 | 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 5 5 💬 |
213 | 4-Benzyl-2-naphthalen-1-yl-1,2,4- thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 💬 |
214 | 4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 💬 |
215 | 4-cholesten-3-one, oxime | - | - | - | - | 2件: 2 2, 3 💬 |
216 | 4-cholesten-3-one,oxime | - | - | - | - | 1件: 3 3 💬 |
217 | 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide | - | - | - | - | 1件: 46 46 💬 |
218 | 40 MG- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL | - | - | - | - | 1件: 107 107 💬 |
219 | 400 mg BIA 5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 💬 |
220 | 44/154/85-C | - | - | - | - | 1件: 50 50 💬 |
221 | 44/196/81-C | - | - | - | - | 1件: 50 50 💬 |
222 | 4D-125 IVT Injection | - | - | - | - | 1件: 90 90 💬 |
223 | 4D-310 | - | - | - | - | 1件: 19 19 💬 |
224 | 4D-710 | - | - | - | - | 1件: 299 299 💬 |
225 | 5% lidocaine/5 mg/ml 0.02% estradiol compound cream | 2件: Estradiol Estradiol, Lidocaine | 3件: Estradiol
Estradiol
,
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 7件: ESR1 ESR1, ESR2, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 13件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Breast cancer, Chemical carcinogenesis - receptor activation, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway 💬 | 1件: 226 226 💬 |
226 | 5,6,7,8-tetrahydrobiopterin | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
227 | 5-[4-[2-(5-(1-hydroxyethyl)-2- pyridinyl)ethoxy]benzyl]-2,4- thiazolidinedione hydrochloride | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
228 | 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
229 | 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]METHYL]-2,4-THIAZOLIDINEDIONE HYDROCHLORIDE | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
230 | 5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin | 1件: Chlorine Chlorine | - | - | - | 2件: 46 46, 271 💬 |
231 | 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium | - | - | - | - | 1件: 8 8 💬 |
232 | 5-Methyl-1-Phenyl-2-1-(H)-Pyridone | - | - | - | - | 1件: 228 228 💬 |
233 | 50 mg BIA 9 1067 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
234 | 50 mg ELX/25 mg TEZ/37.5 mg IVA | - | - | - | - | 1件: 299 299 💬 |
235 | 50 mg ELX/25 mg TEZ/37.5 mg IVA fixed dose combination | - | - | - | - | 1件: 299 299 💬 |
236 | 500 0500 0 | - | - | - | - | 1件: 19 19 💬 |
237 | 50mcg rhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
238 | 52069.00.01 | - | - | - | - | 1件: 13 13 💬 |
239 | 534-1508 | - | - | - | - | 1件: 85 85 💬 |
240 | 549-0261/F02-01 | - | - | - | - | 2件: 96 96, 97 💬 |
241 | 552-02 | - | - | - | - | 2件: 53 53, 299 💬 |
242 | 56/104/75-C | - | - | - | - | 1件: 50 50 💬 |
243 | 6 alpha-ethylchenodeoxycholic acid (6-EDCA), OCA, INT-747 | - | - | - | - | 1件: 93 93 💬 |
244 | 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine | - | - | - | - | 1件: 38 38 💬 |
245 | 6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate | - | - | - | - | 1件: 46 46 💬 |
246 | 6-[(methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine | - | - | - | - | 1件: 96 96 💬 |
247 | 6-[18F]Fluorodopa | - | - | - | - | 1件: 6 6 💬 |
248 | 6-[18F]Fluorodopamine | - | - | - | - | 1件: 6 6 💬 |
249 | 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid | - | - | - | - | 1件: 97 97 💬 |
250 | 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one | - | - | - | - | 1件: 2 2 💬 |
251 | 6036937.00.01 | - | - | - | - | 1件: 6 6 💬 |
252 | 66215-101 | - | - | - | - | 1件: 86 86 💬 |
253 | 6?-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747 | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
254 | 6a-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747 | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
255 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
256 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
257 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
258 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
259 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
260 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
261 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
262 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
263 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
264 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
265 | 6abeta - apomorphine-10,11-diol hydrochloride hemihydrate | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
266 | 6aß - apomorphine-10,11-diol hydrochloride hemihydrate | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
267 | 7 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
268 | 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
269 | 70930.00.00 | - | - | - | - | 1件: 46 46 💬 |
270 | 750 mg metformin and 7.5 g L-citrulline daily p.o. | 2件: Citrulline Citrulline, Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 113 113 💬 |
271 | 75mg CXA-10 | 1件: CXA-10 CXA-10 | - | - | - | 1件: 86 86 💬 |
272 | 75mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 💬 |
273 | 80 mg DR-6MP | - | - | - | - | 1件: 96 96 💬 |
274 | 800 mg ibuprofen/26.6 mg famotidine | 2件: Famotidine Famotidine, Ibuprofen | 2件: Ibuprofen
Ibuprofen
,
Famotidine
💬 | 3件: HRH2 HRH2, PTGS1, PTGS2 💬 | 26件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Calcium signaling pathway, Chemical carcinogenesis - DNA adducts, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 107 107 💬 |
275 | 80mg ELX / 40mg TEZ / 60mg IVA | - | - | - | - | 1件: 299 299 💬 |
276 | 89Zr-SBC-103 | - | - | - | - | 1件: 19 19 💬 |
277 | 9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxaline | - | - | - | - | 1件: 46 46 💬 |
278 | 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER | 1件: Linoleic acid Linoleic acid | - | - | - | 2件: 2 2, 5 💬 |
279 | 98-92-0 | - | - | - | - | 1件: 107 107 💬 |
280 | 99mTc-3PRGD2 | - | - | - | - | 1件: 46 46 💬 |
281 | 99mTc-rhAnnexin V-128 | - | - | - | - | 2件: 46 46, 271 💬 |
282 | : 2-{4-[(5,6-difenilpirazin-2-yl)(isopropil)amino]butoxi}-N- | - | - | - | - | 1件: 86 86 💬 |
283 | : immunoglobulina umana normale 10% per somministrazione endovenosa | - | - | - | - | 1件: 14 14 💬 |
284 | ?-3 polyunsaturated fatty acid | - | - | - | - | 1件: 96 96 💬 |
285 | [11C]-GSK2256098 500 MBq | 1件: GSK2256098 GSK2256098 | - | - | - | 1件: 86 86 💬 |
286 | [11C]-PIB | - | - | - | - | 1件: 6 6 💬 |
287 | [11C]MPC6827 | - | - | - | - | 1件: 2 2 💬 |
288 | [11C]PXT012253 | - | - | - | - | 1件: 6 6 💬 |
289 | [123I] 5-IA | - | - | - | - | 1件: 6 6 💬 |
290 | [123I] IBVM and SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
291 | [123I] mZINT injection and serial dynamic SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
292 | [123I]-IBVM | - | - | - | - | 1件: 6 6 💬 |
293 | [123I]B-CIT | - | - | - | - | 1件: 6 6 💬 |
294 | [123I]B-CIT SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
295 | [123I]beta CIT | - | - | - | - | 1件: 6 6 💬 |
296 | [123I]beta CIT and SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
297 | [123I]beta-CIT | - | - | - | - | 1件: 6 6 💬 |
298 | [123I]beta-CIT and SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
299 | [123I]CLINDE | - | - | - | - | 2件: 6 6, 13 💬 |
300 | [123I]MNI-420 | - | - | - | - | 2件: 6 6, 8 💬 |
301 | [123I]ß CIT | - | - | - | - | 1件: 6 6 💬 |
302 | [123I]ß CIT and SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
303 | [123I]ß-CIT | - | - | - | - | 1件: 6 6 💬 |
304 | [123I]ß-CIT and SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
305 | [124I]IB PF 06687234 | - | - | - | - | 2件: 96 96, 97 💬 |
306 | [14C] AT1001 | - | - | - | - | 1件: 19 19 💬 |
307 | [14C]-BIA 9-1067 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
308 | [15-O]water | 1件: Water Water | 1件: Water
Water
💬 | - | - | 1件: 206 206 💬 |
309 | [18F] CFPyPB | - | - | - | - | 1件: 6 6 💬 |
310 | [18F] FES | - | - | - | - | 1件: 86 86 💬 |
311 | [18F] GE-180 | - | - | - | - | 1件: 2 2 💬 |
312 | [18F] LBT-999 PET | - | - | - | - | 1件: 6 6 💬 |
313 | [18F] PBR06 | - | - | - | - | 2件: 6 6, 13 💬 |
314 | [18F] PI-2620 | - | - | - | - | 1件: 6 6 💬 |
315 | [18F]-FBA-A20FMDV2 | - | - | - | - | 1件: 85 85 💬 |
316 | [18F]-FEPPA | - | - | - | - | 2件: 6 6, 13 💬 |
317 | [18F]-FLT-PET/CT scans | - | - | - | - | 1件: 34 34 💬 |
318 | [18F]-PI2620 | - | - | - | - | 1件: 5 5 💬 |
319 | [18F]DPA-714 PET | - | - | - | - | 1件: 2 2 💬 |
320 | [18F]DPA-714 PET scan | - | - | - | - | 1件: 6 6 💬 |
321 | [18F]FDOPA | - | - | - | - | 2件: 6 6, 17 💬 |
322 | [18F]FDOPA PET/CT | - | - | - | - | 1件: 6 6 💬 |
323 | [18F]Florbetaben | - | - | - | - | 1件: 28 28 💬 |
324 | [18F]Florbetapir | - | - | - | - | 1件: 5 5 💬 |
325 | [18F]Florbetapir PET imaging | - | - | - | - | 1件: 13 13 💬 |
326 | [18F]flumazenil | 1件: Flumazenil Flumazenil | 1件: Flumazenil
Flumazenil
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 206 206 💬 |
327 | [18F]Fluoro-2-deoxy-2-D-glucose | 2件: D-glucose D-glucose, Dextrose, unspecified form | 1件: Glucose
Glucose
💬 | - | - | 2件: 86 86, 88 💬 |
328 | [18F]FP-R01-MG-F2 | - | - | - | - | 2件: 85 85, 94 💬 |
329 | [18F]FPEB | - | - | - | - | 3件: 6 6, 8, 206 💬 |
330 | [18F]FPEB PET imaging | - | - | - | - | 1件: 206 206 💬 |
331 | [18F]FSPG | - | - | - | - | 2件: 96 96, 97 💬 |
332 | [18F]MK-9470 | - | - | - | - | 1件: 6 6 💬 |
333 | [18F]MNI-1126 | - | - | - | - | 1件: 6 6 💬 |
334 | [18F]MNI-815 (MNI-815) | - | - | - | - | 1件: 5 5 💬 |
335 | [18F]MNI-952 | - | - | - | - | 1件: 5 5 💬 |
336 | [18F]MNI-958 | - | - | - | - | 1件: 5 5 💬 |
337 | [18F]MPPF | - | - | - | - | 1件: 6 6 💬 |
338 | [18F]P17-059 | - | - | - | - | 1件: 6 6 💬 |
339 | [18F]PBR06 | - | - | - | - | 1件: 2 2 💬 |
340 | [18F]PI-2620 | - | - | - | - | 2件: 6 6, 127 💬 |
341 | [18F]T807 ([18F]MNI-777) | - | - | - | - | 2件: 5 5, 6 💬 |
342 | [18F]UCB-2897 | - | - | - | - | 1件: 6 6 💬 |
343 | [21CFR640.30] Plasma from 18 - 25 year old volunteer donors | - | - | - | - | 1件: 6 6 💬 |
344 | [68Ga]CBP8 | - | - | - | - | 1件: 85 85 💬 |
345 | [68Ga]Ga-PentixaFor PET/CT | - | - | - | - | 1件: 84 84 💬 |
346 | [C-11]Methylreboxetine | - | - | - | - | 1件: 13 13 💬 |
347 | [C-11]PBR28 | - | - | - | - | 1件: 13 13 💬 |
348 | [C11]PK-1195 PET scan | - | - | - | - | 1件: 13 13 💬 |
349 | [F-18]PBR06 | - | - | - | - | 1件: 13 13 💬 |
350 | [F-18]SDM-8 | - | - | - | - | 1件: 13 13 💬 |
351 | A fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine | 3件: Clarithromycin Clarithromycin, Clofazimine, Rifabutin | 3件: Clarithromycin
Clarithromycin
,
Clofazimine
,
Rifabutin
💬 | - | - | 1件: 96 96 💬 |
352 | A novel synthetic, orally-administered, non-peptide small molecule, which acts as an agonist of the melanocortin-1 receptor (MC1R) | - | - | - | - | 1件: 51 51 💬 |
353 | A-1293543.74 | - | - | - | - | 1件: 96 96 💬 |
354 | A-623 | - | - | - | - | 1件: 49 49 💬 |
355 | A-623 or AMG 623 | - | - | - | - | 1件: 66 66 💬 |
356 | A-glucosidasi acida umana ricombinante coniugata con multiple copie di bis-mannosio-6- fosfato-tetra-mannosio glicano sintetico (NEOGAA) | 1件: Avalglucosidase alfa Avalglucosidase alfa | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
357 | A4250 (1200 µg) | - | - | - | - | 1件: 338 338 💬 |
358 | A4250 (600 µg) | - | - | - | - | 1件: 338 338 💬 |
359 | A4250-015 | - | - | - | - | 1件: 297 297 💬 |
360 | A: 1 dosis | - | - | - | - | 1件: 97 97 💬 |
361 | A: PTH (1-84) | - | - | - | - | 1件: 235 235 💬 |
362 | AAV BBP-631 | - | - | - | - | 1件: 81 81 💬 |
363 | AAV-GAD Dose 1 | - | - | - | - | 1件: 6 6 💬 |
364 | AAV2CUhCLN2 (3x10^12 particle units) | - | - | - | - | 1件: 19 19 💬 |
365 | AAVrh.10-hMPSIIIA | - | - | - | - | 1件: 19 19 💬 |
366 | AAVrh.10cuARSA | - | - | - | - | 1件: 19 19 💬 |
367 | AAVrh.10CUCLN2 | - | - | - | - | 1件: 19 19 💬 |
368 | AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies | - | - | - | - | 1件: 19 19 💬 |
369 | AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies | - | - | - | - | 1件: 19 19 💬 |
370 | AB 1003 | - | - | - | - | 1件: 2 2 💬 |
371 | AB-1001 Gene Therapy | - | - | - | - | 1件: 8 8 💬 |
372 | Abacavir 300mg twice daily | 1件: Abacavir Abacavir | 1件: Abacavir
Abacavir
💬 | - | - | 1件: 265 265 💬 |
373 | Abatacept (BMS-188667) | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
374 | ABBV-006 | - | - | - | - | 1件: 97 97 💬 |
375 | ABBV-066 | - | - | - | - | 2件: 96 96, 97 💬 |
376 | ABBV-0805 | - | - | - | - | 1件: 6 6 💬 |
377 | ABBV-105 | - | - | - | - | 2件: 46 46, 49 💬 |
378 | ABBV-105, A-1519938.0 | - | - | - | - | 1件: 46 46 💬 |
379 | ABBV-119 | - | - | - | - | 1件: 299 299 💬 |
380 | ABBV-154 | - | - | - | - | 2件: 46 46, 96 💬 |
381 | ABBV-3067 | - | - | - | - | 1件: 299 299 💬 |
382 | ABBV-323 | - | - | - | - | 2件: 53 53, 97 💬 |
383 | ABBV-323 Dose A | - | - | - | - | 1件: 97 97 💬 |
384 | ABBV-323 Dose B | - | - | - | - | 1件: 97 97 💬 |
385 | ABBV-3373 | - | - | - | - | 1件: 46 46 💬 |
386 | ABBV-668 | - | - | - | - | 1件: 97 97 💬 |
387 | ABBV-951 | - | - | - | - | 1件: 6 6 💬 |
388 | ABBV-CLS-7262 | - | - | - | - | 1件: 2 2 💬 |
389 | ABC/DTG/3TC STR - Tablet | - | - | - | - | 1件: 256 256 💬 |
390 | Abetimus sodium (LJP 394) | 1件: Abetimus Abetimus | - | - | - | 1件: 49 49 💬 |
391 | AbGn-168H | - | - | - | - | 1件: 97 97 💬 |
392 | Abituzumab 1500 mg | 1件: Abituzumab Abituzumab | - | - | - | 1件: 51 51 💬 |
393 | ABO-101 | - | - | - | - | 1件: 19 19 💬 |
394 | ABO-102 | - | - | - | - | 1件: 19 19 💬 |
395 | ABP 710 | - | - | - | - | 1件: 46 46 💬 |
396 | ABP 710 - Biosimilar to infliximab | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
397 | ABP 798 | - | - | - | - | 1件: 46 46 💬 |
398 | ABP 798 - Biosimilar to rituximab | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
399 | ABP 798 Biosimilar to Rituximab | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
400 | ABP 959 | - | - | - | - | 1件: 62 62 💬 |
401 | ABP 959 - biosimilar to eculizumab | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
402 | ABP 959 - proposed biosimilar to eculizumab | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
403 | ABT 494 12mg | - | - | - | - | 2件: 46 46, 96 💬 |
404 | ABT 494 3mg | - | - | - | - | 2件: 46 46, 96 💬 |
405 | ABT-122 | - | - | - | - | 1件: 46 46 💬 |
406 | ABT-199 | - | - | - | - | 1件: 49 49 💬 |
407 | ABT-494 15mg | - | - | - | - | 1件: 46 46 💬 |
408 | ABT-494 30mg | - | - | - | - | 1件: 46 46 💬 |
409 | ABT-874/Human monoclonal antibody against IL-12 | - | - | - | - | 1件: 13 13 💬 |
410 | ABX-1431 | 1件: ABX-1431 ABX-1431 | - | - | - | 1件: 13 13 💬 |
411 | ABX-1431 HCl | 1件: ABX-1431 ABX-1431 | - | - | - | 1件: 13 13 💬 |
412 | ABX464 100mg | - | - | - | - | 2件: 46 46, 97 💬 |
413 | ABY-035 | - | - | - | - | 1件: 271 271 💬 |
414 | AC-203 1% Topical Ointment | - | - | - | - | 1件: 162 162 💬 |
415 | Accelerated 1 hour-infusion | - | - | - | - | 2件: 96 96, 97 💬 |
416 | Accelerated 30 minutes-infusion | - | - | - | - | 2件: 96 96, 97 💬 |
417 | ACE-011 | - | - | - | - | 1件: 86 86 💬 |
418 | ACE-011 / MK - 7962 | - | - | - | - | 1件: 86 86 💬 |
419 | ACE-011 / MK-7962 | - | - | - | - | 1件: 86 86 💬 |
420 | ACE-011/ MK-7962 | - | - | - | - | 1件: 86 86 💬 |
421 | ACE-031 (Extension of cohort 1 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
422 | ACE-031 (Extension of cohort 2 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
423 | ACE-031 (Extension of cohort 3 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
424 | ACE-031 0.5 mg/kg q4wk | - | - | - | - | 1件: 113 113 💬 |
425 | ACE-031 1.0 mg/kg q2wk | - | - | - | - | 1件: 113 113 💬 |
426 | ACE-083 | - | - | - | - | 2件: 10 10, 113 💬 |
427 | ACER-002 (celiprolol) 200 mg BID | 1件: Celiprolol Celiprolol | 1件: Celiprolol
Celiprolol
💬 | 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 168 168 💬 |
428 | Acetaminophen Tablet 650mg | 1件: Acetaminophen Acetaminophen | 1件: Acetaminophen
Acetaminophen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
429 | Acetyl-L-carnitine 1000mg 2X per day for 3 months | 2件: Acetylcarnitine Acetylcarnitine, Levocarnitine | 1件: Levocarnitine
Levocarnitine
💬 | - | - | 1件: 298 298 💬 |
430 | Acetylsalicylic acid at 1st visit, | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: Aspirin
Aspirin
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
431 | ACH-0144471 | - | - | - | - | 2件: 62 62, 222 💬 |
432 | ACH-0144471 compresse | - | - | - | - | 1件: 222 222 💬 |
433 | ACH-0145228 | - | - | - | - | 1件: 62 62 💬 |
434 | ACHIM as solute (10^9 intestinal microbes/ml) | - | - | - | - | 1件: 51 51 💬 |
435 | ACIDE TRANEXAMIQUE MYLAN 0,5 g/ 5 mL, solution injectable | - | - | - | - | 1件: 299 299 💬 |
436 | Acoziborole (SCYX-7158) | 1件: Acoziborole Acoziborole | - | - | - | 1件: 65 65 💬 |
437 | ACP-001 | - | - | - | - | 1件: 78 78 💬 |
438 | ACP-001 (TransCon hGH) | - | - | - | - | 1件: 78 78 💬 |
439 | ACP-011 | - | - | - | - | 1件: 78 78 💬 |
440 | ACP-103 | - | - | - | - | 1件: 6 6 💬 |
441 | ACR16 10 mg | - | - | - | - | 1件: 8 8 💬 |
442 | ACT - 064992 | - | - | - | - | 1件: 86 86 💬 |
443 | ACT-050089 | - | - | - | - | 1件: 86 86 💬 |
444 | ACT-050089 (Ro 61-0612) | - | - | - | - | 1件: 86 86 💬 |
445 | ACT-064992 | - | - | - | - | 5件: 51 51, 85, 86, 88, 210 💬 |
446 | ACT-064992 (macitentan) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 💬 |
447 | ACT-064992 / JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
448 | ACT-064992/ JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
449 | ACT-064992D | - | - | - | - | 1件: 86 86 💬 |
450 | ACT-1 | - | - | - | - | 1件: 13 13 💬 |
451 | ACT-128800 | - | - | - | - | 1件: 13 13 💬 |
452 | ACT-128800 Dose 1 | - | - | - | - | 1件: 13 13 💬 |
453 | ACT-128800 Dose 2 | - | - | - | - | 1件: 13 13 💬 |
454 | ACT-128800 Dose 3 | - | - | - | - | 1件: 13 13 💬 |
455 | ACT-178418 | - | - | - | - | 1件: 86 86 💬 |
456 | ACT-293987 (NS-304) | - | - | - | - | 1件: 86 86 💬 |
457 | ACT-293987 / JNJ-67896049 | - | - | - | - | 1件: 84 84 💬 |
458 | ACT-334441 | - | - | - | - | 1件: 49 49 💬 |
459 | ACT-385781A | - | - | - | - | 1件: 86 86 💬 |
460 | ACT-385781A (Actelion Epoprostenol) | 1件: Epoprostenol Epoprostenol | 1件: Epoprostenol
Epoprostenol
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
461 | ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 2件: 61 61, 62 💬 |
462 | ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 2件: 62 62, 66 💬 |
463 | Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. | - | - | - | - | 1件: 276 276 💬 |
464 | Active drug (BIIB014) at 10, 30, 100, or 300 mg once daily. | - | - | - | - | 1件: 6 6 💬 |
465 | Active drug: pimavanserin 17mg (2 strength tablets) | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 💬 |
466 | Active Investigational Treatment ENT-01 | - | - | - | - | 1件: 6 6 💬 |
467 | Active topical NS2 1% dermatologic cream | - | - | - | - | 1件: 160 160 💬 |
468 | Active Treatment Group 7% Hypertonic Saline | - | - | - | - | 1件: 299 299 💬 |
469 | Actonel Once a Week 35 mg film-coated tablets | 1件: Risedronic acid Risedronic acid | 1件: Risedronic acid
Risedronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
470 | Actos 15 mg | 1件: Pioglitazone Pioglitazone | 1件: Pioglitazone
Pioglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 2 2 💬 |
471 | Actos 30 mg | 1件: Pioglitazone Pioglitazone | 1件: Pioglitazone
Pioglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 2 2 💬 |
472 | Actrapid 100 IU/ml, Solution for injection in a vial | - | - | - | - | 1件: 299 299 💬 |
473 | Actrapid Penfill 100UI/ml | - | - | - | - | 1件: 299 299 💬 |
474 | ACTUS-101 | - | - | - | - | 1件: 256 256 💬 |
475 | ACZ885 150 mg (Canakinumab) | 1件: Canakinumab Canakinumab | 1件: Canakinumab
Canakinumab
💬 | 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 107 107 💬 |
476 | ACZ885, 150mg/1.0ml | - | - | - | - | 2件: 266 266, 267 💬 |
477 | AD 452 18 mg tablet | - | - | - | - | 1件: 46 46 💬 |
478 | AD 452 9 mg tablet | - | - | - | - | 1件: 46 46 💬 |
479 | Ad26.COV2-S.02 | - | - | - | - | 1件: 299 299 💬 |
480 | Adalimumab (up to 9 months exposure) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
481 | Adalimumab, Solution for Injection 40 mg/ (0.8 ml) Pre-filled Syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
482 | Adderall XR 10 mg | - | - | - | - | 1件: 13 13 💬 |
483 | ADEMPAS - 0,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
484 | ADEMPAS - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
485 | ADEMPAS - 1,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
486 | Adempas 0.125 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
487 | Adempas 0.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
488 | Adempas 0.5 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
489 | Adempas 1 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
490 | Adempas 1.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
491 | Adempas 1.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
492 | Adempas 1.5 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
493 | Adempas 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
494 | Adempas® 0.5 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
495 | Adempas® 1.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
496 | Adempas® 1.5 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
497 | Adempas® 2.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
498 | Adempas¿ 0.5 mg compressa rivestita con film | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
499 | Adempas¿ 1.0 | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
500 | Adempas¿ 1.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
501 | Adempas¿ 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
502 | Adeno-associated viral vector serotype 3B encoding shortened human ATP7B | - | - | - | - | 1件: 171 171 💬 |
503 | Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene | - | - | - | - | 1件: 113 113 💬 |
504 | Adeno-associated viral vector serotype 9 containing the human N-acetyl-alpha-glucosaminidase gene | - | - | - | - | 1件: 19 19 💬 |
505 | Adeno-associated viral vector serotype 9 encoding human ATP7B | - | - | - | - | 1件: 171 171 💬 |
506 | Adeno-associated virus (AAV) serotype rh.10 expressing human betagalactosidase (AAVrh.10-CAG-betagal) | - | - | - | - | 1件: 19 19 💬 |
507 | Adeno-associated virus (AAV) serotype rh.10 expressing human betagalactosidase (AAVrh.10-CAG-ßgal) | - | - | - | - | 1件: 19 19 💬 |
508 | Adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA | 1件: Agalsidase alfa Agalsidase alfa | 1件: Agalsidase alfa
Agalsidase alfa
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
509 | Adeno-associated virus serotype 2/6 encoding Human Iduronate 2-sulfatase (hIDS) gene donor vector, SB-A6P-HNT Donor Vector | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
510 | Adeno-associated virus serotype 2/6 encoding human iduronidase (hIDUA) gene donor vector, SB-A6P-HRL Donor Vector | - | - | - | - | 1件: 19 19 💬 |
511 | Adeno-associated virus serotype 2/6 encoding Left side-zinc finger nuclease (ZFN1), SB-A6P-ZLEFT Vector | - | - | - | - | 1件: 19 19 💬 |
512 | Adeno-associated virus serotype 2/6 encoding Right side-zinc finger nuclease (ZFN2), SB-A6P-ZRIGHT Vector | - | - | - | - | 1件: 19 19 💬 |
513 | Adeno-associated virus serotype 9 carrying the human fukutin-related protein and target sequence of the miR-208a | - | - | - | - | 1件: 113 113 💬 |
514 | Adeno-associated virus serotype rh.10 expressing beta-galactosidase | 1件: Tilactase Tilactase | 1件: Lactase
Lactase
💬 | - | - | 1件: 19 19 💬 |
515 | Adeno-associated virus type 2 vector encoding Rab escort protein 1 | - | - | - | - | 1件: 90 90 💬 |
516 | Administration of drug (Interferon-gamma 1-b) subcutaneously | - | - | - | - | 1件: 65 65 💬 |
517 | ADS-001 | - | - | - | - | 1件: 231 231 💬 |
518 | ADS-5102, 137 mg | - | - | - | - | 1件: 13 13 💬 |
519 | Advagraf 0,5mg | 1件: Tacrolimus Tacrolimus | 2件: Tacrolimus
Tacrolimus
,
Tacrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
520 | Advagraf 1mg | 1件: Tacrolimus Tacrolimus | 2件: Tacrolimus
Tacrolimus
,
Tacrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
521 | ADVATE 1000 IU powder and solvent for solution for injection | 1件: Antihemophilic factor, human recombinant Antihemophilic factor, human recombinant | - | - | - | 1件: 288 288 💬 |
522 | ADVATE 1000IU powder and solvent for solution for injection | 1件: Antihemophilic factor, human recombinant Antihemophilic factor, human recombinant | - | - | - | 1件: 288 288 💬 |
523 | Adverse Reactions of Gammagard subcutaneously at Week 12 | - | - | - | - | 1件: 65 65 💬 |
524 | Adverse Reactions of Gammagard subcutaneously at Week 36 | - | - | - | - | 1件: 65 65 💬 |
525 | Adverse Reactions of Gammagard subdermally at Week 12 | - | - | - | - | 1件: 65 65 💬 |
526 | Adverse Reactions of Gammagard subdermally at Week 36 | - | - | - | - | 1件: 65 65 💬 |
527 | ADVM-043 | - | - | - | - | 1件: 231 231 💬 |
528 | ADX-102 1% Topical Dermal Cream (reproxalap) | 1件: Reproxalap Reproxalap | 1件: Reproxalap
Reproxalap
💬 | - | - | 1件: 160 160 💬 |
529 | ADX-629 | - | - | - | - | 1件: 160 160 💬 |
530 | AEGR-733 | - | - | - | - | 1件: 79 79 💬 |
531 | AER-901 Solution for Nebulization | - | - | - | - | 1件: 86 86 💬 |
532 | Aerolised Liposomal Ciclosporin A 10mg | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 💬 |
533 | Aerosolized human Alpha-1 Antitrypsin | - | - | - | - | 1件: 231 231 💬 |
534 | Aerosolized, human, plasma-derived Alpha-1 Antitrypsin | - | - | - | - | 1件: 299 299 💬 |
535 | AEZS-130 | - | - | - | - | 1件: 78 78 💬 |
536 | AEZS-130 (formerly ARD-07) | - | - | - | - | 1件: 78 78 💬 |
537 | Afamelanotide (16 mg implant) | 1件: Afamelanotide Afamelanotide | 1件: Afamelanotide
Afamelanotide
💬 | 1件: MC1R MC1R 💬 | 2件: Melanogenesis Melanogenesis, Neuroactive ligand-receptor interaction 💬 | 1件: 159 159 💬 |
538 | Afimetoran (10mg) | 1件: Afimetoran Afimetoran | 1件: Afimetoran
Afimetoran
💬 | - | - | 1件: 49 49 💬 |
539 | Agalsidase beta from Biosidus 1 mg/kg | 1件: Agalsidase beta Agalsidase beta | 1件: Agalsidase beta
Agalsidase beta
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
540 | AGLE 102 | - | - | - | - | 1件: 36 36 💬 |
541 | AGM 719 | - | - | - | - | 1件: 46 46 💬 |
542 | AGS-009 | - | - | - | - | 1件: 49 49 💬 |
543 | AGT-181 | - | - | - | - | 1件: 19 19 💬 |
544 | AGT-181 (HIRMAb-IDUA) | - | - | - | - | 1件: 19 19 💬 |
545 | AGT-182 | - | - | - | - | 1件: 19 19 💬 |
546 | AIN457, 150 mg | - | - | - | - | 1件: 271 271 💬 |
547 | AIN457, 150mg | - | - | - | - | 1件: 37 37 💬 |
548 | AIN457, 75 mg | - | - | - | - | 1件: 271 271 💬 |
549 | AK106-001616 | 1件: AK106-001616 AK106-001616 | - | - | - | 1件: 46 46 💬 |
550 | AKBM-3031 | - | - | - | - | 1件: 49 49 💬 |
551 | AL-108 | - | - | - | - | 1件: 5 5 💬 |
552 | ALD518 monoclonal antibody (anti IL-6 mAb) | - | - | - | - | 1件: 46 46 💬 |
553 | ALDURAZYME*INFUS 1FL 5ML 500U | 1件: Laronidase Laronidase | 1件: Laronidase
Laronidase
💬 | 1件: IDUA IDUA 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
554 | Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994 | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 46 46 💬 |
555 | Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994) | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 46 46 💬 |
556 | Alemtuzumab 0.2 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
557 | Alemtuzumab 0.3 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
558 | Alemtuzumab 12 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 13 13 💬 |
559 | Alendronate versus alfacalcidol (1-alpha OH vitamin D) | 3件: Alendronic acid Alendronic acid, Alfacalcidol, Vitamin D | 2件: Alfacalcidol
Alfacalcidol
,
Alendronic acid
💬 | 2件: FDPS FDPS, VDR 💬 | 9件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Terpenoid backbone biosynthesis, Tuberculosis 💬 | 3件: 41 41, 46, 50 💬 |
560 | ALK-001 | - | - | - | - | 1件: 301 301 💬 |
561 | ALK-001 (No generic name) | - | - | - | - | 1件: 301 301 💬 |
562 | All subjects will receive maraviroc 300mg orally twice a day for 6 weeks | 1件: Maraviroc Maraviroc | 1件: Maraviroc
Maraviroc
💬 | 1件: CCR5 CCR5 💬 | 11件: Chemokine signaling pathway Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 84 84 💬 |
563 | All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-P-thioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidine | - | - | - | - | 1件: 2 2 💬 |
564 | All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-Pthioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy- | - | - | - | - | 1件: 2 2 💬 |
565 | Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
566 | Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
567 | Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
568 | Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
569 | Allogeneic Cardiosphere-Derived Cells (CAP-1002) | 1件: CAP-1002 CAP-1002 | - | - | - | 1件: 113 113 💬 |
570 | Allopurinol Sandoz 100 mg, tabletten | 1件: Allopurinol Allopurinol | 1件: Allopurinol
Allopurinol
💬 | 1件: XDH XDH 💬 | 6件: Caffeine metabolism Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Peroxisome, Purine metabolism 💬 | 1件: 96 96 💬 |
571 | ALN-60212 | - | - | - | - | 1件: 79 79 💬 |
572 | ALN-60519 | - | - | - | - | 1件: 254 254 💬 |
573 | ALN-61444 | - | - | - | - | 1件: 231 231 💬 |
574 | ALN-62643 | - | - | - | - | 2件: 62 62, 109 💬 |
575 | ALN-65585 | - | - | - | - | 1件: 234 234 💬 |
576 | ALN-77412 | - | - | - | - | 1件: 231 231 💬 |
577 | Alpha 1-Proteinase Inhibitor | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
578 | Alpha 1-proteinase inhibitor (human) | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
579 | Alpha-1 Antitrypsin (AAT) | - | - | - | - | 1件: 231 231 💬 |
580 | Alpha-1 Antitrypsin (human) | - | - | - | - | 1件: 231 231 💬 |
581 | Alpha-1 HC 100 mg | - | - | - | - | 1件: 299 299 💬 |
582 | Alpha-1 HC 200 mg | - | - | - | - | 1件: 299 299 💬 |
583 | Alpha-1 MP | - | - | - | - | 1件: 231 231 💬 |
584 | Alpha-1 proteinase inhibitor (human) | - | - | - | - | 1件: 231 231 💬 |
585 | ALPHA-1-ANTITRYPSIN | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
586 | Alphanate 1000 I.U. | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
587 | Alphanate 1500 I.U. | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
588 | ALPHANATE*INF 1F 1000UI+F 10ML | 2件: Beroctocog alfa Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
589 | ALPHANATE*INF 1F 1500UI+F 10ML | 2件: Beroctocog alfa Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
590 | ALPHANATE*INF 1F 250UI+F 5ML | 2件: Beroctocog alfa Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
591 | ALPHANATE*INF 1F 500UI+F 5ML | 2件: Beroctocog alfa Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
592 | ALPN-101 | - | - | - | - | 1件: 49 49 💬 |
593 | ALRN-5281 0.015 mg/kg | - | - | - | - | 1件: 78 78 💬 |
594 | ALRN-5281 0.05 mg/kg | - | - | - | - | 1件: 78 78 💬 |
595 | ALRN-5281 0.15 mg/kg | - | - | - | - | 1件: 78 78 💬 |
596 | ALTH12-1:4 | - | - | - | - | 1件: 97 97 💬 |
597 | Altropane (123I) Injection | 1件: Altropane Altropane | - | - | - | 1件: 6 6 💬 |
598 | ALTU-135 | 1件: ALTU-135 ALTU-135 | - | - | - | 1件: 299 299 💬 |
599 | ALTUS-135 | - | - | - | - | 1件: 299 299 💬 |
600 | Alvelestat oral tablet - dose 1 | 1件: Alvelestat Alvelestat | - | - | - | 1件: 231 231 💬 |
601 | ALX-0061 | - | - | - | - | 2件: 46 46, 49 💬 |
602 | ALX-0061 150 mg/mL | - | - | - | - | 1件: 49 49 💬 |
603 | ALX-0061 Nanobody | - | - | - | - | 1件: 46 46 💬 |
604 | ALX-0081 | - | - | - | - | 1件: 64 64 💬 |
605 | ALX-009 | - | - | - | - | 1件: 299 299 💬 |
606 | ALX-0600 | - | - | - | - | 1件: 96 96 💬 |
607 | ALXN2040 (ACH-0144471) | - | - | - | - | 1件: 62 62 💬 |
608 | AM-01 | - | - | - | - | 1件: 51 51 💬 |
609 | Amantadin-ratiopharm 100mg | - | - | - | - | 1件: 6 6 💬 |
610 | Amantadine 300 mg | 1件: Amantadine Amantadine | 1件: Amantadine
Amantadine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
611 | AMB-05X | - | - | - | - | 1件: 85 85 💬 |
612 | AMBROSAN 60mg Tablets | - | - | - | - | 1件: 6 6 💬 |
613 | American ginseng extract HT-1001 | 2件: Ginseng Ginseng, Panax quinquefolius whole | 1件: Ginseng
Ginseng
💬 | - | - | 1件: 13 13 💬 |
614 | AMG 108 | 1件: AMG 108 AMG 108 | - | - | - | 1件: 46 46 💬 |
615 | AMG 139 | - | - | - | - | 1件: 96 96 💬 |
616 | AMG 145 | - | - | - | - | 1件: 79 79 💬 |
617 | AMG 157 | 1件: Tezepelumab Tezepelumab | 1件: Tezepelumab
Tezepelumab
💬 | 1件: TSLP TSLP 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 98 98 💬 |
618 | AMG 162 | - | - | - | - | 2件: 46 46, 274 💬 |
619 | AMG 181 | - | - | - | - | 2件: 96 96, 97 💬 |
620 | AMG 357 | - | - | - | - | 1件: 46 46 💬 |
621 | AMG 623 | - | - | - | - | 1件: 49 49 💬 |
622 | AMG 714 | - | - | - | - | 1件: 46 46 💬 |
623 | AMG 719 | - | - | - | - | 1件: 46 46 💬 |
624 | AMG 785 | - | - | - | - | 1件: 274 274 💬 |
625 | AMG 827 140 mg | - | - | - | - | 1件: 46 46 💬 |
626 | AMG 827 350 MG | - | - | - | - | 1件: 96 96 💬 |
627 | AMG 827 70 mg | - | - | - | - | 1件: 46 46 💬 |
628 | AMG 827 700 MG | - | - | - | - | 1件: 96 96 💬 |
629 | Amifampridine Phosphate 10 MG Oral Tablet | 2件: Amifampridine Amifampridine, Phosphate ion | 1件: Amifampridine
Amifampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 3 3 💬 |
630 | Ammonium (15N) chloride | 1件: Chloride ion Chloride ion | - | - | - | 1件: 251 251 💬 |
631 | AMP-110 | - | - | - | - | 1件: 46 46 💬 |
632 | AMT-101 | - | - | - | - | 2件: 46 46, 97 💬 |
633 | AMT-101 (oral) | - | - | - | - | 1件: 97 97 💬 |
634 | AMT-130 | 1件: AMT-130 AMT-130 | - | - | - | 1件: 8 8 💬 |
635 | ANA001XHCl (Syntagon) or VEXA-04 (Patheon) | - | - | - | - | 1件: 156 156 💬 |
636 | Anakinra (r-metHuIL-1ra) | 1件: Anakinra Anakinra | 1件: Anakinra
Anakinra
💬 | 2件: IL1R1 IL1R1, IL1R2 💬 | 15件: Amoebiasis Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 1件: 46 46 💬 |
637 | ANAVEX2-73 | - | - | - | - | 2件: 6 6, 156 💬 |
638 | ANAVEX2-73 (blarcamesine) | 1件: Blarcamesine Blarcamesine | 1件: Blarcamesine
Blarcamesine
💬 | 6件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SIGMAR1 💬 | 14件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 156 156 💬 |
639 | ANAVEX2-73 oral liquid | - | - | - | - | 1件: 156 156 💬 |
640 | AndroGel 1 % Topical Gel | - | - | - | - | 1件: 13 13 💬 |
641 | Androgel 10 grams of gel containing 100 mg of testosterone | 1件: Testosterone Testosterone | 1件: Testosterone
Testosterone
💬 | 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 💬 |
642 | ANG-3070 | - | - | - | - | 1件: 85 85 💬 |
643 | Angiotensin-(1-7) | 1件: Angiotensin II Angiotensin II | 2件: Angiotensin II
Angiotensin II
,
Angiotensin II
💬 | 2件: AGTR1 AGTR1, AGTR2 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 17 17 💬 |
644 | Anifrolumab 1000 mg | 1件: Anifrolumab Anifrolumab | 1件: Anifrolumab
Anifrolumab
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 49 49 💬 |
645 | Anifrolumab 300 mg | 1件: Anifrolumab Anifrolumab | 1件: Anifrolumab
Anifrolumab
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 49 49 💬 |
646 | ANK-700 | - | - | - | - | 1件: 13 13 💬 |
647 | Anti IL 6 mAb | - | - | - | - | 1件: 46 46 💬 |
648 | Anti IL-1beta antibody | - | - | - | - | 1件: 46 46 💬 |
649 | Anti IL-1beta antibody, subclass IgG4 | - | - | - | - | 1件: 46 46 💬 |
650 | Anti IL-1ß antibody | - | - | - | - | 1件: 46 46 💬 |
651 | Anti IL-1ß antibody, subclass IgG4 | - | - | - | - | 1件: 46 46 💬 |
652 | Anti-(misfolded human superoxide dismutase 1) human IgG1m3 monoclonal antibody | - | - | - | - | 1件: 2 2 💬 |
653 | Anti-Beta Interferon (PF-06823859) | - | - | - | - | 1件: 50 50 💬 |
654 | Anti-IL-12 | - | - | - | - | 2件: 13 13, 96 💬 |
655 | Anti-IL-20 (109-0012) | 1件: Fletikumab Fletikumab | 1件: Fletikumab
Fletikumab
💬 | 1件: IL20 IL20 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
656 | Anti-IL-36R monoclonal antibody | - | - | - | - | 1件: 37 37 💬 |
657 | Anti-IL-6 mAb | - | - | - | - | 2件: 46 46, 96 💬 |
658 | Anti-interleukin-1B monoclonal antibody | - | - | - | - | 1件: 106 106 💬 |
659 | Anti-Interleukin-6 Monoclonal | - | - | - | - | 1件: 46 46 💬 |
660 | Anti-Interleukin-6 Monoclonal Antibody | - | - | - | - | 2件: 46 46, 96 💬 |
661 | Anti-IP-10 Antibody | - | - | - | - | 1件: 97 97 💬 |
662 | Anticuerpo monoclonal anti-humano recombinante humanizado, receptor de IL-6R. | - | - | - | - | 1件: 46 46 💬 |
663 | Anticuerpo monoclonal anti-LINGO-1 humano | - | - | - | - | 1件: 13 13 💬 |
664 | Antiepileptic drug (1 to 3 only) | - | - | - | - | 1件: 158 158 💬 |
665 | ANTOX (vers) 1.2 | - | - | - | - | 1件: 298 298 💬 |
666 | ANTOX (vers.)1.2 | - | - | - | - | 1件: 298 298 💬 |
667 | Antox version 1.2 | - | - | - | - | 1件: 298 298 💬 |
668 | AOC 1001 | - | - | - | - | 1件: 113 113 💬 |
669 | AOC 1020 | - | - | - | - | 1件: 113 113 💬 |
670 | AOC 1044 | - | - | - | - | 1件: 113 113 💬 |
671 | AODG (Apigenin-7-O-glucuronide) | 1件: Apigenin Apigenin | - | - | - | 1件: 97 97 💬 |
672 | AP-101 | - | - | - | - | 1件: 2 2 💬 |
673 | AP1189, 100 mg | - | - | - | - | 1件: 46 46 💬 |
674 | AP1189, 60 mg | - | - | - | - | 1件: 46 46 💬 |
675 | APL-130277 | - | - | - | - | 1件: 6 6 💬 |
676 | APL-1401 | - | - | - | - | 1件: 97 97 💬 |
677 | Apomorphine 0.25% (2.5mg/ml) | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
678 | Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
679 | Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
680 | ApoTamox 10mg | - | - | - | - | 1件: 111 111 💬 |
681 | Apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side | 1件: Sinecatechins Sinecatechins | 1件: Sinecatechins
Sinecatechins
💬 | - | - | 1件: 160 160 💬 |
682 | Apraclonidine Hcl 0.5% Oph Soln | 1件: Apraclonidine Apraclonidine | 1件: Apraclonidine
Apraclonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 11 11 💬 |
683 | Apremilast (CC-10004) | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 56 56 💬 |
684 | Apremilast 10 mg | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 2件: 56 56, 107 💬 |
685 | Apremilast 30 mg | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 3件: 46 46, 56, 107 💬 |
686 | Apremilast 30mg | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 50 50 💬 |
687 | Apremilast tablet 30 mg BID | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 271 271 💬 |
688 | Apriso 0.375G ER CAP | - | - | - | - | 1件: 97 97 💬 |
689 | APRISO 375 mg extended-release capsules | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 97 97 💬 |
690 | Aprovel (150 mg) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
691 | Aprovel 150 mg Tablets | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
692 | APT-1011 | - | - | - | - | 1件: 98 98 💬 |
693 | APT-1011 - 3 mg | - | - | - | - | 1件: 98 98 💬 |
694 | APT-1011 3 mg HS | - | - | - | - | 1件: 98 98 💬 |
695 | AQX-1125 | 1件: AQX-1125 AQX-1125 | - | - | - | 1件: 226 226 💬 |
696 | AQX-1125 100 mg | 1件: AQX-1125 AQX-1125 | - | - | - | 1件: 226 226 💬 |
697 | AQX-1125 200 mg | 1件: AQX-1125 AQX-1125 | - | - | - | 1件: 226 226 💬 |
698 | Arbaclofen placarbil 15 mg BID | 2件: Arbaclofen Arbaclofen, Arbaclofen Placarbil | 2件: Arbaclofen placarbil
Arbaclofen placarbil
,
Arbaclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
699 | Arbaclofen placarbil 30 mg BID | 2件: Arbaclofen Arbaclofen, Arbaclofen Placarbil | 2件: Arbaclofen placarbil
Arbaclofen placarbil
,
Arbaclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
700 | ARC 1779 | - | - | - | - | 2件: 64 64, 288 💬 |
701 | ARCOXIA 90 mg comprimidos recubiertos con película | - | - | - | - | 1件: 271 271 💬 |
702 | ARCT-032 | - | - | - | - | 1件: 299 299 💬 |
703 | ARD-3150 | - | - | - | - | 1件: 299 299 💬 |
704 | ARGX-113 | - | - | - | - | 5件: 11 11, 14, 35, 53, 63 💬 |
705 | ARGX-117 | - | - | - | - | 1件: 14 14 💬 |
706 | ARGX-117 IV | - | - | - | - | 1件: 14 14 💬 |
707 | Aricept 10 mg | 1件: Donepezil Donepezil | 1件: Donepezil
Donepezil
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 13 13 💬 |
708 | Aricept 10 mg filmdragerade tabletter | 1件: Donepezil Donepezil | 1件: Donepezil
Donepezil
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 13 13 💬 |
709 | Arikayce™ 140 mg | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
710 | Arikayce™ 70 mg | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
711 | ARINA-1 | - | - | - | - | 2件: 228 228, 299 💬 |
712 | Arm 1 - GEH120714 (18F) Injection | - | - | - | - | 1件: 13 13 💬 |
713 | ARN-6039 | - | - | - | - | 1件: 13 13 💬 |
714 | ARO-ANG 3 Injection | - | - | - | - | 1件: 79 79 💬 |
715 | ARRY-371797 | - | - | - | - | 1件: 271 271 💬 |
716 | ARRY-371797, p38 inhibitor | - | - | - | - | 2件: 46 46, 271 💬 |
717 | ART-123 | - | - | - | - | 1件: 85 85 💬 |
718 | Artamin 150 mg | - | - | - | - | 1件: 171 171 💬 |
719 | ARZERRA - 100 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONE(VETRO) - 5 ML(20MG/ML) 3 FLACONI | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
720 | ARZERRA - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 50 ML (20 MG/ML) 1 FLACONCINO + 2 KIT DI PROLUNGA | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
721 | ASB-683699 | - | - | - | - | 1件: 13 13 💬 |
722 | ASC42 10 mg | - | - | - | - | 1件: 93 93 💬 |
723 | ASC42 15 mg | - | - | - | - | 1件: 93 93 💬 |
724 | ASF-1096 Cream 0.25% | - | - | - | - | 1件: 49 49 💬 |
725 | ASF-1096 Cream 0.5% | - | - | - | - | 1件: 49 49 💬 |
726 | ASF-1096 Cream 1.0% | - | - | - | - | 1件: 49 49 💬 |
727 | ASP015K hydrobromide, AS1940150-BR, JKT-201A, 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide | - | - | - | - | 1件: 46 46 💬 |
728 | Aspirin 650mg Oral Capsule | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: Aspirin
Aspirin
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
729 | AST-120 | - | - | - | - | 2件: 96 96, 97 💬 |
730 | AT 10 | - | - | - | - | 2件: 6 6, 85 💬 |
731 | AT-1501 | - | - | - | - | 1件: 66 66 💬 |
732 | AT1001 150 mg | - | - | - | - | 1件: 19 19 💬 |
733 | AT2221 65 mg Formulated Capsules | - | - | - | - | 1件: 256 256 💬 |
734 | Atacicept 150 mg | 1件: Atacicept Atacicept | 1件: Atacicept
Atacicept
💬 | 2件: TNFSF13 TNFSF13, TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 13 13, 49 💬 |
735 | Atacicept 75 mg | 1件: Atacicept Atacicept | 1件: Atacicept
Atacicept
💬 | 2件: TNFSF13 TNFSF13, TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 3件: 13 13, 49, 66 💬 |
736 | Atacicept 75 milligram (mg) | 1件: Atacicept Atacicept | 1件: Atacicept
Atacicept
💬 | 2件: TNFSF13 TNFSF13, TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
737 | Ataluren 1000 mg | 1件: Ataluren Ataluren | 1件: Ataluren
Ataluren
💬 | - | - | 1件: 113 113 💬 |
738 | Ataluren 1000mg | 1件: Ataluren Ataluren | 1件: Ataluren
Ataluren
💬 | - | - | 1件: 246 246 💬 |
739 | Ataluren 125 mg | 1件: Ataluren Ataluren | 1件: Ataluren
Ataluren
💬 | - | - | 1件: 113 113 💬 |
740 | Ataluren 125mg | 1件: Ataluren Ataluren | 1件: Ataluren
Ataluren
💬 | - | - | 1件: 246 246 💬 |
741 | ATH-1017 | - | - | - | - | 1件: 6 6 💬 |
742 | ATH434 dose level 1 | - | - | - | - | 1件: 17 17 💬 |
743 | ATN-103 | - | - | - | - | 1件: 46 46 💬 |
744 | ATN-103 10 mg q4wks | - | - | - | - | 1件: 46 46 💬 |
745 | ATN-103 10 mg q8wks | - | - | - | - | 1件: 46 46 💬 |
746 | ATN-103 30 mg q4wks | - | - | - | - | 1件: 46 46 💬 |
747 | ATN-103 80 mg q4wks | - | - | - | - | 1件: 46 46 💬 |
748 | ATN-103 80 mg q8wks | - | - | - | - | 1件: 46 46 💬 |
749 | Atorvastatin 10mg | 1件: Atorvastatin Atorvastatin | 1件: Atorvastatin
Atorvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 63 63 💬 |
750 | ATR-101 | - | - | - | - | 2件: 75 75, 81 💬 |
751 | ATX-MS-1467 | - | - | - | - | 1件: 13 13 💬 |
752 | ATYR1923 1.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
753 | ATYR1923 3.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
754 | ATYR1923 5.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
755 | AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BISTER (ALU/ALU) PERFORATO MONODOSE - 10 X 1 COMPRESSA | 1件: Teriflunomide Teriflunomide | 1件: Teriflunomide
Teriflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
756 | AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 28 COMPRESSE | 1件: Teriflunomide Teriflunomide | 1件: Teriflunomide
Teriflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
757 | Aubagio 14 mg film-coated tablets | 1件: Teriflunomide Teriflunomide | 1件: Teriflunomide
Teriflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
758 | Autologous cardiac stem cells (JRM-001) | - | - | - | - | 2件: 210 210, 211 💬 |
759 | AUTOLOGOUS CD34+CELLS TRANSDUCED WITH THE W1.6_HWASP_WPRE (VSVG) LENTIVIRAL VECTOR | - | - | - | - | 1件: 65 65 💬 |
760 | Autologous ovalbumin-specific type 1 regulatory T lymphocytes expanded population | - | - | - | - | 1件: 96 96 💬 |
761 | Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells | - | - | - | - | 1件: 51 51 💬 |
762 | AV-101 | 1件: AV-101 AV-101 | - | - | - | 2件: 6 6, 86 💬 |
763 | Avandia administration for 6-12 weeks | - | - | - | - | 1件: 265 265 💬 |
764 | AVB-114 | - | - | - | - | 1件: 96 96 💬 |
765 | AVCN583601 (3% Cannabidiol cream) | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 36 36 💬 |
766 | Aviptadil, 66 microgram/mL | 1件: Aviptadil Aviptadil | 1件: Aviptadil
Aviptadil
💬 | - | - | 1件: 85 85 💬 |
767 | Avonex (Interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
768 | Avonex (interferon beta-1a), Biogen Idec Ltd | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
769 | AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
770 | Avonex 30 microgram/0.5 ml Solution for Injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
771 | AVONEX 30 microgramos/0,5 ml (Interferón Beta - 1a) Solución inyectable | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
772 | Avonex 30 microgramos/0.5 ml Solución para inyección | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
773 | AVONEX 30 µg/0,5 ml solution for injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
774 | AVONEX IM 4SIR 30MCG/0,5ML 4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
775 | AVONEX*IM 4SIR 30MCG/0,5ML+4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
776 | Avonex® monotherapy (6.0 MIU administered i.m. each week) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
777 | AVP-923 | - | - | - | - | 3件: 2 2, 6, 13 💬 |
778 | AVP-923-45 | - | - | - | - | 1件: 6 6 💬 |
779 | AVR-RD-01 | - | - | - | - | 1件: 19 19 💬 |
780 | AVR-RD-02 | - | - | - | - | 1件: 19 19 💬 |
781 | AVXS-101 | - | - | - | - | 1件: 3 3 💬 |
782 | AVXS-101 (previously known as scAAV9.CB.SMN) | - | - | - | - | 1件: 3 3 💬 |
783 | Azathioprine (AZA) or 6-mercaptopurine (6-MP) | 2件: Azathioprine Azathioprine, Mercaptopurine | 3件: Mercaptopurine
Mercaptopurine
,
Azathioprine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 2件: 96 96, 97 💬 |
784 | Azathioprine / 6 Mercaptopurine | 2件: Azathioprine Azathioprine, Mercaptopurine | 3件: Mercaptopurine
Mercaptopurine
,
Azathioprine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 96 96 💬 |
785 | Azathioprine or 6-mercaptopurine | 2件: Azathioprine Azathioprine, Mercaptopurine | 3件: Mercaptopurine
Mercaptopurine
,
Azathioprine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 2件: 96 96, 97 💬 |
786 | AZD3241 100mg | - | - | - | - | 1件: 17 17 💬 |
787 | AZD3241 300 mg BID | - | - | - | - | 1件: 6 6 💬 |
788 | AZD3241 300mg | - | - | - | - | 1件: 17 17 💬 |
789 | AZD3241 600 mg BID | - | - | - | - | 1件: 6 6 💬 |
790 | AZD3241 Alternative titration scheme with formulation 1 or 2 | - | - | - | - | 1件: 6 6 💬 |
791 | AZD3241 ER formulation 1 | - | - | - | - | 1件: 6 6 💬 |
792 | AZD3241 Extended release tablets 100 mg | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 6 6 💬 |
793 | AZD9567 10 mg | - | - | - | - | 1件: 46 46 💬 |
794 | AZD9567 125 mg | - | - | - | - | 1件: 46 46 💬 |
795 | AZD9567 155 mg | - | - | - | - | 1件: 46 46 💬 |
796 | AZILECT 1 mg comprimidos | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 2件: 6 6, 17 💬 |
797 | Azilect 1mg | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
798 | AZILECT® 1 mg Tabletten | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 2 2 💬 |
799 | AZLI 75 mg three times a day (TID) | - | - | - | - | 1件: 299 299 💬 |
800 | AZLI 75 mg three times daily (TID) | - | - | - | - | 1件: 299 299 💬 |
801 | AZLI 75 mg two times a day (BID)/ three times a day (TID) | - | - | - | - | 1件: 299 299 💬 |
802 | AZLI 75 mg two times a day (BID)/three times a day (TID) | - | - | - | - | 1件: 299 299 💬 |
803 | AZP-3601 | - | - | - | - | 1件: 235 235 💬 |
804 | AZT/3TC | - | - | - | - | 1件: 265 265 💬 |
805 | B / Phuket / 3073/2013-like virus) | - | - | - | - | 1件: 53 53 💬 |
806 | Baclofen (baclofen Tab. 10mg) treatment | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 70 70 💬 |
807 | Baclofen ER Capsules (GRS) 10 mg | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
808 | Baclofen ER Capsules (GRS) 30mg | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
809 | Baclofen Tablets USP 10 mg | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
810 | BAF312 0,25 mg tablet | - | - | - | - | 1件: 13 13 💬 |
811 | BAF312 0,5 mg tablet | - | - | - | - | 1件: 50 50 💬 |
812 | BAF312 0.25 mg | - | - | - | - | 1件: 50 50 💬 |
813 | BAF312 0.25 mg tablet | - | - | - | - | 1件: 50 50 💬 |
814 | BAF312 0.25mg tablet | - | - | - | - | 1件: 50 50 💬 |
815 | BAF312 0.5 mg | - | - | - | - | 1件: 50 50 💬 |
816 | BAF312 0.50 mg | - | - | - | - | 1件: 50 50 💬 |
817 | BAF312 1 mg | - | - | - | - | 1件: 50 50 💬 |
818 | BAF312 1 mg tablet | - | - | - | - | 2件: 13 13, 50 💬 |
819 | BAF312 1mg | - | - | - | - | 1件: 50 50 💬 |
820 | BAF312 1mg tablet | - | - | - | - | 1件: 50 50 💬 |
821 | Bardoxolone methyl 10 mg | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: Bardoxolone
Bardoxolone
,
Bardoxolone methyl
💬 | - | - | 1件: 67 67 💬 |
822 | Bardoxolone methyl 15 mg | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: Bardoxolone
Bardoxolone
,
Bardoxolone methyl
💬 | - | - | 1件: 67 67 💬 |
823 | BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: Bardoxolone
Bardoxolone
,
Bardoxolone methyl
💬 | - | - | 1件: 86 86 💬 |
824 | BASSADO 10CPS 100MG | - | - | - | - | 1件: 23 23 💬 |
825 | Batoclimab 340 mg SC bi-weekly | 1件: Batoclimab Batoclimab | 1件: Batoclimab
Batoclimab
💬 | 1件: FCGRT FCGRT 💬 | - | 1件: 11 11 💬 |
826 | Batoclimab 340 mg SC weekly | 1件: Batoclimab Batoclimab | 1件: Batoclimab
Batoclimab
💬 | 1件: FCGRT FCGRT 💬 | - | 2件: 11 11, 14 💬 |
827 | Batoclimab 680 mg SC weekly | 1件: Batoclimab Batoclimab | 1件: Batoclimab
Batoclimab
💬 | 1件: FCGRT FCGRT 💬 | - | 1件: 11 11 💬 |
828 | Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly | 1件: Batoclimab Batoclimab | 1件: Batoclimab
Batoclimab
💬 | 1件: FCGRT FCGRT 💬 | - | 1件: 14 14 💬 |
829 | BAX 111 | - | - | - | - | 1件: 288 288 💬 |
830 | BAY 59-7939 | - | - | - | - | 1件: 210 210 💬 |
831 | BAY 63-2521 | - | - | - | - | 2件: 86 86, 88 💬 |
832 | BAY 63-2521 0.06 % | - | - | - | - | 1件: 86 86 💬 |
833 | BAY 63-2521 0.3 % | - | - | - | - | 1件: 86 86 💬 |
834 | BAY 63-2521 coated tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
835 | BAY 63-2521 coated tablets 1 mg | - | - | - | - | 2件: 86 86, 88 💬 |
836 | BAY 63-2521 coated tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
837 | BAY 63-2521 coated tablets 2 mg | - | - | - | - | 2件: 86 86, 88 💬 |
838 | BAY 63-2521 coated tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
839 | BAY 63-2521 IR coated tablet 1.0 mg | - | - | - | - | 1件: 88 88 💬 |
840 | BAY 63-2521 IR coated tablet 1.5 mg | - | - | - | - | 1件: 88 88 💬 |
841 | BAY 63-2521 IR coated tablet 2.0 mg | - | - | - | - | 1件: 88 88 💬 |
842 | BAY 63-2521 IR coated tablet 2.5 mg | - | - | - | - | 1件: 88 88 💬 |
843 | BAY 63-2521 IR tablet 0.5 mg | - | - | - | - | 1件: 88 88 💬 |
844 | BAY 63-2521 IR tablet 1.0 mg | - | - | - | - | 1件: 88 88 💬 |
845 | BAY 63-2521 IR tablet 1.5 mg | - | - | - | - | 1件: 88 88 💬 |
846 | BAY 63-2521 IR tablet 2.0 mg | - | - | - | - | 1件: 88 88 💬 |
847 | BAY 63-2521 IR tablet 2.5 mg | - | - | - | - | 1件: 88 88 💬 |
848 | BAY 63-2521 IR tablets 0.5 mg | - | - | - | - | 1件: 86 86 💬 |
849 | BAY 63-2521 IR tablets 1 mg | - | - | - | - | 1件: 86 86 💬 |
850 | BAY 63-2521 IR tablets 1.0 mg | - | - | - | - | 1件: 86 86 💬 |
851 | BAY 63-2521 IR tablets 1.5 mg | - | - | - | - | 1件: 86 86 💬 |
852 | BAY 63-2521 IR tablets 2.0 mg | - | - | - | - | 1件: 86 86 💬 |
853 | BAY 63-2521 IR tablets 2.5 mg | - | - | - | - | 1件: 86 86 💬 |
854 | BAY 63-2521 Tablet | - | - | - | - | 1件: 86 86 💬 |
855 | BAY 63-2521 tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
856 | BAY 63-2521 tablets 1 mg | - | - | - | - | 2件: 86 86, 88 💬 |
857 | BAY 63-2521 tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
858 | BAY 63-2521 tablets 2 mg | - | - | - | - | 2件: 86 86, 88 💬 |
859 | BAY 63-2521 tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
860 | BAY 79-4998 | - | - | - | - | 1件: 13 13 💬 |
861 | BAY q 3939 | - | - | - | - | 1件: 299 299 💬 |
862 | Bay Q 6256 | - | - | - | - | 1件: 86 86 💬 |
863 | BAY86-5046_Interferon-beta-1b | - | - | - | - | 1件: 13 13 💬 |
864 | BBP-671 | - | - | - | - | 2件: 245 245, 246 💬 |
865 | BBT-401-1S | - | - | - | - | 1件: 97 97 💬 |
866 | BBT-401-1S, Multiple doses | - | - | - | - | 1件: 97 97 💬 |
867 | BBT-401-1S, Single dose | - | - | - | - | 1件: 97 97 💬 |
868 | BCD-033 (interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
869 | BCD-054 180 mcg | - | - | - | - | 1件: 13 13 💬 |
870 | BCD-054 240 mcg | - | - | - | - | 1件: 13 13 💬 |
871 | BCD-055 | - | - | - | - | 2件: 46 46, 271 💬 |
872 | BCD-063 | - | - | - | - | 1件: 13 13 💬 |
873 | BCD-085 | - | - | - | - | 2件: 93 93, 271 💬 |
874 | BCD-089 | - | - | - | - | 1件: 46 46 💬 |
875 | BCD-089, 162 mg, s/c, q2w | - | - | - | - | 1件: 46 46 💬 |
876 | BCD-089, 162 mg, s/c, qw | - | - | - | - | 1件: 46 46 💬 |
877 | BCD-132 | - | - | - | - | 1件: 13 13 💬 |
878 | BCD-132, 125 mg | - | - | - | - | 1件: 13 13 💬 |
879 | BCD-132, 500 mg | - | - | - | - | 1件: 13 13 💬 |
880 | BCD-148 | - | - | - | - | 1件: 62 62 💬 |
881 | BCG20-0134 | - | - | - | - | 1件: 13 13 💬 |
882 | Beetainterferoni -1a | - | - | - | - | 1件: 13 13 💬 |
883 | Belantamab mafodotin 1.9 mg/kg (8 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
884 | Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
885 | Belantamab mafodotin 2.5 mg/kg (6 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
886 | Belimumab 1 mg/kg | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 46 46, 49 💬 |
887 | Belimumab 10 mg | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 222 222 💬 |
888 | Belimumab 10 mg/kg | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 3件: 43 43, 46, 49 💬 |
889 | Belimumab 10 mg/kg plus standard therapy | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
890 | Belimumab 100 mg SC | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
891 | Belimumab 10mg/kg | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
892 | Benazepril hydrochloride 10 milligram (mg) Tab | 1件: Benazepril Benazepril | 1件: Benazepril
Benazepril
💬 | 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 218 218 💬 |
893 | BENLYSTA - 120 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 120 MG 1 FLACONCINO | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 53 53 💬 |
894 | Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 💬 |
895 | Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 💬 |
896 | Benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala) | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 298 298 💬 |
897 | Beraprost Sodium 314d Modified Release Tablets | 1件: Beraprost Beraprost | 1件: Beraprost
Beraprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
898 | Beta-1,3/1,6-D-Glucan | - | - | - | - | 1件: 97 97 💬 |
899 | Beta-1b interferoni | - | - | - | - | 1件: 13 13 💬 |
900 | BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
901 | BETAFERON SC 15F 0,25MG 15SIR | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
902 | BETAFERON*15CONFEZ 0,25MG/ML+ | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
903 | BETAFERON® (interferon beta-1b) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
904 | Betaloc ZOK 100, 95 mg | - | - | - | - | 1件: 113 113 💬 |
905 | Betaloc ZOK 25, 23,75 mg | - | - | - | - | 1件: 113 113 💬 |
906 | Betamethasone Oral Solution Period 1 and Period 2 | 1件: Betamethasone Betamethasone | 1件: Betamethasone
Betamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 💬 |
907 | Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days | 3件: Acetate Acetate, Betamethasone, Phosphate ion | 1件: Betamethasone
Betamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 2 2 💬 |
908 | Betamethasone solution as intramuscular injection Period 1 and Period 2 | 1件: Betamethasone Betamethasone | 1件: Betamethasone
Betamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 💬 |
909 | Betaseron (Interferon beta-1b, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
910 | Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
911 | BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO | 4件: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle, Neisseria meningitidis serogroup b fhbp fusion protein antigen, Neisseria meningitidis serogroup b nada protein antigen, Neisseria meningitidis serogroup b nhba fusion protein antigen | - | - | - | 1件: 66 66 💬 |
912 | Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy | 2件: Bezafibrate Bezafibrate, Ursodeoxycholic acid | 2件: Ursodiol
Ursodiol
,
Bezafibrate
💬 | 2件: NR1H4 NR1H4, PPARA 💬 | 11件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 94 94 💬 |
913 | Bezafibrate (INN 3968) | 1件: Bezafibrate Bezafibrate | 1件: Bezafibrate
Bezafibrate
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 324 324 💬 |
914 | BF 2.649 | - | - | - | - | 1件: 6 6 💬 |
915 | BF 2.649 10 mg | - | - | - | - | 1件: 6 6 💬 |
916 | BF 2.649 20 mg | - | - | - | - | 1件: 6 6 💬 |
917 | BF 2.649 40 mg | - | - | - | - | 1件: 6 6 💬 |
918 | BF 2.649 5 mg | - | - | - | - | 1件: 6 6 💬 |
919 | BF2.649 | - | - | - | - | 1件: 6 6 💬 |
920 | BF2.649 (Pitolisant) | 1件: Pitolisant Pitolisant | 1件: Pitolisant
Pitolisant
💬 | 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
921 | BG-12 120 | - | - | - | - | 1件: 13 13 💬 |
922 | BG00012 (DMF) (Tecfidera®.) | - | - | - | - | 1件: 13 13 💬 |
923 | BG9418 (interferon beta 1-a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
924 | BG9418 (interferon beta-1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 2件: 13 13, 97 💬 |
925 | BGC20-0134 | - | - | - | - | 1件: 13 13 💬 |
926 | BGP-014 | - | - | - | - | 1件: 97 97 💬 |
927 | BGP-014 Capsules | - | - | - | - | 1件: 97 97 💬 |
928 | BGX-0214 | - | - | - | - | 1件: 46 46 💬 |
929 | BHT-3009 | - | - | - | - | 1件: 13 13 💬 |
930 | BHT-3009 0.5 mg | - | - | - | - | 1件: 13 13 💬 |
931 | BHT-3009 1.5 mg | - | - | - | - | 1件: 13 13 💬 |
932 | BHT-3009-01 | - | - | - | - | 1件: 13 13 💬 |
933 | BHV-0223 | - | - | - | - | 1件: 2 2 💬 |
934 | BHV-3241 | - | - | - | - | 1件: 17 17 💬 |
935 | BI 1015550 | - | - | - | - | 1件: 85 85 💬 |
936 | BI 1015550 18 mg Film Coated Tablet | - | - | - | - | 1件: 85 85 💬 |
937 | BI 1015550 9 mg Film Coated Tablet | - | - | - | - | 1件: 85 85 💬 |
938 | BI 1265162 | - | - | - | - | 1件: 299 299 💬 |
939 | BI 1265162 10 µg | - | - | - | - | 1件: 299 299 💬 |
940 | BI 1265162 100 µg | - | - | - | - | 1件: 299 299 💬 |
941 | BI 1265162 25 µg | - | - | - | - | 1件: 299 299 💬 |
942 | BI 1265162 50 µg | - | - | - | - | 1件: 299 299 💬 |
943 | BI 655064 | - | - | - | - | 1件: 46 46 💬 |
944 | BI 655064 high dose | - | - | - | - | 1件: 46 46 💬 |
945 | BI 655064 low dose | - | - | - | - | 1件: 46 46 💬 |
946 | BI 655064 medium dose | - | - | - | - | 1件: 46 46 💬 |
947 | BI 655066 | - | - | - | - | 2件: 96 96, 271 💬 |
948 | BI 655066 10 mg/ml | - | - | - | - | 1件: 96 96 💬 |
949 | BI 655066 90 mg/ml | - | - | - | - | 2件: 96 96, 271 💬 |
950 | BI 655130 | - | - | - | - | 3件: 37 37, 96, 97 💬 |
951 | BI 685509 | - | - | - | - | 1件: 51 51 💬 |
952 | BI 695500 | - | - | - | - | 1件: 46 46 💬 |
953 | BI 695501 | - | - | - | - | 2件: 46 46, 96 💬 |
954 | BI 695501 Autoinjector | - | - | - | - | 1件: 46 46 💬 |
955 | BI 695501 Prefilled syringe | - | - | - | - | 1件: 46 46 💬 |
956 | BI 705564 | - | - | - | - | 1件: 49 49 💬 |
957 | BI 706321 | - | - | - | - | 1件: 96 96 💬 |
958 | BI 730357 | - | - | - | - | 1件: 271 271 💬 |
959 | BI 764198 | - | - | - | - | 1件: 222 222 💬 |
960 | BIA 3-202 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
961 | BIA 3-202 (200 mg) | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
962 | BIA 5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 💬 |
963 | BIA 6-512 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
964 | BIA 6-512 100 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
965 | BIA 6-512 100 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
966 | BIA 6-512 200 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
967 | BIA 6-512 25 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
968 | BIA 6-512 25 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
969 | BIA 6-512 400 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
970 | BIA 6-512 50 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
971 | BIA 9-1067 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
972 | BIA 9-1067 (test) | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
973 | BIA 9-1067 15 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
974 | BIA 9-1067 25 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
975 | BIA 9-1067 30 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
976 | BIA 9-1067 5 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
977 | BIA 9-1067 micronized | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
978 | BIA 9-1067 non-micronized | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
979 | BIA-5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 💬 |
980 | BIBF 1120 | - | - | - | - | 2件: 51 51, 85 💬 |
981 | BIBF 1120 ES | - | - | - | - | 1件: 85 85 💬 |
982 | BIBR 796 BS | - | - | - | - | 1件: 46 46 💬 |
983 | BIBR 796 BS, 20 mg | - | - | - | - | 1件: 96 96 💬 |
984 | BIBR 796 BS, 5 mg | - | - | - | - | 1件: 96 96 💬 |
985 | Bifidobacterium infantis 35624 | 1件: Bifidobacterium longum infantis Bifidobacterium longum infantis | - | - | - | 2件: 96 96, 97 💬 |
986 | BIIB 017 | - | - | - | - | 1件: 13 13 💬 |
987 | BIIB017 (Peginterferon beta-1a) | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
988 | BIIB050 / KNS-760704 | - | - | - | - | 1件: 2 2 💬 |
989 | BIIB050/KNS-760704 | - | - | - | - | 1件: 2 2 💬 |
990 | BINOCRIT*1SIR 40000UI/1ML | 1件: Erythropoietin Erythropoietin | - | - | - | 1件: 18 18 💬 |
991 | Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 14 14 💬 |
992 | BION-1301 Multiple Doses | - | - | - | - | 1件: 66 66 💬 |
993 | BION-1301 Single Dose | - | - | - | - | 1件: 66 66 💬 |
994 | BIRB 796 BS, high dose | - | - | - | - | 1件: 46 46 💬 |
995 | BIRB 796 BS, low dose | - | - | - | - | 1件: 46 46 💬 |
996 | Bitterschleifenblume-ganzpflanze 1,5ml/10ml | - | - | - | - | 1件: 97 97 💬 |
997 | BL-7040 | - | - | - | - | 1件: 97 97 💬 |
998 | BLI-1300 high dose | - | - | - | - | 1件: 96 96 💬 |
999 | BLI-1300 low dose | - | - | - | - | 1件: 96 96 💬 |
1000 | BMN 044 | - | - | - | - | 1件: 113 113 💬 |
1001 | BMN 044 IV 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
1002 | BMN 044 IV 9 mg/kg | - | - | - | - | 1件: 113 113 💬 |
1003 | BMN 044 SC 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
1004 | BMN 045 | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
1005 | BMN 053 | - | - | - | - | 1件: 113 113 💬 |
1006 | BMN 110 | - | - | - | - | 1件: 19 19 💬 |
1007 | BMN 110 - Every Other Week | - | - | - | - | 1件: 19 19 💬 |
1008 | BMN 110 - Weekly | - | - | - | - | 1件: 19 19 💬 |
1009 | BMN 110 Every Other Week | - | - | - | - | 1件: 19 19 💬 |
1010 | BMN 110 Weekly | - | - | - | - | 1件: 19 19 💬 |
1011 | BMN 111 | - | - | - | - | 1件: 276 276 💬 |
1012 | BMN 165 | - | - | - | - | 1件: 240 240 💬 |
1013 | BMN 165 (rAvPAL-PEG) | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
1014 | BMN 190 | - | - | - | - | 1件: 19 19 💬 |
1015 | BMN 307 | - | - | - | - | 1件: 240 240 💬 |
1016 | BMN 701 | - | - | - | - | 1件: 256 256 💬 |
1017 | BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1) | - | - | - | - | 1件: 19 19 💬 |
1018 | BMS 188667 (Abatacept) | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 13 13 💬 |
1019 | BMS-188667 | - | - | - | - | 9件: 46 46, 49, 53, 65, 96, 97, 107, 222, 271 💬 |
1020 | BMS-931699 | 1件: Lulizumab pegol Lulizumab pegol | - | - | - | 3件: 49 49, 53, 160 💬 |
1021 | BMS-936557 | - | - | - | - | 2件: 96 96, 97 💬 |
1022 | BMS-936557 (Anti-IP-10 Antibody) | - | - | - | - | 1件: 96 96 💬 |
1023 | BMS-945429 | 1件: Clazakizumab Clazakizumab | 1件: Clazakizumab
Clazakizumab
💬 | - | - | 2件: 46 46, 96 💬 |
1024 | BMS-986004 | - | - | - | - | 1件: 63 63 💬 |
1025 | BMS-986004 1500 mg IV | - | - | - | - | 1件: 63 63 💬 |
1026 | BMS-986004 225 mg IV | - | - | - | - | 1件: 63 63 💬 |
1027 | BMS-986004 675 mg IV | - | - | - | - | 1件: 63 63 💬 |
1028 | BMS-986004 75 mg IV | - | - | - | - | 1件: 63 63 💬 |
1029 | BMS-986020 | 1件: BMS-986020 BMS-986020 | - | - | - | 2件: 51 51, 85 💬 |
1030 | BMS-986089 | - | - | - | - | 1件: 113 113 💬 |
1031 | BMS-986089-01 (RO7239361) , anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
1032 | BMS-986089-01 (RO7239361) Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
1033 | BMS-986089-01 (RO7239361) Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
1034 | BMS-986089-01 (RO7239361) Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
1035 | BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
1036 | BMS-986089-01 (RO7239361), anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
1037 | BMS-986089-01 Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
1038 | BMS-986089-01 Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
1039 | BMS-986089-01 Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
1040 | BMS-986089-01 Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
1041 | BMS-986089-01, Anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
1042 | BMS-986104 | 1件: BMS-986104 BMS-986104 | - | - | - | 1件: 46 46 💬 |
1043 | BMS-986142 | 1件: BMS-986142 BMS-986142 | - | - | - | 3件: 46 46, 53, 160 💬 |
1044 | BMS-986142 200mg | 1件: BMS-986142 BMS-986142 | - | - | - | 1件: 46 46 💬 |
1045 | BMS-986142 350mg | 1件: BMS-986142 BMS-986142 | - | - | - | 1件: 46 46 💬 |
1046 | BMS-986165 | - | - | - | - | 3件: 49 49, 96, 97 💬 |
1047 | BMS-986165 Capsule | - | - | - | - | 1件: 49 49 💬 |
1048 | BMS-986165 Tablet | - | - | - | - | 1件: 49 49 💬 |
1049 | BMS-986166 | - | - | - | - | 1件: 97 97 💬 |
1050 | BMS-986168 | 1件: Gosuranemab Gosuranemab | 1件: Gosuranemab
Gosuranemab
💬 | 1件: MAPT MAPT 💬 | 4件: Alzheimer disease Alzheimer disease, MAPK signaling pathway, Parkinson disease, Pathways of neurodegeneration - multiple diseases 💬 | 1件: 5 5 💬 |
1051 | BMS-986184 | - | - | - | - | 1件: 97 97 💬 |
1052 | BMS-986195 | 1件: Branebrutinib Branebrutinib | 1件: Branebrutinib
Branebrutinib
💬 | 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 3件: 46 46, 49, 53 💬 |
1053 | BMS-986251 | - | - | - | - | 2件: 46 46, 271 💬 |
1054 | BMS-986256 | 1件: Afimetoran Afimetoran | 1件: Afimetoran
Afimetoran
💬 | - | - | 1件: 49 49 💬 |
1055 | BMS-986256-06, TLR7/8 Antagonist | 1件: Afimetoran Afimetoran | 1件: Afimetoran
Afimetoran
💬 | - | - | 1件: 49 49 💬 |
1056 | BMS-986278 | - | - | - | - | 1件: 85 85 💬 |
1057 | BMS-986325 | - | - | - | - | 1件: 53 53 💬 |
1058 | Bosentan 125 mg | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
1059 | Bosentan 62.5 mg | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
1060 | Bosutinib (Phase 1 part) | 1件: Bosutinib Bosutinib | 1件: Bosutinib
Bosutinib
💬 | 2件: ABL1 ABL1, SRC 💬 | 49件: Adherens junction Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬 | 1件: 2 2 💬 |
1061 | BOTOX 100 UNITES ALLERGAN (PR1) | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 2 2 💬 |
1062 | Botox 100 UNT Injection | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
1063 | BOTOX 100U in normal saline | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 226 226 💬 |
1064 | Botulinum Toxin Type A 300U | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
1065 | BPLG-003 | - | - | - | - | 1件: 78 78 💬 |
1066 | BPS-314d-MR | - | - | - | - | 1件: 86 86 💬 |
1067 | BRAMICIL - 100 MG/ 2 ML SOLUZIONE INIETTABILE 10 FIALE DA 2 ML | - | - | - | - | 1件: 299 299 💬 |
1068 | BRAMITOB - 300 MG/4 ML SOLUZIONE DA NEBULIZZARE 56 CONTENITORI MONODOSE 4 ML | - | - | - | - | 1件: 299 299 💬 |
1069 | Bramitob 300mg/4ml Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
1070 | BRAMITOB*NEBUL 28F 300MG/4ML | - | - | - | - | 1件: 299 299 💬 |
1071 | BRAMITOB*NEBUL 56F 300MG/4ML | - | - | - | - | 1件: 299 299 💬 |
1072 | Bredinin tablet 150mg | 1件: Mizoribine Mizoribine | 1件: Mizoribine
Mizoribine
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 46 46 💬 |
1073 | Brensocatib 10 mg | 1件: Brensocatib Brensocatib | 1件: Brensocatib
Brensocatib
💬 | 1件: CTSC CTSC 💬 | 2件: Apoptosis Apoptosis, Lysosome 💬 | 1件: 299 299 💬 |
1074 | BRL-049653 | - | - | - | - | 1件: 46 46 💬 |
1075 | BRX-345 | - | - | - | - | 2件: 2 2, 15 💬 |
1076 | Bryostatin 1 | 1件: Bryostatin 1 Bryostatin 1 | - | - | - | 1件: 62 62 💬 |
1077 | BT-11 | - | - | - | - | 2件: 96 96, 97 💬 |
1078 | BT-11 (1000 mg) | - | - | - | - | 1件: 97 97 💬 |
1079 | BT-11 (500 mg) | - | - | - | - | 1件: 97 97 💬 |
1080 | BT-11 (Omilancor) | - | - | - | - | 1件: 96 96 💬 |
1081 | BT-11 1,000 mg | - | - | - | - | 1件: 96 96 💬 |
1082 | BT-11 1000mg | - | - | - | - | 3件: 96 96, 97, 98 💬 |
1083 | BT-11 500 mg | - | - | - | - | 2件: 96 96, 97 💬 |
1084 | BT-11 500mg | - | - | - | - | 1件: 98 98 💬 |
1085 | BT-11 Active | - | - | - | - | 2件: 96 96, 97 💬 |
1086 | BT051 3200 mg | - | - | - | - | 1件: 97 97 💬 |
1087 | BTT-1023 | - | - | - | - | 1件: 46 46 💬 |
1088 | Budenofalk 3mg | - | - | - | - | 2件: 93 93, 97 💬 |
1089 | Budenofalk 3mg gastro-resistant capsules | - | - | - | - | 1件: 96 96 💬 |
1090 | Budenofalk 9mg gastro-resistant granules | - | - | - | - | 1件: 96 96 💬 |
1091 | Budesonide ( Zentacort Capsules 3mg ) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
1092 | Budesonide (6 mg) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1093 | Budesonide (9 mg) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1094 | Budesonide 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1095 | Budesonide 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1096 | Budesonide 0.5mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1097 | Budesonide 1 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1098 | Budesonide 1 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1099 | Budesonide 1 mg orodispersible tablets (BUL 1 mg) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1100 | Budesonide 1mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1101 | Budesonide 6 mg prolonged-release capsule, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1102 | Budesonide 6 mg prolonged-release capsules, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1103 | Budesonide 9 mg capsules, hard (BUX-PV) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1104 | Budesonide 9 mg prolonged-release capsule, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1105 | Budesonide 9 mg prolonged-release capsules, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1106 | Budesonide [0.4mg/ml] viscous suspension | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1107 | Budesonide MMX 6 mg Tablet | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1108 | Budesonide MMX® 6 mg | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1109 | Budesonide MMX® 9 mg | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1110 | Budesonide oral suspension [0.2 mg/ml] | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1111 | Budesonide-MMX® 6 mg | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1112 | Budesonide-MMX® 9 mg | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1113 | BUET 0.5 mg | - | - | - | - | 1件: 98 98 💬 |
1114 | BUET 1 mg | - | - | - | - | 1件: 98 98 💬 |
1115 | BUET 1mg | - | - | - | - | 1件: 98 98 💬 |
1116 | BUL 0.5 mg | - | - | - | - | 1件: 98 98 💬 |
1117 | BUL 1 mg | - | - | - | - | 1件: 98 98 💬 |
1118 | Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) | 1件: Bupivacaine Bupivacaine | 1件: Bupivacaine
Bupivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 46 46 💬 |
1119 | Bupivacaine Injection 0.5% | 1件: Bupivacaine Bupivacaine | 1件: Bupivacaine
Bupivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 168 168 💬 |
1120 | Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine | 3件: Bupivacaine Bupivacaine, Clonidine, Epinephrine | 3件: Epinephrine
Epinephrine
,
Clonidine
,
Bupivacaine
💬 | 14件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 16件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 70 70 💬 |
1121 | Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml | 1件: Sufentanil Sufentanil | 1件: Sufentanil
Sufentanil
💬 | 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 70 70 💬 |
1122 | BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI | 1件: Busulfan Busulfan | 1件: Busulfan
Busulfan
💬 | - | - | 2件: 19 19, 65 💬 |
1123 | BUU 0.4mg/ml | - | - | - | - | 1件: 98 98 💬 |
1124 | BV-101 | - | - | - | - | 1件: 8 8 💬 |
1125 | BX-1 | - | - | - | - | 1件: 13 13 💬 |
1126 | C-028380 | - | - | - | - | 1件: 106 106 💬 |
1127 | C-11 PiB | 1件: Pittsburgh Compound B Pittsburgh Compound B | - | - | - | 1件: 127 127 💬 |
1128 | C-82 Topical Gel, 1% | - | - | - | - | 1件: 51 51 💬 |
1129 | C326, IL-6 Inhibitory Avimer protein | - | - | - | - | 1件: 96 96 💬 |
1130 | Cabaseril, 1,0 mg Tablette | - | - | - | - | 1件: 6 6 💬 |
1131 | Cabaseril, 2,0 mg Tablette | - | - | - | - | 1件: 6 6 💬 |
1132 | CAEL-101 | - | - | - | - | 1件: 28 28 💬 |
1133 | Caffeine 100-200 mg BID | 1件: Caffeine Caffeine | 2件: Caffeine
Caffeine
,
Caffeine hydrate
💬 | 11件: ADORA1 ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 | 22件: Alcoholism Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1134 | CALCIUM D3 SANDOZ - 1000 MG + 880 U.I. COMPRESSE EFFERVESCENTI 30 COMPRESSE DIVISIBILI | 2件: Calcium Calcium, Calcium carbonate | 2件: Calcium carbonate
Calcium carbonate
,
Calcium carbonate
💬 | - | - | 1件: 274 274 💬 |
1135 | Calvan® 100 mg | - | - | - | - | 1件: 8 8 💬 |
1136 | CALY-002 | - | - | - | - | 1件: 98 98 💬 |
1137 | CAM-3001 | 1件: Mavrilimumab Mavrilimumab | 1件: Mavrilimumab
Mavrilimumab
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 💬 |
1138 | Camoteskimab (CERC-007, AVTX-007, AEVI-007) | - | - | - | - | 1件: 107 107 💬 |
1139 | Campath -1H | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 65 65 💬 |
1140 | Campath 1H | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 4件: 60 60, 65, 164, 285 💬 |
1141 | Campath-1H | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 6件: 19 19, 20, 60, 234, 285, 326 💬 |
1142 | CAMPATH-1H (Alemtuzumab) | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 60 60 💬 |
1143 | Cannabidiol Oral Solution, is known as Epidyolex 100 mg/mL oral solution and is the approved name in the EU. Epidiolex (cannabidiol) oral solution is the approved name in the US. | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 158 158 💬 |
1144 | Cannabidiol tablet 10 mg | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 2件: 46 46, 271 💬 |
1145 | CAP-1002 | 1件: CAP-1002 CAP-1002 | - | - | - | 1件: 113 113 💬 |
1146 | Caplacizumab (ALX-0081) | 1件: Caplacizumab Caplacizumab | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
1147 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
1148 | Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1149 | Capsules with 160 mg Teavigo (at least 94% EGCG) | 1件: Epigallocatechin gallate Epigallocatechin gallate | - | - | - | 1件: 13 13 💬 |
1150 | Carbidopa 65 mg capsule | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
1151 | Carbidopa and Levodopa 25mg/100mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1152 | Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1153 | CARBOLITHIUM*100CPS 150MG | - | - | - | - | 1件: 2 2 💬 |
1154 | Carbomer 974P | 2件: Carbomer Carbomer, Carbopol 974P | - | - | - | 1件: 53 53 💬 |
1155 | Carbon-14 BIA 28-6156 | 2件: Activated charcoal Activated charcoal, BIA | - | - | - | 1件: 6 6 💬 |
1156 | CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 💬 |
1157 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
1158 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
1159 | CAS No.: 7758-16-9 | - | - | - | - | 1件: 166 166 💬 |
1160 | CAS# in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 💬 |
1161 | CAT-1004 | - | - | - | - | 1件: 113 113 💬 |
1162 | CAT-354 | - | - | - | - | 1件: 97 97 💬 |
1163 | Catapresan 75 | - | - | - | - | 1件: 78 78 💬 |
1164 | Catapresan 75, Tabletten | - | - | - | - | 1件: 65 65 💬 |
1165 | Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) | - | - | - | - | 1件: 85 85 💬 |
1166 | Cayston 75 mg Pulver und Lösungsmittel zur Herstellung einer Lösung für einen Vernebler | 1件: Aztreonam Aztreonam | 1件: Aztreonam
Aztreonam
💬 | - | - | 1件: 299 299 💬 |
1167 | CAYSTON aztreonam 75 mg powder and solvent for nebuliser solution | 1件: Aztreonam Aztreonam | 1件: Aztreonam
Aztreonam
💬 | - | - | 1件: 299 299 💬 |
1168 | CB-01-02 | - | - | - | - | 1件: 97 97 💬 |
1169 | CB-01-05-MMX | - | - | - | - | 1件: 97 97 💬 |
1170 | CBD - Oral Solution, is known as Epidyolex 100 mg/ml oral solution, | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 158 158 💬 |
1171 | CBP-307 | - | - | - | - | 1件: 97 97 💬 |
1172 | CC-100004 | - | - | - | - | 1件: 84 84 💬 |
1173 | CC-10004 | - | - | - | - | 5件: 46 46, 56, 97, 162, 271 💬 |
1174 | CC-220 0.3 mg Daily | - | - | - | - | 1件: 84 84 💬 |
1175 | CC-220 0.6mg Daily | - | - | - | - | 1件: 84 84 💬 |
1176 | CC-90001 | - | - | - | - | 1件: 85 85 💬 |
1177 | CC-930 | - | - | - | - | 1件: 85 85 💬 |
1178 | CC-93538 | - | - | - | - | 1件: 98 98 💬 |
1179 | CC-99677 | - | - | - | - | 1件: 271 271 💬 |
1180 | CC-99677 30mg Capsule | - | - | - | - | 1件: 271 271 💬 |
1181 | CC-99677 60mg Capsule | - | - | - | - | 1件: 271 271 💬 |
1182 | CCD 1042 | - | - | - | - | 1件: 152 152 💬 |
1183 | CCD 1042, MD 9150000, Mepalon 1042, SPT316 | - | - | - | - | 2件: 152 152, 206 💬 |
1184 | CCD 1042, MD 9150000, Mepalon 1042, SPT3162 | - | - | - | - | 1件: 152 152 💬 |
1185 | CCI-779 | - | - | - | - | 2件: 13 13, 46 💬 |
1186 | CCP-020 | - | - | - | - | 1件: 36 36 💬 |
1187 | CCP-690-550-10 | - | - | - | - | 1件: 107 107 💬 |
1188 | CCX 354 | - | - | - | - | 1件: 46 46 💬 |
1189 | CCX 354-C | - | - | - | - | 1件: 46 46 💬 |
1190 | CCX-354 | 1件: CCX-354 CCX-354 | - | - | - | 1件: 46 46 💬 |
1191 | CCX-354-C | 1件: CCX-354 CCX-354 | - | - | - | 1件: 46 46 💬 |
1192 | CDP870 100mg | - | - | - | - | 1件: 46 46 💬 |
1193 | CDX 6114 | - | - | - | - | 1件: 240 240 💬 |
1194 | CDX-1135 | - | - | - | - | 1件: 222 222 💬 |
1195 | Cenerimod 0.5 mg | 1件: Cenerimod Cenerimod | 1件: Cenerimod
Cenerimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 💬 |
1196 | Cenerimod 1 mg | 1件: Cenerimod Cenerimod | 1件: Cenerimod
Cenerimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 💬 |
1197 | Cenicriviroc 150 mg | 1件: Cenicriviroc Cenicriviroc | 1件: Cenicriviroc
Cenicriviroc
💬 | 2件: CCR2 CCR2, CCR5 💬 | 11件: Chemokine signaling pathway Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 94 94 💬 |
1198 | CEP-1347 | 1件: CEP-1347 CEP-1347 | - | - | - | 1件: 6 6 💬 |
1199 | CEP-1347 10mg | 1件: CEP-1347 CEP-1347 | - | - | - | 1件: 6 6 💬 |
1200 | CEP-1347 50mg | 1件: CEP-1347 CEP-1347 | - | - | - | 1件: 6 6 💬 |
1201 | CEP-33457 | - | - | - | - | 1件: 49 49 💬 |
1202 | CER-001 | - | - | - | - | 1件: 79 79 💬 |
1203 | CERC-006 | - | - | - | - | 1件: 278 278 💬 |
1204 | CERE-120 | - | - | - | - | 1件: 6 6 💬 |
1205 | CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) | - | - | - | - | 1件: 6 6 💬 |
1206 | CERE-120: AAV2-NTN | - | - | - | - | 1件: 6 6 💬 |
1207 | CERE-120: Adeno-Associated Virus Delivery of Neurturin | - | - | - | - | 1件: 6 6 💬 |
1208 | Certican 0,5 | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
1209 | Certican 0,5 mg Tabletten | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
1210 | Certican 0,75mg | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
1211 | Certican 0,75mg Tabletten | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
1212 | Certican 1 mg tablets | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
1213 | CETIRIZINA SANDOZ - 10 MG COMPRESSE RIVESTITE CON FILM 20 COMPRESSE IN BLISTER PVC/ALU | 1件: Cetirizine Cetirizine | 1件: Cetirizine
Cetirizine
💬 | 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 300 300 💬 |
1214 | CF101 1 mg | - | - | - | - | 1件: 46 46 💬 |
1215 | CFZ533 active - Cohort 1 | - | - | - | - | 1件: 53 53 💬 |
1216 | CFZ533 active - Cohort 3 | - | - | - | - | 1件: 53 53 💬 |
1217 | CFZ533 active -Cohort 3 | - | - | - | - | 1件: 53 53 💬 |
1218 | CGP 77116 | - | - | - | - | 1件: 13 13 💬 |
1219 | CH-1504 | - | - | - | - | 1件: 46 46 💬 |
1220 | Ch11-1F4 (NSC-711516) | - | - | - | - | 1件: 28 28 💬 |
1221 | ChAdOx1 nCoV-19 | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 299 💬 |
1222 | CHF 6333 | - | - | - | - | 1件: 299 299 💬 |
1223 | CHF6333 (Part 1 - SAD) | - | - | - | - | 1件: 299 299 💬 |
1224 | CHIMERIC FIBRIL-REACTIVE IGG1K MONOCLONAL ANTIBODY 11-1F4 | - | - | - | - | 1件: 28 28 💬 |
1225 | Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4 | - | - | - | - | 1件: 28 28 💬 |
1226 | Chimeric murine human anti-IL-6 monoclonal antibody | - | - | - | - | 1件: 331 331 💬 |
1227 | Chinese herbal concoction twice a day for 6 months | - | - | - | - | 1件: 60 60 💬 |
1228 | Cholecalciferol 10,000 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
1229 | CHR-1103 / GBR500 | - | - | - | - | 1件: 13 13 💬 |
1230 | Chronocort 10mg | - | - | - | - | 1件: 81 81 💬 |
1231 | Chronocort® 10 mg | - | - | - | - | 1件: 81 81 💬 |
1232 | CHS-0214 | - | - | - | - | 1件: 46 46 💬 |
1233 | CI-984 | - | - | - | - | 1件: 75 75 💬 |
1234 | CI-984, 17AA70, PD 132301-2 | - | - | - | - | 1件: 81 81 💬 |
1235 | Cialis 10 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: Tadalafil
Tadalafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 113 💬 |
1236 | Cilostazol 100 MG | 1件: Cilostazol Cilostazol | 1件: Cilostazol
Cilostazol
💬 | 3件: PDE3A PDE3A, PDE3B, TBXA2R 💬 | 14件: Apelin signaling pathway Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Platelet activation, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
1237 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1238 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1239 | CIPROXIN - 500 MG COMPRESSE RIVESTITE 14 COMPRESSE | - | - | - | - | 1件: 299 299 💬 |
1240 | CIPROXIN*6CPR RIV 500MG | - | - | - | - | 1件: 299 299 💬 |
1241 | CITICOLIN*1G/4ML IM IV 5 F | - | - | - | - | 1件: 6 6 💬 |
1242 | Citicolina 1000 mg/die | 1件: Citicoline Citicoline | 1件: Citicoline
Citicoline
💬 | - | - | 1件: 6 6 💬 |
1243 | CJNJ-68150420-ZZZ-G001 (ACT- 064992D) | - | - | - | - | 1件: 86 86 💬 |
1244 | CJNJ-68150420-ZZZ-G001 (ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
1245 | CJNJ-68150420-ZZZ-G001(ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
1246 | CK-3773274 | - | - | - | - | 1件: 58 58 💬 |
1247 | CK-3773274 (10 - 30 mg) | - | - | - | - | 1件: 58 58 💬 |
1248 | CK-3773274 (5 - 15 mg) | - | - | - | - | 1件: 58 58 💬 |
1249 | CK-3773274 (5 - 20 mg) | - | - | - | - | 1件: 58 58 💬 |
1250 | CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg) | - | - | - | - | 1件: 58 58 💬 |
1251 | CK-3773274 - Granules in Capsule | - | - | - | - | 1件: 58 58 💬 |
1252 | CK-3773274 - Tablets | - | - | - | - | 1件: 58 58 💬 |
1253 | CKD-374 5mg Tab. | - | - | - | - | 1件: 46 46 💬 |
1254 | Cladribine 3.5 mg/kg | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
1255 | Clemastine Milstein 1 mg, tabletten | 1件: Clemastine Clemastine | 1件: Clemastine
Clemastine
💬 | 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
1256 | Clipper 30 cpr 5mg R.M. | - | - | - | - | 1件: 97 97 💬 |
1257 | CLIPPER*30CPR 5MG R.M. | - | - | - | - | 1件: 97 97 💬 |
1258 | Clobazam Tablets 10mg | 1件: Clobazam Clobazam | 1件: Clobazam
Clobazam
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 💬 |
1259 | Clobetasol 0.05% ointment | 1件: Clobetasol Clobetasol | 1件: Clobetasol
Clobetasol
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 39 39 💬 |
1260 | Clobetasol 0.05% Topical Ointment | 1件: Clobetasol Clobetasol | 1件: Clobetasol
Clobetasol
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 💬 |
1261 | Clonidine HCl CF 0,150 mg, tabletten | 1件: Clonidine Clonidine | 1件: Clonidine
Clonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 78 78 💬 |
1262 | CLORURO SODICO 7% | - | - | - | - | 1件: 299 299 💬 |
1263 | CLTX-305 | - | - | - | - | 1件: 235 235 💬 |
1264 | CM-101 | - | - | - | - | 1件: 94 94 💬 |
1265 | CNP-104 | - | - | - | - | 1件: 93 93 💬 |
1266 | Cnp-MS-0601 | - | - | - | - | 1件: 13 13 💬 |
1267 | CNSA-001 | - | - | - | - | 1件: 240 240 💬 |
1268 | CNT-02 | - | - | - | - | 1件: 160 160 💬 |
1269 | CNTO 1275 | - | - | - | - | 2件: 13 13, 96 💬 |
1270 | CNTO 136 | - | - | - | - | 2件: 41 41, 46 💬 |
1271 | CNTO 136 100 mg | - | - | - | - | 1件: 46 46 💬 |
1272 | CNTO 136 25 mg | - | - | - | - | 1件: 46 46 💬 |
1273 | CNTO 136 50 mg | - | - | - | - | 1件: 46 46 💬 |
1274 | CNTO 136 IgG | - | - | - | - | 1件: 46 46 💬 |
1275 | CNTO 148 | - | - | - | - | 4件: 46 46, 84, 97, 271 💬 |
1276 | CNTO 148 (Golimumab) | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
1277 | CNTO 1959 | - | - | - | - | 1件: 46 46 💬 |
1278 | CNTO 1959 + MTX (Group 4) | - | - | - | - | 1件: 46 46 💬 |
1279 | CNTO 1959 + MTX (Group 5) | - | - | - | - | 1件: 46 46 💬 |
1280 | CNTO 1959 IgG | - | - | - | - | 1件: 46 46 💬 |
1281 | CNTO 328 | - | - | - | - | 1件: 331 331 💬 |
1282 | CNTO 6785 100 mg | - | - | - | - | 1件: 46 46 💬 |
1283 | CNTO 6785 15 mg | - | - | - | - | 1件: 46 46 💬 |
1284 | CNTO 6785 200 mg | - | - | - | - | 1件: 46 46 💬 |
1285 | CNTO 6785 50 mg | - | - | - | - | 1件: 46 46 💬 |
1286 | CNTO 888 1 mg/kg | - | - | - | - | 1件: 85 85 💬 |
1287 | CNTO 888 15 mg/kg | - | - | - | - | 1件: 85 85 💬 |
1288 | CNTO-148 | - | - | - | - | 1件: 97 97 💬 |
1289 | CO-14 | - | - | - | - | 1件: 13 13 💬 |
1290 | Coenzyme Q-10 | 1件: Ubidecarenone Ubidecarenone | 1件: Ubidecarenone
Ubidecarenone
💬 | - | - | 1件: 86 86 💬 |
1291 | Coenzyme Q-10 in Normal Control subjects | 1件: Ubidecarenone Ubidecarenone | 1件: Ubidecarenone
Ubidecarenone
💬 | - | - | 1件: 86 86 💬 |
1292 | Coenzyme Q-10 in Pulmonary Hypertension subjects | 1件: Ubidecarenone Ubidecarenone | 1件: Ubidecarenone
Ubidecarenone
💬 | - | - | 1件: 86 86 💬 |
1293 | Cohort 1 0.225g | - | - | - | - | 1件: 240 240 💬 |
1294 | Cohort 1: 1.0 x 10^8 PolyTregs | - | - | - | - | 1件: 35 35 💬 |
1295 | Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
1296 | Cohort 1:Nilotinib Oral Capsules (150mg or 300mg) | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
1297 | Cohort 2 0.75g | - | - | - | - | 1件: 240 240 💬 |
1298 | Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
1299 | Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1) | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
1300 | Cohort 3 2.25 g | - | - | - | - | 1件: 240 240 💬 |
1301 | Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
1302 | COLCHICINA LIRCA - 1 MG COMPRESSE 60 COMPRESSE | 1件: Colchicine Colchicine | 1件: Colchicine
Colchicine
💬 | 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 2 2 💬 |
1303 | Colchicine 1 MG Oral Tablet | 1件: Colchicine Colchicine | 1件: Colchicine
Colchicine
💬 | 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 2 2 💬 |
1304 | COLIMICINA - 1000000 U/4 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 4 ML | - | - | - | - | 1件: 299 299 💬 |
1305 | Colistimethate 75 mg inhaled two times daily | 1件: Colistimethate Colistimethate | - | - | - | 1件: 299 299 💬 |
1306 | Collect of 10 ml of peripheric blood for DNA extraction | - | - | - | - | 1件: 46 46 💬 |
1307 | Combination Product: EGCG 300 mg + Nintedanib | 2件: Epigallocatechin gallate Epigallocatechin gallate, Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
1308 | Combination Product: EGCG 300 mg + Pirfenidone | 2件: Epigallocatechin gallate Epigallocatechin gallate, Pirfenidone | 1件: Pirfenidone
Pirfenidone
💬 | 6件: CCL2 CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 | 84件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
1309 | Combination Product: EGCG 600 mg + Nintedanib | 2件: Epigallocatechin gallate Epigallocatechin gallate, Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
1310 | Combination Product: EGCG 600 mg + Pirfenidone | 2件: Epigallocatechin gallate Epigallocatechin gallate, Pirfenidone | 1件: Pirfenidone
Pirfenidone
💬 | 6件: CCL2 CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 | 84件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
1311 | Combination Product: L-dopa 140 mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1312 | Combination Product: L-dopa 35 mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1313 | Combination Product: L-dopa 70mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1314 | Combination Product: L-dopa 70mg/carbidopa 7mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1315 | Combivir (zidovudine [AZT] / lamivudine [3TC]) | 2件: Lamivudine Lamivudine, Zidovudine | 2件: Lamivudine
Lamivudine
,
Zidovudine
💬 | - | - | 1件: 265 265 💬 |
1316 | Compound 1a | - | - | - | - | 2件: 246 246, 299 💬 |
1317 | Compound thrombosis capsule sig: 1.5g/tid | - | - | - | - | 1件: 90 90 💬 |
1318 | Compressa effervescente 0,5 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1319 | Compressa effervescente 1 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1320 | COMTAN 200* 60 CPR 200 MG | 1件: Entacapone Entacapone | 1件: Entacapone
Entacapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
1321 | Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d | 1件: Conjugated estrogens Conjugated estrogens | 1件: Estrogens, conjugated
Estrogens, conjugated
💬 | - | - | 1件: 49 49 💬 |
1322 | Control Group 0.9% Isotonic Saline | - | - | - | - | 1件: 299 299 💬 |
1323 | COP-1 | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
1324 | COP-1/Copolymer-1 | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
1325 | COPAXONE - 20 MG/ML SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE 30 SIRINGHE | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
1326 | COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
1327 | Copolymer 1 | - | - | - | - | 1件: 13 13 💬 |
1328 | Copolymer-1 | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
1329 | COPPER (64CU) CHLORIDE | 2件: Chloride ion Chloride ion, Copper | - | - | - | 1件: 171 171 💬 |
1330 | COR-003 | - | - | - | - | 1件: 75 75 💬 |
1331 | Cortancyl ® 1 mg | 1件: Prednisone acetate Prednisone acetate | 1件: Prednisone acetate
Prednisone acetate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
1332 | CortimentMMX 9 mg | - | - | - | - | 1件: 97 97 💬 |
1333 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 107 107 💬 |
1334 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 107 107 💬 |
1335 | Cosentyx 300 mg solution for injection in pre-filled syringe | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
1336 | Cosentyx 300mg solution for injection in pre-filled syringe | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
1337 | Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin | 2件: Tetracosactide Tetracosactide, Vigabatrin | 2件: Cosyntropin
Cosyntropin
,
Vigabatrin
💬 | 2件: ABAT ABAT, MC2R 💬 | 12件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, Metabolic pathways, Neuroactive ligand-receptor interaction, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, cAMP signaling pathway 💬 | 1件: 145 145 💬 |
1338 | Cosyntropin Injectable Suspension, 1 mg/mL | 1件: Tetracosactide Tetracosactide | 1件: Cosyntropin
Cosyntropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 145 145 💬 |
1339 | COVID-19 mRNA Vaccine (nucleoside modified) | - | - | - | - | 3件: 13 13, 46, 51 💬 |
1340 | COVID-19 mRNA vaccine (nucleoside-modified) | - | - | - | - | 4件: 13 13, 46, 51, 299 💬 |
1341 | COVID-19 mRNA vaccine Moderna (CX-024414) | - | - | - | - | 4件: 13 13, 46, 51, 299 💬 |
1342 | COVID-19 vaccination | - | - | - | - | 1件: 13 13 💬 |
1343 | COVID-19 vaccine | - | - | - | - | 3件: 46 46, 49, 51 💬 |
1344 | COVID-19 vaccine (Ad26.COV2-S [recombinant]) | - | - | - | - | 1件: 299 299 💬 |
1345 | COVID-19 Vaccine (ChAdOx1-S [recombinant]) | - | - | - | - | 3件: 46 46, 51, 299 💬 |
1346 | COVID-19 Vaccine AstraZeneca | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 53 💬 |
1347 | COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19) | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 299 💬 |
1348 | COVID-19 Vaccine AstraZeneca suspension for injection COVID-19 Vaccine (ChAdOx1-S [recombinant]) | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 1件: 53 53 💬 |
1349 | Covid-19 Vaccine Janssen | 1件: Janssen COVID-19 Vaccine Janssen COVID-19 Vaccine | 1件: COVID-19 vaccine
COVID-19 vaccine
💬 | - | - | 2件: 53 53, 299 💬 |
1350 | COVID-19 Vaccine Janssen suspension for injection | 1件: Janssen COVID-19 Vaccine Janssen COVID-19 Vaccine | 1件: COVID-19 vaccine
COVID-19 vaccine
💬 | - | - | 1件: 299 299 💬 |
1351 | COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant]) | 1件: Janssen COVID-19 Vaccine Janssen COVID-19 Vaccine | 1件: COVID-19 vaccine
COVID-19 vaccine
💬 | - | - | 2件: 53 53, 299 💬 |
1352 | COVID-19 Vaccine Moderna | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: Elasomeran
Elasomeran
💬 | - | - | 4件: 46 46, 51, 65, 299 💬 |
1353 | COVID-19 Vaccine Moderna dispersion for injection | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: Elasomeran
Elasomeran
💬 | - | - | 1件: 299 299 💬 |
1354 | COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula | 1件: Losartan Losartan | 1件: Losartan
Losartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 167 167 💬 |
1355 | CP 690,550 | - | - | - | - | 1件: 46 46 💬 |
1356 | CP 690550 MR | - | - | - | - | 1件: 46 46 💬 |
1357 | CP- 690 550 | - | - | - | - | 1件: 97 97 💬 |
1358 | CP-195,543 | - | - | - | - | 1件: 46 46 💬 |
1359 | CP-690, 550 - 10 | - | - | - | - | 1件: 46 46 💬 |
1360 | CP-690, 550-10 | - | - | - | - | 2件: 97 97, 107 💬 |
1361 | CP-690,500 5 mg | - | - | - | - | 1件: 97 97 💬 |
1362 | CP-690,55-10 | - | - | - | - | 1件: 46 46 💬 |
1363 | CP-690,550 | - | - | - | - | 5件: 46 46, 96, 97, 107, 271 💬 |
1364 | CP-690,550 (tasocitinib) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
1365 | CP-690,550 (tofacitinib) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 107 💬 |
1366 | CP-690,550 + methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1367 | CP-690,550 10 mg | - | - | - | - | 1件: 97 97 💬 |
1368 | CP-690,550 – 10 | - | - | - | - | 1件: 46 46 💬 |
1369 | CP-690,550-10 | - | - | - | - | 5件: 46 46, 96, 97, 107, 271 💬 |
1370 | CP-690-550 | - | - | - | - | 1件: 46 46 💬 |
1371 | CP-690-550-10 | - | - | - | - | 1件: 107 107 💬 |
1372 | CP-690-550-10 (DMID D1600180) | - | - | - | - | 1件: 107 107 💬 |
1373 | CR 1 | - | - | - | - | 1件: 46 46 💬 |
1374 | CR 3 | - | - | - | - | 1件: 46 46 💬 |
1375 | CR845 1.0 mg | - | - | - | - | 1件: 93 93 💬 |
1376 | CRC3357, ZK-355322, Leukoton | - | - | - | - | 1件: 299 299 💬 |
1377 | CRD-TMH-001 | - | - | - | - | 1件: 113 113 💬 |
1378 | Creatine-13C | 1件: Creatine Creatine | - | - | - | 1件: 113 113 💬 |
1379 | Crema de rapamicina al 1% y excipientes | - | - | - | - | 1件: 157 157 💬 |
1380 | Creon 10.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
1381 | Creon 10000 | - | - | - | - | 2件: 298 298, 299 💬 |
1382 | CREON 10000 Capsules | - | - | - | - | 1件: 299 299 💬 |
1383 | Creon 25.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
1384 | Creon 40.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
1385 | Creon® 25,000 | - | - | - | - | 1件: 299 299 💬 |
1386 | Crinecerfont is a novel non-peptide selective corticotropin releasing factor 1 (CRF1 ) receptor antagonist. | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 81 81 💬 |
1387 | CRx-102 | - | - | - | - | 1件: 46 46 💬 |
1388 | CRx-102 (2.7/180) | - | - | - | - | 1件: 46 46 💬 |
1389 | CRx-102 (2.7/360) | - | - | - | - | 1件: 46 46 💬 |
1390 | CRX-139 | 1件: CRx-139 CRx-139 | - | - | - | 1件: 46 46 💬 |
1391 | CRx-150 | - | - | - | - | 1件: 46 46 💬 |
1392 | CS-0777 tablets | - | - | - | - | 1件: 13 13 💬 |
1393 | CST-103 | - | - | - | - | 1件: 6 6 💬 |
1394 | CST-107 | - | - | - | - | 1件: 6 6 💬 |
1395 | CST-139 | - | - | - | - | 1件: 6 6 💬 |
1396 | CTI-1601 | 1件: CTI-1601 CTI-1601 | - | - | - | 1件: 18 18 💬 |
1397 | CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST) | - | - | - | - | 1件: 19 19 💬 |
1398 | Cu-64 DOTATATE | 1件: Dotatate Dotatate | - | - | - | 1件: 84 84 💬 |
1399 | Cudetaxestat (BLD-0409) | - | - | - | - | 1件: 85 85 💬 |
1400 | Cuprior 150 mg | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
1401 | Cuprior 150 mg film-coated tablets | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
1402 | Cuprior 150mg film-coated tablets | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
1403 | Cura-100 | - | - | - | - | 1件: 46 46 💬 |
1404 | Curcuma Longa Extract cpl formaat 00 23,2 x 8,5 mm 723 mg | 1件: Turmeric Turmeric | - | - | - | 1件: 299 299 💬 |
1405 | CVL-751 | - | - | - | - | 1件: 6 6 💬 |
1406 | CVT-301 | - | - | - | - | 1件: 6 6 💬 |
1407 | CVT-301 (Dose Level 1) | - | - | - | - | 1件: 6 6 💬 |
1408 | CVT-301 (Dose Level 2) | - | - | - | - | 1件: 6 6 💬 |
1409 | CVT-301 35mg | - | - | - | - | 1件: 6 6 💬 |
1410 | CVT-301 50mg | - | - | - | - | 1件: 6 6 💬 |
1411 | CVT-301 High Dose | - | - | - | - | 1件: 6 6 💬 |
1412 | CVT-301 Low Dose | - | - | - | - | 1件: 6 6 💬 |
1413 | CVT-301, LIP | - | - | - | - | 1件: 6 6 💬 |
1414 | CVXL-0107 | - | - | - | - | 1件: 6 6 💬 |
1415 | CX-016492 | - | - | - | - | 1件: 245 245 💬 |
1416 | CX-017950 | - | - | - | - | 1件: 245 245 💬 |
1417 | CXA-10 | 1件: CXA-10 CXA-10 | - | - | - | 2件: 86 86, 222 💬 |
1418 | Cyclophosphamide (CY) (Plan 1) | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 60 60, 285 💬 |
1419 | Cyclophosphamide 100mg | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 1件: 60 60 💬 |
1420 | Cyclophosphamide 150mg | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 1件: 60 60 💬 |
1421 | Cyclophosphamide 30 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 3件: 65 65, 285, 326 💬 |
1422 | Cyclophosphamide Dose Level 1 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
1423 | Cyclophosphamide Dose Level 3 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
1424 | Cyclophosphamide Injection 1g | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 3件: 50 50, 51, 52 💬 |
1425 | Cyclosporine 0.09% Ophthalmic Solution | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 53 53 💬 |
1426 | Cyclosporine 5 mg/kg bid days 0-14 | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 38 38, 39 💬 |
1427 | CYSTADROPS 0.55% eye drops, solution | 1件: Cysteamine Cysteamine | 1件: Cysteamine
Cysteamine
💬 | - | - | 1件: 19 19 💬 |
1428 | Cystagon 150mg | 1件: Cysteamine Cysteamine | 1件: Cysteamine
Cysteamine
💬 | - | - | 1件: 19 19 💬 |
1429 | Cápsulas de Laquinimod 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1430 | Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada PEI nº 12-088) | - | - | - | - | 1件: 274 274 💬 |
1431 | D-a-tocopheryl PEG 1000 succinate | - | - | - | - | 1件: 299 299 💬 |
1432 | D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1) | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 28 28 💬 |
1433 | D-glucitol, 1-deoxy-1-(methylamino)-,2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1) | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 28 28 💬 |
1434 | D-penicillamine 150mg | 1件: Penicillamine Penicillamine | 1件: Penicillamine
Penicillamine
💬 | - | - | 1件: 171 171 💬 |
1435 | D.3.2 Product code where applicable13: | - | - | - | - | 1件: 193 193 💬 |
1436 | D.3.6.2 - dose massima specificare: giornaliera | - | - | - | - | 1件: 86 86 💬 |
1437 | D.3.6.2.1 - valore: 45 / 0.45 mg/ml | - | - | - | - | 1件: 97 97 💬 |
1438 | D.3.6.2.1 - valore: 5 o 10 mg/kg | - | - | - | - | 1件: 97 97 💬 |
1439 | D9421-C capsule 3 mg | - | - | - | - | 1件: 96 96 💬 |
1440 | D9421-C, 15mg | - | - | - | - | 1件: 96 96 💬 |
1441 | D9421-C, 9mg | - | - | - | - | 1件: 96 96 💬 |
1442 | DA-9701 | - | - | - | - | 1件: 6 6 💬 |
1443 | DA-9805 45mg | - | - | - | - | 1件: 6 6 💬 |
1444 | DA-9805 90mg | - | - | - | - | 1件: 6 6 💬 |
1445 | Dacortín 30mg | - | - | - | - | 1件: 222 222 💬 |
1446 | Dalfampridine ER, 10 Mg Oral Tablet, Extended Release | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1447 | Dalfampridine-ER 10mg | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1448 | DAND (14-Deoxyandrographolide) | - | - | - | - | 1件: 97 97 💬 |
1449 | Dapagliflozin 10 MG [Farxiga] | 1件: Dapagliflozin Dapagliflozin | 1件: Dapagliflozin
Dapagliflozin
💬 | 1件: SLC5A2 SLC5A2 💬 | - | 2件: 86 86, 88 💬 |
1450 | Dapagliflozin 10mg Tab | 1件: Dapagliflozin Dapagliflozin | 1件: Dapagliflozin
Dapagliflozin
💬 | 1件: SLC5A2 SLC5A2 💬 | - | 1件: 19 19 💬 |
1451 | DAS-001 | - | - | - | - | 1件: 11 11 💬 |
1452 | DaTSCAN 74 MBq/ml solution for injection | 1件: Ioflupane I-123 Ioflupane I-123 | - | - | - | 1件: 6 6 💬 |
1453 | Davunetide (AL-108, NAP) | 1件: Davunetide Davunetide | 1件: Davunetide
Davunetide
💬 | - | - | 3件: 5 5, 7, 127 💬 |
1454 | Dazucorilant 150 mg | - | - | - | - | 1件: 2 2 💬 |
1455 | Dazucorilant 300 mg | - | - | - | - | 1件: 2 2 💬 |
1456 | DCI 1020 | - | - | - | - | 1件: 299 299 💬 |
1457 | DCR-1171X | - | - | - | - | 1件: 234 234 💬 |
1458 | DDAND (14-deoxy-11,12-didehydroandrographolide) | - | - | - | - | 1件: 97 97 💬 |
1459 | Decortin H 1 mg | - | - | - | - | 1件: 97 97 💬 |
1460 | Decortin H 10mg | - | - | - | - | 1件: 97 97 💬 |
1461 | Defanyl 50 and 100 mg | - | - | - | - | 1件: 46 46 💬 |
1462 | Deferiprone 30mg | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 6 6 💬 |
1463 | Deferiprone 600 mg delayed release tablet | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 6 6 💬 |
1464 | DEFLAN*10CPR 6MG | - | - | - | - | 1件: 113 113 💬 |
1465 | Deflazacort 6 mg Tablets | 1件: Deflazacort Deflazacort | 1件: Deflazacort
Deflazacort
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
1466 | Dehydroepiandrosterone 100 and 400 mg | 1件: Prasterone Prasterone | 1件: Prasterone
Prasterone
💬 | 3件: AR AR, ESR1, ESR2 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 113 113 💬 |
1467 | Dekristol 20.000 ie | - | - | - | - | 1件: 96 96 💬 |
1468 | Dekristol®-Tablette 1 (400 IE) | - | - | - | - | 1件: 13 13 💬 |
1469 | Delayed Release 6 mercaptopurine | 1件: Mercaptopurine Mercaptopurine | 2件: Mercaptopurine
Mercaptopurine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 96 96 💬 |
1470 | Delayed Release 6MP or Calcitriol vs. Purinethol | 1件: Calcitriol Calcitriol | 1件: Calcitriol
Calcitriol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
1471 | Delta-9-tetrahydrocannabinol | 1件: Dronabinol Dronabinol | 1件: Dronabinol
Dronabinol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 3件: 8 8, 13, 36 💬 |
1472 | Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) | 2件: Cannabidiol Cannabidiol, Dronabinol | 2件: Dronabinol
Dronabinol
,
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 8 8 💬 |
1473 | Deltacortene 10 cpr 25mg | - | - | - | - | 1件: 97 97 💬 |
1474 | DELTACORTENE FORTE*10CPR 25MG | - | - | - | - | 2件: 46 46, 97 💬 |
1475 | DELTACORTENE*10CPR 25MG | - | - | - | - | 1件: 84 84 💬 |
1476 | DEPALGOS*20+325MG 28CPR RP | - | - | - | - | 1件: 46 46 💬 |
1477 | Depot leuprolide acetate 3.75 mg | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 51 51 💬 |
1478 | Descartes-08 | - | - | - | - | 1件: 11 11 💬 |
1479 | Desmopressine nasal spray 10 mg/ml, flacon 60 doses | 1件: Desmopressin Desmopressin | 1件: Desmopressin
Desmopressin
💬 | 2件: AVPR2 AVPR2, F8 💬 | 4件: Complement and coagulation cascades Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 225 225 💬 |
1480 | Desmotabs® 0,2 mg Tabletten | - | - | - | - | 1件: 6 6 💬 |
1481 | Desmotabs® 0,2mg Tabletten | - | - | - | - | 1件: 6 6 💬 |
1482 | Dexamethasone (1 cycle) | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 63 63 💬 |
1483 | Dexamethasone (50mg 1dd6, 3 consecutive days/month) | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 35 35 💬 |
1484 | Dexamethasone 0,1 mg Tablets | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
1485 | Dexamethasone 0,5mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
1486 | Dexamethasone 0.5mg Tablet | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
1487 | Dexamethasone 0.5mg/5ml solution | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 💬 |
1488 | Dexamethasone 0.5mg/5ml solution in Mucolox™ | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 💬 |
1489 | Dexamethasone 1,5 mg Tablets | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
1490 | Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland). | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 235 235 💬 |
1491 | Dexamethasone Oral, 10 mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 28 28 💬 |
1492 | Dexamethasone sodium phosphate 250 mg/ 10 ml | 2件: Dexamethasone Dexamethasone, Phosphate ion | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
1493 | Dexamethasone sodium phosphate 250 mg/10 ml solution | 2件: Dexamethasone Dexamethasone, Phosphate ion | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 299 299 💬 |
1494 | Dexmedetomidine 1 | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 280 280 💬 |
1495 | Dexmedetomidine 3 | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 280 280 💬 |
1496 | Dexmedetomidine Hcl 100 Mcg/mL Inj | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 215 215 💬 |
1497 | Dexpramipexole (dose 1) | 1件: Dexpramipexole Dexpramipexole | 1件: Dexpramipexole
Dexpramipexole
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
1498 | DEXTRAN 1 FOR INJECTION | 1件: Dextran Dextran | 1件: Dextran 1
Dextran 1
💬 | - | - | 1件: 97 97 💬 |
1499 | Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg | 3件: Dextromethorphan Dextromethorphan, Quinidine, Sulfate ion | 2件: Dextromethorphan
Dextromethorphan
,
Quinidine
💬 | 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 2件: 2 2, 13 💬 |
1500 | Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg | 3件: Dextromethorphan Dextromethorphan, Quinidine, Sulfate ion | 2件: Dextromethorphan
Dextromethorphan
,
Quinidine
💬 | 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 2件: 2 2, 13 💬 |
1501 | Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) | 2件: Dextromethorphan Dextromethorphan, Quinidine | 2件: Dextromethorphan
Dextromethorphan
,
Quinidine
💬 | 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 1件: 8 8 💬 |
1502 | DI-17E6 | - | - | - | - | 1件: 51 51 💬 |
1503 | Diacerein 1% Ointment | 1件: Diacerein Diacerein | 1件: Diacerein
Diacerein
💬 | - | - | 1件: 36 36 💬 |
1504 | DIBASE*IM OS 2F 1ML 300000UI/M | - | - | - | - | 1件: 46 46 💬 |
1505 | Diet 1 | - | - | - | - | 1件: 96 96 💬 |
1506 | Diethyl-[6-(4-hydroxycarbamoyl- phenyl carbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride | 2件: Ammonium chloride Ammonium chloride, Chloride ion | 1件: Ammonium chloride
Ammonium chloride
💬 | - | - | 1件: 107 107 💬 |
1507 | Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon | 2件: Ammonium chloride Ammonium chloride, Chloride ion | 1件: Ammonium chloride
Ammonium chloride
💬 | - | - | 1件: 96 96 💬 |
1508 | Digoxin 0.25 mg | 1件: Digoxin Digoxin | 1件: Digoxin
Digoxin
💬 | 4件: ATP1A1 ATP1A1, ATP1A2, ATP1A3, ATP1A4 💬 | 18件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Bile secretion, Carbohydrate digestion and absorption, Cardiac muscle contraction, Endocrine and other factor-regulated calcium reabsorption, Gastric acid secretion, Insulin secretion, Mineral absorption, Pancreatic secretion, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Thyroid hormone signaling pathway, Thyroid hormone synthesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
1509 | Diovan 160 mg | 1件: Valsartan Valsartan | 1件: Valsartan
Valsartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
1510 | DISC-1459 | - | - | - | - | 1件: 254 254 💬 |
1511 | Disodium Pamidronate 15mg (15mg strength) | 1件: Pamidronic acid Pamidronic acid | 1件: Pamidronic acid
Pamidronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
1512 | DIURF-006 | - | - | - | - | 1件: 81 81 💬 |
1513 | Dl-3-n-butylphthalide (NBP) | 1件: Butylphthalide Butylphthalide | - | - | - | 1件: 22 22 💬 |
1514 | DM-1992 | - | - | - | - | 1件: 6 6 💬 |
1515 | DNS-7801 (high dose) | - | - | - | - | 1件: 6 6 💬 |
1516 | DNS-7801 (low-dose) | - | - | - | - | 1件: 6 6 💬 |
1517 | Docosahexaenoic acid administration: 50 mg/kg/day during 12 months | 1件: Doconexent Doconexent | - | - | - | 1件: 299 299 💬 |
1518 | Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO] | 2件: Dolutegravir Dolutegravir, Lamivudine | 2件: Lamivudine
Lamivudine
,
Dolutegravir
💬 | - | - | 1件: 265 265 💬 |
1519 | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] | 4件: Doravirine Doravirine, Lamivudine, Tenofovir, Tenofovir disoproxil | 3件: Lamivudine
Lamivudine
,
Tenofovir
,
Doravirine
💬 | - | - | 1件: 265 265 💬 |
1520 | Dose level 1 | - | - | - | - | 1件: 46 46 💬 |
1521 | Dose level 3 | - | - | - | - | 1件: 46 46 💬 |
1522 | Dose of 60 mg/kg alpha1-proteinase inhibitor | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
1523 | Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
1524 | Dose-Establishing Study 1 Niacin 250mg | 1件: Niacin Niacin | 1件: Niacin
Niacin
💬 | - | - | 1件: 78 78 💬 |
1525 | Dose-Establishing Study 1 Niacin 500mg | 1件: Niacin Niacin | 1件: Niacin
Niacin
💬 | - | - | 1件: 78 78 💬 |
1526 | Dotarem 0,5mmol/ml, | 1件: Gadoteric acid Gadoteric acid | 1件: Gadoteric acid
Gadoteric acid
💬 | - | - | 1件: 13 13 💬 |
1527 | Doxycycline 100 mg Capsules | 1件: Doxycycline Doxycycline | 2件: Doxycycline
Doxycycline
,
Doxycycline
💬 | - | - | 1件: 89 89 💬 |
1528 | Doxycycline 100-200mg capsules daily for 6 months | 1件: Doxycycline Doxycycline | 2件: Doxycycline
Doxycycline
,
Doxycycline
💬 | - | - | 1件: 167 167 💬 |
1529 | DoxyHEXAL® tabs 100 mg Tabletten | - | - | - | - | 1件: 28 28 💬 |
1530 | DPA-714 PET/MRI | - | - | - | - | 1件: 13 13 💬 |
1531 | DPA-714-PET/MRI | - | - | - | - | 1件: 6 6 💬 |
1532 | Dr. Reddy’s Rituximab (DRL_RI) 100mg | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1533 | Droxidopa 100 MG [Northera] | 1件: Droxidopa Droxidopa | 1件: Droxidopa
Droxidopa
💬 | 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1534 | DS-1211b | - | - | - | - | 1件: 166 166 💬 |
1535 | DS-7011a | - | - | - | - | 1件: 49 49 💬 |
1536 | Dulaglutide 0.75Mg/0.5Ml Inj Pen | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
1537 | DUOC-01 | - | - | - | - | 3件: 13 13, 19, 20 💬 |
1538 | Dupilumab 300Mg Solution for Injection | 1件: Dupilumab Dupilumab | 1件: Dupilumab
Dupilumab
💬 | 1件: IL4R IL4R 💬 | 8件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 51 51 💬 |
1539 | DUR-928 | - | - | - | - | 1件: 94 94 💬 |
1540 | DW1809-1 | - | - | - | - | 1件: 46 46 💬 |
1541 | DYNE-101 | - | - | - | - | 1件: 113 113 💬 |
1542 | E. coli Nissle 1917 (Mutaflor®) | - | - | - | - | 1件: 97 97 💬 |
1543 | E6011 10 mg/kg | - | - | - | - | 1件: 96 96 💬 |
1544 | E6011 15 mg/kg | - | - | - | - | 1件: 96 96 💬 |
1545 | EB-101 | - | - | - | - | 1件: 36 36 💬 |
1546 | EB-101 Surgical application of RDEB wounds | - | - | - | - | 1件: 36 36 💬 |
1547 | Ebetrex 15 mg = 0,75 ml, oplossing voor injectie in voorgevulde injectiespuit 20 mg/ml | - | - | - | - | 1件: 96 96 💬 |
1548 | EC 3.1.3.1 | - | - | - | - | 1件: 46 46 💬 |
1549 | EDG-5506 Dose 1 | - | - | - | - | 1件: 113 113 💬 |
1550 | EDG-5506 Dose 3 | - | - | - | - | 1件: 113 113 💬 |
1551 | EDP-305 | - | - | - | - | 1件: 93 93 💬 |
1552 | EDP-305 Dose 1 | - | - | - | - | 1件: 93 93 💬 |
1553 | EDP-305 Dose 2 | - | - | - | - | 1件: 93 93 💬 |
1554 | EDS-EP dose range of ~14-22 mg DSP/infusion | - | - | - | - | 1件: 65 65 💬 |
1555 | EDS-EP dose range of ~5-10 mg DSP/infusion | - | - | - | - | 1件: 65 65 💬 |
1556 | Efexor XL 75 mg | - | - | - | - | 1件: 46 46 💬 |
1557 | Efexor XL 75 mg (venlafaxine) | 1件: Venlafaxine Venlafaxine | 1件: Venlafaxine
Venlafaxine
💬 | 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 46 46 💬 |
1558 | Efficacy of Gammagard subcutaneously at Week 12 | - | - | - | - | 1件: 65 65 💬 |
1559 | Efficacy of Gammagard subcutaneously at Week 36 | - | - | - | - | 1件: 65 65 💬 |
1560 | Efficacy of Gammagard subdermally at Week 12 | - | - | - | - | 1件: 65 65 💬 |
1561 | Efficacy of Gammagard subdermally at Week 36 | - | - | - | - | 1件: 65 65 💬 |
1562 | EFI/ACT-385781A | - | - | - | - | 1件: 86 86 💬 |
1563 | Efmody 10 mg modified release hard capsules | 2件: Hydrocortisone Hydrocortisone, Manganese citrate | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
1564 | Efzofitimod 3 mg/kg | - | - | - | - | 1件: 84 84 💬 |
1565 | EGB 761 (r) 120 mg | - | - | - | - | 1件: 18 18 💬 |
1566 | EGb 761 120 mg | - | - | - | - | 1件: 18 18 💬 |
1567 | EGb 761® (Tanakan®) | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 1件: 13 13 💬 |
1568 | EHP-101 25 mg BID | - | - | - | - | 1件: 13 13 💬 |
1569 | EHP-101 25 mg OD | - | - | - | - | 1件: 13 13 💬 |
1570 | EHP-101 50 mg BID | - | - | - | - | 1件: 13 13 💬 |
1571 | EHP-101 50 mg OD | - | - | - | - | 1件: 13 13 💬 |
1572 | EK-12 | - | - | - | - | 1件: 13 13 💬 |
1573 | Elafibranor 120 mg | 1件: Elafibranor Elafibranor | 1件: Elafibranor
Elafibranor
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 2件: 93 93, 94 💬 |
1574 | Elelyso 60 units/kg | 1件: Taliglucerase alfa Taliglucerase alfa | 1件: Taliglucerase alfa
Taliglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1575 | Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening | 3件: Elexacaftor Elexacaftor, Ivacaftor, Tezacaftor | 3件: Ivacaftor
Ivacaftor
,
Tezacaftor
,
Elexacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
1576 | Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM] | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
1577 | Eltrombopag 12.5 mg | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 60 60 💬 |
1578 | ELX (VX-445)/TEZ (VX-661)/IVA (VX-770) | - | - | - | - | 1件: 299 299 💬 |
1579 | ELX-02 | 1件: ELX-02 ELX-02 | - | - | - | 3件: 19 19, 218, 299 💬 |
1580 | EMD 128130 | - | - | - | - | 2件: 6 6, 156 💬 |
1581 | EMEA/H/C/000109 | - | - | - | - | 1件: 203 203 💬 |
1582 | EMEA/H/C/000125 | - | - | - | - | 1件: 299 299 💬 |
1583 | EMEA/H/C/000240 | - | - | - | - | 2件: 96 96, 97 💬 |
1584 | EMEA/H/C/000481 | - | - | - | - | 1件: 97 97 💬 |
1585 | EMEA/H/C/000638 | - | - | - | - | 1件: 113 113 💬 |
1586 | EMEA/H/C/000701 | - | - | - | - | 1件: 50 50 💬 |
1587 | EMEA/H/C/000712 | - | - | - | - | 1件: 227 227 💬 |
1588 | EMEA/H/C/002576 | - | - | - | - | 1件: 96 96 💬 |
1589 | EMEA/H/C/002778 | - | - | - | - | 1件: 96 96 💬 |
1590 | EMEA/H/C/004214 | - | - | - | - | 1件: 46 46 💬 |
1591 | Empagliflozin 10 MG | 1件: Empagliflozin Empagliflozin | 1件: Empagliflozin
Empagliflozin
💬 | 1件: SLC5A2 SLC5A2 💬 | - | 2件: 58 58, 97 💬 |
1592 | EMSELEX 15 mg Retardtabletten | 1件: Darifenacin Darifenacin | 1件: Darifenacin
Darifenacin
💬 | 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 💬 |
1593 | EMSELEX 7,5 mg Retardtabletten | 1件: Darifenacin Darifenacin | 1件: Darifenacin
Darifenacin
💬 | 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 💬 |
1594 | EnaHexal®, 10mg | - | - | - | - | 1件: 113 113 💬 |
1595 | ENB-0040 | - | - | - | - | 1件: 172 172 💬 |
1596 | ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1597 | ENBREL - 50 MG SOLUZIONE INIETTABILE IN SIRINGA (VETRO DA 1 ML) PRERIEMPITA - USO SOTTOCUTANEO 12 SIRINGHE PRERIEMPITE + 24 TAMPONI IMBEVUTI DI ALCOL | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1598 | ENBREL*BB SC 4FL 25MG 1ML+4SIR | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
1599 | ENBREL*SC 4FL 25MG+4SIR 1ML | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 60, 285 💬 |
1600 | ENBREL*SC 4SIR 25MG 0,5ML+8TAM | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1601 | ENBREL*SC 4SIR 50MG 1ML+8TAMP | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1602 | ENDOPROST - 0.05 MG/0.5 ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FIALA | - | - | - | - | 1件: 51 51 💬 |
1603 | ENDOPROST 0,05MG/0,5ML 1F | - | - | - | - | 1件: 51 51 💬 |
1604 | ENDOPROST 50*INFUS 1F 0,050MG/ | - | - | - | - | 1件: 51 51 💬 |
1605 | Endothelin-3 | - | - | - | - | 1件: 86 86 💬 |
1606 | Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml) | - | - | - | - | 1件: 46 46 💬 |
1607 | ENT-01 | - | - | - | - | 1件: 6 6 💬 |
1608 | EnteraBio's Oral Parathyroid Hormone (1-34) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
1609 | Entocort EC® 3 mg | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1610 | ENTYVIO - 300 MG - POLVERE PE RCONCENTRATO PER SOLUZIONE PER INFU | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1611 | ENTYVIO - 300 MG - POLVERE PE RCONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬 |
1612 | ENTYVIO - 300 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1613 | Entyvio 300 mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1614 | Entyvio 300mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1615 | Eosinophilic Esophagitis (EoE) food introduction-1st | - | - | - | - | 1件: 98 98 💬 |
1616 | Eosinophilic Esophagitis (EoE) Food introduction-3rd dose | - | - | - | - | 1件: 98 98 💬 |
1617 | EP-104IAR | - | - | - | - | 1件: 98 98 💬 |
1618 | Epanova™ (Omega-3 Free Fatty Acids) | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 96 96 💬 |
1619 | EPARMEFOLIN 30 CPR 0,1/0,5MG | - | - | - | - | 1件: 13 13 💬 |
1620 | EPAX 6000 EE 1000mg (0.6 gr DHA+EPA) | - | - | - | - | 1件: 46 46 💬 |
1621 | EPI-743 | - | - | - | - | 3件: 21 21, 156, 337 💬 |
1622 | EPI-743 200mg | - | - | - | - | 1件: 6 6 💬 |
1623 | EPI-743 400mg | - | - | - | - | 1件: 6 6 💬 |
1624 | Epidiolex 100 mg/mL Oral Solution | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 2件: 140 140, 144 💬 |
1625 | Epigallocatechin-3-gallate | 2件: Epigallocatechin Epigallocatechin, Epigallocatechin gallate | - | - | - | 3件: 8 8, 28, 85 💬 |
1626 | Epigallocatechin-3-gallate (EGCG) | 2件: Epigallocatechin Epigallocatechin, Epigallocatechin gallate | - | - | - | 2件: 28 28, 85 💬 |
1627 | Epilim Chrono 300 Controlled Released tablets | - | - | - | - | 1件: 256 256 💬 |
1628 | Epratuzumab 100 mg | 1件: Epratuzumab Epratuzumab | 1件: Epratuzumab
Epratuzumab
💬 | 1件: CD22 CD22 💬 | 3件: B cell receptor signaling pathway B cell receptor signaling pathway, Cell adhesion molecules, Hematopoietic cell lineage 💬 | 1件: 49 49 💬 |
1629 | Epratuzumab 1200 mg | 1件: Epratuzumab Epratuzumab | 1件: Epratuzumab
Epratuzumab
💬 | 1件: CD22 CD22 💬 | 3件: B cell receptor signaling pathway B cell receptor signaling pathway, Cell adhesion molecules, Hematopoietic cell lineage 💬 | 1件: 49 49 💬 |
1630 | Epratuzumab 600 mg | 1件: Epratuzumab Epratuzumab | 1件: Epratuzumab
Epratuzumab
💬 | 1件: CD22 CD22 💬 | 3件: B cell receptor signaling pathway B cell receptor signaling pathway, Cell adhesion molecules, Hematopoietic cell lineage 💬 | 1件: 49 49 💬 |
1631 | EPREX IV SC 1FL 1ML 40000 UI | - | - | - | - | 1件: 2 2 💬 |
1632 | EPREX*1FL 40000UI/ML 1ML | - | - | - | - | 1件: 18 18 💬 |
1633 | EPREX*1SIR 10000UI 1ML | - | - | - | - | 1件: 18 18 💬 |
1634 | EPREX*1SIR 40000UI/ML 1ML | - | - | - | - | 2件: 2 2, 18 💬 |
1635 | EPX-100 | - | - | - | - | 1件: 140 140 💬 |
1636 | EPX-100 (Clemizole HCl) | 1件: Clemizole Clemizole | - | - | - | 1件: 140 140 💬 |
1637 | EPX-100 (Clemizole Hydrochloride) | 1件: Clemizole Clemizole | - | - | - | 1件: 140 140 💬 |
1638 | ER tablet 100 mg AZD3241 | - | - | - | - | 1件: 6 6 💬 |
1639 | ERB-041 | - | - | - | - | 3件: 46 46, 96, 226 💬 |
1640 | Ergocalciferol 1.25 mg tablet | 1件: Ergocalciferol Ergocalciferol | 1件: Ergocalciferol
Ergocalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 46 46 💬 |
1641 | ERMM-1 | - | - | - | - | 1件: 46 46 💬 |
1642 | ERX-963 | - | - | - | - | 1件: 113 113 💬 |
1643 | Escitalopram 10mg | 1件: Escitalopram Escitalopram | 1件: Escitalopram
Escitalopram
💬 | 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 46 46 💬 |
1644 | ESO-101 | - | - | - | - | 1件: 98 98 💬 |
1645 | Etanercept 50 mg sc day 0 and day 3 | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 38 38, 39 💬 |
1646 | ETHANOL (96 PER CENT) | 1件: Ethanol Ethanol | 1件: Ethanol
Ethanol
💬 | - | - | 1件: 279 279 💬 |
1647 | Ethanol 96% Gel | 1件: Ethanol Ethanol | 1件: Ethanol
Ethanol
💬 | - | - | 1件: 279 279 💬 |
1648 | Ethanol 98% Solution | 1件: Ethanol Ethanol | 1件: Ethanol
Ethanol
💬 | - | - | 1件: 279 279 💬 |
1649 | Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below) | - | - | - | - | 1件: 6 6 💬 |
1650 | ETIMS (EDC-fixed autologous PBMCs coupled with 7 immunodominant myelin peptides in MS patients) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
1651 | Etoricoxib 60 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1652 | Etoricoxib 90 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1653 | EU Orphan Designation Number EU/3/02/120 | - | - | - | - | 1件: 299 299 💬 |
1654 | EU/1/03/256/001 | - | - | - | - | 1件: 107 107 💬 |
1655 | EU/1/03/268/002 | - | - | - | - | 1件: 96 96 💬 |
1656 | EU/1/06/362/003: 5µg (1 pen) | - | - | - | - | 1件: 193 193 💬 |
1657 | EU/1/07/389/001 | - | - | - | - | 1件: 107 107 💬 |
1658 | EU/1/08/454/001-002, EU/1/08/454/005-007 | - | - | - | - | 1件: 13 13 💬 |
1659 | EU/1/14/980/002 | - | - | - | - | 1件: 269 269 💬 |
1660 | EU/1/14/980/003 | - | - | - | - | 1件: 269 269 💬 |
1661 | EU/1/95/003/005-010 | - | - | - | - | 1件: 13 13 💬 |
1662 | EU/1/97/033/002 | - | - | - | - | 1件: 13 13 💬 |
1663 | EU/1/98/063/001-003 | - | - | - | - | 1件: 13 13 💬 |
1664 | EU/1/98/063/004-006 | - | - | - | - | 1件: 13 13 💬 |
1665 | EU/1/99/116/003 | - | - | - | - | 1件: 96 96 💬 |
1666 | EU/1/99/126/001 | - | - | - | - | 1件: 107 107 💬 |
1667 | EU/1/99/126/017 | - | - | - | - | 1件: 46 46 💬 |
1668 | EU/1/99/126/020 | - | - | - | - | 1件: 46 46 💬 |
1669 | EU/3/13/1208 orphan | - | - | - | - | 1件: 301 301 💬 |
1670 | EU1/97/031-032 | - | - | - | - | 1件: 18 18 💬 |
1671 | EU1/97/031/031-032 | - | - | - | - | 1件: 18 18 💬 |
1672 | EUR-1008 | - | - | - | - | 1件: 299 299 💬 |
1673 | EUR-1008 (APT-1008) | - | - | - | - | 1件: 299 299 💬 |
1674 | EUR-1008 (APT-1008) High Dose | - | - | - | - | 1件: 298 298 💬 |
1675 | EUR-1008 (APT-1008) Low Dose | - | - | - | - | 1件: 298 298 💬 |
1676 | EUR-1008 25,000 Units | - | - | - | - | 1件: 299 299 💬 |
1677 | EUR-1066-A | - | - | - | - | 1件: 298 298 💬 |
1678 | EUR-1066-B | - | - | - | - | 1件: 298 298 💬 |
1679 | EUR-1100 | - | - | - | - | 1件: 98 98 💬 |
1680 | Evenity 105mg | 1件: Romosozumab Romosozumab | 1件: Romosozumab
Romosozumab
💬 | 1件: SOST SOST 💬 | 2件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Wnt signaling pathway 💬 | 1件: 274 274 💬 |
1681 | Evobrutinib 10mg | 1件: Evobrutinib Evobrutinib | 1件: Evobrutinib
Evobrutinib
💬 | 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 13 13 💬 |
1682 | Evolocumab (AMG 145) | 1件: Evolocumab Evolocumab | 1件: Evolocumab
Evolocumab
💬 | 1件: PCSK9 PCSK9 💬 | 1件: Cholesterol metabolism Cholesterol metabolism 💬 | 1件: 79 79 💬 |
1683 | EVP-0334 | - | - | - | - | 1件: 127 127 💬 |
1684 | EXCL-100, 600 MG Oral Tablet | - | - | - | - | 1件: 85 85 💬 |
1685 | Exelon 1,5 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
1686 | Exelon 3,0 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
1687 | Exelon 4.6 mg/24 h transdermal patch | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
1688 | Exelon 6,0 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
1689 | Exelon 9.5 mg/24 h transdermal patch | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
1690 | Exenatide 10 micrograms | 1件: Exenatide Exenatide | 1件: Exenatide
Exenatide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1691 | EXG001-307 injection | - | - | - | - | 1件: 3 3 💬 |
1692 | EXN-32 | - | - | - | - | 1件: 6 6 💬 |
1693 | EXN-32 (CARBIDOPA E LEVODOPA) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1694 | Extavia (interferon beta-1b), Novartis Pharma AG | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1695 | EXTAVIA*SC 15FL 250MCG/ML+15SI | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1696 | F 18 T807 | - | - | - | - | 2件: 2 2, 127 💬 |
1697 | F-18 | - | - | - | - | 2件: 5 5, 127 💬 |
1698 | F-18 3F4AP | - | - | - | - | 1件: 13 13 💬 |
1699 | F-18 AV 1451 | - | - | - | - | 2件: 5 5, 127 💬 |
1700 | F-18 FDG | - | - | - | - | 1件: 127 127 💬 |
1701 | F-18 FEDAA1106 (BAY85-8101) | - | - | - | - | 1件: 13 13 💬 |
1702 | F-18 FPCIT | - | - | - | - | 1件: 6 6 💬 |
1703 | Fabrazyme (agalsidase beta) 1 mg/kg | 1件: Agalsidase beta Agalsidase beta | 1件: Agalsidase beta
Agalsidase beta
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1704 | FABRAZYME - 35 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE ENDOVENOSA 1 FLACONCINO | 1件: Agalsidase beta Agalsidase beta | 1件: Agalsidase beta
Agalsidase beta
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1705 | Fabrazyme 35 mg | 1件: Agalsidase beta Agalsidase beta | 1件: Agalsidase beta
Agalsidase beta
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1706 | FamC-1 | - | - | - | - | 1件: 2 2 💬 |
1707 | FAMPYRA - 10 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - FLACONE (HDPE) 56 COMPRESSE (4 FLACONI DA 14) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1708 | Fampyra 10 mg prolonged-release tablets | 2件: Dalfampridine Dalfampridine, Manganese citrate | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1709 | Fampyra 10mg prolonged release tablets | 2件: Dalfampridine Dalfampridine, Manganese citrate | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1710 | FANG(30) | - | - | - | - | 1件: 46 46 💬 |
1711 | FANHDI 100 UI | - | - | - | - | 1件: 288 288 💬 |
1712 | Fanhdi 100 UI FVIII-120 UI FVW | - | - | - | - | 1件: 288 288 💬 |
1713 | Fanhdi 25 UI FVIII-30 UI FVW | - | - | - | - | 1件: 288 288 💬 |
1714 | FANHDI 250UI*1F 250UI+F 10ML | - | - | - | - | 1件: 288 288 💬 |
1715 | Fanhdi 50 UI FVIII-60 UI FVW | - | - | - | - | 1件: 288 288 💬 |
1716 | Fasudil (WP-0512) | 1件: Fasudil Fasudil | 1件: Fasudil
Fasudil
💬 | 2件: ROCK1 ROCK1, ROCK2 💬 | 23件: Axon guidance Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, MicroRNAs in cancer, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, TGF-beta signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
1717 | FB-101 | - | - | - | - | 1件: 6 6 💬 |
1718 | FBX-101 | - | - | - | - | 1件: 19 19 💬 |
1719 | FCX-007 | - | - | - | - | 1件: 36 36 💬 |
1720 | FCX-013 | - | - | - | - | 1件: 51 51 💬 |
1721 | FE 992097 | - | - | - | - | 1件: 193 193 💬 |
1722 | FE 999301 | - | - | - | - | 2件: 96 96, 97 💬 |
1723 | Femoston 1/10 | - | - | - | - | 1件: 13 13 💬 |
1724 | Femoston 2/10 | - | - | - | - | 1件: 13 13 💬 |
1725 | Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed). | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1726 | Fenofibrate 160mg | 1件: Fenofibrate Fenofibrate | 1件: Fenofibrate
Fenofibrate
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 97 97 💬 |
1727 | FERRIPROX*100CPR RIV 500MG | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 120 120 💬 |
1728 | Ferrous sulfate 325mg | 1件: Sulfate ion Sulfate ion | - | - | - | 1件: 299 299 💬 |
1729 | FG-3019 | - | - | - | - | 3件: 85 85, 113, 222 💬 |
1730 | FG-3019 10mg/mL in 10 mL vials | - | - | - | - | 1件: 85 85 💬 |
1731 | Fibrogammin® 1250 | - | - | - | - | 1件: 51 51 💬 |
1732 | Fibrovein 3% | - | - | - | - | 1件: 279 279 💬 |
1733 | Fingolimod 0.5 mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1734 | Fingolimod 0.5mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1735 | Fingolimod 1.25 mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1736 | Fipamezole hydrochloride 30 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 💬 |
1737 | Fipamezole hydrochloride 60 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 💬 |
1738 | Fipamezole hydrochloride 90 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 💬 |
1739 | Firategrast 150 mg | 1件: Firategrast Firategrast | 1件: Firategrast
Firategrast
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
1740 | Firategrast 300 mg | 1件: Firategrast Firategrast | 1件: Firategrast
Firategrast
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
1741 | FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE | 1件: Amifampridine Amifampridine | 1件: Amifampridine
Amifampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 3 3, 11 💬 |
1742 | FISH OIL, RICH IN OMEGA-3-ACIDS | 2件: Fish oil Fish oil, Omega-3 fatty acids | - | - | - | 1件: 13 13 💬 |
1743 | FISH OIL,RICH IN OMEGA 3 ACIDS | 1件: Fish oil Fish oil | - | - | - | 1件: 13 13 💬 |
1744 | FK506 level 2-3 ng/ml | - | - | - | - | 1件: 86 86 💬 |
1745 | FK506 level 3-5 ng/ml | - | - | - | - | 1件: 86 86 💬 |
1746 | FLORBETABEN (18F) | - | - | - | - | 1件: 6 6 💬 |
1747 | Florbetapir (18F) | - | - | - | - | 1件: 127 127 💬 |
1748 | Florbetapir 18F | - | - | - | - | 1件: 127 127 💬 |
1749 | Florbetapir 18F Injection | - | - | - | - | 1件: 127 127 💬 |
1750 | Florbetapir F 18 | - | - | - | - | 1件: 6 6 💬 |
1751 | Florence 30 µg/mL | - | - | - | - | 1件: 98 98 💬 |
1752 | Florence 60 µg/mL | - | - | - | - | 1件: 98 98 💬 |
1753 | Florence 90 µg/mL | - | - | - | - | 1件: 98 98 💬 |
1754 | FLUDARABINA TEVA - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 1 FLACONCINO DI VETRO DA 2 ML | 1件: Fludarabine Fludarabine | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 💬 |
1755 | Fludarabine phosphate 30 mg | 2件: Fludarabine Fludarabine, Phosphate ion | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 💬 |
1756 | FLUIMUCIL*20CPR EFF 600MG | - | - | - | - | 2件: 94 94, 298 💬 |
1757 | Fluimucil® 600 mg effervescent tablets | - | - | - | - | 1件: 85 85 💬 |
1758 | FLUORINE (18F) FLUDEOXYGLUCOSE | 1件: Fludeoxyglucose Fludeoxyglucose | 1件: Fludeoxyglucose F 18
Fludeoxyglucose F 18
💬 | - | - | 2件: 84 84, 85 💬 |
1759 | FLUORINE-18 | 1件: Fluorine F-18 Fluorine F-18 | 1件: Sodium fluoride F 18
Sodium fluoride F 18
💬 | - | - | 1件: 41 41 💬 |
1760 | FLX-787-ODT | - | - | - | - | 1件: 2 2 💬 |
1761 | FLX-787-ODT (orally disintegrating tablet) | - | - | - | - | 1件: 10 10 💬 |
1762 | FLX-787-ODT (orally disintigrating tablet) | - | - | - | - | 1件: 2 2 💬 |
1763 | FMP-30 | - | - | - | - | 1件: 53 53 💬 |
1764 | FolateScan (Technetium Tc 99mEC20) | - | - | - | - | 4件: 13 13, 46, 49, 96 💬 |
1765 | Foliglurax 10 mg (treatment A) | 1件: Foliglurax Foliglurax | - | - | - | 1件: 6 6 💬 |
1766 | Foliglurax 30 mg (treatment B) | 1件: Foliglurax Foliglurax | - | - | - | 1件: 6 6 💬 |
1767 | FORMISTIN - 10 MG COMPRESSE RIVESTITE CON FILM 20 COMPRESSE | - | - | - | - | 1件: 13 13 💬 |
1768 | Formistin 10 mg | - | - | - | - | 1件: 13 13 💬 |
1769 | Fosmetpantotenate (RE-024) | - | - | - | - | 1件: 120 120 💬 |
1770 | Fospropofol (Lusedra®) 10 | 1件: Fospropofol Fospropofol | - | - | - | 1件: 226 226 💬 |
1771 | Fospropofol (Lusedra®) 12 | 1件: Fospropofol Fospropofol | - | - | - | 1件: 226 226 💬 |
1772 | Fospropofol (Lusedra®) 6.5 | 1件: Fospropofol Fospropofol | - | - | - | 1件: 226 226 💬 |
1773 | Fostamatinib 100 mg | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
1774 | Fostamatinib 100 mg tablet | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
1775 | Fostamatinib 150 mg | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
1776 | Fostamatinib 150 mg bid | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 61 61 💬 |
1777 | Fostamatinib 150 mg tablet | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
1778 | Fostamatinib Disodium tablet 100 mg | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
1779 | Fostamatinib Disodium tablet 150 mg | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
1780 | FP-110 | - | - | - | - | 1件: 97 97 💬 |
1781 | FP-CYA-050 | - | - | - | - | 1件: 97 97 💬 |
1782 | FP-CYA-053 | - | - | - | - | 1件: 97 97 💬 |
1783 | FPF 300 (thalidomide) | 1件: Thalidomide Thalidomide | 1件: Thalidomide
Thalidomide
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 16 16 💬 |
1784 | FPFS-1169 | - | - | - | - | 1件: 6 6 💬 |
1785 | FRISIUM*30CPS 10MG | - | - | - | - | 1件: 140 140 💬 |
1786 | FRM-0334 | - | - | - | - | 1件: 127 127 💬 |
1787 | FT011 100 mg | - | - | - | - | 1件: 51 51 💬 |
1788 | FTX-1821 | - | - | - | - | 1件: 113 113 💬 |
1789 | Fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody | - | - | - | - | 1件: 13 13 💬 |
1790 | Fx-1006A | 1件: Fx-1006A Fx-1006A | - | - | - | 1件: 28 28 💬 |
1791 | G2-SFM (IFN-beta-1a from clone 484-39,FBS-free process) | - | - | - | - | 1件: 13 13 💬 |
1792 | Ga-68-DOTA-NOC | - | - | - | - | 1件: 84 84 💬 |
1793 | Gabapentin (neurontin® capsule 300mg) treatment | 1件: Gabapentin Gabapentin | 1件: Gabapentin
Gabapentin
💬 | 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 70 70 💬 |
1794 | Gabapentine 300mg | 1件: Gabapentin Gabapentin | 1件: Gabapentin
Gabapentin
💬 | 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
1795 | Gaboxadol (HLX-0206) | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 206 206 💬 |
1796 | Gaboxadol monohydrate 0.5 mg | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1797 | Gaboxadol monohydrate 0.5 mg (intended commercial formulation) | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1798 | Gaboxadol monohydrate 0.5 mg capsule | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1799 | GADOVIST 1 mmol/ml solución inyectable en jeringa precargada/ cartucho precargado | - | - | - | - | 1件: 13 13 💬 |
1800 | Gadovist 1.0 mmol/ml Injektionslösung | 1件: Gadobutrol Gadobutrol | 1件: Gadobutrol
Gadobutrol
💬 | - | - | 1件: 13 13 💬 |
1801 | Gallium-68 DOTATATE | 1件: Dotatate Dotatate | - | - | - | 1件: 84 84 💬 |
1802 | Gallium-68-DOTA-N-Octreotide | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
1803 | Gammanorm 165 mg/mL | - | - | - | - | 1件: 65 65 💬 |
1804 | Gammaplex 10 | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
1805 | GAMUNEX 10% | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 11 11 💬 |
1806 | Ganaxolone, SPT3162, MD 9150000, CCD-1042, Mepalon 1042, (3a-hydroxy-3beta-methyl-5a-pregnan-20-one) | 1件: Ganaxolone Ganaxolone | 1件: Ganaxolone
Ganaxolone
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 152 152 💬 |
1807 | Ganaxolone, SPT3162, MD 9150000, CCD-1042, Mepalon 1042, (3a-hydroxy-3ß-methyl-5a-pregnan-20-one) | 1件: Ganaxolone Ganaxolone | 1件: Ganaxolone
Ganaxolone
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 152 152 💬 |
1808 | GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO | 1件: Obinutuzumab Obinutuzumab | 1件: Obinutuzumab
Obinutuzumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 222 222 💬 |
1809 | GB-0998 | - | - | - | - | 1件: 50 50 💬 |
1810 | GB-0998 (Intravenous immunoglobulin) | - | - | - | - | 1件: 11 11 💬 |
1811 | GB224 10mg | - | - | - | - | 1件: 46 46 💬 |
1812 | GB224 15mg | - | - | - | - | 1件: 46 46 💬 |
1813 | GB224 30mg | - | - | - | - | 1件: 46 46 💬 |
1814 | GBT440 300 mg capsule | - | - | - | - | 1件: 85 85 💬 |
1815 | GBT440 300 mg tablet | - | - | - | - | 1件: 85 85 💬 |
1816 | GC1111_1.0mg/kg | - | - | - | - | 1件: 19 19 💬 |
1817 | GCK 100 mg | - | - | - | - | 1件: 46 46 💬 |
1818 | GCK 300 mg | - | - | - | - | 1件: 46 46 💬 |
1819 | GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
1820 | GDC-0853 | - | - | - | - | 3件: 13 13, 46, 49 💬 |
1821 | GDC-0853 RO7010939 | - | - | - | - | 3件: 13 13, 46, 49 💬 |
1822 | GED-0301 | - | - | - | - | 2件: 96 96, 97 💬 |
1823 | GED-0507-34-LEVO | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1824 | GED-0507-34-Levo 160 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1825 | GED-0507-34-Levo 80 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1826 | Gene Therapy-vMCO-010 | - | - | - | - | 1件: 301 301 💬 |
1827 | Genistein (Unconjugated Isoflavones 100) | 1件: Genistein Genistein | 1件: Genistein
Genistein
💬 | - | - | 1件: 299 299 💬 |
1828 | Genisteine Plus 150 mg cpl formaat 1 18,7 x 6,4 mm 438 mg | - | - | - | - | 1件: 299 299 💬 |
1829 | Genotonorm Kabipen 5.3 mg polvo y disolvente para sol. inyectable (Marca internacional Genotropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1830 | Genotonorm Kabipen 5.3 mg polvo y disolvente para solución inyectable (Marca internacional Genotropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1831 | Genotonorm Miniquick 0,2 mg | - | - | - | - | 1件: 193 193 💬 |
1832 | Genotropin (PN-180,307) Somatropin | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1833 | Genotropin 12 mg | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1834 | GENOTROPIN 12 mg powder and solvent for solution for injection. | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1835 | Genotropin 12 mg/ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1836 | Genotropin 12mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1837 | Genotropin 5.3 mg in injection system Genotropin pen | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1838 | Genotropin 5.3mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1839 | Genotropin Miniquick 0.2mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1840 | Genotropin Miniquick 0.4mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1841 | Genotropin miniquick 0.5 mg, injection | - | - | - | - | 1件: 78 78 💬 |
1842 | Genotropin Miniquick 0.6mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1843 | Genotropin Miniquick 0.8mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1844 | Genotropin Miniquick 1.0mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1845 | Genotropin Miniquick 1.2mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1846 | GENOTROPIN*1TBF 5,3MG (16UI) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 274 274 💬 |
1847 | Gentamicin sulfate 0.1% ointment | 2件: Gentamicin Gentamicin, Sulfate ion | 1件: Gentamicin
Gentamicin
💬 | - | - | 1件: 36 36 💬 |
1848 | Genz-112638 | - | - | - | - | 1件: 19 19 💬 |
1849 | GENZ-682452 | 1件: Venglustat Venglustat | 1件: Venglustat
Venglustat
💬 | 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 3件: 6 6, 19, 67 💬 |
1850 | Genz-682452-AA | 1件: Venglustat Venglustat | 1件: Venglustat
Venglustat
💬 | 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1851 | Genz-682452-AU | 1件: Venglustat Venglustat | 1件: Venglustat
Venglustat
💬 | 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 3件: 6 6, 19, 67 💬 |
1852 | GFI 38518168-AEK-B-007 | - | - | - | - | 1件: 46 46 💬 |
1853 | GILENYA - 0.25 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1854 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1855 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1856 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER(PVC/PVDC/ALU) SCATOLA DA 28 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1857 | GILENYA 0,5 mg cápsulas duras | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 14 14 💬 |
1858 | Gilenya 0,5 mg Hartkapseln | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1859 | Ginkgo biloba pills sig: 300mg/tid | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 1件: 90 90 💬 |
1860 | Glatiramer acetate 150mg enteric coated tablets | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1861 | Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1862 | Glatiramer Acetate 20 mg/0.5 mL | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1863 | Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1864 | Glicerol-1,3-didecanoato-2-octadeca-(6Z,9Z,12Z)-trienoato | - | - | - | - | 1件: 13 13 💬 |
1865 | GLIVEC 100 mg comprimidos recubiertos con película | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 2件: 34 34, 86 💬 |
1866 | Glivec 100 mg Filmtabletten | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 2件: 51 51, 86 💬 |
1867 | Glivec 100 mg Hartkapsel | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 💬 |
1868 | Glivec® 100 mg Filmtabletten | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 💬 |
1869 | GLP-1 | - | - | - | - | 1件: 299 299 💬 |
1870 | GLPG1690 600 mg QD | - | - | - | - | 1件: 85 85 💬 |
1871 | GLPG1837 dose 1 | - | - | - | - | 1件: 299 299 💬 |
1872 | GLPG1837 dose 3 | - | - | - | - | 1件: 299 299 💬 |
1873 | GLPG2222 100 mg | - | - | - | - | 1件: 299 299 💬 |
1874 | GLPG2222 150 mg q.d. | - | - | - | - | 1件: 299 299 💬 |
1875 | GLPG2222 300 mg q.d. | - | - | - | - | 1件: 299 299 💬 |
1876 | GLWL-01 | - | - | - | - | 1件: 193 193 💬 |
1877 | Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate | 1件: Glycerin Glycerin | 1件: Glycerin
Glycerin
💬 | - | - | 1件: 13 13 💬 |
1878 | GLYPRESSINE 1 mg/5 mL, poudre et solvant pour solution injectable (I.V.) | - | - | - | - | 1件: 299 299 💬 |
1879 | GNR-055 | - | - | - | - | 1件: 19 19 💬 |
1880 | GNR-055 1.0-2.0-3.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1881 | GNR-055 2.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1882 | GNR-055 3.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1883 | GNR-069 | - | - | - | - | 1件: 63 63 💬 |
1884 | Golimumab (CNTO 148) | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
1885 | Golimumab 1 mg per kg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1886 | Golimumab 100 mg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 97 💬 |
1887 | Golimumab 100 mg injections | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1888 | Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1889 | Golimumab Dose 1 | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1890 | Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] | 1件: Golodirsen Golodirsen | 1件: Golodirsen
Golodirsen
💬 | 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 💬 |
1891 | GPI 1485 | - | - | - | - | 1件: 6 6 💬 |
1892 | GRANOCYTE - 34 million IU (Lenograstim rHuG-CSF) | 1件: Lenograstim Lenograstim | 1件: Lenograstim
Lenograstim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 57 57 💬 |
1893 | Group 1 or Orencia treated group | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
1894 | Group 1- Control Diet | - | - | - | - | 1件: 97 97 💬 |
1895 | Group 2 ustekinumab 130 mg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
1896 | Group 3: ustekinumab approximately 6 mg/kg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
1897 | Growth hormone administration for 6 months | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1898 | Growth hormone releasing hormone (GHRH) 1-44 | 2件: Somatorelin Somatorelin, Somatotropin | 1件: Somatorelin
Somatorelin
💬 | 1件: GHRHR GHRHR 💬 | 2件: Growth hormone synthesis, secretion and action Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬 | 1件: 78 78 💬 |
1899 | GS-4997 18 mg | - | - | - | - | 1件: 86 86 💬 |
1900 | GS-4997 6 mg | - | - | - | - | 1件: 86 86 💬 |
1901 | GS-6034 | - | - | - | - | 4件: 46 46, 53, 96, 97 💬 |
1902 | GS-6615 3 mg | - | - | - | - | 1件: 58 58 💬 |
1903 | GS-6615 3 mg Pink | - | - | - | - | 1件: 58 58 💬 |
1904 | GS-6615 3 mg White | - | - | - | - | 1件: 58 58 💬 |
1905 | GS-6615 6 mg | - | - | - | - | 1件: 58 58 💬 |
1906 | GS-6615 6 mg White | - | - | - | - | 1件: 58 58 💬 |
1907 | GS-6624 | 1件: Simtuzumab Simtuzumab | - | - | - | 2件: 85 85, 94 💬 |
1908 | GS-9411 | - | - | - | - | 1件: 299 299 💬 |
1909 | GS-9674 | - | - | - | - | 2件: 93 93, 94 💬 |
1910 | GS-9674 100 mg | - | - | - | - | 1件: 93 93 💬 |
1911 | GS-9674 30 mg | - | - | - | - | 1件: 93 93 💬 |
1912 | GS-9876 | - | - | - | - | 2件: 46 46, 53 💬 |
1913 | GSK 3196165 | - | - | - | - | 1件: 46 46 💬 |
1914 | GSK1265744B (sodium salt) containing 14C-GSK1265744B | - | - | - | - | 1件: 265 265 💬 |
1915 | GSK1550188 1mg/kg or 10mg/kg | - | - | - | - | 1件: 49 49 💬 |
1916 | GSK2330811 Solution for Injection, 100mg/ml | - | - | - | - | 1件: 51 51 💬 |
1917 | GSK2402968 3mg/kg/week | - | - | - | - | 1件: 113 113 💬 |
1918 | GSK2402968 6 mg/kg/week | - | - | - | - | 1件: 113 113 💬 |
1919 | GSK2402968 6mg/kg/week | - | - | - | - | 1件: 113 113 💬 |
1920 | GSK2586184 100 mg | - | - | - | - | 1件: 49 49 💬 |
1921 | GSK2982772 60 mg | - | - | - | - | 1件: 46 46 💬 |
1922 | GSK315234 Injection 100mg/mL | - | - | - | - | 1件: 46 46 💬 |
1923 | GSK3196165 Dose 1 | - | - | - | - | 1件: 46 46 💬 |
1924 | GSK3196165 Dose 3 | - | - | - | - | 1件: 46 46 💬 |
1925 | GTG003.08 | - | - | - | - | 1件: 65 65 💬 |
1926 | GTX-102 | 1件: GTX-102 GTX-102 | - | - | - | 2件: 65 65, 201 💬 |
1927 | GTX-102 high dose fast Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
1928 | GTX-102 low dose fast Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
1929 | GTX-102 medium dose fast Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
1930 | GTX-102 medium dose slow Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
1931 | Guna-Anti Interleukin 1 | - | - | - | - | 1件: 46 46 💬 |
1932 | Guna-Antiinterleukin 1 alfa | - | - | - | - | 1件: 46 46 💬 |
1933 | Guna-Antiinterleukin 1 beta | - | - | - | - | 1件: 46 46 💬 |
1934 | Guna-Interleukin 10 | - | - | - | - | 1件: 46 46 💬 |
1935 | Guselkumab 100 mg | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 37 37 💬 |
1936 | Guselkumab Dose 1 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 3件: 51 51, 96, 97 💬 |
1937 | Guselkumab Dose 3 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 2件: 96 96, 97 💬 |
1938 | GW-1000-02 | - | - | - | - | 1件: 13 13 💬 |
1939 | GWP42003-P 10 mg/kg/day Dose | - | - | - | - | 1件: 140 140 💬 |
1940 | GX 623 | - | - | - | - | 1件: 135 135 💬 |
1941 | GYLENIA 0,5 mg | - | - | - | - | 1件: 13 13 💬 |
1942 | GYPP-06 (GKT137831 free base), C10071301-D | - | - | - | - | 1件: 93 93 💬 |
1943 | H-116PI-DE.pdf | - | - | - | - | 1件: 18 18 💬 |
1944 | H5.001CBCFTR | - | - | - | - | 1件: 299 299 💬 |
1945 | H5G1.1-mAb | - | - | - | - | 3件: 13 13, 50, 62 💬 |
1946 | HA 1A ANTICORPO MONOCLONALE UMANO CLASSE IGM | - | - | - | - | 2件: 6 6, 49 💬 |
1947 | HA20 (IMMU-106) | - | - | - | - | 1件: 46 46 💬 |
1948 | Haemocomplettan(R) P 1g/2g | - | - | - | - | 1件: 65 65 💬 |
1949 | HBM9161 Injection (340 mg) | - | - | - | - | 1件: 11 11 💬 |
1950 | HBM9161 Injection (680mg and 340 mg) | - | - | - | - | 1件: 11 11 💬 |
1951 | HBM9161 Injection (680mg) | - | - | - | - | 1件: 11 11 💬 |
1952 | HBVAXPRO 5 micrograms/0.5 ml | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1953 | HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA) | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1954 | HEC 68498 | - | - | - | - | 1件: 85 85 💬 |
1955 | Helium-3 | 2件: Helium Helium, Helium He-3 | 1件: Helium
Helium
💬 | - | - | 2件: 228 228, 299 💬 |
1956 | Hemay007 1200 mg QD group | - | - | - | - | 1件: 46 46 💬 |
1957 | Hemay007 600 mg QD group | - | - | - | - | 1件: 46 46 💬 |
1958 | HGT-1110 | - | - | - | - | 1件: 19 19 💬 |
1959 | HGT-1111 | - | - | - | - | 1件: 19 19 💬 |
1960 | HGT-1410 | - | - | - | - | 1件: 19 19 💬 |
1961 | HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML | 1件: Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 3件: 61 61, 62, 66 💬 |
1962 | HIDONAC*EV 1FL 5G 25ML | - | - | - | - | 1件: 51 51 💬 |
1963 | High dose ANAVEX2-73 | - | - | - | - | 1件: 6 6 💬 |
1964 | High Dose Aspirin (1300 mg/day) | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: Aspirin
Aspirin
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
1965 | High dose BIBF 1120 twice daily | - | - | - | - | 1件: 85 85 💬 |
1966 | High Dose MT-1303 | - | - | - | - | 1件: 97 97 💬 |
1967 | High dose ORTD-1 | - | - | - | - | 1件: 46 46 💬 |
1968 | Hiomega-3 supplement of Naturalis® company - | - | - | - | - | 1件: 49 49 💬 |
1969 | HK-001 | - | - | - | - | 1件: 2 2 💬 |
1970 | HL-085 | - | - | - | - | 1件: 34 34 💬 |
1971 | HLADQA1*05A>G screening | - | - | - | - | 2件: 96 96, 97 💬 |
1972 | HLB-001 | - | - | - | - | 1件: 246 246 💬 |
1973 | HLL2,IMMU-103 | - | - | - | - | 1件: 49 49 💬 |
1974 | HMI-102 | - | - | - | - | 1件: 240 240 💬 |
1975 | HMI-103 | - | - | - | - | 1件: 240 240 💬 |
1976 | HMPL-004 | - | - | - | - | 2件: 96 96, 97 💬 |
1977 | HMPL-004 1800 mg/day | - | - | - | - | 1件: 97 97 💬 |
1978 | HMPL-004 2400 mg/day | - | - | - | - | 1件: 97 97 💬 |
1979 | HMPL-004 high dose | - | - | - | - | 1件: 97 97 💬 |
1980 | HMPL-004 low dose | - | - | - | - | 1件: 97 97 💬 |
1981 | HMPL-523(300mg PO QD) | - | - | - | - | 1件: 61 61 💬 |
1982 | HMPL004-6599 | - | - | - | - | 2件: 96 96, 97 💬 |
1983 | HMR 1726D | - | - | - | - | 1件: 13 13 💬 |
1984 | HOV-12020 (Palm tocotrienols complex) | - | - | - | - | 1件: 124 124 💬 |
1985 | HP 129Xe | - | - | - | - | 1件: 299 299 💬 |
1986 | Hp 129Xenon | - | - | - | - | 1件: 228 228 💬 |
1987 | HP 3He | - | - | - | - | 1件: 299 299 💬 |
1988 | HP-3000 (ropinirole hydrochloride patch) | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1989 | HP-3000 placebo | - | - | - | - | 1件: 6 6 💬 |
1990 | HP-3000(ropinirole hydrochloride patch) | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1991 | HPN-100 | - | - | - | - | 1件: 251 251 💬 |
1992 | HT-100 | - | - | - | - | 1件: 113 113 💬 |
1993 | Hu Leptin (A-100) | 1件: Leptin Leptin | - | - | - | 1件: 265 265 💬 |
1994 | Hu MiK-Beta-1 | - | - | - | - | 1件: 26 26 💬 |
1995 | Humalog Mix50 100 U/ml sospensione iniettabile | - | - | - | - | 1件: 78 78 💬 |
1996 | Human anti-IL 12/23 monoclonal antibody | - | - | - | - | 1件: 84 84 💬 |
1997 | Human Anti-IL-12 Antibody | - | - | - | - | 1件: 96 96 💬 |
1998 | Human anti-IL-12 IgG1 Mab | - | - | - | - | 1件: 13 13 💬 |
1999 | Human anti-IL-12 Mab | - | - | - | - | 1件: 13 13 💬 |
2000 | Human anti-LINGO-1 monoclonal antibody | - | - | - | - | 1件: 13 13 💬 |
2001 | Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody | - | - | - | - | 1件: 51 51 💬 |
2002 | Human Growth Hormone (1-134) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2003 | Human interferon beta 1a (Rebif) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2004 | Human interferon beta-1a and glatiramer acetate | 4件: Acetate Acetate, Glatiramer, Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2005 | Human Monoclonal Antibody (CNTO 1275) to Interleukin 12p-40 | - | - | - | - | 1件: 96 96 💬 |
2006 | Human monoclonal antibody (CNTO 1275) to interleukin-12p40 | - | - | - | - | 1件: 13 13 💬 |
2007 | Human normal 10% immunoglobulin for intravenous administration | - | - | - | - | 1件: 14 14 💬 |
2008 | Human normal 10% immunoglobulin for intravenous administrationn | - | - | - | - | 1件: 14 14 💬 |
2009 | Human normal immunoglobulin G (IgG > 98% purity) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 63, 65 💬 |
2010 | Humanized anti-alpha v beta 6 mAb | - | - | - | - | 1件: 85 85 💬 |
2011 | Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody | - | - | - | - | 1件: 46 46 💬 |
2012 | Humanized recombinant IgG4 monoclonal antibody against CD-127 | - | - | - | - | 1件: 97 97 💬 |
2013 | Humatrope 6 mg/12 mg/24 mg injektiokuiva-aine ja liuotin, liuosta varten | 1件: Somatotropin Somatotropin | - | - | - | 1件: 193 193 💬 |
2014 | Humatrope® 6 mg, powder and solvent for solution for injection | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2015 | HuMax-CD38, 3003-005 | - | - | - | - | 1件: 28 28 💬 |
2016 | Humira (adalimumab) 40 mg in 0.4 ml s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2017 | Humira (adalimumab) 40mg in 0.4 ml s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2018 | Humira (adalimumab) 40mg in 0.4ml s.c.injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2019 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 1 SIRINGA PRERIEMPITA 0.8 ML + 1 TAMPONE IMBEVUTO DI ALCOL IN UN BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 56 56, 97 💬 |
2020 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2021 | HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
2022 | Humira 20 mg solution for injection in pre-filled syringe (20 mg/0.2mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
2023 | Humira 40 mg solution for injection in pre-filled syringe (40 mg/0.4 mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
2024 | Humira 40 mg/0.8 ml solution for injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
2025 | Humira 40 mg/0.8 ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
2026 | Humira 40mg/0.4ml pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2027 | Humira 40mg/0.8 ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2028 | Humira 40mg/0.8ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2029 | Humira 40mg/0.8ml solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2030 | Humira 80 mg solution for injection in pre-filled syringe (80 mg/0.8 mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
2031 | Humira ® (Adalimumab) 40mg/0.8mL Pre-filled Syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2032 | HUMIRA*SC 2SIR+F 40MG 0,8ML+2T | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
2033 | Humira® 40 mg/ 0.8 ml solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2034 | Hydrocortison 100 mg (Pfizer®) in 2 ml solvent | - | - | - | - | 1件: 83 83 💬 |
2035 | Hydrocortisone 100mg/ml | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 83 83 💬 |
2036 | Hydrocortisone 10mg | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2037 | Hydrocortisone 10mg Tablet | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
2038 | Hydrocortisone 10mg Tablets | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
2039 | Hydrocortisone cream 1% | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
2040 | Hydrocortisone cream 10mg/g FNA Fagron | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
2041 | Hydroxychloroquine Sulfate 100 milligram (mg) Tab | 2件: Hydroxychloroquine Hydroxychloroquine, Sulfate ion | 1件: Hydroxychloroquine
Hydroxychloroquine
💬 | - | - | 1件: 218 218 💬 |
2042 | Hyperglycemic clamp with concurrent GLP-1 infusion | - | - | - | - | 1件: 299 299 💬 |
2043 | Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 85 85 💬 |
2044 | Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 85 85 💬 |
2045 | Hyperpolarized 129-Xenon gas | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 85 85 💬 |
2046 | Hyperpolarized 129Xe | - | - | - | - | 1件: 86 86 💬 |
2047 | Hyperpolarized 13C-Pyruvate | - | - | - | - | 1件: 58 58 💬 |
2048 | Hyperpolarized [1-13C]pyruvate | - | - | - | - | 2件: 2 2, 67 💬 |
2049 | Hyperpolarized Helium-3 | 2件: Helium Helium, Helium He-3 | 1件: Helium
Helium
💬 | - | - | 1件: 299 299 💬 |
2050 | Hyperpolarized Helium-3 MRI | 2件: Helium Helium, Helium He-3 | 1件: Helium
Helium
💬 | - | - | 1件: 228 228 💬 |
2051 | Hyperpolarized Helium-3 MRI of the chest | 2件: Helium Helium, Helium He-3 | 1件: Helium
Helium
💬 | - | - | 1件: 299 299 💬 |
2052 | Hyperpolarized Xenon 129 | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
2053 | Hyperpolarized xenon-129 | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
2054 | Hypertonic saline (7 %) and isotonic saline (0.9%) | - | - | - | - | 1件: 299 299 💬 |
2055 | Hypertonic saline (7%) | - | - | - | - | 1件: 299 299 💬 |
2056 | Hypertonic saline 6% - | - | - | - | - | 1件: 299 299 💬 |
2057 | Hypertonic Saline 7% | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
2058 | HyQvia 100 mg/ml solution for infusion for subcutaneous use | 2件: Human immunoglobulin G Human immunoglobulin G, Hyaluronidase (human recombinant) | - | - | - | 1件: 65 65 💬 |
2059 | I 123 | 1件: Iodide I-123 Iodide I-123 | - | - | - | 1件: 6 6 💬 |
2060 | I-123 | 1件: Iodide I-123 Iodide I-123 | - | - | - | 2件: 2 2, 6 💬 |
2061 | I-123-5-IA85380 | 1件: Iodide I-123 Iodide I-123 | - | - | - | 1件: 6 6 💬 |
2062 | I-123] ADAM | 1件: Iodide I-123 Iodide I-123 | - | - | - | 1件: 2 2 💬 |
2063 | IA-14069 | - | - | - | - | 1件: 46 46 💬 |
2064 | IB 1001 | - | - | - | - | 1件: 65 65 💬 |
2065 | ICI 182,780 (Faslodex) | 1件: Fulvestrant Fulvestrant | 1件: Fulvestrant
Fulvestrant
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 49 49 💬 |
2066 | ICP-022 | - | - | - | - | 2件: 46 46, 49 💬 |
2067 | ICX-RHY-013 | - | - | - | - | 1件: 36 36 💬 |
2068 | Idebenone 150 mg film-coated tablets | 1件: Idebenone Idebenone | 1件: Idebenone
Idebenone
💬 | - | - | 1件: 113 113 💬 |
2069 | IdeS (0.25 mg/kg) | 1件: Imlifidase Imlifidase | 1件: Imlifidase
Imlifidase
💬 | - | - | 1件: 64 64 💬 |
2070 | IdeS (0.50 mg/kg) | 1件: Imlifidase Imlifidase | 1件: Imlifidase
Imlifidase
💬 | - | - | 1件: 64 64 💬 |
2071 | IDROCORTISONE ACETATO DYNACREN - 1 % CREMA 1 TUBO DA 30 G | - | - | - | - | 1件: 272 272 💬 |
2072 | IDROCORTISONE ACETATO DYNACREN 1% CREMA | - | - | - | - | 1件: 272 272 💬 |
2073 | Idursulfase IT (1 mg) | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2074 | Idursulfase IT (10 mg) | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2075 | Idursulfase IT (30 mg) | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2076 | Idursulfase(12S)-IT | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2077 | IFB-088 | - | - | - | - | 1件: 2 2 💬 |
2078 | IFB-088 50mg/day | - | - | - | - | 1件: 2 2 💬 |
2079 | IFN beta 1a 44 mcg TIW | - | - | - | - | 1件: 13 13 💬 |
2080 | IFN beta-1a | - | - | - | - | 1件: 13 13 💬 |
2081 | IFN ß-1a | - | - | - | - | 1件: 13 13 💬 |
2082 | IFN-beta-1a (Rebif®) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2083 | IFN-beta-1a, (Avonex®) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2084 | IFN-ß-1a (Rebif®) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2085 | IFN-ß-1a, (Avonex®) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2086 | IFX-1 | 1件: Vilobelimab Vilobelimab | 1件: Vilobelimab
Vilobelimab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 3件: 43 43, 44, 269 💬 |
2087 | Ig VENA (10g/200mL) | - | - | - | - | 1件: 50 50 💬 |
2088 | Ig VENA 100 ml vial | - | - | - | - | 1件: 63 63 💬 |
2089 | Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set | - | - | - | - | 2件: 63 63, 65 💬 |
2090 | IGF-1 | - | - | - | - | 1件: 113 113 💬 |
2091 | IGIV, 10% | - | - | - | - | 2件: 14 14, 65 💬 |
2092 | IGIV-C 10% | - | - | - | - | 1件: 65 65 💬 |
2093 | IGIV3I Grifols 10% | - | - | - | - | 1件: 63 63 💬 |
2094 | IgNextGen 10% | - | - | - | - | 1件: 63 63 💬 |
2095 | IgNextGen 16% | - | - | - | - | 1件: 65 65 💬 |
2096 | IGSC 20% 150 mg/kg | - | - | - | - | 1件: 65 65 💬 |
2097 | IGSC, 16% | - | - | - | - | 1件: 65 65 💬 |
2098 | IGVENA*FL 200ML 10G+SET | - | - | - | - | 2件: 14 14, 50 💬 |
2099 | IkT-148009 | - | - | - | - | 1件: 6 6 💬 |
2100 | IL-1 Trap | - | - | - | - | 1件: 266 266 💬 |
2101 | IL-11 | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 288 288 💬 |
2102 | IL-6 receptor inhibitor, humanized monoclonal antibody | - | - | - | - | 1件: 46 46 💬 |
2103 | IL-6 receptor inhibitor, recombinant humanized monoclonal antibody | - | - | - | - | 2件: 46 46, 107 💬 |
2104 | IL-6R Monoclonal Antibody Injection 4mg/kg | - | - | - | - | 1件: 46 46 💬 |
2105 | IL-6R Monoclonal Antibody Injection 6mg/kg | - | - | - | - | 1件: 46 46 💬 |
2106 | IL-6R Monoclonal Antibody Injection 8mg/kg | - | - | - | - | 1件: 46 46 💬 |
2107 | IL-6R nanobody | - | - | - | - | 1件: 49 49 💬 |
2108 | ILB: 100mg/ml solution for injection and infusion | - | - | - | - | 1件: 2 2 💬 |
2109 | Iloprost (Ventavis, BAYQ 6256) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2110 | Iloprost PD-15 | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2111 | Iloprost PD-6 | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2112 | ILT-101 | 1件: Aldesleukin Aldesleukin | 1件: Aldesleukin
Aldesleukin
💬 | 3件: IL2RA IL2RA, IL2RB, IL2RG 💬 | 14件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 49 49 💬 |
2113 | ILV-094 | - | - | - | - | 1件: 46 46 💬 |
2114 | IMB-1018972 | - | - | - | - | 1件: 58 58 💬 |
2115 | IMCY-0141 | 1件: IMCY-0141 IMCY-0141 | - | - | - | 1件: 13 13 💬 |
2116 | Immediate Release carbidopa/levodopa 10/100 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2117 | Immediate Release carbidopa/levodopa 25/100 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2118 | IMMU-103 | - | - | - | - | 1件: 49 49 💬 |
2119 | Immune Globulin (Human), 10% Caprylate/Chromatography Purified | - | - | - | - | 1件: 11 11 💬 |
2120 | Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) | - | - | - | - | 1件: 11 11 💬 |
2121 | Immune Globulin 10% Intravenous Solution | - | - | - | - | 1件: 14 14 💬 |
2122 | Immune Globulin Infusion (Human), 10% | - | - | - | - | 1件: 65 65 💬 |
2123 | Immune Globulin Intravenous (human), 10% | - | - | - | - | 2件: 14 14, 65 💬 |
2124 | Immune Globulin Intravenous (Human), 10% Solution | - | - | - | - | 1件: 65 65 💬 |
2125 | Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution | - | - | - | - | 1件: 63 63 💬 |
2126 | Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution | - | - | - | - | 1件: 65 65 💬 |
2127 | Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified | - | - | - | - | 1件: 65 65 💬 |
2128 | Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified | - | - | - | - | 1件: 14 14 💬 |
2129 | Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified | - | - | - | - | 1件: 13 13 💬 |
2130 | Immunoglobulin G (Ig NextGen 16%) | - | - | - | - | 1件: 65 65 💬 |
2131 | Immunoscintigraphy with radiolabeled Cimzia®. | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2132 | Imnovid 1 mg hard capsules | 1件: Pomalidomide Pomalidomide | 1件: Pomalidomide
Pomalidomide
💬 | 2件: IL6 IL6, TNF 💬 | 80件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 51 51 💬 |
2133 | IMO-8400 Dose Group 1 | - | - | - | - | 1件: 50 50 💬 |
2134 | IMP will be labeled as ''PF-04236921 106mg/vial, Clonal SC lyophilized form''. | - | - | - | - | 1件: 96 96 💬 |
2135 | IMP will be labeled as PF-04236921 106mg/vial, Clonal SC lyophilized form | - | - | - | - | 1件: 96 96 💬 |
2136 | IMU-838 (30 mg/day) | - | - | - | - | 1件: 13 13 💬 |
2137 | IMUKIN - 6 FLACONI 0.5 ML 100 MCG | - | - | - | - | 2件: 18 18, 58 💬 |
2138 | IMUKIN*SC 6F 0,5ML 100MCG | - | - | - | - | 1件: 18 18 💬 |
2139 | Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus | - | - | - | - | 1件: 53 53 💬 |
2140 | INBRX-101/rhAAT-Fc | - | - | - | - | 1件: 231 231 💬 |
2141 | INCB050465 0.3 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
2142 | INCB050465 0.3mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
2143 | INCB050465 1 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 61 61 💬 |
2144 | INCB050465 1.0 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
2145 | INCB050465 1.0mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
2146 | IncobotulinumtoxinA (100 Units) | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 💬 |
2147 | IncobotulinumtoxinA (75 Units) | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 💬 |
2148 | INCRELEX 10 mg/ml | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 78 78 💬 |
2149 | INCRELEX 10 mg/ml, solución inyectable | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 78 78 💬 |
2150 | Increlex 10mg/ml solution for injection | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2151 | INCRELEX*SC 1FL 4ML 10MG/ML | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 299 299 💬 |
2152 | IND 127861 | - | - | - | - | 2件: 51 51, 53 💬 |
2153 | Indium 111-radiolabelled anti-CD66 | 1件: Indium Indium | - | - | - | 1件: 28 28 💬 |
2154 | Indium-111 Pentreotide | 1件: Indium Indium | - | - | - | 1件: 84 84 💬 |
2155 | Indium 111 labelled Anti-CD66 | 1件: Indium Indium | - | - | - | 1件: 28 28 💬 |
2156 | INDUSIL*OS GTT FL 30MG+FL 15ML | - | - | - | - | 1件: 299 299 💬 |
2157 | INF beta-1a | - | - | - | - | 1件: 13 13 💬 |
2158 | Infigratinib 0.016 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
2159 | Infigratinib 0.032 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
2160 | Infigratinib 0.064 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
2161 | Infigratinib 0.128 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
2162 | Infigratinib 0.25 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
2163 | INFLECTRA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 1 FLACONCINO | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 56 56 💬 |
2164 | Inflectra 100 mg | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
2165 | Inflectra 100 mg powder for concentrate for solution for infusion | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
2166 | Infliximab (BCD-055) | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
2167 | Infliximab (Remicade): 100 mg of lyophilized infliximab | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2168 | Infliximab 10 mg/kg | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 96, 97 💬 |
2169 | Infliximab 3 mg/kg | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2170 | Infliximab 5 mg/kg every 6 weeks | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2171 | Infliximab 7 mg/kg every 8 weeks | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2172 | Infliximab [infliximab biosimilar 3] | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 37 37, 46, 96, 97 💬 |
2173 | Infliximab and azathioprine combination at week 0 | 2件: Azathioprine Azathioprine, Infliximab | 2件: Azathioprine
Azathioprine
,
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2174 | Infliximab and azathioprine combination at week 14 | 2件: Azathioprine Azathioprine, Infliximab | 2件: Azathioprine
Azathioprine
,
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2175 | Infusion of ADR-001 (Mesenchymal stem cell) | - | - | - | - | 1件: 66 66 💬 |
2176 | Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) | - | - | - | - | 1件: 65 65 💬 |
2177 | Inhaled 7% hypertonic saline (HS) | - | - | - | - | 1件: 299 299 💬 |
2178 | Inhaled hypertonic saline (7%) | - | - | - | - | 1件: 299 299 💬 |
2179 | Inhaled Nitric Oxide - 30 mcg/kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 85 85 💬 |
2180 | Inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 85 85 💬 |
2181 | Inhaled nitric oxide 75 mcg/kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 2件: 85 85, 86 💬 |
2182 | INM-755 | - | - | - | - | 1件: 36 36 💬 |
2183 | INM-755 (cannabinol) cream | 1件: Cannabinol Cannabinol | - | - | - | 1件: 36 36 💬 |
2184 | INN Parathyroid Hormone (1-84) human | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
2185 | INS1007 10 mg oral tablet | - | - | - | - | 1件: 299 299 💬 |
2186 | Insulin like growth factor, type 1 | - | - | - | - | 1件: 2 2 💬 |
2187 | INT-747 | - | - | - | - | 1件: 93 93 💬 |
2188 | INT-747, OCA | - | - | - | - | 2件: 93 93, 94 💬 |
2189 | Inteferone Beta-1A | - | - | - | - | 1件: 13 13 💬 |
2190 | INTELENCE - 200 MG - COMPRESSA -USO ORALE - FLACONE (HDPE) 60 COMPRESSE | 1件: Etravirine Etravirine | 1件: Etravirine
Etravirine
💬 | - | - | 1件: 18 18 💬 |
2191 | INTERFERON BETA - 1A | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2192 | Interferon beta - 1a (IFN) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2193 | Interferon beta -1b | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2194 | Interferon Beta 1 | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2195 | Interferon Beta 1-A | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2196 | Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2197 | Interferon Beta 1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2198 | Interferon beta 1a 30 ug IM once weekly | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2199 | Interferon Beta 1a pegilado | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2200 | Interferon beta 1a, oral doxycycline | 3件: Doxycycline Doxycycline, Human interferon beta, Interferon beta-1a | 3件: Doxycycline
Doxycycline
,
Interferon beta-1a
,
Doxycycline
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2201 | Interferon beta 1B | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2202 | Interferon beta 1b (Betaseron, BAY86-5046) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2203 | Interferon beta-1 a | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2204 | INTERFERON BETA-1A | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 4件: 13 13, 26, 96, 97 💬 |
2205 | Interferon beta-1a (Avonex) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2206 | INTERFERON BETA-1A (Avonex®) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2207 | Interferon beta-1a (current approved manufacturing process invloving FBS) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2208 | Interferon beta-1a (new process, manufactured without FBS) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2209 | Interferon beta-1a (Rebif) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2210 | Interferon beta-1a (Rebif®) alone | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2211 | Interferon beta-1a 30 µg | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2212 | Interferon beta-1a FBS-free/HSA free, RNF | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2213 | Interferon beta-1a FBS-free/HSA-free | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2214 | Interferon beta-1a FBS-free/HSA-free, RNF | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2215 | Interferon beta-1a HSA+ biosimilar | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2216 | Interferon beta-1a HSA-free biosimilar | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2217 | Interferon beta-1a original | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2218 | Interferon Beta-1A Prefilled Syringe | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2219 | Interferon beta-1a, 30 µg/0.5 ml | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2220 | INTERFERON BETA-1B | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2221 | Interferon beta-1b (Betaferon, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2222 | Interferon beta-1b (Betaferon, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2223 | Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2224 | Interferon beta-1b (Betaferon®, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2225 | Interferon beta-1b (Betaseron, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2226 | Interferon beta-1b (Betaseron, Betaferon, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2227 | Interferon beta-1b (PF530, Betaferon) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2228 | Interferon beta-1b and Tacrolimus | 3件: Human interferon beta Human interferon beta, Interferon beta-1b, Tacrolimus | 3件: Tacrolimus
Tacrolimus
,
Interferon beta-1b
,
Tacrolimus
💬 | 7件: IFNAR1 IFNAR1, IFNAR2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 48件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Epstein-Barr virus infection, Glucagon signaling pathway, Glutamatergic synapse, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
2229 | Interferon beta-1b group | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2230 | Interferon beta-1b, (Betaseron BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2231 | Interferon beta-1b, FRP about 6 weeks after randomization | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2232 | Interferon beta-1b, FRP within 15 days after randomization | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2233 | Interferon beta-1b/Atorvastatin group | 3件: Atorvastatin Atorvastatin, Human interferon beta, Interferon beta-1b | 2件: Interferon beta-1b
Interferon beta-1b
,
Atorvastatin
💬 | 3件: HMGCR HMGCR, IFNAR1, IFNAR2 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, Metabolic pathways, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Terpenoid backbone biosynthesis, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2234 | Interferon gamma 1b | 1件: Interferon Gamma Interferon Gamma | - | - | - | 1件: 228 228 💬 |
2235 | INTERFERON GAMMA-1B | 2件: Interferon Gamma Interferon Gamma, Interferon gamma-1b | 1件: Interferon gamma-1b
Interferon gamma-1b
💬 | 2件: IFNGR1 IFNGR1, IFNGR2 💬 | 18件: Chagas disease Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬 | 7件: 18 18, 65, 85, 228, 299, 301, 326 💬 |
2236 | Interferon gamma-1b (Actimmune) | 2件: Interferon Gamma Interferon Gamma, Interferon gamma-1b | 1件: Interferon gamma-1b
Interferon gamma-1b
💬 | 2件: IFNGR1 IFNGR1, IFNGR2 💬 | 18件: Chagas disease Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬 | 1件: 85 85 💬 |
2237 | Interferon ß-1a | - | - | - | - | 1件: 13 13 💬 |
2238 | Interferon ß-1a 30 µg | - | - | - | - | 1件: 13 13 💬 |
2239 | Interferon ß-1b | - | - | - | - | 1件: 13 13 💬 |
2240 | Interferon-1beta (Betaseron, BAY86-5046) | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2241 | Interferon-beta 1a | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2242 | Interferon-beta 1a FBS-free/HSA free, RNF | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2243 | Interferon-beta 1a FBS-free/HSA-free, RNF | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2244 | Interferon-beta 1b | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2245 | Interferon-beta 1b (Betaseron) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2246 | Interferon-beta-1 | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2247 | Interferon-beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 2件: 13 13, 97 💬 |
2248 | Interferon-beta-1a (Avonex) plus methylprednisolone | 3件: Human interferon beta Human interferon beta, Interferon beta-1a, Methylprednisolone | 2件: Methylprednisolone
Methylprednisolone
,
Interferon beta-1a
💬 | 3件: IFNAR1 IFNAR1, IFNAR2, NR3C1 💬 | 19件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2249 | Interferon-beta-1a FBS-free/HSA free, RNF | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2250 | Interferon-beta-1a FBS-free/HSA-free | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2251 | Interferon-beta-1a, 44 microgram | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 97 97 💬 |
2252 | Interferon-beta-1a, 66 microgram | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 97 97 💬 |
2253 | Interferon-beta-1b | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2254 | Interferon-beta-1b (BETASERON, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2255 | Interferon-gamma 1b | - | - | - | - | 1件: 85 85 💬 |
2256 | Interferon-ß-1 | - | - | - | - | 1件: 13 13 💬 |
2257 | Interferon-ß-1a | - | - | - | - | 1件: 13 13 💬 |
2258 | Interferon-ß-1b | - | - | - | - | 1件: 13 13 💬 |
2259 | Interferone beta 1a | - | - | - | - | 1件: 13 13 💬 |
2260 | INTERFERONE BETA 1B | - | - | - | - | 1件: 13 13 💬 |
2261 | Interferone beta-1a | - | - | - | - | 1件: 13 13 💬 |
2262 | Interferone Beta-1B | - | - | - | - | 1件: 13 13 💬 |
2263 | Interferón beta 1a | - | - | - | - | 1件: 13 13 💬 |
2264 | Interferón beta 1a pegilado | - | - | - | - | 1件: 13 13 💬 |
2265 | Interferón Beta-1a pegilado | - | - | - | - | 1件: 13 13 💬 |
2266 | Interleukin 10 | - | - | - | - | 1件: 46 46 💬 |
2267 | Interleukin 11 | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 288 288 💬 |
2268 | Interleukin-11 | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 2件: 96 96, 288 💬 |
2269 | Interleukin-2 (aldesleukin). | 2件: Aldesleukin Aldesleukin, Human interleukin-2 | 1件: Aldesleukin
Aldesleukin
💬 | 3件: IL2RA IL2RA, IL2RB, IL2RG 💬 | 14件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 96 96, 97 💬 |
2270 | Interleukin-7 | 1件: Interleukin-7 Interleukin-7 | - | - | - | 1件: 25 25 💬 |
2271 | Intermediate dose BIBF 1120 twice daily | - | - | - | - | 1件: 85 85 💬 |
2272 | Intracerebral administration of AAVrh.10cuARSA | - | - | - | - | 1件: 19 19 💬 |
2273 | Intralipid 10% | - | - | - | - | 1件: 96 96 💬 |
2274 | Intravenous (i.v.) methylprednisolone 1000 mg, total 9 | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
2275 | Intravenous administration of 1 million of MSC | - | - | - | - | 1件: 2 2 💬 |
2276 | Intravenous Dexamethasone 1 mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2277 | Intravenous immunoglobulin (IVIG), 10% solution for infusion | - | - | - | - | 1件: 63 63 💬 |
2278 | INZ-701 | - | - | - | - | 1件: 166 166 💬 |
2279 | IODIO IOFLUPANO-123I | - | - | - | - | 1件: 6 6 💬 |
2280 | IOFLUPANE (123I) | - | - | - | - | 1件: 6 6 💬 |
2281 | Ioflupane 123I | - | - | - | - | 1件: 2 2 💬 |
2282 | Ioflupane 123I (DATSCAN®) | 1件: Ioflupane I-123 Ioflupane I-123 | - | - | - | 1件: 6 6 💬 |
2283 | Ioflupane [123 I] | - | - | - | - | 1件: 6 6 💬 |
2284 | Ioflupane [123I] | - | - | - | - | 1件: 6 6 💬 |
2285 | Ioflupane I 123 | 2件: Iodide I-123 Iodide I-123, Ioflupane I-123 | - | - | - | 1件: 6 6 💬 |
2286 | Iohexol Inj 300 milligrams per milliliter (MG/ML) | 1件: Iohexol Iohexol | 1件: Iohexol
Iohexol
💬 | - | - | 1件: 67 67 💬 |
2287 | ION-682884 | - | - | - | - | 1件: 28 28 💬 |
2288 | IPI 145 | - | - | - | - | 1件: 46 46 💬 |
2289 | IPI-145 | - | - | - | - | 1件: 46 46 💬 |
2290 | IPN60130 10 mg capsules | - | - | - | - | 1件: 272 272 💬 |
2291 | IPX054 100 mg | - | - | - | - | 1件: 6 6 💬 |
2292 | IPX054 150 mg | - | - | - | - | 1件: 6 6 💬 |
2293 | IPX054 300 mg | - | - | - | - | 1件: 6 6 💬 |
2294 | IPX056 10 mg | - | - | - | - | 1件: 13 13 💬 |
2295 | IPX056 30 mg | - | - | - | - | 1件: 13 13 💬 |
2296 | IPX056 35 mg | - | - | - | - | 1件: 13 13 💬 |
2297 | IPX056-10 mg | - | - | - | - | 1件: 13 13 💬 |
2298 | IPX056-30 mg | - | - | - | - | 1件: 13 13 💬 |
2299 | IPX056-35 mg | - | - | - | - | 1件: 13 13 💬 |
2300 | IPX066 145 mg | - | - | - | - | 1件: 6 6 💬 |
2301 | IPX066 145 mg LD | - | - | - | - | 1件: 6 6 💬 |
2302 | IPX066 195 mg | - | - | - | - | 1件: 6 6 💬 |
2303 | IPX066 195 mg LD | - | - | - | - | 1件: 6 6 💬 |
2304 | IPX066 95 mg | - | - | - | - | 1件: 6 6 💬 |
2305 | IPX066 95 mg LD | - | - | - | - | 1件: 6 6 💬 |
2306 | IPX066-145 | - | - | - | - | 1件: 6 6 💬 |
2307 | IPX066-195 | - | - | - | - | 1件: 6 6 💬 |
2308 | IPX066-95 | - | - | - | - | 1件: 6 6 💬 |
2309 | IPX203 140 mg | - | - | - | - | 1件: 6 6 💬 |
2310 | IPX203 180 mg | - | - | - | - | 1件: 6 6 💬 |
2311 | IPX203 350 mg | - | - | - | - | 1件: 6 6 💬 |
2312 | Irbesartan 150-300mg capsules daily for 6 months | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 167 167 💬 |
2313 | Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03 | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 66 66, 222 💬 |
2314 | Irbesartan tablets (NDA 020 757) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 66 66 💬 |
2315 | Irbesartan tablets (NDC# 31722-729-30 approved in the United states) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
2316 | Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
2317 | Iron supplement 300-600 mg/day | 1件: Iron Iron | - | - | - | 2件: 96 96, 97 💬 |
2318 | ISIS 104838 | 1件: ISIS 104838 ISIS 104838 | - | - | - | 1件: 46 46 💬 |
2319 | ISIS 301012 | - | - | - | - | 1件: 79 79 💬 |
2320 | ISIS 301012 phosphorothioate oligonucleotide | - | - | - | - | 1件: 79 79 💬 |
2321 | ISIS 304801 | - | - | - | - | 1件: 265 265 💬 |
2322 | ISIS 333611 | - | - | - | - | 1件: 2 2 💬 |
2323 | ISIS 396443 | - | - | - | - | 1件: 3 3 💬 |
2324 | ISIS 396443 (BIIB058) | - | - | - | - | 1件: 3 3 💬 |
2325 | ISIS 396443, BIIB058 | - | - | - | - | 1件: 3 3 💬 |
2326 | ISIS 443139 10 mg | - | - | - | - | 1件: 8 8 💬 |
2327 | ISIS 443139 120 mg | - | - | - | - | 1件: 8 8 💬 |
2328 | ISIS 443139 30 mg | - | - | - | - | 1件: 8 8 💬 |
2329 | ISIS 443139 60 mg | - | - | - | - | 1件: 8 8 💬 |
2330 | ISIS 443139 90 mg | - | - | - | - | 1件: 8 8 💬 |
2331 | ISIS 703802 | - | - | - | - | 1件: 79 79 💬 |
2332 | Isosorbide Dinitrate 60 mg | 2件: Isosorbide Isosorbide, Isosorbide dinitrate | 2件: Isosorbide
Isosorbide
,
Isosorbide dinitrate
💬 | - | - | 1件: 113 113 💬 |
2333 | Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung | - | - | - | - | 1件: 50 50 💬 |
2334 | Isotonic saline 0.9% | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
2335 | Isotopic Intravenous [13C]-Urea | 1件: Urea Urea | 2件: Urea
Urea
,
Urea C13
💬 | - | - | 1件: 251 251 💬 |
2336 | Isradipine CR 10mg | 1件: Isradipine Isradipine | 1件: Isradipine
Isradipine
💬 | 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
2337 | Istradefylline ( KW-6002) | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2338 | Istradefylline (KW-6002) | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2339 | ITF2357 10 mg/mL | - | - | - | - | 1件: 113 113 💬 |
2340 | Itolizumab [Bmab 600] | 1件: Itolizumab Itolizumab | 1件: Itolizumab
Itolizumab
💬 | 1件: CD6 CD6 💬 | 1件: Cell adhesion molecules Cell adhesion molecules 💬 | 1件: 49 49 💬 |
2341 | IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | 1件: 17 17 💬 |
2342 | IUPAC name: 2-[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylam ino]benzoyl]amino | - | - | - | - | 1件: 337 337 💬 |
2343 | IV treatment with IGSC, 10% | - | - | - | - | 1件: 65 65 💬 |
2344 | IVA 336 | - | - | - | - | 1件: 19 19 💬 |
2345 | Ivacaftor 125mg tablet | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2346 | Ivacaftor 150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2347 | Ivacaftor 150 mg or 250 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2348 | Ivacaftor 25 mg/75 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2349 | Ivacaftor 75 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2350 | Ivacaftor 75 mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2351 | IVACAFTOR 75mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2352 | IW-3300 rectal foam | - | - | - | - | 1件: 226 226 💬 |
2353 | J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0 | - | - | - | - | 1件: 96 96 💬 |
2354 | JAK 3 | - | - | - | - | 1件: 46 46 💬 |
2355 | JAK 3 Ritlecitinib | - | - | - | - | 1件: 46 46 💬 |
2356 | Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 85 85 💬 |
2357 | Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 85 85 💬 |
2358 | JBT-101 | - | - | - | - | 4件: 49 49, 50, 51, 299 💬 |
2359 | JBT-101 (lenabasum) | - | - | - | - | 1件: 299 299 💬 |
2360 | Jevity 1.0 | - | - | - | - | 1件: 2 2 💬 |
2361 | Jevity 1.5 | - | - | - | - | 1件: 2 2 💬 |
2362 | JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2363 | JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2364 | JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2365 | JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2366 | JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2367 | Jinarc 15 mg tablets, Jinarc 45 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2368 | Jinarc 30 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2369 | Jinarc 30 mg tablets, 90 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2370 | Jinarc 30 mg tablets, Jinarc 60 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2371 | Jinarc® 15mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2372 | Jinarc® 30 Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2373 | JKB-122 | - | - | - | - | 1件: 95 95 💬 |
2374 | JKB-122 in capsule or tablet form | - | - | - | - | 1件: 95 95 💬 |
2375 | JM-010 | - | - | - | - | 1件: 6 6 💬 |
2376 | JNJ 38518168 | - | - | - | - | 1件: 46 46 💬 |
2377 | JNJ-16240159-AAC | - | - | - | - | 1件: 46 46 💬 |
2378 | JNJ-31001074 | - | - | - | - | 1件: 6 6 💬 |
2379 | JNJ-38518168 | - | - | - | - | 1件: 46 46 💬 |
2380 | JNJ-38518168 (10 mg) | - | - | - | - | 1件: 46 46 💬 |
2381 | JNJ-38518168 (3 mg) | - | - | - | - | 1件: 46 46 💬 |
2382 | JNJ-38518168 (30 mg) | - | - | - | - | 1件: 46 46 💬 |
2383 | JNJ-38518168 / MTX | - | - | - | - | 1件: 46 46 💬 |
2384 | JNJ-38518168 50-mg Over Encapsulated Tablet | - | - | - | - | 1件: 46 46 💬 |
2385 | JNJ-38518168-AEK - Over Encapsulated Tablet - 50 mg | - | - | - | - | 1件: 46 46 💬 |
2386 | JNJ-38518168-ZBQ | - | - | - | - | 1件: 46 46 💬 |
2387 | JNJ-38518168-ZBQ - film-coated tablet - 10 mg | - | - | - | - | 1件: 46 46 💬 |
2388 | JNJ-38518168-ZBQ - film-coated tablet - 10mg | - | - | - | - | 1件: 46 46 💬 |
2389 | JNJ-38518168-ZBQ - film-coated tablet - 3 mg | - | - | - | - | 1件: 46 46 💬 |
2390 | JNJ-38518168-ZBQ - film-coated tablet - 30 mg | - | - | - | - | 1件: 46 46 💬 |
2391 | JNJ-38518168-ZBQ - film-coated tablet - 30mg | - | - | - | - | 1件: 46 46 💬 |
2392 | JNJ-38518168-ZBQ - film-coated tablet - 3mg | - | - | - | - | 1件: 46 46 💬 |
2393 | JNJ-39039039 | - | - | - | - | 1件: 210 210 💬 |
2394 | JNJ-39758979 | - | - | - | - | 1件: 46 46 💬 |
2395 | JNJ-39758979 (10 mg) | - | - | - | - | 1件: 46 46 💬 |
2396 | JNJ-39758979 (100 mg) | - | - | - | - | 1件: 46 46 💬 |
2397 | JNJ-39758979 (30 mg) | - | - | - | - | 1件: 46 46 💬 |
2398 | JNJ-39758979 (300 mg) | - | - | - | - | 1件: 46 46 💬 |
2399 | JNJ-39758979 / MTX | - | - | - | - | 1件: 46 46 💬 |
2400 | JNJ-39758979-AAC - enteric coated tablet - 10 mg | - | - | - | - | 1件: 46 46 💬 |
2401 | JNJ-39758979-AAC - enteric coated tablet - 100 mg | - | - | - | - | 1件: 46 46 💬 |
2402 | JNJ-39758979-AAC - enteric coated tablet - 30 mg | - | - | - | - | 1件: 46 46 💬 |
2403 | JNJ-54781532 150 mg once daily | - | - | - | - | 1件: 97 97 💬 |
2404 | JNJ-54781532 75 mg once daily | - | - | - | - | 1件: 97 97 💬 |
2405 | JNJ-54781532 75 mg twice daily | - | - | - | - | 1件: 97 97 💬 |
2406 | JNJ-54781532-AAD-10 mg | - | - | - | - | 1件: 97 97 💬 |
2407 | JNJ-54781532-AAD-30 mg | - | - | - | - | 1件: 97 97 💬 |
2408 | JNJ-64304500 | - | - | - | - | 1件: 96 96 💬 |
2409 | JNJ-64304500-AAA | - | - | - | - | 1件: 96 96 💬 |
2410 | JNJ-64841829 | - | - | - | - | 1件: 97 97 💬 |
2411 | JNJ-64841842 | - | - | - | - | 1件: 97 97 💬 |
2412 | JNJ-64841855 | - | - | - | - | 1件: 97 97 💬 |
2413 | JNJ-64841894 | - | - | - | - | 1件: 97 97 💬 |
2414 | JNJ-64841907 | - | - | - | - | 1件: 97 97 💬 |
2415 | JNJ-64841920 | - | - | - | - | 1件: 97 97 💬 |
2416 | JNJ-64841933 | - | - | - | - | 1件: 97 97 💬 |
2417 | JNJ-64841946 | - | - | - | - | 1件: 97 97 💬 |
2418 | JNJ-66525433 | - | - | - | - | 1件: 97 97 💬 |
2419 | JNJ-67484703 | - | - | - | - | 1件: 46 46 💬 |
2420 | JNJ-67864238 | - | - | - | - | 1件: 96 96 💬 |
2421 | JNJ-67896049 | - | - | - | - | 1件: 86 86 💬 |
2422 | JNJ-67896049 (ACT-293987) | - | - | - | - | 1件: 86 86 💬 |
2423 | JNJ-67896062 / ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
2424 | JNJ-67896062/ ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
2425 | JNJ-67896062/ACT-064922 | - | - | - | - | 1件: 86 86 💬 |
2426 | JNJ-67896153/ACT-128800 | - | - | - | - | 1件: 13 13 💬 |
2427 | JNJ-72537634 | - | - | - | - | 1件: 97 97 💬 |
2428 | JNJ-78934804 | - | - | - | - | 2件: 96 96, 97 💬 |
2429 | JNJ31-31001074 | - | - | - | - | 1件: 6 6 💬 |
2430 | Jorveza 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
2431 | Jorveza 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
2432 | Jorveza 1 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
2433 | Jorveza 1 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
2434 | JP 1730 | - | - | - | - | 1件: 6 6 💬 |
2435 | JP-1730/F01 | - | - | - | - | 2件: 6 6, 17 💬 |
2436 | JP-1730/F02 | - | - | - | - | 2件: 6 6, 17 💬 |
2437 | JP-1730/F03 | - | - | - | - | 2件: 6 6, 17 💬 |
2438 | JR-141 | - | - | - | - | 1件: 19 19 💬 |
2439 | JR-141 or Idursulfase | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2440 | JR-171 (lepunafusp alfa) | - | - | - | - | 1件: 19 19 💬 |
2441 | JTE-051 | - | - | - | - | 1件: 46 46 💬 |
2442 | Jyseleca 100 mg film-coated tablets | 1件: Filgotinib Filgotinib | 1件: Filgotinib
Filgotinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2443 | JZP-110 | - | - | - | - | 1件: 6 6 💬 |
2444 | Kalydeco 150 mg film-c | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2445 | Kalydeco 150 mg film-coated tablets | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2446 | Kalydeco 150mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2447 | Kamada-AAT for Inhalation, 160mg | - | - | - | - | 1件: 231 231 💬 |
2448 | Kamillenblüten 3ml/10ml | - | - | - | - | 1件: 97 97 💬 |
2449 | KCT-0809 ophthalmic solution | - | - | - | - | 1件: 53 53 💬 |
2450 | KDT-3594 | 1件: KDT-3594 KDT-3594 | - | - | - | 1件: 6 6 💬 |
2451 | Kedrion IVIG 10% | - | - | - | - | 1件: 65 65 💬 |
2452 | Ketocal 4:1 liquid Nutricia (intervention) | - | - | - | - | 1件: 256 256 💬 |
2453 | KHK4827 140mg SC | - | - | - | - | 1件: 37 37 💬 |
2454 | KIN-1901 | - | - | - | - | 1件: 271 271 💬 |
2455 | KIN-1902 | - | - | - | - | 1件: 84 84 💬 |
2456 | KINERET*SC 7SIR 100MG 0,67ML | 1件: Anakinra Anakinra | 1件: Anakinra
Anakinra
💬 | 2件: IL1R1 IL1R1, IL1R2 💬 | 15件: Amoebiasis Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 3件: 28 28, 46, 107 💬 |
2457 | KIO-301 | - | - | - | - | 1件: 90 90 💬 |
2458 | KIOVIG 100 mg/ml solution for infusion | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 14 14, 65 💬 |
2459 | Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 14 14 💬 |
2460 | KN019, 10 mg/kg | - | - | - | - | 1件: 46 46 💬 |
2461 | KNS-760704 | - | - | - | - | 1件: 2 2 💬 |
2462 | Koselugo 10mg | 1件: Selumetinib Selumetinib | 1件: Selumetinib
Selumetinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
2463 | KPL-301 | - | - | - | - | 1件: 41 41 💬 |
2464 | KPS-0373 | - | - | - | - | 1件: 18 18 💬 |
2465 | KPS-0373, High dose | - | - | - | - | 1件: 18 18 💬 |
2466 | KPS-0373, Low dose | - | - | - | - | 1件: 18 18 💬 |
2467 | Kreon 25 000 | - | - | - | - | 1件: 299 299 💬 |
2468 | Kreon 25,000 Units | - | - | - | - | 1件: 299 299 💬 |
2469 | Kreon® 25,000 | - | - | - | - | 1件: 299 299 💬 |
2470 | KRP-116D | - | - | - | - | 1件: 226 226 💬 |
2471 | Kuvan 100mg soluble tablet | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
2472 | KVD824 300 mg Compresse a rilascio modificato | - | - | - | - | 1件: 65 65 💬 |
2473 | KVD824 300 mg Modified Release Tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 65 65 💬 |
2474 | KVD900 100 mg Film Coated Tablet | - | - | - | - | 1件: 65 65 💬 |
2475 | KVD900 300 mg | - | - | - | - | 1件: 65 65 💬 |
2476 | KVD900 300 mg Film Coated Tablet | - | - | - | - | 1件: 65 65 💬 |
2477 | KVD900 600 mg | - | - | - | - | 1件: 65 65 💬 |
2478 | KW-0761 | - | - | - | - | 1件: 26 26 💬 |
2479 | KW-0761 0.3 mg/kg IV | - | - | - | - | 1件: 26 26 💬 |
2480 | KW-6002 | - | - | - | - | 1件: 6 6 💬 |
2481 | KW-6002 (istradefylline) | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2482 | KW-6356 | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
2483 | KW-6356 High Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
2484 | KW-6356 Low Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
2485 | KW-6356 Middle Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
2486 | KW-6356 X Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
2487 | KW-6356 Y Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
2488 | KW-6500 | - | - | - | - | 1件: 6 6 💬 |
2489 | KZR-616 | 1件: KZR-616 KZR-616 | - | - | - | 3件: 49 49, 50, 61 💬 |
2490 | KZR-616 maleate | 1件: KZR-616 KZR-616 | - | - | - | 1件: 50 50 💬 |
2491 | Kümmel 2ml/10ml | - | - | - | - | 1件: 97 97 💬 |
2492 | L-000124467 | - | - | - | - | 2件: 13 13, 46 💬 |
2493 | L-000124467 (freebase) | - | - | - | - | 1件: 46 46 💬 |
2494 | L-000124467-009J (succinat | - | - | - | - | 1件: 46 46 💬 |
2495 | L-000883191 | - | - | - | - | 1件: 46 46 💬 |
2496 | L-001069957 | - | - | - | - | 1件: 46 46 💬 |
2497 | L-123 Ioflupane | - | - | - | - | 1件: 6 6 💬 |
2498 | L-3-(3,4-Dihydroxyphenyl)alanine | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 6 6 💬 |
2499 | L-METHIONINE ([11C]METHYL) | 1件: Methionine Methionine | 1件: Methionine
Methionine
💬 | - | - | 1件: 84 84 💬 |
2500 | L03 AB 08 | - | - | - | - | 1件: 13 13 💬 |
2501 | LABP-104 250mg | - | - | - | - | 1件: 49 49 💬 |
2502 | Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers | 1件: Lactobacillus acidophilus Lactobacillus acidophilus | 1件: Lactomin
Lactomin
💬 | - | - | 1件: 6 6 💬 |
2503 | Lamotrigin ”Nordic Prime 100 mg | - | - | - | - | 1件: 114 114 💬 |
2504 | Lansoprazole 30mg | 1件: Lansoprazole Lansoprazole | 1件: Lansoprazole
Lansoprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 166 166 💬 |
2505 | Lantus 100 units/ml solution for injection in a cartridge | - | - | - | - | 1件: 299 299 💬 |
2506 | Lantus® 100 Units/ml solution for injection in a vial. Lantus® 100 Units/ml solution for injection in a cartridge. Lantus® 100 Units/ml solution for injection in a pre-filled pen | - | - | - | - | 1件: 299 299 💬 |
2507 | Laquinimod 0.3 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2508 | Laquinimod 0.6 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2509 | Laquinimod 1.2 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2510 | Laquinimod Capsulas 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2511 | Laquinimod Capsules 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2512 | Laquinimod capsules 0.5 mg | 1件: Laquinimod Laquinimod | - | - | - | 2件: 8 8, 96 💬 |
2513 | Laquinimod Capsules 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2514 | Laquinimod Cápsulas 0.5 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 96 96 💬 |
2515 | Laquinimod Tablets 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2516 | LAU-7b | - | - | - | - | 1件: 299 299 💬 |
2517 | LAX-101 | 1件: LAX-101 LAX-101 | - | - | - | 1件: 8 8 💬 |
2518 | LC51-0255 | - | - | - | - | 1件: 97 97 💬 |
2519 | LCI699, 1 mg | - | - | - | - | 1件: 75 75 💬 |
2520 | LCI699, 10 mg | - | - | - | - | 1件: 75 75 💬 |
2521 | LCZ696 100 mg | - | - | - | - | 1件: 58 58 💬 |
2522 | LDP-02 | - | - | - | - | 2件: 96 96, 97 💬 |
2523 | Leflunomide 20 mg+prednisone 0.5mg/kg/d | 2件: Leflunomide Leflunomide, Prednisone | 2件: Prednisone
Prednisone
,
Leflunomide
💬 | 2件: DHODH DHODH, NR3C1 💬 | 4件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Neuroactive ligand-receptor interaction, Pyrimidine metabolism 💬 | 1件: 66 66 💬 |
2524 | LEMTRADA 12 mg Konzentrat zur Herstellung einer Infusionslösung | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 13 13 💬 |
2525 | Letairis 10 mg | 1件: Ambrisentan Ambrisentan | 1件: Ambrisentan
Ambrisentan
💬 | 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 💬 |
2526 | Leuplin DPS 11.25mg | - | - | - | - | 1件: 76 76 💬 |
2527 | Leuprolide acetate 11.25 mg | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
2528 | Leuprolide Acetate 3 Month Depot | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
2529 | Leuprolide acetate 30 mg | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
2530 | Leuprorelin Acetate 3.75mg Injection | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
2531 | Leuprorelin Acetate Depot 3M | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
2532 | Levemir 100 U/ml solution for injection in a cartridge, Levemir 100 U/ml solution for injection in a pre-filled pen | 1件: Insulin detemir Insulin detemir | 1件: Insulin detemir
Insulin detemir
💬 | 1件: INSR INSR 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 299 299 💬 |
2533 | Levodopa 100 mg / benserazide 25 mg | 2件: Benserazide Benserazide, Levodopa | 2件: Levodopa
Levodopa
,
Benserazide
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2534 | Levodopa 100 mg A CAP | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2535 | Levodopa 125 mg A CAP | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2536 | Levodopa 150 mg A CAP | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2537 | Levodopa 25mg/100mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2538 | Levodopa 75 mg A CAP | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2539 | Levodopa, carbidopa, ODM-104 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2540 | Levodopa/benserazide 100/25 mg | 2件: Benserazide Benserazide, Levodopa | 2件: Levodopa
Levodopa
,
Benserazide
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2541 | Levodopa/Carbidopa (4:1) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 201 201 💬 |
2542 | Levodopa/carbidopa 100/25 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2543 | LEVOFOLENE 4 MG 30 CPR | 1件: Levoleucovorin Levoleucovorin | - | - | - | 1件: 13 13 💬 |
2544 | Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1 | 1件: Aminolevulinic acid Aminolevulinic acid | 1件: Aminolevulinic acid
Aminolevulinic acid
💬 | - | - | 1件: 34 34 💬 |
2545 | Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3 | 1件: Aminolevulinic acid Aminolevulinic acid | 1件: Aminolevulinic acid
Aminolevulinic acid
💬 | - | - | 1件: 34 34 💬 |
2546 | Lidocaine 1% Injectable Solution | 1件: Lidocaine Lidocaine | 2件: Lidocaine
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 34 34 💬 |
2547 | LION-101 dose level 1 | - | - | - | - | 1件: 113 113 💬 |
2548 | LION-101 dose level 2 | - | - | - | - | 1件: 113 113 💬 |
2549 | LIORESAL*50CPR 10MG | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
2550 | Liothyronine I 131 | 2件: Liothyronine Liothyronine, Liothyronine I-131 | 1件: Liothyronine
Liothyronine
💬 | 2件: THRA THRA, THRB 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬 | 2件: 210 210, 212 💬 |
2551 | Lipoic acid and omega-3 fatty acids | 2件: Lipoic acid Lipoic acid, Omega-3 fatty acids | - | - | - | 1件: 13 13 💬 |
2552 | Liposomal Cyclosporine A 10 mg | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 💬 |
2553 | LIQ861 100 µg | - | - | - | - | 1件: 86 86 💬 |
2554 | LIQ861 106 µg | - | - | - | - | 1件: 86 86 💬 |
2555 | LIQ861 75 µg | - | - | - | - | 1件: 86 86 💬 |
2556 | LIQ861 79.5 µg | - | - | - | - | 1件: 86 86 💬 |
2557 | Lisuride TTS 10cm² | 1件: Lisuride Lisuride | 1件: Lisuride
Lisuride
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2558 | LIV-GAMMA SN Inj.10% | - | - | - | - | 1件: 63 63 💬 |
2559 | LJN452, 0,01 mg | - | - | - | - | 1件: 93 93 💬 |
2560 | LJN452, 0,03 mg | - | - | - | - | 1件: 93 93 💬 |
2561 | LJN452, 0,1 mg | - | - | - | - | 1件: 93 93 💬 |
2562 | LJP 394 | - | - | - | - | 1件: 49 49 💬 |
2563 | Lloprost(Ventavis,BAYQ6252, 10 µg/mL) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2564 | Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol) | 4件: Acetate Acetate, Estradiol, Ethinylestradiol, Norethisterone | 3件: Estradiol
Estradiol
,
Norethindrone
,
Ethinyl estradiol
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 2件: 46 46, 49 💬 |
2565 | Lojuxta 10 mg hard capsules | 1件: Lomitapide Lomitapide | 1件: Lomitapide
Lomitapide
💬 | 1件: MTTP MTTP 💬 | 1件: Fat digestion and absorption Fat digestion and absorption 💬 | 1件: 79 79 💬 |
2566 | Long-chain n-3 PUFA | - | - | - | - | 1件: 46 46 💬 |
2567 | Loratadina STADA 10 mg | 1件: Loratadine Loratadine | 1件: Loratadine
Loratadine
💬 | 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 89 89 💬 |
2568 | Lovastatin 60 MG | 1件: Lovastatin Lovastatin | 1件: Lovastatin
Lovastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 34 34 💬 |
2569 | Low Dose Aspirin (162 mg/day) | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: Aspirin
Aspirin
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
2570 | Low dose BIBF 1120 twice daily | - | - | - | - | 1件: 85 85 💬 |
2571 | Low Dose MT-1303 | - | - | - | - | 1件: 97 97 💬 |
2572 | Low dose ORTD-1 | - | - | - | - | 1件: 46 46 💬 |
2573 | Low immunogenic interferon-beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2574 | LP-08 20mg | - | - | - | - | 1件: 226 226 💬 |
2575 | LP-08 80mg | - | - | - | - | 1件: 226 226 💬 |
2576 | LP-168 tablet | - | - | - | - | 1件: 13 13 💬 |
2577 | LT-02 | - | - | - | - | 1件: 97 97 💬 |
2578 | LT-02 (modified-release PC pellets) | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 97 97 💬 |
2579 | LTS 0.25mg | - | - | - | - | 1件: 46 46 💬 |
2580 | LTS 0.5mg | - | - | - | - | 1件: 46 46 💬 |
2581 | LTS 1.0mg | - | - | - | - | 1件: 46 46 💬 |
2582 | Lu 00-800 | - | - | - | - | 1件: 6 6 💬 |
2583 | LU 70274 | - | - | - | - | 1件: 299 299 💬 |
2584 | Lumacaftor/ivacaftor 100mg/125mg tablets | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2585 | Lumacaftor/ivacaftor 200mg/125mg | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2586 | Lumacaftor/ivacaftor 200mg/125mg tablets | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2587 | Lung Spheroid Stem Cells 100 million | - | - | - | - | 1件: 85 85 💬 |
2588 | Luphere depot 3.75mg(Leuprolide acetate 3.75mg) | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
2589 | Lutein (10 or 30 mg/day) capsules | 1件: Lutein Lutein | - | - | - | 1件: 90 90 💬 |
2590 | LYC-30937 | - | - | - | - | 1件: 97 97 💬 |
2591 | LYC-30937-EC | - | - | - | - | 1件: 97 97 💬 |
2592 | Lysomucil 10 % | - | - | - | - | 1件: 299 299 💬 |
2593 | LYT-100 | - | - | - | - | 1件: 85 85 💬 |
2594 | M2951 75 mg QD | - | - | - | - | 1件: 46 46 💬 |
2595 | MABCAMPATH 10 mg/ml concentrado para solución para perfusión | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 13 13 💬 |
2596 | MabCampath-1h | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 13 13 💬 |
2597 | MABTHERA - 1 FIALA 500 MG 50 ML | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 14 14, 53 💬 |
2598 | MABTHERA - 2 FIALE 100 MG 10 ML | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 19 19, 65 💬 |
2599 | MabThera 100 mg concentrate for solution for infusion | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 222 222 💬 |
2600 | MabThera 100mg | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2601 | MabThera 500 mg (10 mg/ml) concentrate for solution for infusion | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2602 | MabThera 500 mg (10mg/ml) | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2603 | MABTHERA*EV 1FL 50ML 500MG | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 46 46, 222 💬 |
2604 | MabThera® 100MG | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 43 43 💬 |
2605 | MabThera®, 100 mg Concentrado para solución para perfusión | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2606 | MabThera®, 100 mg concentrate for solution for infusion | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2607 | Macitentan (ACT-064992) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2608 | Macitentan 10 mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 51 51, 86, 88 💬 |
2609 | Macitentan 10 mg tablet, once daily. | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2610 | Macitentan 10mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 88 💬 |
2611 | Macitentan 3 mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2612 | Macitentan 37.5 mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2613 | Macitentan 3mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2614 | Macitentan 75 mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2615 | Madopar 125 mg T, tablets | - | - | - | - | 1件: 6 6 💬 |
2616 | Madopar 125 mg, orodispersible tablet | - | - | - | - | 1件: 6 6 💬 |
2617 | Madopar Tab. 125 or Perkin Tab. 25-100mg | - | - | - | - | 1件: 6 6 💬 |
2618 | Madopar® 125 | - | - | - | - | 1件: 6 6 💬 |
2619 | Madopar® 125 mg T Tablets Levodopa 100 mg Benserazide 25 mg (as benserazide hydrochloride) | 2件: Benserazide Benserazide, Levodopa | 2件: Levodopa
Levodopa
,
Benserazide
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2620 | Madopar® HBS 125 | - | - | - | - | 1件: 6 6 💬 |
2621 | MANNITOLO 18% | - | - | - | - | 1件: 2 2 💬 |
2622 | MANNITOLO 18% LDB | - | - | - | - | 1件: 2 2 💬 |
2623 | MANTADAN*20CPR 100MG | - | - | - | - | 1件: 13 13 💬 |
2624 | Masitinib (3.0) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
2625 | Masitinib (6.0) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
2626 | Masitinib 100 mg Tablets | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
2627 | Masitinib 100mg | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 2件: 2 2, 5 💬 |
2628 | Masitinib 3 mg | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 46 46 💬 |
2629 | Masitinib 6.0 mg | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 46 46 💬 |
2630 | MAVENCLAD - 10 MG - COMPRESSA - USO ORALE - BLISTER (AL/AL) - 6 COMPRESSE | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
2631 | MAVENCLAD 10 mg tablets | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
2632 | Mavenclad tabletter 10 mg | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
2633 | Mavrilimumab 10 mg | 1件: Mavrilimumab Mavrilimumab | 1件: Mavrilimumab
Mavrilimumab
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 💬 |
2634 | Mavrilimumab 100 mg | 1件: Mavrilimumab Mavrilimumab | 1件: Mavrilimumab
Mavrilimumab
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 💬 |
2635 | Mavrilimumab 150 mg | 1件: Mavrilimumab Mavrilimumab | 1件: Mavrilimumab
Mavrilimumab
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 💬 |
2636 | Mavrilimumab 30 mg | 1件: Mavrilimumab Mavrilimumab | 1件: Mavrilimumab
Mavrilimumab
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 💬 |
2637 | Mayzent 0,25 mg Filmtabletten | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
2638 | Mayzent 0.25 mg fi | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
2639 | MB-102 | - | - | - | - | 1件: 96 96 💬 |
2640 | MBM-01 | - | - | - | - | 1件: 65 65 💬 |
2641 | MBX-8025 50 mg (Dose Escalation Period 1) | - | - | - | - | 1件: 79 79 💬 |
2642 | MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) | - | - | - | - | 1件: 79 79 💬 |
2643 | MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3) | - | - | - | - | 1件: 79 79 💬 |
2644 | MCI-186 | - | - | - | - | 1件: 2 2 💬 |
2645 | MCI-186 in open label phase | - | - | - | - | 1件: 2 2 💬 |
2646 | MD-0901 | - | - | - | - | 1件: 97 97 💬 |
2647 | MD-711 | - | - | - | - | 1件: 86 86 💬 |
2648 | MD1003 100 mg capsule | - | - | - | - | 1件: 20 20 💬 |
2649 | MD1003 100mg capsule | - | - | - | - | 1件: 13 13 💬 |
2650 | MDGN-002 | - | - | - | - | 1件: 96 96 💬 |
2651 | MDX-1100 | - | - | - | - | 3件: 46 46, 96, 97 💬 |
2652 | MDX-1100 (anti-CXCL10 human monoclonal antibody) | - | - | - | - | 1件: 97 97 💬 |
2653 | MDX-1342 | - | - | - | - | 1件: 46 46 💬 |
2654 | Mecasermin [rDNA Origin] 10mg/ml solution | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2655 | MEDI-545 600 | - | - | - | - | 1件: 49 49 💬 |
2656 | MEDI-551 100 MG-IV | - | - | - | - | 1件: 13 13 💬 |
2657 | MEDI-551 30 MG-IV | - | - | - | - | 1件: 13 13 💬 |
2658 | MEDI-551 300 MG-SC | - | - | - | - | 1件: 13 13 💬 |
2659 | MEDI-551 60 MG-SC | - | - | - | - | 1件: 13 13 💬 |
2660 | MEDI-551 600 MG-IV | - | - | - | - | 1件: 13 13 💬 |
2661 | MEDI-570 0.03 MG | - | - | - | - | 1件: 49 49 💬 |
2662 | MEDI-570 0.1 MG | - | - | - | - | 1件: 49 49 💬 |
2663 | MEDI-570 0.3 MG | - | - | - | - | 1件: 49 49 💬 |
2664 | MEDI-570 1 MG | - | - | - | - | 1件: 49 49 💬 |
2665 | MEDROL - 4 MG COMPRESSE 30 COMPRESSE | - | - | - | - | 1件: 56 56 💬 |
2666 | Medrol A 16 mg tablets | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2667 | MEDROL*10CPR DIV 4MG | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
2668 | Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d | 2件: Eflornithine Eflornithine, Melarsoprol | 2件: Melarsoprol
Melarsoprol
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
2669 | Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d | 2件: Melarsoprol Melarsoprol, Nifurtimox | 2件: Melarsoprol
Melarsoprol
,
Nifurtimox
💬 | - | - | 1件: 65 65 💬 |
2670 | Melissenblätter 15ml/10ml | - | - | - | - | 1件: 97 97 💬 |
2671 | Meloxicam 0.125 mg/kg | 1件: Meloxicam Meloxicam | 1件: Meloxicam
Meloxicam
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
2672 | Meloxicam 0.25 mg/kg | 1件: Meloxicam Meloxicam | 1件: Meloxicam
Meloxicam
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
2673 | MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 💬 |
2674 | MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 💬 |
2675 | MENINGOCOCCAL GROUP Y OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (Â197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 💬 |
2676 | MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC | 9件: Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, Meningococcal polysaccharide vaccine group A, Meningococcal polysaccharide vaccine group C, Meningococcal polysaccharide vaccine group W-135, Meningococcal polysaccharide vaccine group Y, Neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen, Neisseria meningitidis group c capsular oligosaccharide diphtheria crm197 protein conjugate antigen, Neisseria meningitidis group w-135 capsular oligosaccharide diphtheria crm197 protein conjugate antigen, Neisseria meningitidis group y capsular oligosaccharide diphtheria crm197 protein conjugate antigen | 2件: Meningococcal polysaccharide vaccine group A
Meningococcal polysaccharide vaccine group A
,
Meningococcal polysaccharide vaccine group C
💬 | - | - | 2件: 62 62, 66 💬 |
2677 | Mepolizumab 100 mg | 1件: Mepolizumab Mepolizumab | 1件: Mepolizumab
Mepolizumab
💬 | 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 98 98 💬 |
2678 | Mepolizumab 300 mg | 1件: Mepolizumab Mepolizumab | 1件: Mepolizumab
Mepolizumab
💬 | 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 98 98 💬 |
2679 | Meropenem Fresenius Kabi 1 g poeder voor oplossing voor injectie of infusie | 1件: Meropenem Meropenem | 2件: Meropenem
Meropenem
,
Meropenem
💬 | - | - | 1件: 299 299 💬 |
2680 | Mesalazine (3,600 mg) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2681 | Mesalazine - TID 1000 mg | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2682 | Mesalazine 1000 mg gastro-resistant tablets | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2683 | Mesenchymal stem cell 0.5 | - | - | - | - | 1件: 228 228 💬 |
2684 | Mesenchymal stem cell 1.0 | - | - | - | - | 1件: 228 228 💬 |
2685 | Metalcaptase® 150 mg gastro-resistant tablet | - | - | - | - | 1件: 171 171 💬 |
2686 | Metalcaptase® 300 mg gastro-resistant tablet | - | - | - | - | 1件: 171 171 💬 |
2687 | Metex 10 mg/ml Injektionslösung, Fertigspritze | - | - | - | - | 1件: 46 46 💬 |
2688 | Metex 10mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
2689 | Metex 7,5mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
2690 | MetFORMIN 1000 Mg Oral Tablet | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 13 13 💬 |
2691 | Metformin/CP-690,550 | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2692 | METFORMINA - 500 30 COMPRESSE 500 MG | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 113 113 💬 |
2693 | METHOTREXATE - 20 MG/0.8 ML SOLUZIONE INIETTABILE 4 SIRINGHE PRERIEMPITE MONOUSO DA 1.25 ML | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 96 96 💬 |
2694 | Methotrexate 10 mg | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2695 | Methotrexate 10 mg tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2696 | Methotrexate plus ERB-041 for 12 weeks | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2697 | METHOTREXATE*100CPR 2,5MG | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2698 | METHOTREXATE*10MG/1,33ML 4S | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2699 | METHOTREXATE*15MG/2ML 4SIR | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2700 | METHOTREXATE*20MG/2,66ML 4S | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2701 | METHOTREXATE*7,5MG/ML 4SIR. | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2702 | Methotrexate, Leucovorin and BMS-986142 | 3件: BMS-986142 BMS-986142, Leucovorin, Methotrexate | 3件: Methotrexate
Methotrexate
,
Folinic acid
,
Folinic acid calcium salt pentahydrate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2703 | Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-beta-Dribofuronamide | 1件: Adenine Adenine | 1件: Adenine
Adenine
💬 | - | - | 1件: 46 46 💬 |
2704 | Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-ß-Dribofuronamide | 1件: Adenine Adenine | 1件: Adenine
Adenine
💬 | - | - | 1件: 46 46 💬 |
2705 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo | - | - | - | - | 1件: 86 86 💬 |
2706 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb | - | - | - | - | 2件: 86 86, 88 💬 |
2707 | Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth | - | - | - | - | 2件: 86 86, 88 💬 |
2708 | Methylphenidate 10mg tablets | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 84 84 💬 |
2709 | Methylphenidate modified release 30 mg | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
2710 | Methylprednisolone 1250 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
2711 | Methylprednisolone bolus IV 15 mg/kg/d for 3 days. | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
2712 | Methylprednisolone(intravenously in the 1st-2nd-3rd month ) | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 66 66 💬 |
2713 | Methylprednisolone(intravenously in the 1st-3rd-5th month) | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 66 66 💬 |
2714 | METILPREDNISOLONE HIKMA - 1000 MG POLVERE PER SOLUZIONE INIETTABILE 10 FLACONCINI IN VETRO | - | - | - | - | 1件: 300 300 💬 |
2715 | METOCLOPRAMIDE ACCORD - 10 MG COMPRESSE 28 COMPRESSE IN BLISTER PVC/PVDC/AL | 1件: Metoclopramide Metoclopramide | 1件: Metoclopramide
Metoclopramide
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 51 51 💬 |
2716 | MetoHEXAL® Succ ® 23,75 mg Retardtabletten | - | - | - | - | 1件: 113 113 💬 |
2717 | MetoHEXAL® Succ ® 95 mg Retardtabletten | - | - | - | - | 1件: 113 113 💬 |
2718 | Metoject 10 mg/ml | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 💬 |
2719 | METOJECT 10 mg/ml, solution injectable en seringue pré-remplie | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 44 44 💬 |
2720 | Mexiletine 167 mg | 1件: Mexiletine Mexiletine | 1件: Mexiletine
Mexiletine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 113 113 💬 |
2721 | Mezavant 1200 mg magensaftresistente Retardtabletten | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2722 | Mezavant XL 1200 mg gastro-resistant prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2723 | Mezavant XL 1200 mg gastro-resistant, prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2724 | Mezavant XL 1200 mg gastro-resistant, prolonged release tablets. | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2725 | Mezavant XL 1200mg gastro-resistant, prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2726 | MG-O-1002 | - | - | - | - | 1件: 11 11 💬 |
2727 | MH004 Ia(0.1%) | - | - | - | - | 1件: 46 46 💬 |
2728 | MH004 Ia(0.3%) | - | - | - | - | 1件: 46 46 💬 |
2729 | MH004 Ia(1%) | - | - | - | - | 1件: 46 46 💬 |
2730 | MH004 Ia(3%) | - | - | - | - | 1件: 46 46 💬 |
2731 | MH004 Ib-1(0.1%) | - | - | - | - | 1件: 46 46 💬 |
2732 | MH004 Ib-1(0.3%) | - | - | - | - | 1件: 46 46 💬 |
2733 | MH004 Ib-1(1%) | - | - | - | - | 1件: 46 46 💬 |
2734 | MH004 Ib-2(0.3%) | - | - | - | - | 1件: 46 46 💬 |
2735 | MH004 Ib-2(1%) | - | - | - | - | 1件: 46 46 💬 |
2736 | MH004 Ib-2(3%) | - | - | - | - | 1件: 46 46 💬 |
2737 | MIB-626 | - | - | - | - | 1件: 18 18 💬 |
2738 | Microgynon® 30 (Oral contraceptive) | - | - | - | - | 1件: 46 46 💬 |
2739 | Mid dose ANAVEX2-73 | - | - | - | - | 1件: 6 6 💬 |
2740 | Midazolam 3 mg | 1件: Midazolam Midazolam | 1件: Midazolam
Midazolam
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 96 96 💬 |
2741 | Migalastat HCl 150 mg | 1件: Migalastat Migalastat | 1件: Migalastat
Migalastat
💬 | - | - | 1件: 19 19 💬 |
2742 | MIN-102 | - | - | - | - | 2件: 18 18, 20 💬 |
2743 | Minocycline 100 mg Film-coated Tablets | 1件: Minocycline Minocycline | 1件: Minocycline
Minocycline
💬 | - | - | 1件: 13 13 💬 |
2744 | Minocycline 100mg | 1件: Minocycline Minocycline | 1件: Minocycline
Minocycline
💬 | - | - | 1件: 13 13 💬 |
2745 | MIRAPEXIN*30CPR 0,7MG | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2746 | Mirdametinib (PD-0325901) oral capsule or dispersible tablet | 1件: Mirdametinib Mirdametinib | 1件: Mirdametinib
Mirdametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
2747 | MK-0653 | - | - | - | - | 1件: 260 260 💬 |
2748 | MK-0663 | - | - | - | - | 2件: 46 46, 271 💬 |
2749 | MK-0859 | - | - | - | - | 1件: 79 79 💬 |
2750 | MK-0873 | 1件: MK-0873 MK-0873 | - | - | - | 1件: 46 46 💬 |
2751 | MK-3222 | - | - | - | - | 1件: 271 271 💬 |
2752 | MK-6194 | - | - | - | - | 1件: 97 97 💬 |
2753 | MK-7962 | - | - | - | - | 1件: 86 86 💬 |
2754 | MK-8457 100 mg | - | - | - | - | 1件: 46 46 💬 |
2755 | MK0812 / Duration of Treatment: 12 Weeks | - | - | - | - | 1件: 46 46 💬 |
2756 | MM-093 | 1件: MM-093 MM-093 | - | - | - | 1件: 46 46 💬 |
2757 | MN-001 | - | - | - | - | 1件: 226 226 💬 |
2758 | MN-001 BID | - | - | - | - | 1件: 226 226 💬 |
2759 | MN-08 24 mg/day | - | - | - | - | 1件: 86 86 💬 |
2760 | MN-08 60 mg/day | - | - | - | - | 1件: 86 86 💬 |
2761 | MN-166 | - | - | - | - | 1件: 2 2 💬 |
2762 | MNK-1411 | - | - | - | - | 1件: 113 113 💬 |
2763 | Moderna COVID-19 Vaccine | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: Elasomeran
Elasomeran
💬 | - | - | 1件: 46 46 💬 |
2764 | Moderna mRNA-1273 | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 💬 |
2765 | Moderna mRNA-1273, Bivalent | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 💬 |
2766 | Modopar 125 | - | - | - | - | 1件: 6 6 💬 |
2767 | Modopar 62,5 | - | - | - | - | 1件: 6 6 💬 |
2768 | Molgramostim 300 mcg nebuliser solution | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
2769 | Molgramostim 300 µg nebulizer solution | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
2770 | Molgramostim Nebuliser solution 300 mcg | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
2771 | MOLI 1901 | - | - | - | - | 1件: 299 299 💬 |
2772 | Moli 1901 (2622U90, duramycin) | 1件: Lancovutide Lancovutide | - | - | - | 1件: 299 299 💬 |
2773 | Monomethyl fumarate 190 mg | 1件: Monomethyl fumarate Monomethyl fumarate | 1件: Monomethyl fumarate
Monomethyl fumarate
💬 | - | - | 1件: 13 13 💬 |
2774 | MONORES*30CPR 20MCG | - | - | - | - | 1件: 1 1 💬 |
2775 | Monotherapy (Lopinavir/ritonavir) + ABC/3TC | 2件: Lopinavir Lopinavir, Ritonavir | 2件: Ritonavir
Ritonavir
,
Lopinavir
💬 | - | - | 1件: 265 265 💬 |
2776 | Monovalent [B.1.351] CoV2 preS dTM-AS03 | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 💬 |
2777 | Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142 | 6件: BMS-986142 BMS-986142, Digoxin, Flurbiprofen, Midazolam, Montelukast, Pravastatin | 5件: Digoxin
Digoxin
,
Flurbiprofen
,
Midazolam
,
Montelukast
,
Pravastatin
💬 | 24件: ATP1A1 ATP1A1, ATP1A2, ATP1A3, ATP1A4, CYSLTR1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HMGCR, PTGS1, PTGS2 💬 | 49件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Arachidonic acid metabolism, Bile secretion, C-type lectin receptor signaling pathway, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Chemical carcinogenesis - DNA adducts, Endocrine and other factor-regulated calcium reabsorption, GABAergic synapse, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Insulin secretion, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Mineral absorption, Morphine addiction, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Nicotine addiction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pancreatic secretion, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, Taste transduction, Terpenoid backbone biosynthesis, Thyroid hormone signaling pathway, Thyroid hormone synthesis, VEGF signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
2778 | Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
2779 | MORAb-022 | - | - | - | - | 1件: 46 46 💬 |
2780 | MORF-057 | - | - | - | - | 1件: 97 97 💬 |
2781 | MOZOBIL - 20 MG/ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 24 MG/1.2 ML 1 FLACONCINO | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 💬 |
2782 | MP-376 | - | - | - | - | 1件: 299 299 💬 |
2783 | MP-376 (Levofloxacin Solution for Inhalation) | 1件: Levofloxacin Levofloxacin | 2件: Levofloxacin
Levofloxacin
,
Levofloxacin
💬 | - | - | 1件: 299 299 💬 |
2784 | MR-MC-01 | - | - | - | - | 1件: 226 226 💬 |
2785 | MRA 003 US | - | - | - | - | 1件: 49 49 💬 |
2786 | MRC375 150mg | - | - | - | - | 1件: 46 46 💬 |
2787 | MRNA-3704 | - | - | - | - | 1件: 246 246 💬 |
2788 | MRNA-3705 | - | - | - | - | 1件: 246 246 💬 |
2789 | MRNA-3927 | - | - | - | - | 1件: 245 245 💬 |
2790 | MSC injection 01 | - | - | - | - | 1件: 96 96 💬 |
2791 | MSC injection 02 | - | - | - | - | 1件: 96 96 💬 |
2792 | MSC treatment 01 | - | - | - | - | 1件: 96 96 💬 |
2793 | MSC treatment 02 | - | - | - | - | 1件: 96 96 💬 |
2794 | MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2795 | MSI-1995 | - | - | - | - | 1件: 299 299 💬 |
2796 | MSTC-001 (MS-STAT) | - | - | - | - | 1件: 13 13 💬 |
2797 | MT-1186 | - | - | - | - | 1件: 2 2 💬 |
2798 | MT-1303 | - | - | - | - | 3件: 13 13, 96, 97 💬 |
2799 | MT-1303 [0.1] | - | - | - | - | 1件: 13 13 💬 |
2800 | MT-1303 [0.2] | - | - | - | - | 1件: 13 13 💬 |
2801 | MT-1303 [0.4] | - | - | - | - | 1件: 13 13 💬 |
2802 | MT-1303 High dose | - | - | - | - | 1件: 49 49 💬 |
2803 | MT-1303 Low dose | - | - | - | - | 1件: 49 49 💬 |
2804 | MT-1303-FormA | - | - | - | - | 1件: 13 13 💬 |
2805 | MT-1303-FormB | - | - | - | - | 1件: 13 13 💬 |
2806 | MT-1303-High | - | - | - | - | 1件: 13 13 💬 |
2807 | MT-1303-Low | - | - | - | - | 1件: 13 13 💬 |
2808 | MT-1303-Middle | - | - | - | - | 1件: 13 13 💬 |
2809 | MT-3921 | - | - | - | - | 1件: 26 26 💬 |
2810 | MT-7117 | - | - | - | - | 2件: 51 51, 254 💬 |
2811 | MT-7117 High Dose | - | - | - | - | 1件: 254 254 💬 |
2812 | MT-7117 Low Dose | - | - | - | - | 1件: 254 254 💬 |
2813 | MTC TRx0014-001 capsules | - | - | - | - | 1件: 127 127 💬 |
2814 | MTP-131 | - | - | - | - | 1件: 21 21 💬 |
2815 | MTX 12.5 | - | - | - | - | 1件: 97 97 💬 |
2816 | Mycophenolate Mofetil (MMF) 3 g/Day | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 35 35 💬 |
2817 | Mycophenolate mofetil orally 1000 mg twice a day (BID) | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 222 222 💬 |
2818 | MYELOSTIM - 34 1 FLACONCINO LIOFILIZZATO 33.6 MIU + SIRINGA PRERIEMPITA SOLVENTE 1 ML | - | - | - | - | 2件: 19 19, 65 💬 |
2819 | MYELOSTIM 34 milions UI/ml - powder and solvent for solution for injection/infusion | - | - | - | - | 1件: 65 65 💬 |
2820 | MYELOSTIM 34 milions UI/ml, powder and solvent for solution for injection or infusion | - | - | - | - | 1件: 65 65 💬 |
2821 | MYELOSTIM 34*1FL 263MCG+1SIR | - | - | - | - | 1件: 2 2 💬 |
2822 | Myfortic 180 mg | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 162 162 💬 |
2823 | Myfortic 180 mg Filmtabletten | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 162 162 💬 |
2824 | Myfortic 180mg Tablets | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 2件: 66 66, 222 💬 |
2825 | Myfortic 360mg Tablets | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 2件: 66 66, 222 💬 |
2826 | MYFORTIC*50CPR RIV 360MG | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 49 49 💬 |
2827 | MYO-029 | 1件: Stamulumab Stamulumab | 1件: Stamulumab
Stamulumab
💬 | 1件: MSTN MSTN 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 113 113 💬 |
2828 | MYONAL*30CPR RIV 100MG | - | - | - | - | 1件: 2 2 💬 |
2829 | N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
2830 | N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
2831 | N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
2832 | N-(5-hydroxy-2,4- bis(trimethylsilyl)phenyl)-4-oxo- 1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 💬 |
2833 | N-(5-hydroxy-2,4-bis(trimethylsilyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 💬 |
2834 | N-(5-{4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide | - | - | - | - | 1件: 49 49 💬 |
2835 | N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide | - | - | - | - | 1件: 299 299 💬 |
2836 | N-0923 | - | - | - | - | 1件: 6 6 💬 |
2837 | N-3 LC-PUFA | - | - | - | - | 1件: 46 46 💬 |
2838 | N-3 Polyunsaturated Fatty Acids | - | - | - | - | 1件: 96 96 💬 |
2839 | N-[1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl]-2-[4-(1-(trifluoromethyl)cyclopropyl)phenyl]acetamide | 2件: Acetamide Acetamide, Pyrazole | - | - | - | 1件: 154 154 💬 |
2840 | N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium | - | - | - | - | 1件: 28 28 💬 |
2841 | N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | - | - | - | - | 1件: 13 13 💬 |
2842 | N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate | 2件: Acetate Acetate, Somatotropin | - | - | - | 1件: 265 265 💬 |
2843 | N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamide, sodium | - | - | - | - | 1件: 96 96 💬 |
2844 | N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamidesodium | - | - | - | - | 1件: 96 96 💬 |
2845 | Nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 86 86 💬 |
2846 | Nabilone 0.25 mg | 1件: Nabilone Nabilone | 1件: Nabilone
Nabilone
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 6 6 💬 |
2847 | NaCl 0.9% | - | - | - | - | 1件: 39 39 💬 |
2848 | NACOM 100 | - | - | - | - | 1件: 6 6 💬 |
2849 | Nanogam 100 mg/ml | - | - | - | - | 1件: 65 65 💬 |
2850 | Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.) | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
2851 | Naproxen 10 mg/kg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
2852 | Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.) | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
2853 | Natalizumab 300 MG in 15 ML Injection | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2854 | National Drug Code: 59762-0074 | - | - | - | - | 1件: 81 81 💬 |
2855 | Natriumchlorid 0,9 % | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 288 288 💬 |
2856 | Natriumklorid 9mg/ml | - | - | - | - | 1件: 46 46 💬 |
2857 | NBI-74788 | - | - | - | - | 1件: 81 81 💬 |
2858 | NBI-77860 | - | - | - | - | 1件: 81 81 💬 |
2859 | NBT-NM108 (60 g/day) | - | - | - | - | 1件: 13 13 💬 |
2860 | NBTX-001 | - | - | - | - | 1件: 6 6 💬 |
2861 | NC 1 cell therapy | - | - | - | - | 1件: 117 117 💬 |
2862 | NDC0009-0436-01 | - | - | - | - | 1件: 78 78 💬 |
2863 | NDV-3A | - | - | - | - | 1件: 65 65 💬 |
2864 | NEB/01-07 | - | - | - | - | 1件: 299 299 💬 |
2865 | Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection | 3件: Testosterone Testosterone, Testosterone undecanoate, Undecanoic acid | 2件: Testosterone
Testosterone
,
Testosterone undecanoate
💬 | 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 💬 |
2866 | Nebulization of Amikacin during NIV (RR: 15 cycles/minute) | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
2867 | NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETA | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 50 50 💬 |
2868 | NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 50 50 💬 |
2869 | Neophyr 1000ppm mol/mol | - | - | - | - | 1件: 294 294 💬 |
2870 | NERIXIA*IM EV 1F 25MG | - | - | - | - | 1件: 6 6 💬 |
2871 | NERIXIA*INFUS IV CONC 2F 100MG | - | - | - | - | 1件: 274 274 💬 |
2872 | Neu-120 | - | - | - | - | 1件: 6 6 💬 |
2873 | Neumega (Oprelvekin, Interleukin 11, IL-11) | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 288 288 💬 |
2874 | NEUPRO 6 mg/24 h parche transdérmico | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2875 | Neupro 6 mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2876 | Neupro 6mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2877 | Neupro 6mg/24h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2878 | NEUPRO*28CER 6MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2879 | NEUPRO*7CER 4MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2880 | NEUPRO*7CER 6MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2881 | NEUPRO*7CER 8MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2882 | Neurontin 300 mg hard capsule | 1件: Gabapentin Gabapentin | 1件: Gabapentin
Gabapentin
💬 | 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
2883 | NeuroVax 300ug/mL Dose for IM Injection | 1件: NeuroVax NeuroVax | - | - | - | 1件: 13 13 💬 |
2884 | New Formulation of rebif - human interferon beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2885 | Nexavar (BAY 43-9006) (Sorafenib) | 1件: Sorafenib Sorafenib | 1件: Sorafenib
Sorafenib
💬 | 8件: BRAF BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
2886 | NFC-1 | - | - | - | - | 1件: 203 203 💬 |
2887 | NFX-179 Gel | - | - | - | - | 1件: 34 34 💬 |
2888 | NGN-101 | - | - | - | - | 1件: 19 19 💬 |
2889 | NI-0101 | - | - | - | - | 1件: 46 46 💬 |
2890 | NI-03 | - | - | - | - | 1件: 298 298 💬 |
2891 | NI-0401 (anti-CD3 mAB) | 1件: Muromonab Muromonab | - | - | - | 1件: 96 96 💬 |
2892 | NI-0501 | - | - | - | - | 1件: 107 107 💬 |
2893 | NI-071 | - | - | - | - | 1件: 46 46 💬 |
2894 | NI-0801 | - | - | - | - | 1件: 93 93 💬 |
2895 | Nicorette 10mg/ 16 h | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
2896 | Nicorette 15 mg/ 16 h | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
2897 | Nicorette 5 mg/ 16 h | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
2898 | Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
2899 | Nicotinell 17,5 mg/24-Stunden-Pflaster | - | - | - | - | 1件: 6 6 💬 |
2900 | Nicotinell 35 mg/24-Stunden-Pflaster | - | - | - | - | 1件: 6 6 💬 |
2901 | Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: Nifurtimox
Nifurtimox
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
2902 | Nilotinib 150 MG | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 8 8 💬 |
2903 | Nilotinib 150mg oral capsule [Tasigna] | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
2904 | Nilotinib 300mg oral capsule [Tasigna] | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
2905 | Nintedanib 150 mg and 100 mg soft capsules | 1件: Nintedanib Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 227 227 💬 |
2906 | Nitisinone 10 mg Tablet High Compritol | 1件: Nitisinone Nitisinone | 1件: Nitisinone
Nitisinone
💬 | 1件: HPD HPD 💬 | 5件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 1件: 241 241 💬 |
2907 | Nitric Oxide 160 ppm | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 299 299 💬 |
2908 | NLX-112 | - | - | - | - | 1件: 6 6 💬 |
2909 | NN 1841 | - | - | - | - | 1件: 288 288 💬 |
2910 | NNC 0109-0000-0012 | - | - | - | - | 1件: 46 46 💬 |
2911 | NNC 0141-0000-0100 | - | - | - | - | 1件: 46 46 💬 |
2912 | NNC 0142-0000-0002 | - | - | - | - | 2件: 46 46, 96 💬 |
2913 | NNC 0151-0000-0000 | - | - | - | - | 2件: 46 46, 49 💬 |
2914 | NNC 126-0083 | - | - | - | - | 1件: 78 78 💬 |
2915 | NNC 142-0002 | - | - | - | - | 1件: 46 46 💬 |
2916 | NNC0109-0012 | - | - | - | - | 1件: 46 46 💬 |
2917 | NNC0114-0000-0005 | - | - | - | - | 1件: 46 46 💬 |
2918 | NNC0114-0006 | - | - | - | - | 3件: 46 46, 49, 96 💬 |
2919 | NNC0142-0000-0002 | - | - | - | - | 1件: 96 96 💬 |
2920 | NNC0142-0002 | - | - | - | - | 1件: 46 46 💬 |
2921 | NNC0151-0000-0000 | - | - | - | - | 1件: 46 46 💬 |
2922 | NNC0195-0092 | - | - | - | - | 1件: 78 78 💬 |
2923 | NNC0195-0092 10 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 💬 |
2924 | NNC0195-0092 15 mg/1.5 ml PDS290-15 | - | - | - | - | 1件: 78 78 💬 |
2925 | NNC0195-0092 5 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 💬 |
2926 | NNC0195-0092 DP 6.7 mg ml 3 ml cartridge | - | - | - | - | 1件: 78 78 💬 |
2927 | NNC0195-0092 PDS290 10 mg-1.5 ml | - | - | - | - | 1件: 78 78 💬 |
2928 | NNC0195-0092 PDS290 10 mg/1.5 ml | - | - | - | - | 1件: 78 78 💬 |
2929 | NNC0215-0384 | - | - | - | - | 2件: 46 46, 162 💬 |
2930 | NNC109-0012 | - | - | - | - | 1件: 46 46 💬 |
2931 | NNC126-0083 | 1件: Somatropin pegol Somatropin pegol | - | - | - | 1件: 78 78 💬 |
2932 | NNC142-0002 | - | - | - | - | 1件: 96 96 💬 |
2933 | NNC151-0000 | - | - | - | - | 1件: 46 46 💬 |
2934 | Norditropin FlexPro 10 mg | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2935 | Norditropin FlexPro 10 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2936 | Norditropin FlexPro 10 mg/1.5 ml, solution for injection in pre-filled pen | 1件: Somatotropin Somatotropin | - | - | - | 1件: 195 195 💬 |
2937 | Norditropin FlexPro 5 mg/1.5 mL | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2938 | Norditropin FlexPro 5mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2939 | Norditropin NordiFlex® 10 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2940 | Norditropin NordiFlex® 10mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2941 | Norditropin SimplexX (5mg/1,5 ml) (INN:somatropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2942 | Norditropin SimpleXx 10 mg | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2943 | Norditropin SimpleXx 15 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 3 3 💬 |
2944 | Norditropin SimpleXx 5mg/1.5ml | 1件: Somatotropin Somatotropin | - | - | - | 2件: 78 78, 107 💬 |
2945 | Norditropin® SimpleXx® 5 mg/1.5ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2946 | Normal Saline 0.9% Infusion Solution | - | - | - | - | 1件: 22 22 💬 |
2947 | NORMIX*AD 12CPR RIV 200MG | - | - | - | - | 1件: 96 96 💬 |
2948 | Norvir 100 mg film-coated tablets | - | - | - | - | 1件: 299 299 💬 |
2949 | NovoNorm 0.5 mg | - | - | - | - | 1件: 299 299 💬 |
2950 | NovoNorm 1 mg | - | - | - | - | 1件: 299 299 💬 |
2951 | NovoRapid 100 U/ml, solution for injection in a vial. NovoRapid Penfill 100 U/ml, solution for injection in a cartridge. NovoRapid FlexPen 100 U/ml, solution for injection in a pre-filled pen. | - | - | - | - | 1件: 299 299 💬 |
2952 | NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
2953 | Noxafil 100 mg | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
2954 | Noxafil 100 mg Tablets Gastro-Resistant | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
2955 | NP031112 600mg | - | - | - | - | 1件: 5 5 💬 |
2956 | NPB-01 | - | - | - | - | 3件: 13 13, 14, 162 💬 |
2957 | NPC-02 | - | - | - | - | 1件: 171 171 💬 |
2958 | NPC-09 | - | - | - | - | 1件: 30 30 💬 |
2959 | NPC-12G gel | - | - | - | - | 2件: 34 34, 158 💬 |
2960 | NPC-12Y gel | - | - | - | - | 1件: 158 158 💬 |
2961 | NPC-14 | - | - | - | - | 1件: 113 113 💬 |
2962 | NPI-001 | - | - | - | - | 2件: 90 90, 303 💬 |
2963 | NR2B NMDA Antagonist CP-101,606 (traxoprodil) | 1件: Ketamine Ketamine | 1件: Ketamine
Ketamine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2964 | NRTX-1001 | - | - | - | - | 1件: 141 141 💬 |
2965 | NS-065/NCNP-01 | - | - | - | - | 1件: 113 113 💬 |
2966 | NS-089/NCNP-02 | - | - | - | - | 1件: 113 113 💬 |
2967 | NS-304 | - | - | - | - | 3件: 70 70, 86, 88 💬 |
2968 | NS-304 Placebo | - | - | - | - | 2件: 70 70, 88 💬 |
2969 | NT 101 | - | - | - | - | 4件: 5 5, 6, 7, 17 💬 |
2970 | NT-KO-003 | - | - | - | - | 1件: 13 13 💬 |
2971 | Nucala 100 mg powder for solution for injection | 1件: Mepolizumab Mepolizumab | 1件: Mepolizumab
Mepolizumab
💬 | 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 2件: 44 44, 45 💬 |
2972 | NutropinAq 10 mg/2 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2973 | NutropinAq 10 mg/2 ml (30 UI) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2974 | NUTROPINAq 10 mg/2 ml (30 UI), solución inyectable | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2975 | NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung | 1件: Somatotropin Somatotropin | - | - | - | 1件: 65 65 💬 |
2976 | NutropinAq 10mg/2ml solution for injection | 1件: Somatotropin Somatotropin | - | - | - | 1件: 96 96 💬 |
2977 | NW-1015 | - | - | - | - | 1件: 6 6 💬 |
2978 | NW-1015E, EMD 1195686, MSC2191632B | - | - | - | - | 1件: 6 6 💬 |
2979 | NX-13 250 mg | - | - | - | - | 1件: 97 97 💬 |
2980 | NX-13 250mg IR | - | - | - | - | 1件: 97 97 💬 |
2981 | NX-13 500mg IR | - | - | - | - | 1件: 97 97 💬 |
2982 | NX-13 500mg MR | - | - | - | - | 1件: 97 97 💬 |
2983 | O-15 Water | 1件: Water Water | 1件: Water
Water
💬 | - | - | 1件: 6 6 💬 |
2984 | Obatoclax mesylate (GX15-070MS) | 1件: Obatoclax Obatoclax | - | - | - | 1件: 60 60 💬 |
2985 | Obeticholic Acid 10 MG | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
2986 | OBI-1 | - | - | - | - | 1件: 288 288 💬 |
2987 | OCA (INT-747) | - | - | - | - | 1件: 93 93 💬 |
2988 | OCA 0.1 mg | - | - | - | - | 1件: 296 296 💬 |
2989 | OCA 0.1mg | - | - | - | - | 1件: 296 296 💬 |
2990 | OCA 1,5 mg | - | - | - | - | 1件: 94 94 💬 |
2991 | OCA 1.5mg | - | - | - | - | 1件: 296 296 💬 |
2992 | OCA, INT-747 | - | - | - | - | 1件: 93 93 💬 |
2993 | Ocaliva 10mg | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
2994 | Ocrelizumab 300 mg | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
2995 | Ocrelizumab 300mg | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
2996 | Ocrelizumab 300mg /10ml | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
2997 | Ocrelizumab 300mg/10 ml | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
2998 | Ocrelizumab 300mg/10ml | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
2999 | Ocrelizumab 600 mg | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
3000 | Ocrelizumab Dose 1 | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
3001 | Ocrelizumab Dose 2 and Dose 3 | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
3002 | Ocrevus 300 mg, solution à diluer pour perfusion | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
3003 | Ocrrelizumab 300 mg | - | - | - | - | 1件: 13 13 💬 |
3004 | Octagam 10% | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 50 50, 63, 65 💬 |
3005 | Octagam® 10% | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 63 63 💬 |
3006 | OCTANATE 100 UI/ml, poudre et solvant pour solution injectable | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
3007 | Octanorm 16.5% | - | - | - | - | 2件: 50 50, 65 💬 |
3008 | Octreotide a azione pronta 0,1 mg | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 227 227 💬 |
3009 | ODM-101 | - | - | - | - | 1件: 6 6 💬 |
3010 | ODM-101 105mg Carbidopa | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3011 | ODM-101 65mg Carbidopa | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3012 | ODM-104 | - | - | - | - | 1件: 6 6 💬 |
3013 | ODM-109 | - | - | - | - | 1件: 2 2 💬 |
3014 | ODM-109 capsule 1 mg | - | - | - | - | 1件: 2 2 💬 |
3015 | ODSH at 0.125 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
3016 | ODSH at 0.250 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
3017 | ODSH at 0.375 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
3018 | Ofatumumab 100 | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
3019 | Ofatumumab 300 | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
3020 | Ofatumumab 30mg | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
3021 | Ofatumumab 3mg | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
3022 | Ofatumumab 60mg | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
3023 | Ofatumumab 700 | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
3024 | Ofev 100 mg capsule | 1件: Nintedanib Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
3025 | Ofev 150 mg capsule | 1件: Nintedanib Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
3026 | OGT 918 | - | - | - | - | 2件: 19 19, 299 💬 |
3027 | Okrido 6mg/mL oral solution | - | - | - | - | 1件: 3 3 💬 |
3028 | Oleovit D3 14.400 IU/ml oral drops, solution | - | - | - | - | 1件: 13 13 💬 |
3029 | OligoG (60 mg/ml) | - | - | - | - | 1件: 299 299 💬 |
3030 | OligoG CF-5/20 - 17.5 mg | - | - | - | - | 1件: 299 299 💬 |
3031 | OligoG CF-5/20, 17,5 mg, Hartkapsel mit Pulver zur Inhalation | - | - | - | - | 1件: 299 299 💬 |
3032 | OligoG CF/20 - 37.5 mg | - | - | - | - | 1件: 299 299 💬 |
3033 | OligoG CF/20, 37,5 mg, Hartkapsel mit Pulver zur Inhalation | - | - | - | - | 1件: 299 299 💬 |
3034 | Olokizumab 120 mg | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
3035 | Olokizumab 60 mg | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
3036 | Olokizumab 64 mg SC q2w | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
3037 | Olokizumab 64 mg SC q4w | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
3038 | Olokizumab 64mg q2w | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
3039 | Olokizumab 64mg q4w | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
3040 | Olumiant - EU/1/16/1170/001-008 | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 💬 |
3041 | Olumiant - EU/1/16/1170/009-016 | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 💬 |
3042 | Omaveloxolone Capsules, 10 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
3043 | Omaveloxolone Capsules, 150 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
3044 | Omaveloxolone Capsules, 160 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
3045 | Omaveloxolone Capsules, 300 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
3046 | OMB 157 | - | - | - | - | 1件: 13 13 💬 |
3047 | Omega 3 | - | - | - | - | 3件: 13 13, 53, 299 💬 |
3048 | Omega 3 fatty acid | - | - | - | - | 1件: 53 53 💬 |
3049 | Omega 3 Premium | - | - | - | - | 1件: 299 299 💬 |
3050 | Omega-3 | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 7件: 13 13, 46, 49, 66, 79, 96, 299 💬 |
3051 | Omega-3 and Vitamin E supplementation | 2件: Omega-3 fatty acids Omega-3 fatty acids, Vitamin E | 1件: Vitamin E
Vitamin E
💬 | - | - | 1件: 46 46 💬 |
3052 | Omega-3 fatty acid | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 2件: 46 46, 66 💬 |
3053 | Omega-3 fatty acid ethylester90 | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 66 66 💬 |
3054 | Omega-3 Fatty Acid Fish Oil Supplement | 2件: Fish oil Fish oil, Omega-3 fatty acids | - | - | - | 1件: 66 66 💬 |
3055 | Omega-3 fatty acids | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 2件: 13 13, 79 💬 |
3056 | Omega-3 triglycerides | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 299 299 💬 |
3057 | OMEGA-3-ACID TRIGLYCERIDES | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 299 299 💬 |
3058 | Omegaven (10% fish-oil emulsion | - | - | - | - | 1件: 46 46 💬 |
3059 | Omegaven 10% | - | - | - | - | 1件: 96 96 💬 |
3060 | Omeprazole rectally 1mg/kg | 1件: Omeprazole Omeprazole | 1件: Omeprazole
Omeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 294 294 💬 |
3061 | OMNIPAQUE - 300 MG I/ML SOLUZIONE INIETTABILE FLACONE IN POLIPROPILENE DA 50 ML | 1件: Iohexol Iohexol | 1件: Iohexol
Iohexol
💬 | - | - | 1件: 222 222 💬 |
3062 | OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody | 1件: Narsoplimab Narsoplimab | 1件: Narsoplimab
Narsoplimab
💬 | 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 2件: 64 64, 109 💬 |
3063 | OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody | 1件: Narsoplimab Narsoplimab | 1件: Narsoplimab
Narsoplimab
💬 | 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 2件: 64 64, 109 💬 |
3064 | OMS721 Drug Product 185 mg/mL | - | - | - | - | 1件: 109 109 💬 |
3065 | ON 01910.NA | - | - | - | - | 1件: 36 36 💬 |
3066 | One 20cm2/10cm2 autologous skin sheet graft | - | - | - | - | 1件: 160 160 💬 |
3067 | Only 1 arm: treatment with MSC-AFP | - | - | - | - | 1件: 96 96 💬 |
3068 | OPC-6535 | - | - | - | - | 2件: 96 96, 97 💬 |
3069 | OPC-6535 Tablets (drug) | - | - | - | - | 1件: 97 97 💬 |
3070 | OPC-6535(Tetomilast) | 1件: Tetomilast Tetomilast | - | - | - | 2件: 96 96, 97 💬 |
3071 | Open-label PTH(1-84) | - | - | - | - | 1件: 235 235 💬 |
3072 | Oprelvekin, Interleukin 11, IL-11 | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 288 288 💬 |
3073 | OPRX-106 | - | - | - | - | 1件: 97 97 💬 |
3074 | OPRX-106 (plant cells expressing TNFR-Fc) 2mg | - | - | - | - | 1件: 97 97 💬 |
3075 | OPRX-106 (plant cells expressing TNFR-Fc) 8mg | - | - | - | - | 1件: 97 97 💬 |
3076 | OPS-2071 150 mg | - | - | - | - | 1件: 96 96 💬 |
3077 | OPS-2071 300 mg | - | - | - | - | 1件: 96 96 💬 |
3078 | OPS-2071 600 mg | - | - | - | - | 1件: 96 96 💬 |
3079 | Opsumit 10 Mg Tablet | - | - | - | - | 1件: 51 51 💬 |
3080 | Oral Budesonide Suspension (MB-9) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
3081 | Oral Glucose Tolerance test (75g 2-hour) | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 1件: 299 299 💬 |
3082 | Oral Methylprednisolone 625 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
3083 | Oral treprostinil (UT-15C) Sustained Release Tablets | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
3084 | Orencia 125 mg | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
3085 | ORENCIA 125 mg solution for injection | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
3086 | ORENCIA 125 mg solution for injection in pre-filled syringe | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 3件: 46 46, 49, 53 💬 |
3087 | ORENCIA 125 mg, solution injectable en seringue préremplie | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
3088 | ORENCIA® 125 mg solution for injection in pre-filled syringe | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 65 65 💬 |
3089 | Orkambi 100 mg/125 mg film-coated tablets | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
3090 | Orkambi 200 mg/125 mg film-coated tablets | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
3091 | ORL-1B | - | - | - | - | 1件: 255 255 💬 |
3092 | ORM-12471 | - | - | - | - | 1件: 51 51 💬 |
3093 | ORM-12471 30mg | - | - | - | - | 1件: 51 51 💬 |
3094 | ORM-12741 | 1件: ORM-12741 ORM-12741 | - | - | - | 1件: 51 51 💬 |
3095 | Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg | 3件: Estradiol Estradiol, Ethinylestradiol, Norgestimate | 3件: Estradiol
Estradiol
,
Ethinyl estradiol
,
Norgestimate
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 299 299 💬 |
3096 | Ortho-Novum 777 | 1件: Mestranol Mestranol | 1件: Mestranol
Mestranol
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 49 49 💬 |
3097 | Ortho-Novum® 1/35 | 1件: Mestranol Mestranol | 1件: Mestranol
Mestranol
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 46 46 💬 |
3098 | OSE-127 | - | - | - | - | 2件: 53 53, 97 💬 |
3099 | Osilodrostat 10mg | 1件: Osilodrostat Osilodrostat | 1件: Osilodrostat
Osilodrostat
💬 | 1件: CYP11B2 CYP11B2 💬 | 3件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬 | 1件: 75 75 💬 |
3100 | Osilodrostat 1mg | 1件: Osilodrostat Osilodrostat | 1件: Osilodrostat
Osilodrostat
💬 | 1件: CYP11B2 CYP11B2 💬 | 3件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬 | 1件: 75 75 💬 |
3101 | OsrhAAT 1 mg/kg IV | - | - | - | - | 1件: 231 231 💬 |
3102 | OsrhAAT 10 mg/kg IV | - | - | - | - | 1件: 231 231 💬 |
3103 | OsrhAAT 3 mg/kg IV | - | - | - | - | 1件: 231 231 💬 |
3104 | OsrhAAT 60 mg/kg IV | - | - | - | - | 1件: 231 231 💬 |
3105 | OSSM-001 | - | - | - | - | 1件: 96 96 💬 |
3106 | OST-122 | - | - | - | - | 1件: 97 97 💬 |
3107 | OSU 6162 similar to (-)-OSU 6162 | - | - | - | - | 1件: 6 6 💬 |
3108 | OSU6162 similar to (-)-OSU 6162 | - | - | - | - | 2件: 6 6, 8 💬 |
3109 | OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 2件: 56 56, 107 💬 |
3110 | OTEZLA - 30 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/ALU) - 56 COMPRESSE | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 107 107 💬 |
3111 | OTL-101 | - | - | - | - | 1件: 65 65 💬 |
3112 | OTL-103 | - | - | - | - | 1件: 65 65 💬 |
3113 | OTL-103 Dispersion for Infusion | - | - | - | - | 1件: 65 65 💬 |
3114 | OV101 Regimen 1 | - | - | - | - | 1件: 201 201 💬 |
3115 | Ovastat 1000 | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 2件: 13 13, 65 💬 |
3116 | Ovastat 1000 (Treosulfan injection) | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 1件: 65 65 💬 |
3117 | Ovastat 1000 mg, powder for solution for infusion | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 1件: 65 65 💬 |
3118 | Over-encapsulated 150 mg Irbesartan Tablets | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 66 66 💬 |
3119 | Over-encapsulated 75 mg Irbesartan Tablets | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
3120 | OXB-102 | - | - | - | - | 1件: 6 6 💬 |
3121 | OXN 10 mg / 5 mg PR | - | - | - | - | 1件: 6 6 💬 |
3122 | OXN 10/5 mg PR | - | - | - | - | 1件: 226 226 💬 |
3123 | OXN 20 mg / 10 mg PR | - | - | - | - | 1件: 6 6 💬 |
3124 | OXN 20/10 mg PR | - | - | - | - | 1件: 226 226 💬 |
3125 | Oxycodone/naloxone prolonged release tablets 10 mg /5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
3126 | Oxycodone/naloxone prolonged release tablets 10/5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
3127 | Oxycodone/naloxone prolonged release tablets 20 mg /10 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
3128 | Oxycodone/naloxone prolonged release tablets 20/10 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
3129 | Oxycontin LP 10mg | 1件: Oxycodone Oxycodone | 1件: Oxycodone
Oxycodone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
3130 | Oxygen-15 Water | 2件: Oxygen Oxygen, Water | 2件: Water
Water
,
Oxygen
💬 | - | - | 1件: 6 6 💬 |
3131 | Ozanimod 0.5 mg | 1件: Ozanimod Ozanimod | 1件: Ozanimod
Ozanimod
💬 | 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
3132 | Ozanimod 1 mg | 1件: Ozanimod Ozanimod | 1件: Ozanimod
Ozanimod
💬 | 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
3133 | P 140 | - | - | - | - | 1件: 49 49 💬 |
3134 | P-1037 | - | - | - | - | 1件: 299 299 💬 |
3135 | P-188 NF | - | - | - | - | 1件: 113 113 💬 |
3136 | P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3137 | P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3138 | P32/98 | - | - | - | - | 1件: 37 37 💬 |
3139 | P32/98 3% | - | - | - | - | 1件: 37 37 💬 |
3140 | P38 Inhibitor (4) 150mg | - | - | - | - | 1件: 46 46 💬 |
3141 | P38 Inhibitor (4) 300mg | - | - | - | - | 1件: 46 46 💬 |
3142 | P38 Inhibitor (4) 75mg | - | - | - | - | 1件: 46 46 💬 |
3143 | PALOVAROTENE - 1.5mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3144 | PALOVAROTENE - 10 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3145 | PALOVAROTENE - 1mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3146 | PALOVAROTENE - 3 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3147 | PALOVAROTENE 1.5 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3148 | Palovarotene dose level 1 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3149 | Palovarotene dose level 3 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3150 | PALOVAROTENE-3 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3151 | Pamrevlumab (FG-3019) | 1件: Pamrevlumab Pamrevlumab | 1件: Pamrevlumab
Pamrevlumab
💬 | 1件: CCN2 CCN2 💬 | 2件: Apelin signaling pathway Apelin signaling pathway, Hippo signaling pathway 💬 | 1件: 113 113 💬 |
3152 | Pancrease MT 10.5, or MT 21 | - | - | - | - | 1件: 299 299 💬 |
3153 | Panzytrat 25.000 | - | - | - | - | 1件: 298 298 💬 |
3154 | Panzytrat 25.000 FIP-E units of Lipase | - | - | - | - | 1件: 298 298 💬 |
3155 | Panzytrat® 25,000 | - | - | - | - | 1件: 299 299 💬 |
3156 | Paracetamol 120Mg/5mL Oral Suspension | 1件: Acetaminophen Acetaminophen | 1件: Acetaminophen
Acetaminophen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 3 3 💬 |
3157 | PARACETAMOLO DOC GENERICI - 1000 MG COMPRESSA 16 COMPRESSE | - | - | - | - | 1件: 19 19 💬 |
3158 | Parathyroid hormon 1-84 | - | - | - | - | 1件: 235 235 💬 |
3159 | Parathyroid Hormone (1-84) Human Recombinant | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3160 | Paroxetine hydrochloride 10 & 20 mg and Prednisolone 1 mg BP | 2件: Paroxetine Paroxetine, Prednisolone | 2件: Prednisolone
Prednisolone
,
Paroxetine
💬 | 2件: NR3C1 NR3C1, SLC6A4 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 46 46 💬 |
3161 | Paroxetine Hydrochloride tablets 10 & 20 mg and Prednisolone 1 mg BP | 2件: Paroxetine Paroxetine, Prednisolone | 2件: Prednisolone
Prednisolone
,
Paroxetine
💬 | 2件: NR3C1 NR3C1, SLC6A4 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 46 46 💬 |
3162 | Parsaclisib (1 mg) | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 61 61 💬 |
3163 | Part 1 Levulan injection | - | - | - | - | 1件: 34 34 💬 |
3164 | Part 1 Levulan surface application | - | - | - | - | 1件: 34 34 💬 |
3165 | Part 1 Levulan surface application twice | - | - | - | - | 1件: 34 34 💬 |
3166 | Part 1 Levulan surface application twice with microneedling | - | - | - | - | 1件: 34 34 💬 |
3167 | Part 1, JM-010 component Group A | - | - | - | - | 1件: 6 6 💬 |
3168 | Part 1, JM-010 component Group B | - | - | - | - | 1件: 6 6 💬 |
3169 | Part 1, JM-010 component Group C | - | - | - | - | 1件: 6 6 💬 |
3170 | Part 1: LJN452 | - | - | - | - | 1件: 93 93 💬 |
3171 | Part 2 Adult Alogabat High Dose (aged 15-17) | - | - | - | - | 1件: 201 201 💬 |
3172 | Part 2, JM-010 combination Group A | - | - | - | - | 1件: 6 6 💬 |
3173 | Part 2, JM-010 combination Group B | - | - | - | - | 1件: 6 6 💬 |
3174 | Part 2, JM-010 component Group C | - | - | - | - | 1件: 6 6 💬 |
3175 | Part 2: LJN452 Dose level 1 | - | - | - | - | 1件: 93 93 💬 |
3176 | Part A: 100 mg/mL GSK2618960 | - | - | - | - | 1件: 13 13 💬 |
3177 | Part I - etoricoxib 60 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
3178 | Part I - etoricoxib 90 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
3179 | Part I- naproxen 1000 mg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
3180 | Part II- etoricoxib 60 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
3181 | Part II- etoricoxib 90 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
3182 | Part II- naproxen 1000 mg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
3183 | Pasireotida 300 | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
3184 | Pasireotida 600 | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
3185 | Pasireotida 900 | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
3186 | Pasireotide 0.3mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
3187 | Pasireotide 0.6 MG/ML | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
3188 | Pasireotide 0.6mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
3189 | Pasireotide 0.9 mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
3190 | Pasireotide 60mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
3191 | PAT-001, 0.1% | - | - | - | - | 1件: 160 160 💬 |
3192 | PAT-001, 0.2% | - | - | - | - | 1件: 160 160 💬 |
3193 | Patients will be randomized to receive EHP-101 | - | - | - | - | 1件: 51 51 💬 |
3194 | PB1046, VIP-ELP1-120, Vasomera | - | - | - | - | 1件: 86 86 💬 |
3195 | PBF-677 | - | - | - | - | 1件: 97 97 💬 |
3196 | PBF-999 | - | - | - | - | 1件: 8 8 💬 |
3197 | PBF-999 / 160 mg | - | - | - | - | 1件: 8 8 💬 |
3198 | PBF-999 / 320 mg | - | - | - | - | 1件: 8 8 💬 |
3199 | PD 0299685 | - | - | - | - | 1件: 226 226 💬 |
3200 | PD 0299685 at 15mg BID | - | - | - | - | 1件: 226 226 💬 |
3201 | PD 0299685 at 30mg BID | - | - | - | - | 1件: 226 226 💬 |
3202 | PD 0360324 | - | - | - | - | 2件: 46 46, 84 💬 |
3203 | PD patients H&Y=1.5-2 Medications OFF | - | - | - | - | 1件: 6 6 💬 |
3204 | PD patients H&Y=1.5-2 Medications ON | - | - | - | - | 1件: 6 6 💬 |
3205 | PD patients H&Y=3 Medications OFF | - | - | - | - | 1件: 6 6 💬 |
3206 | PD patients H&Y=3 Medications ON | - | - | - | - | 1件: 6 6 💬 |
3207 | PD-0299685 | 1件: PD-0299685 PD-0299685 | - | - | - | 1件: 226 226 💬 |
3208 | PD-0325901 | 1件: Mirdametinib Mirdametinib | 1件: Mirdametinib
Mirdametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
3209 | PEGINTERFERON BETA-1A | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3210 | Peginterferone beta 1a | - | - | - | - | 1件: 13 13 💬 |
3211 | PEGINTERFERONE BETA-1A | - | - | - | - | 1件: 13 13 💬 |
3212 | PEGINTERFERONE LAMBDA-1A | - | - | - | - | 1件: 13 13 💬 |
3213 | PEGylated Intereron Beta-1a | - | - | - | - | 1件: 13 13 💬 |
3214 | PEGylated Interferon Beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3215 | Pelubiprofen 30 mg | 1件: Pelubiprofen Pelubiprofen | 1件: Pelubiprofen
Pelubiprofen
💬 | - | - | 1件: 46 46 💬 |
3216 | PEMINE - 150 MG CAPSULE RIGIDE 50 CAPSULE | - | - | - | - | 1件: 171 171 💬 |
3217 | Pentasa 2g sachet prolonged release granules (95%) | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
3218 | Pentasa Sachet 1 g | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 2件: 96 96, 97 💬 |
3219 | Pentasa Sachet 1 g prolonged release granules | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 96 96 💬 |
3220 | Pentasa Sachet 1g | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
3221 | Pentosan polysulfate sodium 100 mg | 1件: Pentosan polysulfate Pentosan polysulfate | - | - | - | 1件: 226 226 💬 |
3222 | Peri-neural Dexamethasone 1 mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
3223 | Persantin 100 mg | - | - | - | - | 1件: 46 46 💬 |
3224 | Persantin 100 mg and | - | - | - | - | 1件: 46 46 💬 |
3225 | PET with 11C-Flumazenil | 1件: Flumazenil Flumazenil | 1件: Flumazenil
Flumazenil
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 13 13 💬 |
3226 | PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714 | - | - | - | - | 1件: 85 85 💬 |
3227 | PF 06687234 | - | - | - | - | 2件: 96 96, 97 💬 |
3228 | PF-00489791 | 1件: PF-00489791 PF-00489791 | - | - | - | 1件: 86 86 💬 |
3229 | PF-00547659 | - | - | - | - | 2件: 96 96, 97 💬 |
3230 | PF-00547659 SC injection | - | - | - | - | 2件: 96 96, 97 💬 |
3231 | PF-02545920 | - | - | - | - | 1件: 8 8 💬 |
3232 | PF-04171327 | - | - | - | - | 1件: 46 46 💬 |
3233 | PF-04171327 10 mg | - | - | - | - | 1件: 46 46 💬 |
3234 | PF-04171327 25 mg | - | - | - | - | 1件: 46 46 💬 |
3235 | PF-04236921 | - | - | - | - | 2件: 49 49, 96 💬 |
3236 | PF-04236921 SC injection | - | - | - | - | 1件: 96 96 💬 |
3237 | PF-04383119 | - | - | - | - | 1件: 226 226 💬 |
3238 | PF-05208763 | - | - | - | - | 1件: 67 67 💬 |
3239 | PF-05230917 | - | - | - | - | 1件: 97 97 💬 |
3240 | PF-05280586 | - | - | - | - | 1件: 46 46 💬 |
3241 | PF-05285401 | - | - | - | - | 1件: 97 97 💬 |
3242 | PF-06252616 | 1件: Domagrozumab Domagrozumab | 1件: Domagrozumab
Domagrozumab
💬 | 1件: MSTN MSTN 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 113 113 💬 |
3243 | PF-06291826-83/Fx-1006A | 1件: Fx-1006A Fx-1006A | - | - | - | 1件: 28 28 💬 |
3244 | PF-06342674 0.25 mg/kg | - | - | - | - | 1件: 13 13 💬 |
3245 | PF-06342674 1.5 mg/kg | - | - | - | - | 1件: 13 13 💬 |
3246 | PF-06342674 6.0 mg/kg | - | - | - | - | 1件: 13 13 💬 |
3247 | PF-06410293 | - | - | - | - | 1件: 46 46 💬 |
3248 | PF-06412562 | - | - | - | - | 1件: 6 6 💬 |
3249 | PF-06438179 | - | - | - | - | 1件: 46 46 💬 |
3250 | PF-06462700 | - | - | - | - | 1件: 60 60 💬 |
3251 | PF-06480605 | - | - | - | - | 1件: 97 97 💬 |
3252 | PF-06480605 100 mg/ml | - | - | - | - | 1件: 97 97 💬 |
3253 | PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3254 | PF-06649751 - 15mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3255 | PF-06649751 - 1mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3256 | PF-06649751 - 5mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3257 | PF-06649751 high dose (15 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3258 | PF-06649751 low dose (1 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3259 | PF-06649751 middle dose 1 (3 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3260 | PF-06649751 middle dose 2 (7 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3261 | PF-06650833 | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
3262 | PF-06650833 100 mg | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
3263 | PF-06650833 20 mg | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
3264 | PF-06651600 | 1件: PF-06651600 PF-06651600 | - | - | - | 3件: 46 46, 96, 97 💬 |
3265 | PF-06651600 10 mg | 1件: PF-06651600 PF-06651600 | - | - | - | 1件: 97 97 💬 |
3266 | PF-06651600 50 mg | 1件: PF-06651600 PF-06651600 | - | - | - | 2件: 96 96, 97 💬 |
3267 | PF-06651600 50mg | 1件: PF-06651600 PF-06651600 | - | - | - | 1件: 96 96 💬 |
3268 | PF-06651600-15 | 1件: PF-06651600 PF-06651600 | - | - | - | 2件: 96 96, 97 💬 |
3269 | PF-06669571 | - | - | - | - | 1件: 6 6 💬 |
3270 | PF-06687234 | - | - | - | - | 1件: 97 97 💬 |
3271 | PF-06700841 | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
3272 | PF-06700841 15 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
3273 | PF-06700841 25 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 2件: 96 96, 97 💬 |
3274 | PF-06700841 25mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
3275 | PF-06700841 30 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
3276 | PF-06700841 45 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
3277 | PF-06700841 5 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
3278 | PF-06700841 5mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
3279 | PF-06700841-15 | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
3280 | PF-06730512 | - | - | - | - | 1件: 222 222 💬 |
3281 | PF-06755347 intravenous healthy participant | - | - | - | - | 1件: 63 63 💬 |
3282 | PF-06755347 subcutaneous healthy participant | - | - | - | - | 1件: 63 63 💬 |
3283 | PF-06755347 subcutaneous ITP | - | - | - | - | 1件: 63 63 💬 |
3284 | PF-06823859 | - | - | - | - | 1件: 50 50 💬 |
3285 | PF-06823859 high | - | - | - | - | 1件: 50 50 💬 |
3286 | PF-06823859 low | - | - | - | - | 1件: 50 50 💬 |
3287 | PF-06826647 | - | - | - | - | 1件: 97 97 💬 |
3288 | PF-06826647 100 mg QD | - | - | - | - | 1件: 97 97 💬 |
3289 | PF-06826647 300 mg QD | - | - | - | - | 1件: 97 97 💬 |
3290 | PF-06826647 600 mg QD | - | - | - | - | 1件: 97 97 💬 |
3291 | PF-06835375 | - | - | - | - | 3件: 46 46, 49, 63 💬 |
3292 | PF-06836922 | - | - | - | - | 1件: 78 78 💬 |
3293 | PF-06939926 | - | - | - | - | 1件: 113 113 💬 |
3294 | PF-07054894 | - | - | - | - | 1件: 97 97 💬 |
3295 | PF-07256472 | - | - | - | - | 1件: 276 276 💬 |
3296 | PF-6826647 400 mg QD | - | - | - | - | 1件: 97 97 💬 |
3297 | Pfefferminzblätter 1ml/10ml | - | - | - | - | 1件: 97 97 💬 |
3298 | PG-760564 | - | - | - | - | 1件: 46 46 💬 |
3299 | PGT-1 gene lipid complex | - | - | - | - | 1件: 299 299 💬 |
3300 | PH-797804 | 1件: PH-797804 PH-797804 | - | - | - | 1件: 46 46 💬 |
3301 | Ph. Eur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 6 6 💬 |
3302 | Ph. Eur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid | - | - | - | - | 1件: 6 6 💬 |
3303 | PHA-022121 | - | - | - | - | 1件: 65 65 💬 |
3304 | PHA-022121 high dose | - | - | - | - | 1件: 65 65 💬 |
3305 | PHA-022121 low dose | - | - | - | - | 1件: 65 65 💬 |
3306 | PHA-022121 medium dose | - | - | - | - | 1件: 65 65 💬 |
3307 | PHA-022121 selected dose | - | - | - | - | 1件: 65 65 💬 |
3308 | PHA-794,428 | - | - | - | - | 1件: 78 78 💬 |
3309 | PHA-794428 | - | - | - | - | 1件: 78 78 💬 |
3310 | Phase 1, SQY51 | - | - | - | - | 1件: 113 113 💬 |
3311 | Phase 1: Conventiaonal DMARD | - | - | - | - | 1件: 46 46 💬 |
3312 | Phase 1: Etanercept | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
3313 | Phase 1: Methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
3314 | Phase 2a, SQY51 (cohort 1) | - | - | - | - | 1件: 113 113 💬 |
3315 | Phase 2a, SQY51 (cohort 3) | - | - | - | - | 1件: 113 113 💬 |
3316 | Phase 3 | - | - | - | - | 1件: 13 13 💬 |
3317 | Phase2 and 3 : | - | - | - | - | 1件: 96 96 💬 |
3318 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND DUAL LSD1/MAO-B (LYSINE-SPECIFIC DEMETHYLASE 1 AND MONOAMINE OXIDASE-B) INHIBITOR | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 13 13 💬 |
3319 | PhEur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 6 6 💬 |
3320 | PhEur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid | - | - | - | - | 1件: 6 6 💬 |
3321 | PHP-303 | - | - | - | - | 1件: 231 231 💬 |
3322 | PI-0824 | 1件: PI-0824 PI-0824 | - | - | - | 1件: 35 35 💬 |
3323 | Pimavanserin (ACP-103) | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 💬 |
3324 | Pimavanserin tartrate (ACP-103) | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 💬 |
3325 | Pimecrolimus 1% Cream | 1件: Pimecrolimus Pimecrolimus | 1件: Pimecrolimus
Pimecrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 160 160 💬 |
3326 | Pioglitazone 15 mg | 1件: Pioglitazone Pioglitazone | 1件: Pioglitazone
Pioglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 96 96 💬 |
3327 | PIPE-307 | - | - | - | - | 1件: 13 13 💬 |
3328 | Piperacilline/Tazobactam Fresenius Kabi 2 g/0,25 g poeder voor oplossing voor infusie | 1件: Tazobactam Tazobactam | 1件: Tazobactam
Tazobactam
💬 | - | - | 1件: 299 299 💬 |
3329 | Piperacilline/Tazobactam Fresenius Kabi 4 g/0,5 g poeder voor oplossing voor infusie | 1件: Tazobactam Tazobactam | 1件: Tazobactam
Tazobactam
💬 | - | - | 1件: 299 299 💬 |
3330 | PIR, S-7701 | - | - | - | - | 1件: 85 85 💬 |
3331 | Pirepemat, 100 mg | - | - | - | - | 1件: 6 6 💬 |
3332 | Pittsburgh Compound B (C-11 PiB) | 1件: Pittsburgh Compound B Pittsburgh Compound B | - | - | - | 1件: 127 127 💬 |
3333 | PL 00095/5079R | - | - | - | - | 1件: 46 46 💬 |
3334 | PL 0010/0211 | - | - | - | - | 1件: 299 299 💬 |
3335 | PL 00512/0150 | - | - | - | - | 1件: 298 298 💬 |
3336 | PL 04515/0127 | - | - | - | - | 1件: 13 13 💬 |
3337 | PL 12185/0002 & PL 12185/0005(WATER FOR INJECTION) | 1件: Water Water | 1件: Water
Water
💬 | - | - | 1件: 57 57 💬 |
3338 | PL 12762/0049 | - | - | - | - | 1件: 13 13 💬 |
3339 | PL 17901/0122 | - | - | - | - | 1件: 96 96 💬 |
3340 | PL 20532/0012 | - | - | - | - | 1件: 96 96 💬 |
3341 | PLA-695 | - | - | - | - | 1件: 46 46 💬 |
3342 | PLACENTEX ¿ Polydeoxyribonucleotide 5.625 mg/3 ml | - | - | - | - | 1件: 51 51 💬 |
3343 | PLACENTEX ¿5.625 mg/3 ml soluzione iniettabile¿ | - | - | - | - | 1件: 51 51 💬 |
3344 | PLASMASAFE - SOLUZIONE PER INFUSIONE 1 SACCA DA 200 ML | - | - | - | - | 1件: 274 274 💬 |
3345 | Plegridy (peginterferon beta-1a), Biogen Idec Ltd | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3346 | PLEGRIDY - 125 MCG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - PENNA PRERIEMPITA - 0,5 ML - 6 PENNE PRERIEMPITE | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3347 | Plegridy 125 micrograms | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3348 | Plegridy 63 micrograms | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3349 | Pleneva TM BGC20-0134 | - | - | - | - | 1件: 13 13 💬 |
3350 | PLN-74809 | 1件: PLN-74809 PLN-74809 | - | - | - | 2件: 85 85, 94 💬 |
3351 | PLN-74809-000 | 1件: PLN-74809 PLN-74809 | - | - | - | 1件: 85 85 💬 |
3352 | PLN-74809-020 | 1件: PLN-74809 PLN-74809 | - | - | - | 1件: 85 85 💬 |
3353 | Plovamer acetate 0.5 milligram (mg) | 1件: Acetate Acetate | - | - | - | 1件: 13 13 💬 |
3354 | Plovamer acetate 10 mg | 1件: Acetate Acetate | - | - | - | 1件: 13 13 💬 |
3355 | Plovamer acetate 3 mg | 1件: Acetate Acetate | - | - | - | 1件: 13 13 💬 |
3356 | PMG1015 Dose 1 | - | - | - | - | 1件: 85 85 💬 |
3357 | PMG1015 Dose 3 | - | - | - | - | 1件: 85 85 💬 |
3358 | PMG1015 Dose 6 | - | - | - | - | 1件: 85 85 💬 |
3359 | PMG1015 Dose 7 | - | - | - | - | 1件: 85 85 💬 |
3360 | PN-101 | - | - | - | - | 1件: 50 50 💬 |
3361 | PN-10884A | - | - | - | - | 1件: 97 97 💬 |
3362 | PN-180307 | - | - | - | - | 1件: 78 78 💬 |
3363 | PN-943 | - | - | - | - | 1件: 97 97 💬 |
3364 | PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED) | - | - | - | - | 2件: 13 13, 14 💬 |
3365 | PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED) CONJUGATED TO CRM197 CARRIER PROTEIN AND ADSORBED ON ALUMINIUM PHOSPHATE | 4件: Aluminium Aluminium, Aluminium phosphate, Corynebacterium diphtheriae CRM197 protein, Phosphate ion | - | - | - | 1件: 46 46 💬 |
3366 | Pneumococcal polysaccharide serotype 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F | - | - | - | - | 1件: 46 46 💬 |
3367 | Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | - | - | - | - | 1件: 46 46 💬 |
3368 | Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F | - | - | - | - | 1件: 222 222 💬 |
3369 | Pneumococcal polysaccharide serotype 11 2.2 µg | - | - | - | - | 1件: 222 222 💬 |
3370 | PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml | - | - | - | - | 2件: 62 62, 66 💬 |
3371 | POLY(OXY-1,2-ETHANEDIYL), A | - | - | - | - | 1件: 235 235 💬 |
3372 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2- | 1件: Diethyl ether Diethyl ether | 1件: Ether
Ether
💬 | - | - | 1件: 235 235 💬 |
3373 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DI | 1件: Diethyl ether Diethyl ether | 1件: Ether
Ether
💬 | - | - | 1件: 235 235 💬 |
3374 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DIOXO-3-PYRROLIDINYL]THIO]HEXYL]AMINO]ETHYL]AMINO]CARBONYL]-2-METHYLALANYL-TERIPARATIDE (2:1) | 2件: Diethyl ether Diethyl ether, Teriparatide | 2件: Ether
Ether
,
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3375 | Polyethylene Glycol 3350 | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 2件: 96 96, 299 💬 |
3376 | Ponesimod 10 mg | 1件: Ponesimod Ponesimod | 1件: Ponesimod
Ponesimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
3377 | Posaconazole 100 MG [Noxafil] | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
3378 | Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin) | 1件: Activated charcoal Activated charcoal | - | - | - | 1件: 6 6 💬 |
3379 | Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin) | - | - | - | - | 1件: 6 6 💬 |
3380 | Postoperative 3-month exclusive enteral nutrition | - | - | - | - | 1件: 96 96 💬 |
3381 | PR-06410293 | - | - | - | - | 1件: 46 46 💬 |
3382 | PRALIA 60 mg Subcutaneous Injection Syringe(denosumab) | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 💬 |
3383 | PRALIA 60mg Subcutaneous Injection Syringe(denosumab) | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 💬 |
3384 | Pramipexole 0.125 mg tablets | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3385 | Pramipexole 0.5 mg tablets | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3386 | Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole) | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3387 | Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride) | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3388 | Precedentemente denominato MEDI2070 e AMG 139 | - | - | - | - | 1件: 96 96 💬 |
3389 | PredniHEXAL® 10mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
3390 | PredniHEXAL® 5mg Tabletten, PredniHEXAL® 10mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
3391 | Prednisolene tablets BP 1 mg | - | - | - | - | 1件: 46 46 💬 |
3392 | Prednisolon 1 mg JENAPHARM | - | - | - | - | 1件: 41 41 💬 |
3393 | Prednisolon 10 mg JENAPHARM | - | - | - | - | 1件: 41 41 💬 |
3394 | Prednisolone 1mg Tablets | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
3395 | Prednisolone Tablets BP 1 mg | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
3396 | Prednison 10 mg GALEN | - | - | - | - | 1件: 35 35 💬 |
3397 | Prednisone 0,5 mg/kg orally on alternate days | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
3398 | Prednisone 1 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
3399 | Prednisone 15 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
3400 | Prednisone 3 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
3401 | Prednisone 7.5 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
3402 | PREDNISONE DOC GENERICI - 5 MG COMPRESSE 10 COMPRESSE IN BLISTER PVC-PVDC/ALU | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 19 19 💬 |
3403 | PREDNISONE DOC GENERICI - 5 MG COMPRESSE 30 COMPRESSE IN BLISTER PVC-PVDC/ALU | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 300 300 💬 |
3404 | PredniSONE Tablets USP, 1 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 41 41, 46 💬 |
3405 | PredniSONE Tablets USP, 10 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
3406 | PredniSONE Tablets USP, 1mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
3407 | PredniSONE Tablets, USP 10 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
3408 | PredniSONE Tablets, USP, 1 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
3409 | PREFOLIC 15*30CPR GASTROR 15MG | - | - | - | - | 1件: 337 337 💬 |
3410 | PREFOLIC*30CPR GASTROR 15MG | - | - | - | - | 1件: 299 299 💬 |
3411 | Pregabalin 75mg | 1件: Pregabalin Pregabalin | 1件: Pregabalin
Pregabalin
💬 | 4件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4 💬 | 7件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway 💬 | 1件: 70 70 💬 |
3412 | Preladenant 10 mg tablet | 1件: Preladenant Preladenant | 1件: Preladenant
Preladenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3413 | Preparative regimen 4-6 weeks after Leukapheresis | - | - | - | - | 1件: 96 96 💬 |
3414 | Prevenar 13 | 12件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen, Streptococcus pneumoniae type 14 capsular polysaccharide antigen, Streptococcus pneumoniae type 18c capsular polysaccharide antigen, Streptococcus pneumoniae type 19a capsular polysaccharide antigen, Streptococcus pneumoniae type 19f capsular polysaccharide antigen, Streptococcus pneumoniae type 23f capsular polysaccharide antigen, Streptococcus pneumoniae type 3 capsular polysaccharide antigen, Streptococcus pneumoniae type 4 capsular polysaccharide antigen, Streptococcus pneumoniae type 5 capsular polysaccharide antigen, Streptococcus pneumoniae type 6b capsular polysaccharide antigen, Streptococcus pneumoniae type 7f capsular polysaccharide antigen, Streptococcus pneumoniae type 9v capsular polysaccharide antigen | - | - | - | 5件: 13 13, 14, 46, 96, 222 💬 |
3415 | PREVENAR 13 - 0.5 ML SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - FLACONCINO MONODOSE (0,5 ML VETRO TIPO I) - 1 FLACONCINO MONODOSE | 12件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen, Streptococcus pneumoniae type 14 capsular polysaccharide antigen, Streptococcus pneumoniae type 18c capsular polysaccharide antigen, Streptococcus pneumoniae type 19a capsular polysaccharide antigen, Streptococcus pneumoniae type 19f capsular polysaccharide antigen, Streptococcus pneumoniae type 23f capsular polysaccharide antigen, Streptococcus pneumoniae type 3 capsular polysaccharide antigen, Streptococcus pneumoniae type 4 capsular polysaccharide antigen, Streptococcus pneumoniae type 5 capsular polysaccharide antigen, Streptococcus pneumoniae type 6b capsular polysaccharide antigen, Streptococcus pneumoniae type 7f capsular polysaccharide antigen, Streptococcus pneumoniae type 9v capsular polysaccharide antigen | - | - | - | 1件: 222 222 💬 |
3416 | Prevenar 13 sospensione per iniezione | 12件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen, Streptococcus pneumoniae type 14 capsular polysaccharide antigen, Streptococcus pneumoniae type 18c capsular polysaccharide antigen, Streptococcus pneumoniae type 19a capsular polysaccharide antigen, Streptococcus pneumoniae type 19f capsular polysaccharide antigen, Streptococcus pneumoniae type 23f capsular polysaccharide antigen, Streptococcus pneumoniae type 3 capsular polysaccharide antigen, Streptococcus pneumoniae type 4 capsular polysaccharide antigen, Streptococcus pneumoniae type 5 capsular polysaccharide antigen, Streptococcus pneumoniae type 6b capsular polysaccharide antigen, Streptococcus pneumoniae type 7f capsular polysaccharide antigen, Streptococcus pneumoniae type 9v capsular polysaccharide antigen | - | - | - | 1件: 14 14 💬 |
3417 | Prevenar 13 suspension for injection | 12件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen, Streptococcus pneumoniae type 14 capsular polysaccharide antigen, Streptococcus pneumoniae type 18c capsular polysaccharide antigen, Streptococcus pneumoniae type 19a capsular polysaccharide antigen, Streptococcus pneumoniae type 19f capsular polysaccharide antigen, Streptococcus pneumoniae type 23f capsular polysaccharide antigen, Streptococcus pneumoniae type 3 capsular polysaccharide antigen, Streptococcus pneumoniae type 4 capsular polysaccharide antigen, Streptococcus pneumoniae type 5 capsular polysaccharide antigen, Streptococcus pneumoniae type 6b capsular polysaccharide antigen, Streptococcus pneumoniae type 7f capsular polysaccharide antigen, Streptococcus pneumoniae type 9v capsular polysaccharide antigen | - | - | - | 1件: 222 222 💬 |
3418 | Prevenar® (7-valent pneumococcal conjugate vaccine) | - | - | - | - | 1件: 65 65 💬 |
3419 | Previously referred to as MEDI2070 and AMG 139 | - | - | - | - | 2件: 96 96, 97 💬 |
3420 | Previously referred to as MEDI2070 and AMG 139, AGN-151-598 | - | - | - | - | 1件: 96 96 💬 |
3421 | Previously termed sc.AAV9.CB.SMN and AVXS-101 | - | - | - | - | 1件: 3 3 💬 |
3422 | Pridia 10mg | - | - | - | - | 1件: 6 6 💬 |
3423 | Pridopidine (90 mg) | 1件: Pridopidine Pridopidine | 1件: Pridopidine
Pridopidine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 8 8 💬 |
3424 | Prior Donzepezil 10mg | - | - | - | - | 1件: 6 6 💬 |
3425 | PRIVIGEN - 100 MG/ML - SOLUZIONE PER INFUSIONE USO ENDOVENOSO FLACONCINO(VETRO) 1 FLACONCINO DA 100 ML | - | - | - | - | 1件: 51 51 💬 |
3426 | Privigen 100 mg/ml, solution pour perfusion | - | - | - | - | 1件: 53 53 💬 |
3427 | PRIVIGEN 100mg/ml | - | - | - | - | 1件: 85 85 💬 |
3428 | PRM-151 | 1件: PRM-151 PRM-151 | - | - | - | 1件: 85 85 💬 |
3429 | PRM-151 (Zinpentraxin Alfa) | 1件: PRM-151 PRM-151 | - | - | - | 1件: 85 85 💬 |
3430 | PRO044 IV 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
3431 | PRO044 IV 9 mg/kg | - | - | - | - | 1件: 113 113 💬 |
3432 | PRO044 SC 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
3433 | PRO045, 0.15 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
3434 | PRO045, 1.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
3435 | PRO045, 3.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
3436 | PRO045, 6.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
3437 | PRO045, 9.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
3438 | Probiotic - VSL#3 | - | - | - | - | 1件: 96 96 💬 |
3439 | Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 | 1件: Lactobacillus delbrueckii bulgaricus Lactobacillus delbrueckii bulgaricus | - | - | - | 1件: 46 46 💬 |
3440 | PROCAPTAN - 10 MG COMPRESSE RIVESTITE CON FILM 60 COMPRESSE IN CONTENITORE PER COMPRESSE PP | - | - | - | - | 1件: 58 58 💬 |
3441 | PROCAPTAN - 5 MG COMPRESSE RIVESTITE CON FILM 10 COMPRESSE IN CONTENITORE PER COMPRESSE PP | - | - | - | - | 1件: 58 58 💬 |
3442 | Products containing azathioprine or 6-mercaptopurine | 2件: Azathioprine Azathioprine, Mercaptopurine | 3件: Mercaptopurine
Mercaptopurine
,
Azathioprine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 97 97 💬 |
3443 | Prolastin-C, 120 mg/kg | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
3444 | Prolastin-C, 60 mg/kg | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
3445 | Proleukin 18 MUI | 1件: Aldesleukin Aldesleukin | 1件: Aldesleukin
Aldesleukin
💬 | 3件: IL2RA IL2RA, IL2RB, IL2RG 💬 | 14件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 2 2 💬 |
3446 | Prometic's Immune Globulin Intravenous 10% | - | - | - | - | 1件: 65 65 💬 |
3447 | Promixin 1 million International Units (IU) Powder for Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
3448 | PROMIXIN*NEBUL 30MONOD 1MUI | - | - | - | - | 1件: 299 299 💬 |
3449 | Promixin, 1 million International Units (IU) Powder for Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
3450 | Promixin,1 millón de Unidades Internacionales,polvo para solución para inhalación por nebulizador | - | - | - | - | 1件: 299 299 💬 |
3451 | PROSCAR*30CPR RIV 5MG | 1件: Finasteride Finasteride | 1件: Finasteride
Finasteride
💬 | 1件: SRD5A2 SRD5A2 💬 | 3件: Metabolic pathways Metabolic pathways, Prostate cancer, Steroid hormone biosynthesis 💬 | 1件: 6 6 💬 |
3452 | Prototype capsule GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
3453 | PROVIGIL - 100 MG COMPRESSE 30 COMPRESSE | 1件: Modafinil Modafinil | 1件: Modafinil
Modafinil
💬 | - | - | 1件: 113 113 💬 |
3454 | PRTX-100 | - | - | - | - | 1件: 46 46 💬 |
3455 | PRTX-100 (Staphylococcal protein A) | 1件: Bevifimod Bevifimod | - | - | - | 1件: 63 63 💬 |
3456 | PRTX-100 at 1.5 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
3457 | PRTX-100 at 12.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
3458 | PRTX-100 at 240 mcg | - | - | - | - | 1件: 46 46 💬 |
3459 | PRTX-100 at 3.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
3460 | PRTX-100 at 420 mcg | - | - | - | - | 1件: 46 46 💬 |
3461 | PRTX-100 at 6.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
3462 | PRV-300 | - | - | - | - | 1件: 97 97 💬 |
3463 | PRV-6527 | - | - | - | - | 1件: 96 96 💬 |
3464 | PRV-6527 (JNJ-40346527) | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 💬 |
3465 | PRV-6527(JNJ-40346527) | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 💬 |
3466 | PRX-102 | - | - | - | - | 1件: 19 19 💬 |
3467 | PRX-102 (pegunigalsidase alfa) | 1件: Pegunigalsidase alfa Pegunigalsidase alfa | 1件: Pegunigalsidase alfa
Pegunigalsidase alfa
💬 | - | - | 1件: 19 19 💬 |
3468 | PRX-102 1 mg/kg every 2 weeks | - | - | - | - | 1件: 19 19 💬 |
3469 | PRX-102 2 mg/kg every 4 weeks | - | - | - | - | 1件: 19 19 💬 |
3470 | PRX-112 | - | - | - | - | 1件: 19 19 💬 |
3471 | PT320 2.0 mg | - | - | - | - | 1件: 6 6 💬 |
3472 | PTC-0161480 | - | - | - | - | 2件: 246 246, 299 💬 |
3473 | PTC-124 | - | - | - | - | 2件: 246 246, 299 💬 |
3474 | PTC0161480, PTC124 Compound 1a, RPS2505, PTC-C124, 291844 | - | - | - | - | 1件: 113 113 💬 |
3475 | PTG-100 | - | - | - | - | 1件: 97 97 💬 |
3476 | PTH 1-34 | 1件: Teriparatide Teriparatide | 1件: Teriparatide
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 2件: 65 65, 235 💬 |
3477 | PTR-01 | - | - | - | - | 1件: 36 36 💬 |
3478 | PTW-002 10 mg/g gel | - | - | - | - | 1件: 36 36 💬 |
3479 | PUR 0110 | - | - | - | - | 1件: 97 97 💬 |
3480 | PUR 0110 Rectal Enema | - | - | - | - | 1件: 97 97 💬 |
3481 | PUR 0110 Rectal Enema 1000 mg | - | - | - | - | 1件: 97 97 💬 |
3482 | PUR 0110 Rectal Enema 250 mg | - | - | - | - | 1件: 97 97 💬 |
3483 | PUR 0110 Rectal Enema 500 mg | - | - | - | - | 1件: 97 97 💬 |
3484 | PXT002331 - dose 1 | - | - | - | - | 1件: 6 6 💬 |
3485 | PXT3003 Dose 1 | - | - | - | - | 1件: 10 10 💬 |
3486 | PXT3003 Dose 2 (equivalent to twice Dose 1) | - | - | - | - | 1件: 10 10 💬 |
3487 | Pyridoxine 10mg | 1件: Pyridoxine Pyridoxine | 1件: Pyridoxine
Pyridoxine
💬 | - | - | 1件: 93 93 💬 |
3488 | Pyridoxine 10mg BP | 1件: Pyridoxine Pyridoxine | 1件: Pyridoxine
Pyridoxine
💬 | - | - | 1件: 93 93 💬 |
3489 | Q4W GMA301 IV injections (1000 mg) | - | - | - | - | 1件: 86 86 💬 |
3490 | Q4W GMA301 IV injections (300 mg) | - | - | - | - | 1件: 86 86 💬 |
3491 | Q4W GMA301 IV injections (600 mg) | - | - | - | - | 1件: 86 86 💬 |
3492 | QBW276 1500mcg | - | - | - | - | 1件: 299 299 💬 |
3493 | QBW276 300mcg | - | - | - | - | 1件: 299 299 💬 |
3494 | QCC374 0.015 mg | - | - | - | - | 1件: 86 86 💬 |
3495 | QCC374 0.06 mg | - | - | - | - | 1件: 86 86 💬 |
3496 | QLS-101 ophthalmic solution, 2.0 % | - | - | - | - | 1件: 157 157 💬 |
3497 | QR-010 | - | - | - | - | 1件: 299 299 💬 |
3498 | QR-1123 | - | - | - | - | 1件: 90 90 💬 |
3499 | QR-313 | - | - | - | - | 1件: 36 36 💬 |
3500 | QR-313 Gel for Topical (Cutaneous) Administration | - | - | - | - | 1件: 36 36 💬 |
3501 | QRL-201 - Dose 1 | - | - | - | - | 1件: 2 2 💬 |
3502 | QRL-201 - Dose 3 | - | - | - | - | 1件: 2 2 💬 |
3503 | QRL-201 - Dose 6 | - | - | - | - | 1件: 2 2 💬 |
3504 | QRL-201 - Dose 7 | - | - | - | - | 1件: 2 2 💬 |
3505 | QTXEW2-04-AF, EW2, GC-1, QRX-431 | - | - | - | - | 1件: 20 20 💬 |
3506 | R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride | 1件: Benzofuran Benzofuran | - | - | - | 1件: 6 6 💬 |
3507 | R-021 | - | - | - | - | 1件: 222 222 💬 |
3508 | R-3750 | - | - | - | - | 1件: 97 97 💬 |
3509 | R-Gene 10 | 1件: Arginine Arginine | 1件: Arginine
Arginine
💬 | - | - | 1件: 78 78 💬 |
3510 | R-hIL-18BP | - | - | - | - | 1件: 65 65 💬 |
3511 | R788 sodium hexahydrate, RIG2-01, RIG-G | - | - | - | - | 1件: 46 46 💬 |
3512 | RAAV 2/6 hIDS DONOR | - | - | - | - | 1件: 19 19 💬 |
3513 | RAAV2/5-PBGD vector dosage 1 | - | - | - | - | 1件: 254 254 💬 |
3514 | RAAV2/5-PBGD vector dosage 3 | - | - | - | - | 1件: 254 254 💬 |
3515 | RAAV2/6 Left ZFN Vector | - | - | - | - | 1件: 19 19 💬 |
3516 | RAAV2/6 Right ZFN Vector | - | - | - | - | 1件: 19 19 💬 |
3517 | RAD001 1mg | - | - | - | - | 1件: 158 158 💬 |
3518 | RADAMTS-13 | - | - | - | - | 1件: 64 64 💬 |
3519 | Radiolabelled OligoG CF-5/20 6% Solution | - | - | - | - | 1件: 299 299 💬 |
3520 | Radiolabelled OligoG CF-5/20 6% Solution for Nebulisation | - | - | - | - | 1件: 299 299 💬 |
3521 | RANEXA - 750 MG - COMPRESSA A RILASCIO PROLUNGATO- USO ORALE - BLISTER (PVC/PVDC/ALLUMINIO) 60 COMPRESSE | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
3522 | RANEXA*60CPR 500MG R.P. | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
3523 | RANEXA*60CPR 750MG R.P. | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
3524 | Ranibizumab injection (0.5 mg) | 1件: Ranibizumab Ranibizumab | 1件: Ranibizumab
Ranibizumab
💬 | 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 2件: 166 166, 301 💬 |
3525 | Ranolazine 1000 MG | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 2 2 💬 |
3526 | Ranolazine 1000 mg PR tablets | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
3527 | Ranolazine 750 mg PR tablets | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
3528 | Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
3529 | Rapamicina tópica al 1% y excipiente | - | - | - | - | 1件: 157 157 💬 |
3530 | RAPAMUNE - 1 MG 100 COMPRESSE RIVESTITE IN BLISTER USO ORALE | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 2 2 💬 |
3531 | RAPAMUNE 1 mg/ml oral solution | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
3532 | Rapamune 1 mg/ml solución oral | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
3533 | Rapamune 1mg tablets | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
3534 | RAPAMUNE*100CPR RIV 1MG | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
3535 | RAPAMUNE*30CPR RIV 1MG | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
3536 | RAPAMUNE*30CPR RIV 2MG | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
3537 | Rapamycin cream, topical, 0.5%, 1.0% w/w | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
3538 | Raptiva 100 mg/ml powder and solvent for solution for injection | 1件: Efalizumab Efalizumab | 1件: Efalizumab
Efalizumab
💬 | 1件: ITGAL ITGAL 💬 | 12件: Cell adhesion molecules Cell adhesion molecules, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis 💬 | 7件: 11 11, 13, 46, 53, 61, 95, 96 💬 |
3539 | Rasagilina mesilato (12 weeks) | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3540 | Rasagiline 1 mg capsule | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3541 | Rasagiline 1mg tablet | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3542 | Rasagiline mesylate 1.0 mg | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3543 | RAvPAL-PEG 0.001 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
3544 | RAvPAL-PEG 0.003 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
3545 | RAvPAL-PEG 0.01 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
3546 | RAvPAL-PEG 0.03 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
3547 | RAvPAL-PEG 0.1 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
3548 | RAXONE - 150 MG- COMPRESSE RIVESTITE CON FILM- USO ORALE- FLACONE (HDPE)- 180 COMPRESSE | 1件: Idebenone Idebenone | 1件: Idebenone
Idebenone
💬 | - | - | 1件: 113 113 💬 |
3549 | RC18 160 mg | - | - | - | - | 2件: 13 13, 53 💬 |
3550 | RC18 160 mg plus MTX | - | - | - | - | 1件: 46 46 💬 |
3551 | RC18 160 mg plus standard therapy | - | - | - | - | 1件: 49 49 💬 |
3552 | RC18 160mg | - | - | - | - | 3件: 11 11, 13, 66 💬 |
3553 | Rcombinant Human Parathyroid Hormone [rhPTH(1-84)] | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3554 | RE-021 | - | - | - | - | 3件: 66 66, 218, 222 💬 |
3555 | RE-021 (Sparsentan) | 1件: Sparsentan Sparsentan | 1件: Sparsentan
Sparsentan
💬 | 2件: AGTR1 AGTR1, EDNRA 💬 | 17件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
3556 | RE-024 | - | - | - | - | 1件: 120 120 💬 |
3557 | Rebif (IFN beta-1a subcutaneous three times per week) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3558 | Rebif (IFN ß-1a subcutaneous three times per week) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3559 | Rebif (interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3560 | Rebif (Interferon beta-1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3561 | Rebif (interferon beta-1a), Merck Serono Europe Ltd | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3562 | REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3563 | Rebif 44 microgrammi/0.5ml soluzione iniettabile in cartuccia | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3564 | REBIF SC 12SIR 12000000UI44MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3565 | REBIF SC 12SIR 6000000UI 22MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3566 | REBIF*SC 12SIR 12000000UI44MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3567 | REBIF*SC 12SIR 6000000UI 22MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3568 | Rebif® (clone 484-39) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3569 | Rebif® New Formulation (IFN-beta-1a, RNF) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3570 | Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13 | - | - | - | - | 1件: 64 64 💬 |
3571 | Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 | - | - | - | - | 1件: 64 64 💬 |
3572 | Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs | - | - | - | - | 1件: 64 64 💬 |
3573 | Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs 13 | - | - | - | - | 1件: 64 64 💬 |
3574 | Recombinant A Disintegrin And Metalloproteinase with Thrombospondin Type-1 Motifs 13 (rADAMTS13) | - | - | - | - | 1件: 64 64 💬 |
3575 | RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR EXPRESSING THE HUMAN ALPHA-1-ANTITRYPSIN GENE | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
3576 | Recombinant adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene | - | - | - | - | 1件: 90 90 💬 |
3577 | Recombinant Adeno-associated virus 2/6 vector encoding the cDNA for human alpha galactosidase A | - | - | - | - | 1件: 19 19 💬 |
3578 | Recombinant antihumanized anti-human monoclonal antibody directed against the IL-6R | - | - | - | - | 1件: 107 107 💬 |
3579 | RECOMBINANT HUMAN ?-GLUCOSIDASE CONJUGATED WITH SYNTHETIC BISMANNOSE-6-PHOSPHATE-MAN6 GLYCAN | 1件: Phosphate ion Phosphate ion | - | - | - | 1件: 256 256 💬 |
3580 | Recombinant human a-glucosidase conjugated with multiple copies of synthetic bis-mannose-6-phosphate-tetra-mannose glycan (NEOGAA) | 3件: Avalglucosidase alfa Avalglucosidase alfa, Mannose, Phosphate ion | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
3581 | Recombinant human a-glucosidase conjugated with multiple copies of synthetic bis-mannose-6-phosphate-tetra-mannose glycan Avalglucosidase Alfa (NeoGAA) | 3件: Avalglucosidase alfa Avalglucosidase alfa, Mannose, Phosphate ion | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
3582 | RECOMBINANT HUMAN ALFA-GLUCOSIDASE CONJUGATED WITH SYNTHETIC BISMANNOSE-6-PHOSPHATE-MAN6 GLYCAN | 1件: Phosphate ion Phosphate ion | - | - | - | 1件: 256 256 💬 |
3583 | RECOMBINANT HUMAN ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 FUSED TO THE FC FRAGMENT OF IGG1 | - | - | - | - | 1件: 166 166 💬 |
3584 | Recombinant human IGF-1 | - | - | - | - | 2件: 78 78, 299 💬 |
3585 | Recombinant Human Insulin Growth Factor 1 (rhIGF-1) | 1件: Insulin human Insulin human | 1件: Insulin human
Insulin human
💬 | 1件: INSR INSR 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 156 156 💬 |
3586 | Recombinant human interferon beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 26 26 💬 |
3587 | Recombinant Human Interleukin-11 (rhIL-11) | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 96 96 💬 |
3588 | Recombinant human interleukin-7 | 1件: Interleukin-7 Interleukin-7 | - | - | - | 1件: 25 25 💬 |
3589 | Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class | - | - | - | - | 3件: 106 106, 107, 108 💬 |
3590 | Recombinant human monoclonal antibody to Il-17 of the IgG1-k-class | - | - | - | - | 1件: 271 271 💬 |
3591 | Recombinant human monoclonal antibody to inerleukin-1beta of the IgG1-K-class | - | - | - | - | 1件: 46 46 💬 |
3592 | Recombinant human monoclonal antibody to interleukin-1beta of the IgG1-Kappa-class | - | - | - | - | 1件: 46 46 💬 |
3593 | Recombinant human N-acetylgalactosamine 6-sulfatase, BMN 110 | - | - | - | - | 1件: 19 19 💬 |
3594 | Recombinant human N-acetylgalactosamine 6-sulfatase, BMN 110 drug substance | - | - | - | - | 1件: 19 19 💬 |
3595 | Recombinant human N-acetylgalactosamine-6-sulfatase | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
3596 | Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
3597 | Recombinant human N-acetylgalactosamine-6-sulfatase, BMN 110 | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
3598 | Recombinant human N-acetylgalactosamine-6-sulfatase, BMN 110 drug substance | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
3599 | RECOMBINANT HUMAN PARATHYROID HORMONE (1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3600 | Recombinant Human Parathyroid Hormone [rhPTH(1-84)] | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3601 | Recombinant human Pentraxin-2 (PRM-151) | 1件: PRM-151 PRM-151 | - | - | - | 1件: 85 85 💬 |
3602 | Recombinant human tripeptidyl peptidase-1 | - | - | - | - | 1件: 19 19 💬 |
3603 | RECOMBINANT HUMAN TRIPEPTIDYL PEPTIDASE-1 (RHTPP1) | - | - | - | - | 1件: 19 19 💬 |
3604 | Recombinant humanised anti-human monoclonal antibody directed against the IL-6R | - | - | - | - | 1件: 46 46 💬 |
3605 | Recombinant humanized anti-human Interleukin 6-Receptor (IL-6R) monoclonal | - | - | - | - | 1件: 46 46 💬 |
3606 | Recombinant humanized anti-human Interleukin 6-Receptor (IL-6R) monoclonal antibody | - | - | - | - | 1件: 46 46 💬 |
3607 | Recombinant humanized anti-human Interleukin-6 | - | - | - | - | 1件: 46 46 💬 |
3608 | Recombinant humanized anti-human Interleukin-6 Receptor (IL-6R) monoclonal antibody | - | - | - | - | 1件: 46 46 💬 |
3609 | Recombinant humanized anti-human monoclonal antibody directed against the IL-6R | - | - | - | - | 3件: 46 46, 51, 107 💬 |
3610 | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg | - | - | - | - | 1件: 331 331 💬 |
3611 | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg | - | - | - | - | 1件: 331 331 💬 |
3612 | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg | - | - | - | - | 1件: 331 331 💬 |
3613 | RECOMBINANT INTERFERON BETA-1B | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3614 | Recombinant interleukin-11 | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 288 288 💬 |
3615 | Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN6 gene | - | - | - | - | 1件: 19 19 💬 |
3616 | Recombinant von Willebrand Factor 1300IU | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
3617 | Recombinant von Willebrand Factor 650IU | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
3618 | Reduced Glutathione 100mg | 1件: Glutathione Glutathione | 2件: Glutathione
Glutathione
,
Oxiglutatione
💬 | - | - | 1件: 6 6 💬 |
3619 | REF CRUZADA PEI Nº 12-088 | - | - | - | - | 1件: 274 274 💬 |
3620 | Reference capsule GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
3621 | Regimen Selection Phase Group 1 (COMPLETED) | - | - | - | - | 1件: 113 113 💬 |
3622 | Regimen Selection Phase Group 3 | - | - | - | - | 1件: 113 113 💬 |
3623 | REGN1500 250 mg SC/15 mg/kg IV/450 mg SC | - | - | - | - | 1件: 79 79 💬 |
3624 | Reldesemtiv 150 mg | 1件: Reldesemtiv Reldesemtiv | 1件: Reldesemtiv
Reldesemtiv
💬 | 1件: TNNC2 TNNC2 💬 | 1件: Calcium signaling pathway Calcium signaling pathway 💬 | 1件: 3 3 💬 |
3625 | REMICADE - 100 MG POLVERE PER CONCENTRATO PER INFUSIONE ENDOVENOSA 1 FLACONE VETRO 20 ML USO EV | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
3626 | Remicade 100 mg | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 56 56, 96 💬 |
3627 | Remicade 100 mg infuusiokuiva-aine, konsentraattiliuosta varten | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
3628 | REMICADE 100 mg polvo para concentrado para solución para perfusión | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 271 💬 |
3629 | Remicade 100 mg powder for concentrate for solution for infusion. | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
3630 | Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
3631 | Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning. | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
3632 | REMICADE*EV F 100MG+F 2ML | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
3633 | Remodulin 10mg/ml 20ml | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 88 88 💬 |
3634 | Remodulin 1mg/ml 20ml | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 88 88 💬 |
3635 | Remodulin® (treprostinil) 1 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
3636 | Remodulin® (treprostinil) 10 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
3637 | REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
3638 | Remsima 100 mg pulver til konsentrat til infusjonsvæske, oppløsning | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
3639 | Repatha 140 mg Solution for Injection in Pre-filled Pen | 1件: Evolocumab Evolocumab | 1件: Evolocumab
Evolocumab
💬 | 1件: PCSK9 PCSK9 💬 | 1件: Cholesterol metabolism Cholesterol metabolism 💬 | 1件: 79 79 💬 |
3640 | Repatha 140 mg soluzione per iniezione in penna preriempita. | 1件: Evolocumab Evolocumab | 1件: Evolocumab
Evolocumab
💬 | 1件: PCSK9 PCSK9 💬 | 1件: Cholesterol metabolism Cholesterol metabolism 💬 | 1件: 79 79 💬 |
3641 | REQUIP 21 CPR 0,25 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3642 | REQUIP 21 CPR 0,5 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3643 | REQUIP 21 CPR 1 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3644 | REQUIP*21CPR 0,25MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3645 | REQUIP*21CPR 0,5MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3646 | REQUIP*21CPR 1MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3647 | REVATIO - 0.8 MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO DA 20 ML | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 294 294 💬 |
3648 | Revatio 0.8mg/ml solution for injection | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 294 294 💬 |
3649 | Revatio 10 mg/ml powder for oral suspension | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
3650 | Revolade 75 mg | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 60 60 💬 |
3651 | REYATAZ 150MG 60 CPS BL | 1件: Atazanavir Atazanavir | 1件: Atazanavir
Atazanavir
💬 | - | - | 1件: 265 265 💬 |
3652 | RG-012 | - | - | - | - | 1件: 218 218 💬 |
3653 | RG2133 (2',3',5'-tri-O-acetyluridine) | 1件: Uridine triacetate Uridine triacetate | 1件: Uridine triacetate
Uridine triacetate
💬 | - | - | 1件: 21 21 💬 |
3654 | RGB-03 | - | - | - | - | 1件: 46 46 💬 |
3655 | RGH-706 | - | - | - | - | 1件: 193 193 💬 |
3656 | RGX-111 | - | - | - | - | 1件: 19 19 💬 |
3657 | RGX-121 | - | - | - | - | 1件: 19 19 💬 |
3658 | RhASA - Dose Level 1 | - | - | - | - | 1件: 19 19 💬 |
3659 | RhASA - Dose Level 3 | - | - | - | - | 1件: 19 19 💬 |
3660 | RHB-104 | - | - | - | - | 2件: 13 13, 96 💬 |
3661 | RhGH Norditropin® pen (34 µg/kg) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
3662 | RhHNS-10 mg | - | - | - | - | 1件: 19 19 💬 |
3663 | RhHNS-90 mg | - | - | - | - | 1件: 19 19 💬 |
3664 | RhIFN beta-1b | - | - | - | - | 1件: 13 13 💬 |
3665 | RhIGF-1 | - | - | - | - | 1件: 156 156 💬 |
3666 | RhIGF-1 (CEP-151) | - | - | - | - | 1件: 13 13 💬 |
3667 | RhIGF-1/rhIGFBP-3 | 1件: rhIGFBP-3 rhIGFBP-3 | - | - | - | 1件: 195 195 💬 |
3668 | RhIGF-I/rhIGFBP-3 | 1件: rhIGFBP-3 rhIGFBP-3 | - | - | - | 1件: 113 113 💬 |
3669 | RhIGFBP-3 | 1件: rhIGFBP-3 rhIGFBP-3 | - | - | - | 2件: 113 113, 195 💬 |
3670 | RhIL-11 | - | - | - | - | 1件: 97 97 💬 |
3671 | RhNGF 180 µg/ml eye drops solution | 1件: Cenegermin Cenegermin | 1件: Cenegermin
Cenegermin
💬 | 1件: NGFR NGFR 💬 | 9件: Apoptosis - multiple species Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer, Virion - Lyssavirus 💬 | 1件: 90 90 💬 |
3672 | RhNGF 60 µg/ml eye drops solution | 1件: Cenegermin Cenegermin | 1件: Cenegermin
Cenegermin
💬 | 1件: NGFR NGFR 💬 | 9件: Apoptosis - multiple species Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer, Virion - Lyssavirus 💬 | 1件: 90 90 💬 |
3673 | RhPTH (1-34) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 70 70 💬 |
3674 | RhPTH (1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3675 | RhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3676 | RhuDex 100 mg (127 mg RhuDex choline salt) granules | 1件: Choline Choline | 1件: Choline
Choline
💬 | - | - | 1件: 93 93 💬 |
3677 | RhuDex 25 mg (31.75 mg RhuDex choline salt) granules | 1件: Choline Choline | 1件: Choline
Choline
💬 | - | - | 1件: 93 93 💬 |
3678 | RhuDex 50 mg (63.5 mg RhuDex choline salt) granules | 1件: Choline Choline | 1件: Choline
Choline
💬 | - | - | 1件: 93 93 💬 |
3679 | RhuMAb Beta7, Anti Beta 7, PRO145223 | - | - | - | - | 1件: 97 97 💬 |
3680 | RhumAb to Il-17A (IgG1-k-class) | - | - | - | - | 4件: 13 13, 46, 56, 96 💬 |
3681 | RhumAb to Il-17A (IgG1-k-class) rhumAb to Il-17A (IgG1-k-class) | - | - | - | - | 1件: 96 96 💬 |
3682 | RhumAb to IL-17A igG1-k-class | - | - | - | - | 1件: 13 13 💬 |
3683 | Rhustoxicodendron 30 | - | - | - | - | 1件: 46 46 💬 |
3684 | RI-002 | - | - | - | - | 1件: 65 65 💬 |
3685 | Rifampin 300mg BID + istradefylline 40mg Day 8 only | 2件: Istradefylline Istradefylline, Rifampicin | 2件: Rifampin
Rifampin
,
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3686 | RIL-1RA | - | - | - | - | 1件: 107 107 💬 |
3687 | Rilonacept (IL-1 Trap) | 1件: Rilonacept Rilonacept | 1件: Rilonacept
Rilonacept
💬 | 2件: IL1A IL1A, IL1B 💬 | 45件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 107 107 💬 |
3688 | Rilonacept 160 mg | 1件: Rilonacept Rilonacept | 1件: Rilonacept
Rilonacept
💬 | 2件: IL1A IL1A, IL1B 💬 | 45件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 106 106 💬 |
3689 | Riluzole (100 mg) | 1件: Riluzole Riluzole | 1件: Riluzole
Riluzole
💬 | 14件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 23件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
3690 | Riluzole 100mg/day | 1件: Riluzole Riluzole | 1件: Riluzole
Riluzole
💬 | 14件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 23件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
3691 | RILUZOLO TEVA - 50 MG COMPRESSE RIVESTITE CON FILM 90 COMPRESSE IN BLISTER AL/PVC | - | - | - | - | 1件: 114 114 💬 |
3692 | Riociguat coated tablet 0.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
3693 | Riociguat coated tablet 1.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
3694 | Riociguat coated tablet 1.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
3695 | Riociguat coated tablet 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
3696 | Riociguat granules 0.3% for oral application | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
3697 | Risankizumab 10 mg/ml | 1件: Risankizumab Risankizumab | 1件: Risankizumab
Risankizumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
3698 | Risankizumab 180 mg SC | 1件: Risankizumab Risankizumab | 1件: Risankizumab
Risankizumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
3699 | Risankizumab 600 mg IV | 1件: Risankizumab Risankizumab | 1件: Risankizumab
Risankizumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
3700 | Risankizumab 90 mg/ml | 1件: Risankizumab Risankizumab | 1件: Risankizumab
Risankizumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
3701 | Risperidone 1Mg Tab | 1件: Risperidone Risperidone | 1件: Risperidone
Risperidone
💬 | 2件: DRD2 DRD2, HTR2A 💬 | 11件: Alcoholism Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway 💬 | 1件: 8 8 💬 |
3702 | Ritalin LA 30mg capsules | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
3703 | Ritlecitinib 10 mg | - | - | - | - | 1件: 97 97 💬 |
3704 | Ritlecitinib/JAK 3 | - | - | - | - | 1件: 46 46 💬 |
3705 | Rituximab (MABTHERA® or RITUXAN®). | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 35 35, 61 💬 |
3706 | Rituximab 1g IV | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 162 162 💬 |
3707 | Rituximab konsentrat til infusjonsvaeske oppløsning 10 mg/ml | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
3708 | Rituximab-Pfizer (PF-05280586) x 3 courses | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
3709 | RIV-TDS 13.3 mg/24 h | - | - | - | - | 1件: 6 6 💬 |
3710 | Rivastigmin Luye Transdermal Patches - 4.6mg/24h | - | - | - | - | 1件: 6 6 💬 |
3711 | Rivastigmine Luye Transdermal Patch- 9.5mg/24h | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
3712 | Rivastigmine Patch 9.5 cm2 | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
3713 | Rivastigmine transdermal system 13.3 mg/24 h | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
3714 | RM-131 | - | - | - | - | 1件: 6 6 💬 |
3715 | RNS60 125 ml | - | - | - | - | 1件: 13 13 💬 |
3716 | Ro 001-9265 | - | - | - | - | 1件: 41 41 💬 |
3717 | Ro 001-9265/F02 | - | - | - | - | 1件: 41 41 💬 |
3718 | RO 001-9265/F02-01 | - | - | - | - | 1件: 46 46 💬 |
3719 | Ro 001-9265/F03 | - | - | - | - | 1件: 41 41 💬 |
3720 | Ro 001-9265/F04 | - | - | - | - | 1件: 41 41 💬 |
3721 | Ro 002-9893/F02 | - | - | - | - | 1件: 46 46 💬 |
3722 | Ro 106-1443 | - | - | - | - | 1件: 49 49 💬 |
3723 | Ro 47-0203 | - | - | - | - | 4件: 51 51, 85, 86, 88 💬 |
3724 | Ro 47-0203 / ACT-050088 | - | - | - | - | 1件: 86 86 💬 |
3725 | Ro 48-77533 | - | - | - | - | 1件: 46 46 💬 |
3726 | RO 487-7533 | - | - | - | - | 1件: 46 46 💬 |
3727 | Ro 487-7533/F01 | - | - | - | - | 3件: 46 46, 107, 271 💬 |
3728 | Ro 487-7533/F10 | - | - | - | - | 2件: 46 46, 107 💬 |
3729 | Ro 487-7533/F10-02 | - | - | - | - | 1件: 46 46 💬 |
3730 | Ro 487-7533/F10-04 | - | - | - | - | 4件: 41 41, 46, 51, 107 💬 |
3731 | Ro 491-7523/F18 | - | - | - | - | 1件: 206 206 💬 |
3732 | Ro 491-7523/F19 | - | - | - | - | 1件: 206 206 💬 |
3733 | Ro 533-3787/F01- 06 | - | - | - | - | 1件: 13 13 💬 |
3734 | Ro 533-3787/F01-06 | - | - | - | - | 1件: 11 11 💬 |
3735 | Ro 549-0261/F04 | - | - | - | - | 1件: 97 97 💬 |
3736 | Ro 549-0261/F04-02 | - | - | - | - | 1件: 96 96 💬 |
3737 | Ro 549-0261/F08-02 | - | - | - | - | 1件: 96 96 💬 |
3738 | RO 551-6922 | - | - | - | - | 1件: 46 46 💬 |
3739 | Ro 723-4292/F02 | - | - | - | - | 1件: 8 8 💬 |
3740 | Ro-47-0203 | - | - | - | - | 1件: 86 86 💬 |
3741 | Ro-47-0203/029 | - | - | - | - | 1件: 86 86 💬 |
3742 | RO001-9265/F04 | - | - | - | - | 1件: 46 46 💬 |
3743 | Ro106-1443 | - | - | - | - | 1件: 43 43 💬 |
3744 | Ro47-0203 | - | - | - | - | 1件: 86 86 💬 |
3745 | Ro47-0203 / ACT-050088 | - | - | - | - | 2件: 51 51, 86 💬 |
3746 | Ro487-7533 | - | - | - | - | 1件: 46 46 💬 |
3747 | RO487-7533/F01-F05 | - | - | - | - | 1件: 46 46 💬 |
3748 | RO487-7533/F10-04 | - | - | - | - | 2件: 46 46, 51 💬 |
3749 | RO4917523 0.5 mg | - | - | - | - | 1件: 206 206 💬 |
3750 | RO4917523 1.5 mg | - | - | - | - | 1件: 206 206 💬 |
3751 | RO4964913/F07-01 | - | - | - | - | 1件: 13 13 💬 |
3752 | RO545-9072/F03 | - | - | - | - | 1件: 53 53 💬 |
3753 | Ro549-0261/F04-02 | - | - | - | - | 1件: 96 96 💬 |
3754 | RO5490255/F01-02 | - | - | - | - | 1件: 85 85 💬 |
3755 | RO5490261/F04-02 | - | - | - | - | 1件: 97 97 💬 |
3756 | RO7112689/F03-01 | - | - | - | - | 2件: 62 62, 109 💬 |
3757 | RO7112689/F03-10 | - | - | - | - | 2件: 62 62, 109 💬 |
3758 | RO7123520/F03-01 | - | - | - | - | 1件: 46 46 💬 |
3759 | RO7204239/F01-01 | - | - | - | - | 1件: 3 3 💬 |
3760 | RO7239361 (BMS-986089) | - | - | - | - | 1件: 113 113 💬 |
3761 | RO7239361 Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
3762 | RO7239361 Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
3763 | RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
3764 | RO7239361 Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
3765 | RO7248824/F02-01 | - | - | - | - | 1件: 201 201 💬 |
3766 | RO7248824/F03-01 (Diluent for RO7248824/F02-01 | - | - | - | - | 1件: 201 201 💬 |
3767 | RO7490677 160 mg/8 ml | - | - | - | - | 1件: 85 85 💬 |
3768 | RO7490677 160 mg/8mL | - | - | - | - | 1件: 85 85 💬 |
3769 | RO7490677 160mg/8mL | - | - | - | - | 1件: 85 85 💬 |
3770 | RO7490677 320 mg/16 ml (2nd generation) | - | - | - | - | 1件: 85 85 💬 |
3771 | RO7490677 320mg/16mL (1st generation) | - | - | - | - | 1件: 85 85 💬 |
3772 | RO7490677 320mg/16mL (2nd generation) | - | - | - | - | 1件: 85 85 💬 |
3773 | RO7490677/ F01-02 | - | - | - | - | 1件: 85 85 💬 |
3774 | RO7490677/F01-01 | - | - | - | - | 1件: 85 85 💬 |
3775 | RO7490677/F01-02 | - | - | - | - | 1件: 85 85 💬 |
3776 | RO7490677/F01-03 | - | - | - | - | 1件: 85 85 💬 |
3777 | ROACTEMRA - 162 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA 0,9ML (VETRO) - 4 SIRINGHE PRERIEMPITE | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 51 💬 |
3778 | ROACTEMRA - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 4ML 1 FLACONCINO | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
3779 | RoActemra 162 mg | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 51 💬 |
3780 | RoActemra 162 mg solution for injection in pre-filled syringe | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
3781 | RoActemra 162 mg solution injectable en seringue préremplie | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
3782 | RoActemra 162 mg soluzione iniettabile in siringa preriempita | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 50 50 💬 |
3783 | Rob 803 (9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxali | - | - | - | - | 1件: 46 46 💬 |
3784 | Rob 803 (capsules 12.5 mg) | - | - | - | - | 1件: 46 46 💬 |
3785 | Rob 803 (capsules 15 mg) | - | - | - | - | 1件: 46 46 💬 |
3786 | Rob 803 (capsules 6.25 mg) | - | - | - | - | 1件: 46 46 💬 |
3787 | Rob 803 12.5mg capsule | - | - | - | - | 1件: 46 46 💬 |
3788 | Rob 803 15mg capsule | - | - | - | - | 1件: 46 46 💬 |
3789 | Rob 803 6.25mg capsule | - | - | - | - | 1件: 46 46 💬 |
3790 | Rob 803 6.5mg capsule | - | - | - | - | 1件: 46 46 💬 |
3791 | Rodatristat ethyl 300 mg tablet BID | - | - | - | - | 1件: 86 86 💬 |
3792 | Rodatristat ethyl 600 mg BID | - | - | - | - | 1件: 86 86 💬 |
3793 | Roferon-A 3miu | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: Interferon alfa-2a
Interferon alfa-2a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 💬 |
3794 | Roferon-A, 3miu | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: Interferon alfa-2a
Interferon alfa-2a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 💬 |
3795 | Roferon-A, 6miu | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: Interferon alfa-2a
Interferon alfa-2a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 💬 |
3796 | Rokan (r) Novo 120 mg | - | - | - | - | 1件: 18 18 💬 |
3797 | Rosuvastatin 10 mg | 1件: Rosuvastatin Rosuvastatin | 1件: Rosuvastatin
Rosuvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 96 96 💬 |
3798 | Rosuvastatin 10mg | 1件: Rosuvastatin Rosuvastatin | 1件: Rosuvastatin
Rosuvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 97 97 💬 |
3799 | Rotigotine (Reference product PR 2.1.1) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3800 | Rotigotine (Test product PR 2.3.1) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3801 | Rotigotine transdermal patch 2mg/24h(10cm2) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3802 | Rotigotine transdermal patch 6mg/24h (30cm2) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3803 | RP 103 | - | - | - | - | 2件: 8 8, 19 💬 |
3804 | RPC-1063 | - | - | - | - | 1件: 13 13 💬 |
3805 | RPH-104 | - | - | - | - | 1件: 266 266 💬 |
3806 | RQ-00000010 | - | - | - | - | 1件: 6 6 💬 |
3807 | RSLV-132 | - | - | - | - | 2件: 49 49, 53 💬 |
3808 | RST-001 | - | - | - | - | 1件: 90 90 💬 |
3809 | RTX-134 | - | - | - | - | 1件: 240 240 💬 |
3810 | RVG 03820 | - | - | - | - | 1件: 3 3 💬 |
3811 | RVG 05565 | - | - | - | - | 1件: 96 96 💬 |
3812 | RVG 07151 | - | - | - | - | 1件: 96 96 💬 |
3813 | RVG 08740 | - | - | - | - | 1件: 6 6 💬 |
3814 | RVG 08938 | - | - | - | - | 1件: 75 75 💬 |
3815 | RVG 101614 | - | - | - | - | 1件: 60 60 💬 |
3816 | RVG 104433 | - | - | - | - | 1件: 107 107 💬 |
3817 | RVG 105155 | - | - | - | - | 1件: 60 60 💬 |
3818 | RVG 114681 | - | - | - | - | 1件: 96 96 💬 |
3819 | RVG 116648 | - | - | - | - | 1件: 96 96 💬 |
3820 | RVG 13760 | - | - | - | - | 1件: 298 298 💬 |
3821 | RVG 15375 | - | - | - | - | 1件: 75 75 💬 |
3822 | RVG 15790 or RVG 25480 | - | - | - | - | 1件: 78 78 💬 |
3823 | RVG 18236 | - | - | - | - | 2件: 75 75, 227 💬 |
3824 | RVG 18388 | - | - | - | - | 1件: 160 160 💬 |
3825 | RVG 33865 | - | - | - | - | 1件: 86 86 💬 |
3826 | RVT-101 35 mg | - | - | - | - | 1件: 6 6 💬 |
3827 | RVT-1201 | - | - | - | - | 1件: 86 86 💬 |
3828 | RVT-1401 | - | - | - | - | 2件: 11 11, 61 💬 |
3829 | RVT-1601 | - | - | - | - | 1件: 85 85 💬 |
3830 | RVT-1601 (formerly, PA101B) | - | - | - | - | 1件: 85 85 💬 |
3831 | RVT-1601 (in precedenza PA101B) | - | - | - | - | 1件: 85 85 💬 |
3832 | RWJ-445380 100 mg | - | - | - | - | 1件: 46 46 💬 |
3833 | RWJ-445380 300 mg | - | - | - | - | 1件: 46 46 💬 |
3834 | RWJ-445380 capsule 100 mg | - | - | - | - | 1件: 46 46 💬 |
3835 | RWJ-445380 capsules 150 mg | - | - | - | - | 1件: 46 46 💬 |
3836 | RWJ-445380-002 | - | - | - | - | 1件: 46 46 💬 |
3837 | Rytary 145 mg | - | - | - | - | 1件: 6 6 💬 |
3838 | Rytary 195 mg | - | - | - | - | 1件: 6 6 💬 |
3839 | S 90049 | - | - | - | - | 1件: 6 6 💬 |
3840 | S 90049 - F36 | - | - | - | - | 1件: 6 6 💬 |
3841 | S 90049 - F38 | - | - | - | - | 1件: 6 6 💬 |
3842 | S(-)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl]-N,4-dimethylbenzamide | - | - | - | - | 1件: 46 46 💬 |
3843 | S-1226 | - | - | - | - | 1件: 299 299 💬 |
3844 | SA-001 | - | - | - | - | 1件: 298 298 💬 |
3845 | SAF-301 | - | - | - | - | 1件: 19 19 💬 |
3846 | Saffron 100 | - | - | - | - | 1件: 97 97 💬 |
3847 | Safinamide metansolfonato (12 weeks) | 1件: Safinamide Safinamide | 1件: Safinamide
Safinamide
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3848 | Safinamide Methanesulfonate 100mg | 1件: Safinamide Safinamide | 1件: Safinamide
Safinamide
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3849 | Safinamide Methanesulfonate 150mg | 1件: Safinamide Safinamide | 1件: Safinamide
Safinamide
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3850 | Safinimide 50-100 mg/day | - | - | - | - | 1件: 6 6 💬 |
3851 | SAGE-718 | - | - | - | - | 2件: 6 6, 8 💬 |
3852 | SAIZEN - 1 FLACONCINO POLV. 8 MG + 1 CARTUCCIA. SOLV. INSERITI IN UN DISPOSITIVO PER LA RICOSTITUZIONE | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
3853 | Saline 0.9% inhalation solution | - | - | - | - | 1件: 299 299 💬 |
3854 | Saline 0.9% NaCl | - | - | - | - | 1件: 235 235 💬 |
3855 | Salofalk 1000mg Granu-Stix | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
3856 | Salofalk 1000mg Granu-Stix® | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
3857 | Salofalk 3g gastro-resistant prolonged-release granules | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
3858 | Salofalk 4g/60ml Klysma | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
3859 | Salofalk® 1000mg Granu-Stix® | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
3860 | Samsca 15 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
3861 | Samsca 30 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
3862 | SAMSCA 7.5 mg oral tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
3863 | SAMSCA*10CPR 15MG | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 72 72 💬 |
3864 | SAN-300 0.5 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
3865 | SAN-300 1.0 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
3866 | SAN-300 2.0 mg/kg QOW | - | - | - | - | 1件: 46 46 💬 |
3867 | SAN-300 4.0 mg/kg QOW | - | - | - | - | 1件: 46 46 💬 |
3868 | SAN-300 4.0 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
3869 | SANDIMMUN NEORAL - 10 MG CAPSULE MOLLI 50 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
3870 | SANDIMMUN NEORAL - 100 MG CAPSULE MOLLI 30 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
3871 | SANDIMMUN NEORAL*30CPS 100MG | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
3872 | Sapropterin dihydrochloride (6R-BH4) | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 86 86 💬 |
3873 | Sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
3874 | Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] | 1件: Sarilumab Sarilumab | 1件: Sarilumab
Sarilumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
3875 | Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1 | 1件: Sarilumab Sarilumab | 1件: Sarilumab
Sarilumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 84 84 💬 |
3876 | Saroglitazar Magnesium 1 mg | 2件: Magnesium Magnesium, Saroglitazar | - | - | - | 1件: 93 93 💬 |
3877 | Sativex 2,7mg/2,5 mg Solucion para pulverizacion bucal | 2件: Cannabidiol Cannabidiol, Dronabinol | 2件: Dronabinol
Dronabinol
,
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
3878 | Satralizumab (120 mg/PFS with NSD) | 1件: Satralizumab Satralizumab | 1件: Satralizumab
Satralizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
3879 | Satralizumab (120 mg/vial) | 1件: Satralizumab Satralizumab | 1件: Satralizumab
Satralizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
3880 | Satralizumab (120mg/vial) | 1件: Satralizumab Satralizumab | 1件: Satralizumab
Satralizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
3881 | Satralizumab 120 mg | 1件: Satralizumab Satralizumab | 1件: Satralizumab
Satralizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
3882 | SB 681323 | - | - | - | - | 1件: 46 46 💬 |
3883 | SB-318 | - | - | - | - | 1件: 19 19 💬 |
3884 | SB-497115-GR 12.5mg | - | - | - | - | 1件: 63 63 💬 |
3885 | SB-656933 | - | - | - | - | 1件: 97 97 💬 |
3886 | SB-656933 Tablets | - | - | - | - | 2件: 97 97, 299 💬 |
3887 | SB-656933-AAA | - | - | - | - | 1件: 299 299 💬 |
3888 | SB-681323 | - | - | - | - | 1件: 46 46 💬 |
3889 | SB-681323 oral tablets | - | - | - | - | 1件: 46 46 💬 |
3890 | SB-681323 Tablets | - | - | - | - | 1件: 46 46 💬 |
3891 | SB-683699 | - | - | - | - | 1件: 13 13 💬 |
3892 | SB-913 | - | - | - | - | 1件: 19 19 💬 |
3893 | SBC-102 | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
3894 | SBC-102, recombinant human lysosomal acid lipase | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
3895 | SBC-103 | - | - | - | - | 1件: 19 19 💬 |
3896 | SBI-087 | - | - | - | - | 2件: 46 46, 49 💬 |
3897 | SBT-020 | - | - | - | - | 1件: 8 8 💬 |
3898 | SC interferon beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3899 | SC interferon beta-1b | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3900 | SC Peginterferon beta-1a | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3901 | SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety) | - | - | - | - | 1件: 65 65 💬 |
3902 | SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety) | - | - | - | - | 1件: 65 65 💬 |
3903 | SC12267 (4SC-101) | 1件: SC12267 SC12267 | - | - | - | 3件: 46 46, 96, 97 💬 |
3904 | SCH 420814 10 mg | - | - | - | - | 1件: 6 6 💬 |
3905 | SCH 420814 100 mg | - | - | - | - | 1件: 6 6 💬 |
3906 | SCH 900050 | - | - | - | - | 1件: 97 97 💬 |
3907 | SCH 900259 | - | - | - | - | 1件: 46 46 💬 |
3908 | SCH 900800 | - | - | - | - | 1件: 6 6 💬 |
3909 | SCM-010 | - | - | - | - | 1件: 13 13 💬 |
3910 | SCYX-7158 | - | - | - | - | 1件: 65 65 💬 |
3911 | SD-101 | - | - | - | - | 1件: 36 36 💬 |
3912 | SD-101 dermal cream (3%) | - | - | - | - | 1件: 36 36 💬 |
3913 | SD-101 Dermal Cream (6%) | - | - | - | - | 1件: 36 36 💬 |
3914 | SD-101-6.0 cream | - | - | - | - | 1件: 36 36 💬 |
3915 | Search for exocrine pancreatic insufficiency at week 0 and 12 | - | - | - | - | 1件: 96 96 💬 |
3916 | Sebelipase alfa (SBC-102) | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
3917 | Sebelipase alfa 0.35 mg/kg | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
3918 | Sebelipase alfa 1 mg/kg | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
3919 | Sebelipase alfa 3 mg/kg | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
3920 | Secukinumab (150 mg) | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
3921 | Secukinumab (75 mg) | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
3922 | Secukinumab (AIN457) 150 mg s.c. | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
3923 | Secukinumab 150 mg | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
3924 | Secukinumab 150 mg (2 injections per dose | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 269 269 💬 |
3925 | Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection. | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
3926 | Secukinumab 150 mg/1 mL Solution for injection | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 2件: 37 37, 271 💬 |
3927 | Secukinumab 150 mg/ml | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
3928 | Secukinumab 150 milligram [Cosentyx] | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
3929 | Secukinumab 150mg | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 37 37 💬 |
3930 | Secukinumab 300 mg | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
3931 | Secukinumab 300 mg, s.c. | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
3932 | Secukinumab 300mg | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 37 37 💬 |
3933 | Secukinumab 75 mg/0.5 ml Solution for injection | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
3934 | See D.3.9.3 'Other descriptive name' below | - | - | - | - | 1件: 46 46 💬 |
3935 | Seladelpar 10 mg | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
3936 | Seladelpar 10 mg Capsule | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
3937 | Seladelpar 10 mg or less | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
3938 | Seladelpar 5-10 mg | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
3939 | Selexipag, ACT-293987 (NS-304) | 1件: Selexipag Selexipag | 1件: Selexipag
Selexipag
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
3940 | Selumetinib 10mg capsule | 1件: Selumetinib Selumetinib | 1件: Selumetinib
Selumetinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
3941 | Selumetinib capsules 10mg | 1件: Selumetinib Selumetinib | 1件: Selumetinib
Selumetinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
3942 | Selumetinib granules in sprinkle capsules for opening 7.5 mg | 1件: Selumetinib Selumetinib | 1件: Selumetinib
Selumetinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
3943 | SEP-363856 | 1件: SEP-363856 SEP-363856 | - | - | - | 1件: 6 6 💬 |
3944 | Serum physiologique 0.9 % | - | - | - | - | 1件: 96 96 💬 |
3945 | Sezione * D.3.6.2.1 - valore: 400mg alla settimana 0, in seguito 200mg ogni due settimane | - | - | - | - | 1件: 96 96 💬 |
3946 | SGT-001 | - | - | - | - | 1件: 113 113 💬 |
3947 | SHP 655 (BAX 930) | - | - | - | - | 1件: 64 64 💬 |
3948 | SHR-1209 | - | - | - | - | 1件: 79 79 💬 |
3949 | SHR-1314 | - | - | - | - | 1件: 271 271 💬 |
3950 | SHR-1906 | - | - | - | - | 1件: 85 85 💬 |
3951 | SI-722 | - | - | - | - | 1件: 226 226 💬 |
3952 | Sifalimumab 1,200 mg | 1件: Sifalimumab Sifalimumab | 1件: Sifalimumab
Sifalimumab
💬 | 13件: IFNA1 IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8 💬 | 25件: Alcoholic liver disease Alcoholic liver disease, Autoimmune thyroid disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, PI3K-Akt signaling pathway, Pathways in cancer, RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway, Tuberculosis 💬 | 1件: 49 49 💬 |
3953 | Sifalimumab 600 mg | 1件: Sifalimumab Sifalimumab | 1件: Sifalimumab
Sifalimumab
💬 | 13件: IFNA1 IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8 💬 | 25件: Alcoholic liver disease Alcoholic liver disease, Autoimmune thyroid disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, PI3K-Akt signaling pathway, Pathways in cancer, RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway, Tuberculosis 💬 | 1件: 49 49 💬 |
3954 | Sifrol 0,088 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3955 | Sifrol 0,18 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3956 | Sifrol 0,35 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3957 | Sifrol 0,7 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3958 | Sifrol, 0,35 mg Tablette | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3959 | Sifrol, 0,70 mg Tablette | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3960 | Sildenafil (Acute-1 hour) | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
3961 | Sildenafil 20mg and Bosentan 62.5mg | 2件: Bosentan Bosentan, Sildenafil | 3件: Bosentan
Bosentan
,
Bosentan
,
Sildenafil
💬 | 3件: EDNRA EDNRA, EDNRB, PDE5A 💬 | 11件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
3962 | Sildenafil citrate (UK-92,480) | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
3963 | Silikis 3µg/g Salbe | - | - | - | - | 1件: 37 37 💬 |
3964 | SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
3965 | SINEMET - 100 MG + 25 MG COMPRESSE 50 COMPRESSE DIVISIBILI | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3966 | SINEMET 10-100 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3967 | SINEMET 100 mg + 25 mg compresse | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3968 | SINEMET 100 mg + 25 mg tablets | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3969 | SINEMET 125 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3970 | Sinemet 125 mg | - | - | - | - | 1件: 6 6 💬 |
3971 | SINEMET 25-100 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3972 | Sinemet 25-100 Oral Tablet | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3973 | SINEMET 25/100 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3974 | Sinemet CR 25Mg-100Mg Extended-Release Tablet | 3件: Carbidopa Carbidopa, Levodopa, Manganese citrate | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3975 | SINEMET*50CPR 100MG+25MG | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3976 | Sinemet® 100/25 | - | - | - | - | 1件: 6 6 💬 |
3977 | Sinemet® 100/25 mg | - | - | - | - | 1件: 6 6 💬 |
3978 | Sinemet® CR 100/25 | - | - | - | - | 1件: 6 6 💬 |
3979 | SINEMET® Plus 25 mg/100 mg Tablets | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3980 | Sinemet®25-100 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3981 | Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg) | - | - | - | - | 1件: 28 28 💬 |
3982 | Siponimod 0,25 mg | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
3983 | Siponimod 0.25 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
3984 | Siponimod 0.5 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
3985 | Siponimod 1 mg | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
3986 | Siponimod 1 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
3987 | SIRIO*30CPR EFF 25MG+100MG | - | - | - | - | 1件: 6 6 💬 |
3988 | Sirolimus 0,1% crème | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 2件: 278 278, 280 💬 |
3989 | Sirolimus 0.2% | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
3990 | Sirolimus 0.4% | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
3991 | Sirolimus 1mg/mL | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 2件: 278 278, 280 💬 |
3992 | Sirolimus Oral Liquid Product 1mg/mL | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 278 278 💬 |
3993 | Sirukumab 100 mg | 1件: Sirukumab Sirukumab | 1件: Sirukumab
Sirukumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
3994 | SKF-101468A | - | - | - | - | 1件: 6 6 💬 |
3995 | SKI-606 | - | - | - | - | 1件: 67 67 💬 |
3996 | SKI-O-703 | - | - | - | - | 1件: 46 46 💬 |
3997 | SKI-O-703 capsule | - | - | - | - | 1件: 46 46 💬 |
3998 | SLS-005 | - | - | - | - | 1件: 2 2 💬 |
3999 | SLS-005 Trehalose | 1件: Trehalose Trehalose | - | - | - | 1件: 2 2 💬 |
4000 | SMOFKABIVEN - EMULSIONE PER INFUSIONE SENZA ELETTROLITI 1 SACCA BIOFINE MULTICOMPARTIMENTATE DA 493 ML | 2件: Medium-chain triglycerides Medium-chain triglycerides, Sodium glycerophosphate | 1件: Sodium glycerophosphate
Sodium glycerophosphate
💬 | - | - | 1件: 66 66 💬 |
4001 | SMP-114 | - | - | - | - | 1件: 46 46 💬 |
4002 | SND 919 CL2 Y | - | - | - | - | 1件: 6 6 💬 |
4003 | SND 919 CL2Y | - | - | - | - | 1件: 6 6 💬 |
4004 | Sodium (R)-8-methyl-2-(3-methylbenzofuran-2-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)ethoxy)quinoline-4-ca | - | - | - | - | 1件: 299 299 💬 |
4005 | Sodium (S)-3-(4-hydroxyphenyl)-2-(2-((S)-1-((S)-1-palmitoylpyrrolidine-2-carbonyl)pyrrolidine-2-carboxamido)acetamido)propanoate | 1件: Pyrrolidine Pyrrolidine | - | - | - | 1件: 97 97 💬 |
4006 | Sodium acetate (1-13C) | 2件: Acetate Acetate, Sodium acetate | 1件: Sodium acetate
Sodium acetate
💬 | - | - | 1件: 251 251 💬 |
4007 | Sodium chloride (7%) | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
4008 | Sodium chloride 0,9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
4009 | Sodium Chloride 0.9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 2件: 14 14, 227 💬 |
4010 | Sodium chloride 6% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
4011 | SODIUM CHLORIDE 7% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
4012 | SODIUM CHLORIDE SOLUTION 0.9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 4件: 51 51, 60, 288, 299 💬 |
4013 | Sodium Ethanoate (1- 13 C) | 1件: Acetic acid Acetic acid | 1件: Acetic acid, glacial
Acetic acid, glacial
💬 | - | - | 1件: 251 251 💬 |
4014 | Sodium Ethanoate (1-13C) | 1件: Acetic acid Acetic acid | 1件: Acetic acid, glacial
Acetic acid, glacial
💬 | - | - | 1件: 251 251 💬 |
4015 | Sodium fluoride 18F | 1件: Sodium fluoride Sodium fluoride | 1件: Sodium fluoride
Sodium fluoride
💬 | - | - | 1件: 51 51 💬 |
4016 | Sodium Pyruvate in 0.9% Sodium Chloride Solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
4017 | Sodium Thiosulfate 10% | - | - | - | - | 2件: 50 50, 51 💬 |
4018 | Sodium-[o-[(2,6-dichlorophenyl)-amino]- phenyl]-acetate | 1件: Acetate Acetate | - | - | - | 1件: 46 46 💬 |
4019 | Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate | 1件: Acetate Acetate | - | - | - | 1件: 46 46 💬 |
4020 | Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 195 195 💬 |
4021 | Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 195 195 💬 |
4022 | SOL-116 | - | - | - | - | 1件: 46 46 💬 |
4023 | SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML) | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 3件: 13 13, 62, 109 💬 |
4024 | Soliris 300 | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
4025 | SOLIRIS 300 mg concentrado para solución para perfusión | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 109 109 💬 |
4026 | Soliris 300 mg concentrate for solution for infusion | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
4027 | Soliris 300mg/30ml | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
4028 | SOLU MEDROL - 125 MG/2 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 125 MG/2 ML | - | - | - | - | 3件: 13 13, 14, 53 💬 |
4029 | SOLU MEDROL - 40 MG/ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 40 MG/ML | - | - | - | - | 1件: 56 56 💬 |
4030 | SOLU MEDROL - 500 MG/8 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE DI POLVERE DA 500 MG+ FIALA SOLVENTE DA 8 ML | - | - | - | - | 1件: 56 56 💬 |
4031 | Solu-Cortef 100 MG Injection | 3件: Hydrocortisone Hydrocortisone, Hydrocortisone cypionate, Hydrocortisone succinate | 3件: Hydrocortisone
Hydrocortisone
,
Hydrocortisone cypionate
,
Hydrocortisone succinate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 83 83 💬 |
4032 | Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial' | 3件: Hydrocortisone Hydrocortisone, Hydrocortisone cypionate, Hydrocortisone succinate | 3件: Hydrocortisone
Hydrocortisone
,
Hydrocortisone cypionate
,
Hydrocortisone succinate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
4033 | Solu-Medrone 125mg | - | - | - | - | 1件: 46 46 💬 |
4034 | SOLU-MODERIN 1 g | - | - | - | - | 1件: 13 13 💬 |
4035 | Solumedrol IM 125mg/2ml | - | - | - | - | 1件: 13 13 💬 |
4036 | SOM230 300µg | - | - | - | - | 1件: 75 75 💬 |
4037 | SOM230 600µg | - | - | - | - | 1件: 75 75 💬 |
4038 | SOM230 900µg | - | - | - | - | 1件: 75 75 💬 |
4039 | SOM230 LAR 10 mg | - | - | - | - | 1件: 75 75 💬 |
4040 | SOM230 LAR 30 mg | - | - | - | - | 1件: 75 75 💬 |
4041 | SOM230, 300micrograms | - | - | - | - | 1件: 75 75 💬 |
4042 | SOM230, 600 micrograms | - | - | - | - | 1件: 75 75 💬 |
4043 | SOM230, 900 micrograms | - | - | - | - | 1件: 75 75 💬 |
4044 | SOM3355 100mg BID | - | - | - | - | 1件: 8 8 💬 |
4045 | Somapacitan 10 mg/1.5ml PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
4046 | Somapacitan 10 mg/1.5ml PDS290S | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
4047 | Somapacitan 15 mg/1.5 mL PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 195 195 💬 |
4048 | Somapacitan 15 mg/1.5ml PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
4049 | Somapacitan 5 mg/1.5 mL PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 195 195 💬 |
4050 | Somapacitan 5 mg/1.5ml PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
4051 | Somatuline Autogel 90 mg | 1件: Lanreotide Lanreotide | - | - | - | 1件: 298 298 💬 |
4052 | Somavaratan (VRS-317) | 1件: Somavaratan Somavaratan | 1件: Somavaratan
Somavaratan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
4053 | Sortis 10 mg | - | - | - | - | 1件: 93 93 💬 |
4054 | Sotatercept - 60 mg/vial | 1件: Sotatercept Sotatercept | 1件: Sotatercept
Sotatercept
💬 | 1件: ACVR2A ACVR2A 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 86 86 💬 |
4055 | SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM | 1件: Ioflupane I-123 Ioflupane I-123 | - | - | - | 1件: 2 2 💬 |
4056 | SPI-1005 Ebselen 200mg Capsule x1 | 1件: Ebselen Ebselen | - | - | - | 1件: 299 299 💬 |
4057 | SPI-1005 Ebselen 200mg Capsule x2 | 1件: Ebselen Ebselen | - | - | - | 1件: 299 299 💬 |
4058 | SPI-1005 Ebselen 200mg Capsule x3 | 1件: Ebselen Ebselen | - | - | - | 1件: 299 299 💬 |
4059 | SPI-62 | - | - | - | - | 1件: 75 75 💬 |
4060 | SPI-62 dose 2 | - | - | - | - | 1件: 75 75 💬 |
4061 | SPI-62 dose 3 | - | - | - | - | 1件: 75 75 💬 |
4062 | SPI-62 dose 4 | - | - | - | - | 1件: 75 75 💬 |
4063 | SPI-62 dose1 | - | - | - | - | 1件: 75 75 💬 |
4064 | SPK-3006 | - | - | - | - | 1件: 256 256 💬 |
4065 | SPM 926 | - | - | - | - | 1件: 6 6 💬 |
4066 | SPM 962 | - | - | - | - | 1件: 6 6 💬 |
4067 | Sporanox 10 mg/ml Oral Solution | 1件: Itraconazole Itraconazole | 1件: Itraconazole
Itraconazole
💬 | - | - | 1件: 299 299 💬 |
4068 | SPP-004 | - | - | - | - | 1件: 21 21 💬 |
4069 | SPX-101 | - | - | - | - | 1件: 299 299 💬 |
4070 | SRK-015 | - | - | - | - | 1件: 3 3 💬 |
4071 | SRP-9001 | - | - | - | - | 1件: 113 113 💬 |
4072 | SRP-9003 | 1件: SRP-9003 SRP-9003 | - | - | - | 1件: 113 113 💬 |
4073 | SRP-9004 | - | - | - | - | 1件: 113 113 💬 |
4074 | SS-1 | - | - | - | - | 1件: 53 53 💬 |
4075 | SSGJ-613 | - | - | - | - | 1件: 107 107 💬 |
4076 | SSP-004184 100 mg | - | - | - | - | 1件: 284 284 💬 |
4077 | SSP-004184 100 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4078 | SSP-004184 250 mg | - | - | - | - | 1件: 284 284 💬 |
4079 | SSP-004184 250 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4080 | SSP-004184 375 mg | - | - | - | - | 1件: 284 284 💬 |
4081 | SSP-004184 375 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4082 | SSP-004184 50 mg | - | - | - | - | 1件: 284 284 💬 |
4083 | SSP-004184 50 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4084 | SSP-004184 500 mg | - | - | - | - | 1件: 284 284 💬 |
4085 | SSP-004184 500 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4086 | SSP-004184AQ 100 mg | - | - | - | - | 1件: 284 284 💬 |
4087 | SSP-004184AQ 100 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4088 | SSP-004184AQ 200 mg | - | - | - | - | 1件: 284 284 💬 |
4089 | SSP-004184AQ 200 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4090 | SSP-004184AQ 250 mg | - | - | - | - | 1件: 284 284 💬 |
4091 | SSP-004184AQ 250 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4092 | SSP-004184AQ 375 mg | - | - | - | - | 1件: 284 284 💬 |
4093 | SSP-004184AQ 375 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4094 | SSP-004184AQ 50 mg | - | - | - | - | 1件: 284 284 💬 |
4095 | SSP-004184AQ 50 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4096 | ST 36 | - | - | - | - | 1件: 49 49 💬 |
4097 | ST-0529 | - | - | - | - | 1件: 97 97 💬 |
4098 | ST-920 | - | - | - | - | 1件: 19 19 💬 |
4099 | ST10-021 | - | - | - | - | 2件: 96 96, 97 💬 |
4100 | STA-6838, STA-5326 m, S38 | - | - | - | - | 1件: 96 96 💬 |
4101 | Stalevo 100 | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4102 | Stalevo 100 mg/ 25 mg/ 200 mg Filmtabletten | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4103 | Stalevo 100 mg/25 mg / 200 mg | - | - | - | - | 1件: 6 6 💬 |
4104 | Stalevo 100/25/200 mg | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4105 | Stalevo 150 | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4106 | Stalevo 150/37.5/200 mg | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4107 | STALEVO*100CPR 100/25/200MG | 2件: Entacapone Entacapone, Levodopa | 2件: Levodopa
Levodopa
,
Entacapone
💬 | 6件: COMT COMT, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Steroid hormone biosynthesis, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4108 | STALEVO*100CPR 50/12,5/200MG | 2件: Entacapone Entacapone, Levodopa | 2件: Levodopa
Levodopa
,
Entacapone
💬 | 6件: COMT COMT, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Steroid hormone biosynthesis, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4109 | Standard Dose YPT-01 | - | - | - | - | 1件: 299 299 💬 |
4110 | Standardized Ginkgo Biloba Extract (EGb 761 (r) | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 1件: 18 18 💬 |
4111 | STELARA - 45 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 0.5 ML (90 MG/ML) 1 FLACONCINO | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4112 | STELARA - 90 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) 1 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 1 ML | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4113 | STELARA - 90 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 1.0 ML (90 MG/ML) 1 FLACONCINO | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 2件: 96 96, 97 💬 |
4114 | STELARA 130 mg concentrate for solution for infusion | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4115 | Stelara 130mg / 26mL concentrate for solution for | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4116 | Stelara 130mg / 26mL concentrate for solution for infusion | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4117 | STELARA 90 mg solution for injection in pre-filled syringe | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4118 | Stelara 90mg/1ml solution for injecti | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4119 | Stelara 90mg/1ml solution for injection in pre-filled syringe (PFS) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4120 | Sterile Normal Saline (0.9% NaCl) | - | - | - | - | 2件: 62 62, 254 💬 |
4121 | STERILE PYROGEN-FREE ISOTONIC NACL SOLUTE (0.9% W / V) | - | - | - | - | 1件: 299 299 💬 |
4122 | STG-001 | 1件: STG-001 STG-001 | - | - | - | 1件: 301 301 💬 |
4123 | STI-6129 | - | - | - | - | 1件: 28 28 💬 |
4124 | STK-001 | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
4125 | STK-001 - Multiple Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
4126 | STK-001 - Single Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
4127 | STNM01 1.84 mg | - | - | - | - | 1件: 97 97 💬 |
4128 | STW5-II (Iberogast N, BAY98-7410) | - | - | - | - | 1件: 97 97 💬 |
4129 | Subcutaneous hydrocortisone 10mg | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
4130 | Subcutaneous tocilizumab 162mg/biweekly | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4131 | Subjects will undergo the 123-I IBVM imaging visit | - | - | - | - | 1件: 6 6 💬 |
4132 | Sublingual tizanidine 12 mg | 1件: Tizanidine Tizanidine | 1件: Tizanidine
Tizanidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
4133 | Sulindac (HLX-0201), dose strength 1 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
4134 | Sulindac (HLX-0201), dose strength 2 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
4135 | Suspension containing 250 embryonated, viable Trichuris suis ova (TSO)/15ml | - | - | - | - | 1件: 96 96 💬 |
4136 | Suspension containing 250 embryonated, viable TSO/15ml | - | - | - | - | 1件: 96 96 💬 |
4137 | Suspension containing 2500 embryonated, viable Trichuris suis ova (TSO)/15ml | - | - | - | - | 1件: 96 96 💬 |
4138 | Suspension containing 2500 embryonated, viable TSO/15ml | - | - | - | - | 1件: 96 96 💬 |
4139 | SUSPENSION CONTAINING 7500 EMBRYONATED VIABLE TRICHURIS SUIS OVA/15ML | - | - | - | - | 1件: 97 97 💬 |
4140 | Suspension containing 7500 embryonated, viable Trichuris suis ova (TSO)/15ml | - | - | - | - | 1件: 96 96 💬 |
4141 | Suspension of 7500 embryonated, viable TSO/15ml | - | - | - | - | 1件: 96 96 💬 |
4142 | Suspension of human autologous MSC 3P in 1,5 ml | - | - | - | - | 1件: 2 2 💬 |
4143 | Suspension of human autologous MSC 3P in 1.5 ml | - | - | - | - | 1件: 2 2 💬 |
4144 | Symkevi 100mg/150mg Film-coated tablets | 2件: Ivacaftor Ivacaftor, Tezacaftor | 2件: Ivacaftor
Ivacaftor
,
Tezacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4145 | SYN115 Tablets, 60 mg | - | - | - | - | 1件: 6 6 💬 |
4146 | Synacthen Depot 1mg | 1件: Tetracosactide Tetracosactide | 1件: Cosyntropin
Cosyntropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 222 222 💬 |
4147 | Synergy-1 | - | - | - | - | 1件: 97 97 💬 |
4148 | Synthetic 15-amino-acid macrocyclic peptide | - | - | - | - | 1件: 62 62 💬 |
4149 | Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol24 | - | - | - | - | 1件: 62 62 💬 |
4150 | Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol24 palmitoylated linker | - | - | - | - | 1件: 62 62 💬 |
4151 | Synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker | - | - | - | - | 1件: 62 62 💬 |
4152 | Synthetic Human Parathyroid Hormone 1-34 | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
4153 | Sübetaholzwurzel 1ml/10ml | - | - | - | - | 1件: 97 97 💬 |
4154 | Süßholzwurzel 1ml/10ml | - | - | - | - | 1件: 97 97 💬 |
4155 | T 100 PARI | - | - | - | - | 1件: 299 299 💬 |
4156 | T 614 | - | - | - | - | 1件: 300 300 💬 |
4157 | T-326 | - | - | - | - | 1件: 299 299 💬 |
4158 | T-614 | - | - | - | - | 1件: 46 46 💬 |
4159 | TA-650 | - | - | - | - | 4件: 37 37, 56, 96, 97 💬 |
4160 | TA-650 (Infliximab) | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 97, 271 💬 |
4161 | TA-650 10 mg/kg | - | - | - | - | 1件: 46 46 💬 |
4162 | TA-650 3 mg/kg | - | - | - | - | 1件: 46 46 💬 |
4163 | TA-650 6 mg/kg | - | - | - | - | 1件: 46 46 💬 |
4164 | TACHIPIRINA - 1000 MG COMPRESSE 8 COMPRESSE | - | - | - | - | 1件: 14 14 💬 |
4165 | TAD 600 | - | - | - | - | 1件: 299 299 💬 |
4166 | TAK-018 | - | - | - | - | 1件: 96 96 💬 |
4167 | TAK-071 | - | - | - | - | 1件: 6 6 💬 |
4168 | TAK-079 | - | - | - | - | 3件: 11 11, 49, 63 💬 |
4169 | TAK-079, TSF-021, TSF79 | - | - | - | - | 1件: 11 11 💬 |
4170 | TAK-341 | - | - | - | - | 1件: 17 17 💬 |
4171 | TAK-625 | - | - | - | - | 2件: 297 297, 338 💬 |
4172 | TAK-672 | - | - | - | - | 1件: 288 288 💬 |
4173 | TAK-715 | 1件: TAK-715 TAK-715 | - | - | - | 1件: 46 46 💬 |
4174 | TAK-715 and methotrexate | 2件: Methotrexate Methotrexate, TAK-715 | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
4175 | TAK-755 | - | - | - | - | 1件: 64 64 💬 |
4176 | TAK-755 or BAX930 or SHP655 | - | - | - | - | 1件: 64 64 💬 |
4177 | TAK-755 orBAX930 or SHP655 | - | - | - | - | 1件: 64 64 💬 |
4178 | TAK-771 | - | - | - | - | 2件: 14 14, 65 💬 |
4179 | TAK-783 | - | - | - | - | 1件: 46 46 💬 |
4180 | TAK-783 and methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
4181 | TAK-935 | - | - | - | - | 2件: 140 140, 144 💬 |
4182 | TAP-144-SR(3M) | - | - | - | - | 1件: 1 1 💬 |
4183 | Targinact 10 mg/5 mg prolonged-release tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 2件: 6 6, 226 💬 |
4184 | Targinact 20 mg/10 mg prolonged-release tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 6 6 💬 |
4185 | Targinact 20mg/10 mg prolonged-release tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 226 226 💬 |
4186 | Tasigna 150mg | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 34 34 💬 |
4187 | Tasigna® 150 mg | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 💬 |
4188 | Tau (18-F-AV-1451) | - | - | - | - | 1件: 127 127 💬 |
4189 | Tavapadon 0.25 mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4190 | Tavapadon 0.25mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4191 | Tavapadon 1mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4192 | TAVT-18 (sirolimus) | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
4193 | TBX-1400 | - | - | - | - | 1件: 65 65 💬 |
4194 | Tc 99m tilmanocept | 1件: Tilmanocept Tilmanocept | - | - | - | 1件: 46 46 💬 |
4195 | TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt) | 1件: Hydrogen Hydrogen | - | - | - | 1件: 6 6 💬 |
4196 | TD-1058 | - | - | - | - | 1件: 85 85 💬 |
4197 | TD-1473 | - | - | - | - | 2件: 96 96, 97 💬 |
4198 | TD-1473 Dose A | - | - | - | - | 1件: 97 97 💬 |
4199 | TD-1473 Dose B | - | - | - | - | 1件: 97 97 💬 |
4200 | TD-1473 Dose C | - | - | - | - | 1件: 97 97 💬 |
4201 | TD-3504 | - | - | - | - | 1件: 97 97 💬 |
4202 | TD-9855 | - | - | - | - | 2件: 6 6, 17 💬 |
4203 | Tecfidera® 120 mg | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: Dimethyl fumarate
Dimethyl fumarate
💬 | 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 💬 |
4204 | Tecfidera® 120mg magensaftresistente Hartkapseln | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: Dimethyl fumarate
Dimethyl fumarate
💬 | 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 💬 |
4205 | TECHNETIUM (99MTC) EXAMETAZIME | 2件: Exametazime Exametazime, Technetium Tc-99m exametazime | 1件: Exametazime
Exametazime
💬 | - | - | 1件: 6 6 💬 |
4206 | Technetium Tc 99m | 1件: Technetium Tc-99m Technetium Tc-99m | - | - | - | 1件: 46 46 💬 |
4207 | Technetium Tc 99m Tilmanocept | 3件: Technetium Tc-99m Technetium Tc-99m, Technetium Tc-99m tilmanocept, Tilmanocept | - | - | - | 1件: 46 46 💬 |
4208 | Teduglutide (ALX-0600) | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
4209 | Teduglutide 0.05 | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
4210 | Teduglutide 0.05 dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
4211 | Teduglutide 0.1 mg dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
4212 | Teduglutide 0.2 mg | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
4213 | Tehalose 30gr | - | - | - | - | 1件: 113 113 💬 |
4214 | Telitacicept 160 mg | - | - | - | - | 1件: 53 53 💬 |
4215 | Telitacicept 160mg | - | - | - | - | 1件: 66 66 💬 |
4216 | Terguride 0,5mg tablet | 1件: Terguride Terguride | 1件: Terguride
Terguride
💬 | 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 86 86 💬 |
4217 | Terguride 0.5 mg tablet | 1件: Terguride Terguride | 1件: Terguride
Terguride
💬 | 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 86 86 💬 |
4218 | Teriflunomide 14 MG | 1件: Teriflunomide Teriflunomide | 1件: Teriflunomide
Teriflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
4219 | Teriflunomide 14 MG Oral Tablet [Aubagio] | 1件: Teriflunomide Teriflunomide | 1件: Teriflunomide
Teriflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
4220 | Teriparatide [rDNA origin] contains recombinant human parathyroid hormone (1-34) | 2件: Parathyroid hormone Parathyroid hormone, Teriparatide | 2件: Parathyroid hormone
Parathyroid hormone
,
Teriparatide
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 70 70 💬 |
4221 | TETRACT-HIB - 1 SIRINGA PRECARICATA 0.5 ML | - | - | - | - | 1件: 222 222 💬 |
4222 | Tetrahydro-6,6,9-tri methyl-3-penthyl-6 H-dibenzo[ b,d ]pyran-1-ol | - | - | - | - | 1件: 298 298 💬 |
4223 | Tezacaftor/Ivacaftor 100mg/150mg | 2件: Ivacaftor Ivacaftor, Tezacaftor | 2件: Ivacaftor
Ivacaftor
,
Tezacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4224 | Tezacaftor/Ivacaftor/100mg/150mg | 2件: Ivacaftor Ivacaftor, Tezacaftor | 2件: Ivacaftor
Ivacaftor
,
Tezacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4225 | TG-1101 | - | - | - | - | 1件: 13 13 💬 |
4226 | Thalidomide 100mg | 1件: Thalidomide Thalidomide | 1件: Thalidomide
Thalidomide
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
4227 | Thalidomide 150mg | 1件: Thalidomide Thalidomide | 1件: Thalidomide
Thalidomide
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
4228 | The 0.5 mL dose of vaccine contains 25 micrograms of each of the following 23 pneumococcal polysaccharide | - | - | - | - | 1件: 222 222 💬 |
4229 | The investigational medicinal product (IMP) may be labelled as either PF-04236921 106 mg/vial, Clonal SC lyophilized form” or PF-04236921 Powder for Injection, 106 mg/vial”. Supplies labelled with either nomenclature are equivalent. | - | - | - | - | 1件: 96 96 💬 |
4230 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA | - | - | - | - | 1件: 96 96 💬 |
4231 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA. | - | - | - | - | 1件: 96 96 💬 |
4232 | THRX-139060 | - | - | - | - | 2件: 96 96, 97 💬 |
4233 | THRX-199687 hydrochloride | - | - | - | - | 1件: 99 99 💬 |
4234 | Thymosin alpha 1 | - | - | - | - | 1件: 299 299 💬 |
4235 | Tildrakizumab 100 mg/ml | 1件: Tildrakizumab Tildrakizumab | 1件: Tildrakizumab
Tildrakizumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 271 271 💬 |
4236 | Timolol Alcon 0.5% collyre | 1件: Timolol Timolol | 2件: Timolol
Timolol
,
Timolol
💬 | 2件: ADRB1 ADRB1, ADRB2 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 227 227 💬 |
4237 | Tiotropium Respimat 1.25 microgram solution for inhalation | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
4238 | Tiotropium Respimat 1.25 microgram, solution for inhalation | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
4239 | Tiotropium Respimat 1.25 micrograms solution for inhalation | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
4240 | TJ-68 | - | - | - | - | 1件: 2 2 💬 |
4241 | TJ301 300mg | - | - | - | - | 1件: 97 97 💬 |
4242 | TJ301 600mg | - | - | - | - | 1件: 97 97 💬 |
4243 | TLL-018 | - | - | - | - | 1件: 46 46 💬 |
4244 | TLR7/8 Antagonist (10mg) | - | - | - | - | 1件: 49 49 💬 |
4245 | TMI-005 | - | - | - | - | 1件: 46 46 💬 |
4246 | TMI-005 (WAY-177005) | - | - | - | - | 1件: 46 46 💬 |
4247 | TMI-005 WAY-177005 | - | - | - | - | 1件: 46 46 💬 |
4248 | TNR-001 | - | - | - | - | 2件: 46 46, 271 💬 |
4249 | TNR-001, TNFR:FC | - | - | - | - | 1件: 271 271 💬 |
4250 | TNX-650, rhuMAb anti-IL13, aIL-13, MILR1444A | - | - | - | - | 1件: 85 85 💬 |
4251 | TOBI 300 mg / 5 mL nebuliser solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4252 | TOBI 300 mg/5 ml Lösung für einen | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4253 | TOBI 300 mg/5 ml Lösung für einen Vernebler | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4254 | TOBI 300 mg/5 ml Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4255 | TOBI 300 mg/5 ml solución para inhalación por nebulizador | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4256 | TOBI 300 mg/5 ml, solution pour inhalation par nébuliseur | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4257 | TOBI 300mg/ 5ml solución para inhalación con nebulizador | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4258 | TOBI 300mg/5mL Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4259 | Tobi 300mg/5ml Nebuliser solution. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4260 | Tobi 300mg/5ml Solución para inhalación por nebulizador. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4261 | TOBI PODHALER - 28 MG POLVERE PER INALAZIONE CAPSULA RIGIDA USO INALATORIO BLISTER(ALU/ALU) 56 CAPSULE + 1 INALATORE | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4262 | TOBI PODHALER*448CPS 28MG+10IN | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4263 | TOBI*NEBUL 56F 1D 300MG/5ML | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4264 | TOBI™ Podhaler™ 112 mg inhaled twice daily | - | - | - | - | 1件: 299 299 💬 |
4265 | Tobramycin 100 PARI | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4266 | Tobramycin Inhalation Powder TIP delivered by the T-326 Inhaler | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4267 | Tobramycin injection 40mg/1ml | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4268 | Tobramycin solution for inhalation 300 mg | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4269 | Tobramycin Steri-Neb 300 mg/5 ml, inhalation solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4270 | Tocilizumab 162 mg | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4271 | Tocilizumab 162Mg/0.9Ml Autoinjector | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
4272 | Tocilizumab 162mg/0.9ml jeringa SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4273 | Tocilizumab 162mg/0.9ml SC PFS SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4274 | Tocilizumab 162mg/0.9ml syringe SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4275 | Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4276 | Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4277 | Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 51 51 💬 |
4278 | Tocovid Suprabio (HOV-12020) | - | - | - | - | 1件: 6 6 💬 |
4279 | Tofacitinib (CP-690,550) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 96 96 💬 |
4280 | Tofacitinib (Xeljanz®) 11mg Prolonged Release Tablet | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4281 | Tofacitinib 10 mg | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 271 271 💬 |
4282 | Tofacitinib 10 MG [Xeljanz] | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
4283 | Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 84 84 💬 |
4284 | TOFACITINIB CITRATE CP-690550 | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4285 | Tolebrutinib 120mg | - | - | - | - | 1件: 13 13 💬 |
4286 | Tolebrutinib 60mg | - | - | - | - | 1件: 13 13 💬 |
4287 | TOLVAPTAN 15 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4288 | Tolvaptan 15 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4289 | Tolvaptan 15 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4290 | Tolvaptan 15mg | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4291 | TOLVAPTAN 30 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4292 | Tolvaptan 30 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4293 | Tolvaptan 30 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4294 | Tolvaptan 30mg | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4295 | TOLVAPTAN 45/15 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4296 | TOLVAPTAN 60/30 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4297 | Tolvaptan 7.5 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4298 | Tominersen 100 mg | - | - | - | - | 1件: 8 8 💬 |
4299 | Tominersen 60 mg | - | - | - | - | 1件: 8 8 💬 |
4300 | Topical 0.1% Sirolimus | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 278 278 💬 |
4301 | Topical BPM31510 3.0% Cream | - | - | - | - | 1件: 36 36 💬 |
4302 | Topical calcipotriene 0.005% ointment | 1件: Calcipotriol Calcipotriol | 1件: Calcipotriene
Calcipotriene
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 51 51 💬 |
4303 | TORVAST*10CPR 10MG | - | - | - | - | 1件: 13 13 💬 |
4304 | Total Body Irradiation (TBI) (Plan 1) | - | - | - | - | 2件: 60 60, 285 💬 |
4305 | TOTTIZIM - 1 G/10 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO ENDOVENOSO 1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 10 ML | - | - | - | - | 1件: 299 299 💬 |
4306 | Tozadenant (SYN115) 120 mg BID | 1件: Tozadenant Tozadenant | 1件: Tozadenant
Tozadenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4307 | Tozadenant (SYN115) 180 mg BID | 1件: Tozadenant Tozadenant | 1件: Tozadenant
Tozadenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4308 | Tozadenant (SYN115) 60 mg BID | 1件: Tozadenant Tozadenant | 1件: Tozadenant
Tozadenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4309 | TPI-287 6.3 mg/m2 | 1件: TPI-287 TPI-287 | - | - | - | 2件: 5 5, 7 💬 |
4310 | TPN-101 | - | - | - | - | 3件: 2 2, 127, 325 💬 |
4311 | TPN-101, 400 mg/day | - | - | - | - | 2件: 2 2, 127 💬 |
4312 | TRACLEER 125MG 56CPR RIV. | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 88 88 💬 |
4313 | TRACLEER 62,5 mg comprimidos recubiertos con película | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
4314 | TRACLEER 62,5MG 56CPR RIV. | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
4315 | TRACLEER*125MG 56CPR RIV. | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
4316 | TRACLEER*56CPR RIV 125MG | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 51 51, 86, 88 💬 |
4317 | Tralokinumab cohort 1 | 1件: Tralokinumab Tralokinumab | 1件: Tralokinumab
Tralokinumab
💬 | 1件: IL13 IL13 💬 | 8件: Asthma Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬 | 1件: 85 85 💬 |
4318 | Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor | 1件: Tralokinumab Tralokinumab | 1件: Tralokinumab
Tralokinumab
💬 | 1件: IL13 IL13 💬 | 8件: Asthma Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬 | 1件: 85 85 💬 |
4319 | Trametinib (0.5 mg) | 1件: Trametinib Trametinib | 1件: Trametinib
Trametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 2 2 💬 |
4320 | Trametinib (1 mg) | 1件: Trametinib Trametinib | 1件: Trametinib
Trametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 2 2 💬 |
4321 | TransCon CNP 3.9 mg CNP-38/vial | - | - | - | - | 1件: 276 276 💬 |
4322 | TransCon hGH (ACP-011) | - | - | - | - | 1件: 78 78 💬 |
4323 | TransCon hGH (ACP-011) - 12,1mg | - | - | - | - | 1件: 78 78 💬 |
4324 | TransCon hGH (ACP-011) - 12.1mg | - | - | - | - | 1件: 78 78 💬 |
4325 | TransCon hGH (ACP-011) - 24.2mg | - | - | - | - | 1件: 78 78 💬 |
4326 | TransCon hGH CT-301 (ACP-011) - 12,1mg | - | - | - | - | 1件: 78 78 💬 |
4327 | Translarna 1000 mg granules for oral suspension | 1件: Ataluren Ataluren | 1件: Ataluren
Ataluren
💬 | - | - | 1件: 113 113 💬 |
4328 | Translarna 125 mg granules for oral suspension | 1件: Ataluren Ataluren | 1件: Ataluren
Ataluren
💬 | - | - | 1件: 113 113 💬 |
4329 | Transvamix (100mg/mL THC, 50mg/mL CBD) | - | - | - | - | 1件: 36 36 💬 |
4330 | Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms | 1件: Lansoprazole Lansoprazole | 1件: Lansoprazole
Lansoprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 98 98 💬 |
4331 | TREPROSTINIL SODIUM, UT-15 | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
4332 | Treprostinil, UT-15, LRX-15, 15AU81, BW A15AU, U-62, 840 | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
4333 | Trientine dihydrochloride 300mg capsules | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
4334 | Triheptanoin 1g/kg/day | 1件: Triheptanoin Triheptanoin | 1件: Triheptanoin
Triheptanoin
💬 | - | - | 1件: 8 8 💬 |
4335 | TRIMETON - 10 MG/1 ML SOLUZIONE INIETTABILE 5 FIALE 1 ML | - | - | - | - | 1件: 14 14 💬 |
4336 | Triomar™ (omega-3 fatty acids) | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 13 13 💬 |
4337 | Triptorelin pamoate 15mg | 1件: Triptorelin Triptorelin | 1件: Triptorelin
Triptorelin
💬 | 1件: GNRHR GNRHR 💬 | 2件: GnRH signaling pathway GnRH signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 76 76 💬 |
4338 | TRK-100STP | - | - | - | - | 1件: 86 86 💬 |
4339 | TRK-170 | - | - | - | - | 1件: 96 96 💬 |
4340 | TRU-015 | 1件: TRU-015 TRU-015 | - | - | - | 3件: 46 46, 49, 222 💬 |
4341 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
4342 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere. | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
4343 | TS-152 | - | - | - | - | 1件: 46 46 💬 |
4344 | TSHA-101 | - | - | - | - | 1件: 19 19 💬 |
4345 | TSHA-102 | - | - | - | - | 1件: 156 156 💬 |
4346 | TSO 7500 | - | - | - | - | 1件: 96 96 💬 |
4347 | TTI-101 | - | - | - | - | 1件: 85 85 💬 |
4348 | TTI-1612 | - | - | - | - | 1件: 226 226 💬 |
4349 | TU-100 | 1件: TU-100 TU-100 | - | - | - | 1件: 96 96 💬 |
4350 | TV-1106 | - | - | - | - | 1件: 78 78 💬 |
4351 | TV-7110 | - | - | - | - | 1件: 2 2 💬 |
4352 | TV-7820 | - | - | - | - | 1件: 8 8 💬 |
4353 | TVP-1012 | - | - | - | - | 1件: 6 6 💬 |
4354 | TVP-1012 (1 mg/day) with levodopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4355 | TVP-1012 0.5mg | - | - | - | - | 1件: 6 6 💬 |
4356 | TVP-1012 1mg | - | - | - | - | 1件: 6 6 💬 |
4357 | Twice-daily dosage with 0.5% cyclosporine-A eyedrops | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 90 90 💬 |
4358 | TY-0305 | - | - | - | - | 1件: 58 58 💬 |
4359 | TYSABRI 300 mg concentrado para solución para perfusión | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
4360 | TYSABRI 300 mg concentrate for solution for infusion | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
4361 | TYSABRI 300 mg solution à diluer pour perfusion | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
4362 | TYSABRI*IV 1FL 300MG 15ML | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
4363 | UB-312 | - | - | - | - | 1件: 6 6 💬 |
4364 | UB-312 Injection | - | - | - | - | 2件: 6 6, 17 💬 |
4365 | Ucb 34714 | - | - | - | - | 2件: 149 149, 309 💬 |
4366 | UF-021 | - | - | - | - | 1件: 90 90 💬 |
4367 | UF-021 (isopropyl unoprostone) | 1件: Unoprostone Unoprostone | 1件: Unoprostone
Unoprostone
💬 | 1件: PTGFR PTGFR 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬 | 1件: 90 90 💬 |
4368 | UF-021(isopropyl unoprostone) | 1件: Unoprostone Unoprostone | 1件: Unoprostone
Unoprostone
💬 | 1件: PTGFR PTGFR 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬 | 1件: 90 90 💬 |
4369 | UK 092480 | - | - | - | - | 1件: 86 86 💬 |
4370 | UK-92,480 | - | - | - | - | 1件: 86 86 💬 |
4371 | UK-92,480-10 | - | - | - | - | 1件: 86 86 💬 |
4372 | ULTOMIRIS - 300 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 3 ML (100 MG / ML) - 1 FLACONCINO | 1件: Ravulizumab Ravulizumab | 1件: Ravulizumab
Ravulizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
4373 | Ultomiris 1,100 mg/11 mL | 1件: Ravulizumab Ravulizumab | 1件: Ravulizumab
Ravulizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 11 11 💬 |
4374 | Ultomiris 300 mg/30 ml | 1件: Ravulizumab Ravulizumab | 1件: Ravulizumab
Ravulizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 66 66 💬 |
4375 | Ultomiris 300mg/30ml | 1件: Ravulizumab Ravulizumab | 1件: Ravulizumab
Ravulizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
4376 | UN-ALPHA-R 0.25µg | - | - | - | - | 1件: 235 235 💬 |
4377 | Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein) | 1件: Genistein Genistein | 1件: Genistein
Genistein
💬 | - | - | 1件: 299 299 💬 |
4378 | Upadacitinib 12mg | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4379 | Upadacitinib 15mg | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4380 | Upadacitinib 30mg | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4381 | Upadacitinib 3mg | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4382 | UR-12746-S | - | - | - | - | 1件: 97 97 💬 |
4383 | Urbason solubile forte 1000mg | - | - | - | - | 1件: 13 13 💬 |
4384 | URBASON*IM EV 1F 250MG+1F 5ML | - | - | - | - | 1件: 222 222 💬 |
4385 | Urbason® solubile forte 1000 mg | - | - | - | - | 1件: 13 13 💬 |
4386 | Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
4387 | URSOCHOL 300 | - | - | - | - | 1件: 67 67 💬 |
4388 | Ursodeoxycholic Acid 300mg capsule | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
4389 | Ursodeoxycholic Acid 300mg tablet | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
4390 | Ustekinumab (approximately 6 mg/kg) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 49 49 💬 |
4391 | Ustekinumab + MTX (Group 3) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 46 46 💬 |
4392 | Ustekinumab 130 mg IV | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4393 | Ustekinumab 180 mg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 93 93 💬 |
4394 | Ustekinumab 1mg/kg (IP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4395 | Ustekinumab 3 mg/kg (IP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4396 | Ustekinumab 6 mg/kg (IP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4397 | Ustekinumab 90 mg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 3件: 49 49, 93, 96 💬 |
4398 | Ustekinumab 90 mg (SC) Group 1 | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4399 | Ustekinumab 90 mg (SC) Group 2 | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4400 | Ustekinumab 90 mg SC q12w | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4401 | Ustekinumab 90 mg SC q8w | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4402 | Ustekinumab 90 milligram (mg) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 49 49 💬 |
4403 | Ustekinumab approximately 6 mg/kg (IV) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4404 | Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4405 | Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4406 | UT-15 SR | - | - | - | - | 1件: 51 51 💬 |
4407 | UT-15C | - | - | - | - | 1件: 86 86 💬 |
4408 | UT-15C (treprostinil diethanolamine) | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
4409 | UT-15C 0.25 mg | - | - | - | - | 1件: 86 86 💬 |
4410 | UT-15C 1 mg | - | - | - | - | 1件: 86 86 💬 |
4411 | UT-15C 5 mg | - | - | - | - | 1件: 86 86 💬 |
4412 | UT-15C LP | - | - | - | - | 1件: 86 86 💬 |
4413 | UT-15C SR | - | - | - | - | 2件: 51 51, 86 💬 |
4414 | UT-15C SR (treprostinil diethanolamine) | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
4415 | UT-15C-SR | - | - | - | - | 2件: 51 51, 86 💬 |
4416 | UVEDOSE 100 000 UI | - | - | - | - | 1件: 13 13 💬 |
4417 | UVEDOSE 100 000 UI, solution buvable en ampoule | - | - | - | - | 1件: 13 13 💬 |
4418 | UX701 (1.0 × 10^13 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
4419 | UX701 (2.0 × 10^13 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
4420 | UX701 (5.0 × 10^12 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
4421 | VACCINO POLISACCARIDICO ANTI-MENINGOCOCCICO (A.C.Y E W-135) | - | - | - | - | 3件: 61 61, 62, 66 💬 |
4422 | VAL-1221 | - | - | - | - | 1件: 256 256 💬 |
4423 | Vamorolone 0.25 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4424 | Vamorolone 0.25 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4425 | Vamorolone 0.75 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4426 | Vamorolone 0.75 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4427 | Vamorolone 2.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4428 | Vamorolone 2.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4429 | Vamorolone 6.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4430 | Vamorolone 6.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4431 | Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 1件: 299 299 💬 |
4432 | VB-201 160mg | 1件: VB-201 VB-201 | - | - | - | 1件: 97 97 💬 |
4433 | Vector viral adenoasociado de serotipo 9 que contiene el gen de la sulfamidasa humana | - | - | - | - | 1件: 19 19 💬 |
4434 | Vedolizumab 108 mg SC | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
4435 | Vedolizumab 300 mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
4436 | Vedolizumab 300 MG Injection [Entyvio] | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 💬 |
4437 | Vedolizumab 300 mg IV | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
4438 | Vedolizumab IV 300 mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 💬 |
4439 | Vedolizumab SC 108 mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬 |
4440 | Vehicle (SD-101 0%) | - | - | - | - | 1件: 36 36 💬 |
4441 | Vehicle of ADX-102 Topical Dermal Cream | - | - | - | - | 1件: 160 160 💬 |
4442 | VELCADE*1FL 3,5MG | 2件: Bortezomib Bortezomib, Bortezomib D-mannitol | 1件: Bortezomib
Bortezomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 💬 |
4443 | VELCADE*EV 1FL 3,5MG 1MG/ML | 2件: Bortezomib Bortezomib, Bortezomib D-mannitol | 1件: Bortezomib
Bortezomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 61 61 💬 |
4444 | Veltuzumab solution 75mg/ml | 1件: Veltuzumab Veltuzumab | 1件: Veltuzumab
Veltuzumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
4445 | Ventavis 10 | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
4446 | Ventoline oral solution 0,4mg/ml | - | - | - | - | 1件: 111 111 💬 |
4447 | VESIcare 10Mg Tablet | - | - | - | - | 1件: 13 13 💬 |
4448 | VEYONDI 650IU powder and solvent for solution for injection | - | - | - | - | 1件: 288 288 💬 |
4449 | VEYVONDI 1300 IU powder and solvent for solution for injection | 1件: Vonicog alfa Vonicog alfa | 1件: Vonicog alfa
Vonicog alfa
💬 | - | - | 1件: 288 288 💬 |
4450 | VEYVONDI 1300I IU powder and solvent for solution for injection | 1件: Vonicog alfa Vonicog alfa | 1件: Vonicog alfa
Vonicog alfa
💬 | - | - | 1件: 288 288 💬 |
4451 | VEYVONDI 1300IU powder and solvent for solution for injection | 1件: Vonicog alfa Vonicog alfa | 1件: Vonicog alfa
Vonicog alfa
💬 | - | - | 1件: 288 288 💬 |
4452 | VEYVONDI 650IU powder and solvent for solution for injection | 1件: Vonicog alfa Vonicog alfa | 1件: Vonicog alfa
Vonicog alfa
💬 | - | - | 1件: 288 288 💬 |
4453 | Vibrox 100mg Capsules | - | - | - | - | 1件: 167 167 💬 |
4454 | VigantOL oil plus interferon beta-1a (Rebif) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
4455 | Vigantol® Öl 20.000 I.E./ml | - | - | - | - | 1件: 13 13 💬 |
4456 | VIMOVO 375/20 | - | - | - | - | 1件: 107 107 💬 |
4457 | VIOKASE 16 | - | - | - | - | 1件: 298 298 💬 |
4458 | Viokase 16 (pancrelipase) + Nexium | 2件: Esomeprazole Esomeprazole, Pancrelipase | 2件: Pancrelipase
Pancrelipase
,
Esomeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 298 298 💬 |
4459 | Viokase® 16 | - | - | - | - | 1件: 298 298 💬 |
4460 | VIREAD - 245 MG 30 COMPRESSE RIVESTITE CON FILM IN FLACONE USO ORALE | - | - | - | - | 1件: 46 46 💬 |
4461 | VIREAD 30 CPR 245 MG | - | - | - | - | 1件: 46 46 💬 |
4462 | Vitamin AD sig: 1 tablet/tid | - | - | - | - | 1件: 90 90 💬 |
4463 | Vitamin B sig: 10mg/tid | - | - | - | - | 1件: 90 90 💬 |
4464 | Vitamin D 100ug | 1件: Vitamin D Vitamin D | - | - | - | 1件: 298 298 💬 |
4465 | Vitamin D 10ug | 1件: Vitamin D Vitamin D | - | - | - | 1件: 298 298 💬 |
4466 | Vitamin D3 3000 UI daily | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
4467 | Vitamin D3 6000 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 💬 |
4468 | Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
4469 | Vitamin K supplementation, dose #1 | 1件: Phylloquinone Phylloquinone | - | - | - | 1件: 299 299 💬 |
4470 | Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1 | 1件: Choline Choline | 1件: Choline
Choline
💬 | - | - | 1件: 299 299 💬 |
4471 | Vizamyl (flutemetamol(F-18)) | 2件: Flutemetamol Flutemetamol, Flutemetamol (18F) | - | - | - | 3件: 5 5, 7, 127 💬 |
4472 | VOLIBRIS 10 mg comprimidos recubiertos con película | 1件: Ambrisentan Ambrisentan | 1件: Ambrisentan
Ambrisentan
💬 | 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
4473 | VOLMAX*30CPR 4MG R.P. | - | - | - | - | 1件: 3 3 💬 |
4474 | VPD-737 | - | - | - | - | 1件: 36 36 💬 |
4475 | VPRIV - 400 U - POLVERE PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: Velaglucerase alfa
Velaglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
4476 | VRS-317 | - | - | - | - | 1件: 78 78 💬 |
4477 | VRT-893661 VRT-0893661 | - | - | - | - | 1件: 299 299 💬 |
4478 | VSL#3 | - | - | - | - | 4件: 96 96, 97, 107, 291 💬 |
4479 | VSL#3® | - | - | - | - | 2件: 96 96, 97 💬 |
4480 | VSN16R 100mg | - | - | - | - | 1件: 13 13 💬 |
4481 | VT-001 | - | - | - | - | 1件: 66 66 💬 |
4482 | VWF SD-35-DH | - | - | - | - | 1件: 288 288 💬 |
4483 | VX-121 | - | - | - | - | 1件: 299 299 💬 |
4484 | VX-121/TEZ/D-IVA | - | - | - | - | 1件: 299 299 💬 |
4485 | VX-121/tezacaftor/deutivacaftor | 2件: Deutivacaftor Deutivacaftor, Tezacaftor | 2件: Tezacaftor
Tezacaftor
,
Deutivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4486 | VX-147 | - | - | - | - | 1件: 222 222 💬 |
4487 | VX-152 | - | - | - | - | 1件: 299 299 💬 |
4488 | VX-371 | - | - | - | - | 1件: 299 299 💬 |
4489 | VX-371 in hypertonic saline | - | - | - | - | 1件: 299 299 💬 |
4490 | VX-371 in saline | - | - | - | - | 1件: 299 299 💬 |
4491 | VX-561 (CTP-656) | - | - | - | - | 1件: 299 299 💬 |
4492 | VX-634 | - | - | - | - | 1件: 231 231 💬 |
4493 | VX-659 | 1件: VX-659 VX-659 | - | - | - | 1件: 299 299 💬 |
4494 | VX-659/ TEZ/IVA | 1件: VX-659 VX-659 | - | - | - | 1件: 299 299 💬 |
4495 | VX-659/TEZ/IVA | 1件: VX-659 VX-659 | - | - | - | 1件: 299 299 💬 |
4496 | VX-659/Tezacaftor/Ivacaftor | 3件: Ivacaftor Ivacaftor, Tezacaftor, VX-659 | 2件: Ivacaftor
Ivacaftor
,
Tezacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4497 | VX-661 | - | - | - | - | 1件: 299 299 💬 |
4498 | VX-661 / VX-770 | - | - | - | - | 1件: 299 299 💬 |
4499 | VX-661 Plus Ivacaftor Combination | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4500 | VX-661, VRT-893661 | - | - | - | - | 1件: 299 299 💬 |
4501 | VX-661/Ivacaftor | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4502 | VX-661/ivacaftor (VX-770) 100mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4503 | VX-661/ivacaftor 100 mg/ 150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4504 | VX-661/ivacaftor 100mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4505 | VX-661/ivacaftor 100mg/150mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4506 | VX-661/ivacaftor 50 mg/ 75 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4507 | VX-661/VX-770 | - | - | - | - | 1件: 299 299 💬 |
4508 | VX-661/VX-770 (TEZ/IVA) | - | - | - | - | 1件: 299 299 💬 |
4509 | VX-668 | - | - | - | - | 1件: 231 231 💬 |
4510 | VX-702 | 1件: VX-702 VX-702 | - | - | - | 1件: 46 46 💬 |
4511 | VX-745 | - | - | - | - | 1件: 8 8 💬 |
4512 | VX-77 | - | - | - | - | 1件: 299 299 💬 |
4513 | VX-770 | - | - | - | - | 1件: 299 299 💬 |
4514 | VX-770, VRT-8130077 | - | - | - | - | 1件: 299 299 💬 |
4515 | VX-770, VRT-813077 | - | - | - | - | 1件: 299 299 💬 |
4516 | VX-809 & VX-770 | - | - | - | - | 1件: 299 299 💬 |
4517 | VX-809 / VX-770 | - | - | - | - | 1件: 299 299 💬 |
4518 | VX-809/VX-770 | - | - | - | - | 1件: 299 299 💬 |
4519 | VYNT-0126 | - | - | - | - | 1件: 156 156 💬 |
4520 | WAY-130799 | - | - | - | - | 1件: 13 13 💬 |
4521 | WAY-177005 | - | - | - | - | 1件: 46 46 💬 |
4522 | WD-1603 | - | - | - | - | 1件: 6 6 💬 |
4523 | WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4524 | WD-1603 Carbidopa-Levodopa Extended-Release Tablets | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4525 | WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4526 | White chocolate (0% cocoa) | 1件: Cocoa Cocoa | - | - | - | 1件: 6 6 💬 |
4527 | Wilate 1000 | 2件: Antihemophilic factor human Antihemophilic factor human, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
4528 | WILATE 1000 I.U. | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
4529 | WILATE 900 | 2件: Antihemophilic factor human Antihemophilic factor human, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
4530 | WIN-1001X | - | - | - | - | 1件: 6 6 💬 |
4531 | WVE-003 | - | - | - | - | 1件: 8 8 💬 |
4532 | WVE-004 | - | - | - | - | 2件: 2 2, 127 💬 |
4533 | WVE-120101 | - | - | - | - | 1件: 8 8 💬 |
4534 | WVE-120102 | - | - | - | - | 1件: 8 8 💬 |
4535 | X4P-001 | - | - | - | - | 1件: 65 65 💬 |
4536 | XADAGO - 100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE | 1件: Safinamide Safinamide | 1件: Safinamide
Safinamide
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
4537 | XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE | 1件: Safinamide Safinamide | 1件: Safinamide
Safinamide
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
4538 | Xeljanz® 11mg Prolonged Release Tablet | 2件: Manganese citrate Manganese citrate, Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4539 | Xenon-129 | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
4540 | XGEVA - 120 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 1.7 ML 4 FLACONCINI | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 274 274 💬 |
4541 | XmAb5871_0.3MG | - | - | - | - | 1件: 46 46 💬 |
4542 | XmAb5871_1.0MG | - | - | - | - | 1件: 46 46 💬 |
4543 | XmAb5871_10.0MG | - | - | - | - | 1件: 46 46 💬 |
4544 | XmAb5871_3.0MG | - | - | - | - | 1件: 46 46 💬 |
4545 | Xolair 150 mg Pulver und Injektionslösung zur Herstellung einer Injektionslösung | 1件: Omalizumab Omalizumab | 1件: Omalizumab
Omalizumab
💬 | 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 1件: 299 299 💬 |
4546 | XOMA 052 | - | - | - | - | 5件: 41 41, 46, 50, 56, 106 💬 |
4547 | Yellow Fever vaccine (17D) | 1件: Yellow fever vaccine Yellow fever vaccine | 1件: Yellow fever vaccine
Yellow fever vaccine
💬 | - | - | 8件: 40 40, 44, 46, 50, 51, 52, 53, 107 💬 |
4548 | YONDELIS 0,25 mg polvo para concentrado para solución para perfusión | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
4549 | Yondelis 0.25 mg powder for concentrate for solution for infusion. | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
4550 | YONDELIS 1 mg polvo para concentrado para solución para perfusión | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
4551 | Yondelis 1 mg powder for concentrate for solution for infusion. | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
4552 | YRA-1909 high dose | - | - | - | - | 1件: 46 46 💬 |
4553 | YRA-1909 low dose | - | - | - | - | 1件: 46 46 💬 |
4554 | YRA-1909 mid dose | - | - | - | - | 1件: 46 46 💬 |
4555 | Yttrium-90 | 1件: Yttrium Y-90 Yttrium Y-90 | - | - | - | 1件: 28 28 💬 |
4556 | Yttrium-90 radiolabelled anti-CD66 antibody | 1件: Yttrium Y-90 Yttrium Y-90 | - | - | - | 1件: 28 28 💬 |
4557 | Yttrium90 radiolabelled antiCD66 | - | - | - | - | 1件: 28 28 💬 |
4558 | Z102 (Prednisolone and Dipyridamole). | 2件: Dipyridamole Dipyridamole, Prednisolone | 2件: Dipyridamole
Dipyridamole
,
Prednisolone
💬 | 3件: NR3C1 NR3C1, PDE4A, PDE5A 💬 | 7件: Metabolic pathways Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
4559 | ZAVESCA 84CPS 100MG | 1件: Miglustat Miglustat | 1件: Miglustat
Miglustat
💬 | 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
4560 | Zestoretic 10,20 | 1件: Lisinopril Lisinopril | 2件: Lisinopril
Lisinopril
,
Lisinopril
💬 | 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 19 19 💬 |
4561 | ZK 157046 | - | - | - | - | 1件: 13 13 💬 |
4562 | Zoenasa-1:4 | - | - | - | - | 1件: 97 97 💬 |
4563 | Zoledronic Acid 5Mg/Bag 100Ml Inj | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 3件: 5 5, 6, 17 💬 |
4564 | Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
4565 | Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product. | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
4566 | Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion,generic medicinal product | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
4567 | Zolgensma 2 x 1013 vector genomes/mL solution for infusion | 1件: Onasemnogene abeparvovec Onasemnogene abeparvovec | 1件: Onasemnogene abeparvovec
Onasemnogene abeparvovec
💬 | 1件: SMN1 SMN1 💬 | - | 1件: 3 3 💬 |
4568 | Zolgensma 2 x 1013 vg (vector genomes)/mL solution for infusion | 1件: Onasemnogene abeparvovec Onasemnogene abeparvovec | 1件: Onasemnogene abeparvovec
Onasemnogene abeparvovec
💬 | 1件: SMN1 SMN1 💬 | - | 1件: 3 3 💬 |
4569 | Zomacton 10 mg/ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
4570 | ZSP1603 12.5 mg | - | - | - | - | 1件: 85 85 💬 |
4571 | ZSP1603 7.5 mg | - | - | - | - | 1件: 85 85 💬 |
4572 | ZUGLIMET - 500 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/AL | - | - | - | - | 1件: 67 67 💬 |
4573 | ZX008 - 0.2 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
4574 | ZX008 - 0.8 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
4575 | ZX008 0.2 or 0.8 mg/kg/day | - | - | - | - | 1件: 144 144 💬 |
4576 | ZX008 0.2 to 0.8 mg/kg/day | - | - | - | - | 2件: 140 140, 144 💬 |
4577 | ZYTIGA - 250 MG - COMPRESSA - USO ORALE - FLACONE 120 COMPRESSE | 1件: Abiraterone Abiraterone | - | - | - | 1件: 75 75 💬 |